
<html lang="en"     class="pb-page"  data-request-id="d0f09756-3d46-4f1d-91be-321f9b6acf5c"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;issue:issue:10.1021/jmcmar.2014.57.issue-15;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:10.1021/jm500496m;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Discovery of 1-Butyl-3-chloro-4-(4-phenyl-1-piperidinyl)-(1H)-pyridone (JNJ-40411813): A Novel Positive Allosteric Modulator of the Metabotropic Glutamate 2 Receptor" /></meta><meta name="dc.Creator" content="José María  Cid" /></meta><meta name="dc.Creator" content="Gary  Tresadern" /></meta><meta name="dc.Creator" content="Guillaume  Duvey" /></meta><meta name="dc.Creator" content="Robert  Lütjens" /></meta><meta name="dc.Creator" content="Terry  Finn" /></meta><meta name="dc.Creator" content="Jean-Philippe  Rocher" /></meta><meta name="dc.Creator" content="Sonia  Poli" /></meta><meta name="dc.Creator" content="Juan Antonio  Vega" /></meta><meta name="dc.Creator" content="Ana Isabel  de Lucas" /></meta><meta name="dc.Creator" content="Encarnación  Matesanz" /></meta><meta name="dc.Creator" content="María Lourdes  Linares" /></meta><meta name="dc.Creator" content="José Ignacio  Andrés" /></meta><meta name="dc.Creator" content="Jesús  Alcazar" /></meta><meta name="dc.Creator" content="José Manuel  Alonso" /></meta><meta name="dc.Creator" content="Gregor J.  Macdonald" /></meta><meta name="dc.Creator" content="Daniel  Oehlrich" /></meta><meta name="dc.Creator" content="Hilde  Lavreysen" /></meta><meta name="dc.Creator" content="Abdelah  Ahnaou" /></meta><meta name="dc.Creator" content="Wilhelmus  Drinkenburg" /></meta><meta name="dc.Creator" content="Claire  Mackie" /></meta><meta name="dc.Creator" content="Stefan  Pype" /></meta><meta name="dc.Creator" content="David  Gallacher" /></meta><meta name="dc.Creator" content="Andrés A.  Trabanco" /></meta><meta name="dc.Description" content="We previously reported the discovery of 4-aryl-substituted pyridones with mGlu2 PAM activity starting from the HTS hit 5. In this article, we describe a different exploration from 5 that led to the..." /></meta><meta name="Description" content="We previously reported the discovery of 4-aryl-substituted pyridones with mGlu2 PAM activity starting from the HTS hit 5. In this article, we describe a different exploration from 5 that led to the..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="July 28, 2014" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/jm500496m" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2014 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Fjm500496m" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Fjm500496m" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Fjm500496m" /></link>
        
    
    

<title>Discovery of 1-Butyl-3-chloro-4-(4-phenyl-1-piperidinyl)-(1H)-pyridone (JNJ-40411813): A Novel Positive Allosteric Modulator of the Metabotropic Glutamate 2 Receptor | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/jm500496m" /></meta><meta property="og:title" content="Discovery of 1-Butyl-3-chloro-4-(4-phenyl-1-piperidinyl)-(1H)-pyridone (JNJ-40411813): A Novel Positive Allosteric Modulator of the Metabotropic Glutamate 2 Receptor" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-15/jm500496m/production/images/large/jm-2014-00496m_0016.jpeg" /></meta><meta property="og:description" content="We previously reported the discovery of 4-aryl-substituted pyridones with mGlu2 PAM activity starting from the HTS hit 5. In this article, we describe a different exploration from 5 that led to the discovery of a novel subseries of phenylpiperidine-substituted pyridones. The optimization strategy involved the introduction of different spacers between the pyridone core and the phenyl ring of 5. The fine tuning of metabolism and hERG followed by differentiation of advanced leads that were identified on the basis of PK profiles and in vivo potency converged on lead compound 36 (JNJ-40411813). Full in vitro and in vivo profiles indicate that 36 displayed an optimal interplay between potency, selectivity, favorable ADMET/PK and cardiovascular safety profile, and central EEG activity. Compound 36 has been investigated in the clinic for schizophrenia and anxious depression disorders." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/jm500496m"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/jm500496m">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Fjm500496m&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Fjm500496m&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/jm500496m&amp;href=/doi/10.1021/jm500496m" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2014</span><span class="cit-fg-volume">, 57</span><span class="cit-fg-issue">, 15</span><span class="cit-fg-pageRange">, 6495-6512</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/57/15" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/jm500483b" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/jm500521n" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of 1-Butyl-3-chloro-4-(4-phenyl-1-piperidinyl)-(1<i>H</i>)-pyridone (JNJ-40411813): A Novel Positive Allosteric Modulator of the Metabotropic Glutamate 2 Receptor</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jos%C3%A9+Mar%C3%ADa++Cid">José María Cid</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Gary++Tresadern">Gary Tresadern</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Guillaume++Duvey">Guillaume Duvey</a></span><span class="author-xref-symbol author-aff-symbol"><sup>⊥</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>○</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Robert++L%C3%BCtjens">Robert Lütjens</a></span><span class="author-xref-symbol author-aff-symbol"><sup>⊥</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>○</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Terry++Finn">Terry Finn</a></span><span class="author-xref-symbol author-aff-symbol"><sup>⊥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jean-Philippe++Rocher">Jean-Philippe Rocher</a></span><span class="author-xref-symbol author-aff-symbol"><sup>⊥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Sonia++Poli">Sonia Poli</a></span><span class="author-xref-symbol author-aff-symbol"><sup>⊥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Juan+Antonio++Vega">Juan Antonio Vega</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ana+Isabel++de+Lucas">Ana Isabel de Lucas</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Encarnaci%C3%B3n++Matesanz">Encarnación Matesanz</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Mar%C3%ADa+Lourdes++Linares">María Lourdes Linares</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jos%C3%A9+Ignacio++Andr%C3%A9s">José Ignacio Andrés</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jes%C3%BAs++Alcazar">Jesús Alcazar</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jos%C3%A9+Manuel++Alonso">José Manuel Alonso</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Gregor+J.++Macdonald">Gregor J. Macdonald</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Daniel++Oehlrich">Daniel Oehlrich</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Hilde++Lavreysen">Hilde Lavreysen</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Abdelah++Ahnaou">Abdelah Ahnaou</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Wilhelmus++Drinkenburg">Wilhelmus Drinkenburg</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Claire++Mackie">Claire Mackie</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Stefan++Pype">Stefan Pype</a></span><span class="author-xref-symbol author-aff-symbol"><sup>#</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=David++Gallacher">David Gallacher</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∇</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Andr%C3%A9s+A.++Trabanco">Andrés A. Trabanco</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">†</span> <span class="aff-text">Neuroscience Medicinal Chemistry, Janssen Research & Development, Janssen-Cilag S.A., C/Jarama 75, 45007 Toledo, Spain</span></div><div class="aff-info" id="aff2"><span class="aff-text"><sup>‡</sup>Neuroscience Medicinal Chemistry, <sup>§</sup>Neuroscience Biology, <sup>∥</sup>Discovery ADME/Tox, <sup>⊥</sup>Molecular Sciences, <sup>#</sup>Project Management Office, <sup>∇</sup>Translational Sciences, Janssen Research & Development, Turnhoutseweg 30, B-2340, Beerse, Belgium</span></div><div class="aff-info" id="aff3"><span class="aff-symbol">○</span> <span class="aff-text">Addex Therapeutics, 12 Chemin des Aulx, 1228 Plan-les-Ouates, Geneva, Switzerland</span></div><div class="corresp-info"><strong>*</strong>Tel: +34 925 245767. Fax: +34 925 245771. E-mail: <a href="/cdn-cgi/l/email-protection#8de7eee4e9cde4f9fea3e7e3e7a3eee2e0"><span class="__cf_email__" data-cfemail="016b626865416875722f6b6f6b2f626e6c">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Fjm500496m&amp;href=/doi/10.1021%2Fjm500496m" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2014</span></span><span class="cit-volume">, 57</span><span class="cit-issue">, 15</span><span class="cit-pageRange">, 6495–6512</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">July 17, 2014</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>28 March 2014</li><li><span class="item_label"><b>Published</b> online</span>28 July 2014</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 14 August 2014</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/jm500496m" title="DOI URL">https://doi.org/10.1021/jm500496m</a></div><div class="article_header-article-copyright"><strong>Copyright © 2014 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D6495%26pageCount%3D18%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DJos%25C3%25A9%2BMar%25C3%25ADa%2BCid%252C%2BGary%2BTresadern%252C%2BGuillaume%2BDuvey%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D57%26issueNum%3D15%26contentID%3Djm500496m%26title%3DDiscovery%2Bof%2B1-Butyl-3-chloro-4-%25284-phenyl-1-piperidinyl%2529-%25281H%2529-pyridone%2B%2528JNJ-40411813%2529%253A%2BA%2BNovel%2BPositive%2BAllosteric%2BModulator%2Bof%2Bthe%2BMetabotropic%2BGlutamate%2B2%2BReceptor%26numPages%3D18%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D6512%26publicationDate%3DAugust%2B2014">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/jm500496m"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1852</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">40</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/jm500496m" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of 1-Butyl-3-chloro-4-(4-phenyl-1-piperidinyl)-(1H)-pyridone (JNJ-40411813): A Novel Positive Allosteric Modulator of the Metabotropic Glutamate 2 Receptor&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;José&quot;,&quot;last_name&quot;:&quot;María Cid&quot;},{&quot;first_name&quot;:&quot;Gary&quot;,&quot;last_name&quot;:&quot;Tresadern&quot;},{&quot;first_name&quot;:&quot;Guillaume&quot;,&quot;last_name&quot;:&quot;Duvey&quot;},{&quot;first_name&quot;:&quot;Robert&quot;,&quot;last_name&quot;:&quot;Lütjens&quot;},{&quot;first_name&quot;:&quot;Terry&quot;,&quot;last_name&quot;:&quot;Finn&quot;},{&quot;first_name&quot;:&quot;Jean-Philippe&quot;,&quot;last_name&quot;:&quot;Rocher&quot;},{&quot;first_name&quot;:&quot;Sonia&quot;,&quot;last_name&quot;:&quot;Poli&quot;},{&quot;first_name&quot;:&quot;Juan&quot;,&quot;last_name&quot;:&quot;Antonio Vega&quot;},{&quot;first_name&quot;:&quot;Ana&quot;,&quot;last_name&quot;:&quot;Isabel de Lucas&quot;},{&quot;first_name&quot;:&quot;Encarnación&quot;,&quot;last_name&quot;:&quot;Matesanz&quot;},{&quot;first_name&quot;:&quot;María&quot;,&quot;last_name&quot;:&quot;Lourdes Linares&quot;},{&quot;first_name&quot;:&quot;José&quot;,&quot;last_name&quot;:&quot;Ignacio Andrés&quot;},{&quot;first_name&quot;:&quot;Jesús&quot;,&quot;last_name&quot;:&quot;Alcazar&quot;},{&quot;first_name&quot;:&quot;José&quot;,&quot;last_name&quot;:&quot;Manuel Alonso&quot;},{&quot;first_name&quot;:&quot;Gregor&quot;,&quot;last_name&quot;:&quot;J. Macdonald&quot;},{&quot;first_name&quot;:&quot;Daniel&quot;,&quot;last_name&quot;:&quot;Oehlrich&quot;},{&quot;first_name&quot;:&quot;Hilde&quot;,&quot;last_name&quot;:&quot;Lavreysen&quot;},{&quot;first_name&quot;:&quot;Abdelah&quot;,&quot;last_name&quot;:&quot;Ahnaou&quot;},{&quot;first_name&quot;:&quot;Wilhelmus&quot;,&quot;last_name&quot;:&quot;Drinkenburg&quot;},{&quot;first_name&quot;:&quot;Claire&quot;,&quot;last_name&quot;:&quot;Mackie&quot;},{&quot;first_name&quot;:&quot;Stefan&quot;,&quot;last_name&quot;:&quot;Pype&quot;},{&quot;first_name&quot;:&quot;David&quot;,&quot;last_name&quot;:&quot;Gallacher&quot;},{&quot;first_name&quot;:&quot;Andrés&quot;,&quot;last_name&quot;:&quot;A. Trabanco&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2014&quot;,&quot;month&quot;:&quot;07&quot;,&quot;day&quot;:&quot;28&quot;,&quot;issue&quot;:&quot;15&quot;,&quot;volume&quot;:&quot;57&quot;,&quot;pages&quot;:&quot;6495-6512&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/jm500496m&quot;},&quot;abstract&quot;:&quot;We previously reported the discovery of 4-aryl-substituted pyridones with mGlu2 PAM activity starting from the HTS hit 5. In this article, we describe a different exploration from 5 that led to the discovery of a novel subseries of phenylpiperidine-substituted pyridones. The optimization strategy involved the introduction of different spacers between the pyridone core and the phenyl ring of 5. The fine tuning of metabolism and hERG followed by differentiation of advanced leads that were identified on the basis of PK profiles and in vivo potency converged on lead compound 36 (JNJ-40411813). Full in vitro and in vivo profiles indicate that 36 displayed an optimal interplay between potency, selectivity, favorable ADMET/PK and cardiovascular safety profile, and central EEG activity. Compound 36 has been investigated in the clinic for schizophrenia and anxious depression disorders.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Fjm500496m&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm500496m" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm500496m&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=jm500496m" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm500496m&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=jm500496m" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Fjm500496m&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm500496m&amp;href=/doi/10.1021/jm500496m" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/jm500496m" /></input><a href="/doi/pdf/10.1021/jm500496m" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (1 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/jm500496m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Fjm500496m%26sid%3Dliteratum%253Aachs%26pmid%3D25032784%26genre%3Darticle%26aulast%3DCid%26date%3D2014%26atitle%3DDiscovery%2Bof%2B1-Butyl-3-chloro-4-%25284-phenyl-1-piperidinyl%2529-%25281H%2529-pyridone%2B%2528JNJ-40411813%2529%253A%2BA%2BNovel%2BPositive%2BAllosteric%2BModulator%2Bof%2Bthe%2BMetabotropic%2BGlutamate%2B2%2BReceptor%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D57%26issue%3D15%26spage%3D6495%26epage%3D6512%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291594" title="Silica">Silica</a>,</li><li><a href="/action/doSearch?ConceptID=291316" title="Mixtures">Mixtures</a>,</li><li><a href="/action/doSearch?ConceptID=291152" title="Gels">Gels</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=292186" title="Receptors">Receptors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/57/15" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-15/jmcmar.2014.57.issue-15/production/jmcmar.2014.57.issue-15.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-15/jm500496m/production/images/medium/jm-2014-00496m_0016.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-15/jm500496m/production/images/large/jm-2014-00496m_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500496m&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">We previously reported the discovery of 4-aryl-substituted pyridones with mGlu2 PAM activity starting from the HTS hit <b>5</b>. In this article, we describe a different exploration from <b>5</b> that led to the discovery of a novel subseries of phenylpiperidine-substituted pyridones. The optimization strategy involved the introduction of different spacers between the pyridone core and the phenyl ring of <b>5</b>. The fine tuning of metabolism and hERG followed by differentiation of advanced leads that were identified on the basis of PK profiles and in vivo potency converged on lead compound <b>36</b> (JNJ-40411813). Full in vitro and in vivo profiles indicate that <b>36</b> displayed an optimal interplay between potency, selectivity, favorable ADMET/PK and cardiovascular safety profile, and central EEG activity. Compound <b>36</b> has been investigated in the clinic for schizophrenia and anxious depression disorders.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_67711" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_67711" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Glutamate is the major excitatory neurotransmitter in the central nervous system (CNS) of vertebrates and elicits and modulates synaptic responses in the CNS by activating ionotropic glutamate (iGlu) receptors and metabotropic glutamate (mGlu) receptors.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> To date, eight mGlu receptor subtypes and multiple splice variants have been cloned and classified into three groups based on sequence homology, pharmacological profile, and preferential signal transduction pathways:<a onclick="showRef(event, 'ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref2 ref3">(2, 3)</a> group I (mGlu1 and mGlu5), group II (mGlu2 and mGlu3), and group III mGlu receptors (mGlu4, mGlu6, mGlu7, and mGlu8). Pharmaceutical companies and academic groups have primarily focused on the pharmacology and development of ligands acting at group I (mGlu1 and 5) and II (mGlu2 and 3) receptors, whereas group III (mGlu4, 6, 7, and 8) receptors have started to attract more attention recently.<a onclick="showRef(event, 'ref4 ref5'); return false;" href="javascript:void(0);" class="ref ref4 ref5">(4, 5)</a> Group II mGlu receptors, which are located presynaptically in the periphery of the synapse, reduce glutamatergic transmission in brain regions such as the prefrontal cortex and hippocampus,<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> where excessive glutamatergic transmission has been implicated in the pathophysiology of anxiety and schizophrenia. Mixed mGlu2/3 orthosteric agonists such as (+)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid <b>1</b> (LY354740) have shown activity in a wide range of preclinical animal models of anxiety and schizophrenia.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> Animal studies with the NMDA receptor antagonist phencyclidine (PCP) and mixed mGlu2/3 receptor agonists provided the first insights that revealed that mGlu2 receptor activation may represent a novel target for the treatment of schizophrenia.<a onclick="showRef(event, 'ref8 ref9'); return false;" href="javascript:void(0);" class="ref ref8 ref9">(8, 9)</a> In its first clinical trial, (1<i>R</i>,4<i>S</i>,5<i>S</i>,6<i>S</i>)-2-thiabicyclo[3.1.0]hexane-4,6-dicarboxylic acid 4-[(2<i>S</i>)-2-amino-4-(methylthio)-1-oxobutyl]amino-2,2-dioxide monohydrate <b>2</b> (LY2140023), a prodrug of (−)-(1<i>R</i>,4<i>S</i>,5<i>S</i>,6<i>S</i>)-4-amino-2-sulfonylbicyclo[3.1.0]-hexane-4,6-dicarboxylic acid <b>3</b> (LY404039), demonstrated improvements in positive and negative symptoms compared to placebo in schizophrenic patients.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> However, these positive data could not be confirmed in follow-up studies,<a onclick="showRef(event, 'ref11 ref12'); return false;" href="javascript:void(0);" class="ref ref11 ref12">(11, 12)</a> and very recently, Eli Lilly and Co. announced the decision to stop the phase III development of <b>2</b> for the treatment of patients suffering from schizophrenia based on efficacy results.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a></div><div class="NLM_p">On the other hand, the anxiolytic potential of <b>1</b> was confirmed in healthy human volunteers, showing activity in fear-potentiated startle and panic induction after CO<sub>2</sub> challenge.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a></div><div class="NLM_p">Despite the interesting findings, there remain hurdles in developing clinically useful agonists. First, all agonists identified so far lack mGlu2 receptor subtype selectivity and also act on the mGlu3 receptor. It has been shown that the mGlu2, and not the mGlu3 receptor, mediates the actions of the mGlu2/3 receptor agonists (1<i>S</i>,2<i>R</i>,5<i>R</i>,6<i>R</i>)-2-amino-4-oxabicyclo[3.1.0]hexane-2,6-dicarboxylic acid (LY379268) and <b>3</b> in mouse models predictive of antipsychotic activity.<a onclick="showRef(event, 'ref15 ref16'); return false;" href="javascript:void(0);" class="ref ref15 ref16">(15, 16)</a> Second, the development of tolerance by group II mGlu receptor agonists has been observed in several rodent behavioral models.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a></div><div class="NLM_p">Receptor activation with positive allosteric modulators (PAMs), which act via alternative allosteric site(s), offers several advantages.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> Allosteric molecules are likely to be less polar and to have improved CNS penetration, as they do not require amino-acid functional groups for activity at the orthosteric site. Furthermore, the less conserved nature of allosteric site(s) can allow for improved mGlu receptor subtype selectivity. Finally, allosteric modulators exert their effects only in the presence of endogenous glutamate, so they may be less prone to cause receptor desensitization,<a onclick="showRef(event, 'ref19 ref20'); return false;" href="javascript:void(0);" class="ref ref19 ref20">(19, 20)</a> and they respond to physiological glutamate fluctuations. Given these potential advantages, the number of reported mGlu2 receptor-selective PAMs has increased in recent years.<a onclick="showRef(event, 'ref21 ref22'); return false;" href="javascript:void(0);" class="ref ref21 ref22">(21, 22)</a> Some of these compounds have been extensively characterized in a number of animal models, providing preclinical proof of concept that PAMs can mimic the effects of orthosteric agonists.<a onclick="showRef(event, 'ref23 ref24 ref25 ref26 ref27 ref28 ref29 ref30 ref31 ref32'); return false;" href="javascript:void(0);" class="ref ref23 ref24 ref25 ref26 ref27 ref28 ref29 ref30 ref31 ref32">(23-32)</a></div><div class="NLM_p">To date, two mGlu2 PAM molecules have advanced into clinical trials: <b>4</b> (AZD8529) from AstraZeneca AB (structure undisclosed) and <b>36</b><a onclick="showRef(event, 'ref33 ref34 ref35'); return false;" href="javascript:void(0);" class="ref ref33 ref34 ref35">(33-35)</a> (also known as ADX71149 in Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>) from Janssen Pharmaceuticals and Addex Therapeutics. On January 2011, the originating company announced the discontinuation of <b>4</b> phase IIa POC study in schizophrenic patients due to lack of efficacy.<a onclick="showRef(event, 'ref36 ref37'); return false;" href="javascript:void(0);" class="ref ref36 ref37">(36, 37)</a> More promisingly, it has been disclosed that, in an exploratory phase IIa study in schizophrenia, <b>36</b> proved to meet the primary objectives of safety and tolerability. Moreover, patients treated with antipsychotics who experience residual negative symptoms were identified as the subgroup of patients who may potentially benefit from add-on treatment with <b>36</b>, although this is yet to be established in a formal proof-of-concept study.<a onclick="showRef(event, 'ref38 ref39'); return false;" href="javascript:void(0);" class="ref ref38 ref39">(38, 39)</a></div><div class="NLM_p">Additionally, a phase II POC study with <b>36</b> as adjunctive therapy in patients with major depressive disorder (MDD) with significant anxiety symptoms has been completed.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> Overall, <b>36</b> was well-tolerated, and treatment emergent adverse events reported were similar to those seen in previous clinical studies. On the basis of a preliminary analysis of the primary efficacy end point, the 6-Item Hamilton Anxiety Subscale (HAM-A6), <b>36</b> did not meet the criterion for efficacy signal detection versus placebo. Despite a lack of signal on the primary outcome measure, treatment with <b>36</b> showed efficacy signals on several anxiety measures (HDRS17 anxiety somatization factor, IDS-C30 anxiety subscale) and on all depression measures (HDRS17, HAM-D6, and IDS-C30).<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> Although efficacy signals were evident, the data overall does not support the further development of <b>36</b> in anxious depression. Further exploration of <b>36</b> in other indications remains of potential interest.</div><div class="NLM_p">We have recently reported on a series of pyridones derived from the optimization of the HTS hit <b>5</b> that led to the identification of compound <b>6</b>.<a onclick="showRef(event, 'ref29 ref42'); return false;" href="javascript:void(0);" class="ref ref29 ref42">(29, 42)</a> Compound <b>6</b> combined moderate in vitro activity, good pharmacokinetic profile, and robust in vivo activity. The optimization strategy involved the introduction of a variety of substituents in the <i>para</i> position of the phenyl ring in hit <b>5</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>; mapping). Herein, we report on a new optimization strategy consisting of the exploration of different spacers (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>; linker) between the pyridone core and the aromatic ring in hit <b>5</b>.<a onclick="showRef(event, 'ref43 ref44'); return false;" href="javascript:void(0);" class="ref ref43 ref44">(43, 44)</a> This strategy resulted in the identification of our clinical lead, <b>36</b>, whose identification path, SAR, and a general overview of its pharmacological profile are reported herein.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-15/jm500496m/production/images/medium/jm-2014-00496m_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-15/jm500496m/production/images/large/jm-2014-00496m_0001.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Strategies followed for the exploration of HTS hit <b>5</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-15/jm500496m/production/images/large/jm-2014-00496m_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500496m&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_62878" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_62878" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The synthesis of the 1,3,4-trisubstituted 2-pyridone derivatives <b>6</b>–<b>36</b><a onclick="showRef(event, 'ref32 ref42'); return false;" href="javascript:void(0);" class="ref ref32 ref42">(32, 42)</a> is outlined in Schemes <a class="ref internalNav" href="#sch1" aria-label="1">1</a>–<a class="ref internalNav" href="#sch5" aria-label="5">5</a>. The key bromopyridone intermediates, <b>41a</b>–<b>g</b>,<b> 46</b>, and <b>47a</b>–<b>c</b>, were prepared as shown in Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>. Treatment of 2-hydroxypyridine derivative <b>37</b> with the required alkyl halides <b>38a</b>–<b>g</b> afforded the <i>N</i>-alkylated 2-pyridones <b>39a</b>–<b>g</b>. Subsequent cleavage of the methyl ether followed by treatment of the resulting hydroxypyridones <b>40a</b>–<b>g</b> with POBr<sub>3</sub> yielded the intermediates <b>41a</b>–<b>g</b>. In a similar way, intermediates <b>43a</b>–<b>c</b> were obtained by alkylation of the 2-hydroxy-4-benzyloxypyridine <b>42</b> with the corresponding alkyl halides <b>38a</b>–<b>c</b>. Iodination of compound <b>43a</b> (R<sup>1</sup> = cyclopropylmethyl) with <i>N</i>-iodosuccinimide (NIS) afforded the 3-iodopyridone <b>44</b>, which was subsequently converted into the corresponding 3-trifluoromethylpyridone <b>45</b> by treatment with the nucleophilic trifluoromethyl-copper complex generated from fluorosulfonyldifluoroacetate. Finally, cleavage of the benzyl ether in intermediates <b>43a</b>–<b>c</b> and <b>45</b> followed by reaction with POBr<sub>3</sub> under thermal conditions yielded the target intermediates <b>47a</b>–<b>c</b> and <b>46</b>, respectively.</div><figure id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-15/jm500496m/production/images/medium/jm-2014-00496m_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-15/jm500496m/production/images/large/jm-2014-00496m_0003.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Preparation of 4-Bromopyridone Building Blocks <b>41a</b>–<b>g</b>, <b>46</b>, and <b>47a</b>–<b>c</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-15/jm500496m/production/images/large/jm-2014-00496m_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500496m&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) K<sub>2</sub>CO<sub>3</sub>, MeCN, 100 °C, 16 h; (b) NaOH, H<sub>2</sub>O, reflux, 18 h; (c) POBr<sub>3</sub>, DMF, 110 °C, 1–3 h; (d) NIS, AcOH, rt, 1 h; (e) FSO<sub>2</sub>CF<sub>2</sub>CO<sub>2</sub>Me, CuI, DMF, 100 °C, 5 h; (f) H<sub>2</sub>, Pd/C, EtOH, rt, 2 h.</p></p></figure><div class="NLM_p">The synthesis of the final compounds <b>8</b>–<b>21</b>, <b>26</b>–<b>29</b>, <b>31</b>, <b>32</b>, and <b>34</b> is illustrated in Scheme <a class="ref internalNav" href="#sch2" aria-label="2">2</a>. Treatment of bromopyridone intermediates <b>41a</b>–<b>g</b> and <b>46</b> with an array of commercially available amines either under palladium-catalyzed cross-coupling reaction or by nucleophilic substitution under microwave heating conditions afforded the target compounds <b>8</b>–<b>21</b>, <b>26</b>–<b>29</b>, <b>31</b>, <b>32</b>, and <b>34</b>, whose chemical structures are shown in Tables <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>–<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>.</div><figure id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-15/jm500496m/production/images/medium/jm-2014-00496m_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-15/jm500496m/production/images/large/jm-2014-00496m_0004.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of the Final Compounds <b>8</b>–<b>21</b>, <b>26</b>–<b>29</b>, <b>31</b>, <b>32</b>, and <b>34</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-15/jm500496m/production/images/large/jm-2014-00496m_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500496m&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) amine, 2-(2′-di-<i>tert</i>-butylphosphine)biphenylpalladium(II) acetate, K<sub>3</sub>PO<sub>4</sub>, 1,4-dioxane, 85 °C, 2–12 h; (b) amine, DIPEA, CH<sub>3</sub>CN, 140–170 °C, 10–35 min, microwave; (c) amine, Pd(OAc)<sub>2</sub>, BINAP, <sup><i>t</i></sup>BuONa, toluene, 100 °C, 16 h.</p></p></figure><div class="NLM_p">The 4-substituted-1-cyclopropylmethyl-3-cyano-2-pyridones <b>22</b>–<b>25</b> and <b>30</b> were prepared following the synthesis sequence shown in Scheme <a class="ref internalNav" href="#sch3" aria-label="3">3</a>. Nucleophilic substitution of the 4-bromopyridone <b>41a</b> with the corresponding amines led to intermediates <b>48a</b>–<b>d</b> and <b>49</b>. Catalytic hydrogenation using Pd/C as the catalyst of compounds <b>48a</b>–<b>b</b> and <b>48d</b> yielded the target compounds <b>22</b>, <b>23</b>, and <b>30</b>. For intermediate <b>48c</b>, the hydrogenation reaction was accomplished by using PtO<sub>2</sub> as catalyst, yielding compound <b>25</b>. Treatment of intermediate <b>49</b> with triethylsilane in TFA led to the final compound <b>24</b>.</div><figure id="sch3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-15/jm500496m/production/images/medium/jm-2014-00496m_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-15/jm500496m/production/images/large/jm-2014-00496m_0005.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of the Final Compounds <b>22</b>–<b>25</b> and <b>30</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-15/jm500496m/production/images/large/jm-2014-00496m_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500496m&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) amine, DIPEA, CH<sub>3</sub>CN, 140–170 °C, 10–35 min, microwave; (b) H<sub>2</sub>, Pd/C, MeOH or AcOEt, rt, 4–16 h; (c) H<sub>2</sub>, PtO<sub>2</sub>, AcOH, MeOH, rt, 72 h; (d) Et<sub>3</sub>SiH, TFA, rt, 24 h.</p></p></figure><div class="NLM_p">The synthesis of the 3-chloropyridone derivatives <b>33</b>, <b>35</b>, and <b>36</b> was achieved in two steps by Buchwald coupling reaction of the corresponding amines with intermediates <b>47a</b>–<b>c</b> followed by chlorination of the resulting pyridones <b>50a</b>–<b>c</b> with NCS in DCM (Scheme <a class="ref internalNav" href="#sch4" aria-label="4">4</a>).</div><figure id="sch4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-15/jm500496m/production/images/medium/jm-2014-00496m_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-15/jm500496m/production/images/large/jm-2014-00496m_0006.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of the Final Compounds <b>33</b>,<b> 35</b>, and <b>36</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-15/jm500496m/production/images/large/jm-2014-00496m_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500496m&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) amine, Pd(OAc)<sub>2</sub>, BINAP, <sup><i>t</i></sup>BuONa, toluene, 100 °C, 16 h; (b) NCS, DCM, rt, 10–20 min.</p></p></figure><div class="NLM_p">Finally, compounds <b>6</b> and <b>7</b> were prepared following the reaction pathway depicted in Scheme <a class="ref internalNav" href="#sch5" aria-label="5">5</a>. Sonogashira coupling reaction of intermediate <b>41d</b> with phenylacetylene gave derivative <b>51</b>, which was converted into the target compound <b>6</b> by catalytic hydrogenation of the triple bond. Alkylation of <b>40d</b> with benzyl bromide under microwave irradiation afforded compound <b>7</b>.</div><figure id="sch5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-15/jm500496m/production/images/medium/jm-2014-00496m_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-15/jm500496m/production/images/large/jm-2014-00496m_0007.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of the Final Compounds <b>6</b> and <b>7</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-15/jm500496m/production/images/large/jm-2014-00496m_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500496m&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) POBr<sub>3</sub>, DMF, 110 °C, 1–3 h; (b) phenylacetylene, PdCl<sub>2</sub>(PPh<sub>3</sub>)<sub>2</sub>, Et<sub>3</sub>N, CuI, PPh<sub>3</sub>, THF, 90 °C, 10 h; (c) H<sub>2</sub>, Pd/C, MeOH, rt, 3 h; (d) BnBr, Cs<sub>2</sub>CO<sub>3</sub>, CH<sub>3</sub>CN/DMF, 130 °C, 20 min, microwave.</p></p></figure></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i8">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_48747" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_48747" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Guided by our previously reported overlay model for mGlu2 receptor PAM chemotypes,<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> we expanded the SAR around the 1,4-pyridone series by focusing on introducing a spacer (X) between the pyridone core and the phenyl ring (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>). Representative compounds illustrating the new SAR generated along with mGlu2 receptor functional activity and metabolic stability data are shown in Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>. Introduction of ethylene and methoxy linkers (<b>6</b> and <b>7</b>) led to a 13- and 3-fold increase in potency (EC<sub>50</sub><a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a>), respectively, when compared to that of <b>5</b>. However, that improvement was not observed in compound <b>8</b> that has methylamino as the linker. Conformational restriction of compound <b>8</b> by means of cyclization of the nitrogen spacer onto the phenyl ring, as in isoquinoline derivative <b>9</b>, resulted in a remarkable 12-fold potency increase (<b>9</b>, EC<sub>50</sub> = 871 nM). Further modification around the isoquinoline group in <b>9</b> while keeping the piperidine fragment led to compounds <b>10</b> and <b>11</b> bearing a phenylpiperidine substituent. To our delight, the 4-phenylpiperidine derivative <b>10</b> exhibited a further boost in potency (EC<sub>50</sub> = 102 nM), whereas the regioisomer <b>11</b>, featuring 3-phenyl substitution on the piperidine, was markedly less active (EC<sub>50</sub> = 3311 nM).</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Functional Activity and Metabolic Stability Data of Representative mGlu2 Receptor PAMs <b>5</b>–<b>15</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-15/jm500496m/production/images/medium/jm-2014-00496m_0008.gif" alt="" id="fx2" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-15/jm500496m/production/images/medium/jm-2014-00496m_0009.gif" alt="" id="fx3" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>Table a</sup><p class="last">Values represent the mean for at least two experiments.</p></div><div class="footnote" id="t1fn2"><sup>Table b</sup><p class="last">CI = confidence interval.</p></div><div class="footnote" id="t1fn3"><sup>Table c</sup><p class="last">HLM and RLM data refer to the percent of compound metabolized after incubation with microsomes for 15 min at a 5 μM concentration.</p></div><div class="footnote" id="t1fn4"><sup>Table d</sup><p class="last">CI and SD not determined.</p></div></div><div></div></div><div class="NLM_p">The distal aromatic group in <b>10</b> seemed to be essential for achieving good activity, as the truncated analogue <b>12</b> showed barely measurable functional PAM activity of the mGlu2 receptor. Both findings suggest the importance of a lipophilic group linearly oriented by a spacer from the pyridone core. Replacement of the piperidine spacer by piperazine (<b>13</b>) led to a ∼6-fold reduction in potency compared to that of the corresponding analogue <b>10</b>. Lastly, introducing a protonatable partially basic nitrogen on the 4-phenylpiperazine template (<b>14</b> and <b>15</b>) was detrimental for the activity (EC<sub>50</sub> values of 3090 and 4677 nM respectively).</div><div class="NLM_p">Alongside the assessment of activity, compounds <b>6</b>–<b>15</b> were assessed for in vitro P450-mediated oxidative stability in human and rat liver microsomes (HLM and RLM, respectively). The results shown in Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a> indicate that most analogues suffered from extensive metabolic degradation in RLM, with somewhat lower metabolic turnover in HLM. Interestingly analogue <b>10</b>, despite having high degradation in RLM (97% metabolized), was relatively stable in HLM (28% metabolized). Metabolic profiling studies on <b>10</b> suggested that the turnover in RLM could be attributed to oxidation of the <i>N</i>-isopentyl chain.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a></div><div class="NLM_p">Given the notable increase in potency observed upon incorporation of the 4-phenylpiperidine substituent, we turned our attention to address the high metabolic turnover of <b>10</b> in RLM. The exploration began by focusing on replacing the isopentyl chain in <b>10</b> by alternative aliphatic groups that would decrease the overall lipophilicity of the molecule (see calculated LogP in Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>, compounds <b>16</b>–<b>21</b>). As seen in Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>, some isopentyl replacements (<b>17</b> and <b>19</b>–<b>21</b>) led to a slight decrease in activity. Some others, such as <i>n</i>-butyl (<b>16</b>), showed comparable potency, and cyclobutylmethyl (<b>18</b>) was the the only replacement that showed superior potency (EC<sub>50</sub> = 55 nM) to that of <b>10</b>. Unfortunately, the metabolic stability in RLM of <b>18</b> did not improve significantly. Compound <b>19</b>, containing a cyclopropylmethyl chain and having the lowest lipophilicity (cLogP = 3.16), presented the best balance of potency and metabolism (EC<sub>50</sub> = 151 nM and HLM and RLM 25 and 44% metabolized, respectively). Detailed characterization of 3-cyano-1-cyclopropylmethyl-4-(4-phenyl-piperidin-1-yl)-pyridine-2(1<i>H</i>)-one <b>19</b> (JNJ-40068782) has been recently published.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a></div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Functional Activity, Metabolic Stability Data, and Calculated LogP of Representative 4-Phenylpiperidine-Substituted mGlu2 Receptor PAMs <b>10</b> and <b>16</b>–<b>21</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-15/jm500496m/production/images/medium/jm-2014-00496m_0010.gif" alt="" id="fx4" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-15/jm500496m/production/images/medium/jm-2014-00496m_0011.gif" alt="" id="fx5" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>Table a</sup><p class="last">Values represent the mean for at least two experiments.</p></div><div class="footnote" id="t2fn2"><sup>Table b</sup><p class="last">CI = confidence interval.</p></div><div class="footnote" id="t2fn3"><sup>Table c</sup><p class="last">HLM and RLM data refer to the percent of compound metabolized after 15 min at 5 μM concentration.</p></div><div class="footnote" id="t2fn4"><sup>Table d</sup><p class="last">cLogP calculated with Biobyte software.</p></div></div><div></div></div><div class="NLM_p">With the more optimal <i>N</i>-cyclopropylmethyl substituent identified, a sequential SAR expansion focusing first on the effect of substitution on the phenyl ring of <b>19</b> and second on alternative groups to the cyano substituent at the 3 position of the pyridone core was conducted. A representative set of analogues to exemplify the SAR trends identified is shown in Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>. Overall, both electron-withdrawing and -donating substituents on the phenyl ring (<b>22</b>–<b>32</b>) were well-tolerated for potency, and the low metabolic turnover seen for <b>19</b> was retained for most examples. The <i>ortho</i> and <i>para</i> fluoro substituent in compounds <b>22</b> and <b>24</b> led to a 2-fold potency increase, whereas the <i>meta</i> fluoro substituent (<b>23</b>) retained the activity observed with the nonsubstituted phenyl derivative <b>19</b>. When the fluorine atom in compounds <b>22</b> and <b>24</b> was replaced with the more lipophilic chlorine (<b>25</b> and <b>26</b>), an additional 2-fold increase in potency was obtained. The trifluoromethyl analogue <b>27</b> showed a consistent potency increase, with an EC<sub>50</sub> of 46 nM.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Functional Activity, Metabolic Stability Data, Calculated LogP, and hERG Inhibition Data of Representative Set of Aryl Modified mGlu2 Receptor PAMs <b>19</b> and <b>22</b>–<b>34</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-15/jm500496m/production/images/medium/jm-2014-00496m_0012.gif" alt="" id="fx6" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-15/jm500496m/production/images/medium/jm-2014-00496m_0013.gif" alt="" id="fx7" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>Table a</sup><p class="last">Values represent the mean for at least two experiments.</p></div><div class="footnote" id="t3fn2"><sup>Table b</sup><p class="last">CI = confidence interval.</p></div><div class="footnote" id="t3fn3"><sup>Table c</sup><p class="last">HLM and RLM data refer to the percent of compound metabolized after 15 min at 5 μM concentration.</p></div><div class="footnote" id="t3fn4"><sup>Table d</sup><p class="last">cLogP calculated with Biobyte software.</p></div><div class="footnote" id="t3fn5"><sup>Table e</sup><p class="last">Experiments were performed using HEK293 cells stably transfected with the hERG potassium channel. Whole-cell currents were recorded with an automated patch-clamp system (PatchXpress 7000A). Three concentrations of compound were tested (0.1, 0.3, and 3 μM; <i>n</i> = 3) and compared to vehicle (0.1% DMSO; <i>n</i> = 3). Data are presented as the percent inhibition at the highest concentration tested (3 μM).</p></div></div><div></div></div><div class="NLM_p">In the case of electron-donating substituents, such as methoxy, <i>ortho</i> substitution was preferred versus <i>para</i> substitution and thus compound <b>28</b> (EC<sub>50</sub> = 35 nM) was found to be ∼3-fold more active than <b>29</b> (EC<sub>50</sub> = 180 nM). Unfortunately, methoxy-substituted compounds were prone to higher metabolic degradation in both HLM and RLM. Some additive effects were observed while mapping the phenyl ring with two fluorine substituents (<b>30</b>–<b>32</b>), with compound <b>31</b>, featuring the bis-<i>ortho</i> substitution, showing the better activity (EC<sub>50</sub> = 31 nM). Finally, SAR from previously reported series<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> prompted us to study the effect of replacing the cyano group by chlorine and trifluoromethyl substituents. Relative to <b>19</b>, compound <b>33</b>, bearing a chlorine substituent, displayed slightly lower potency (EC<sub>50</sub> = 170 nM) and comparable metabolic stability. The trifluoromethyl-substituted analogue <b>34</b> was found to be ∼2-fold less potent than <b>19</b> (EC<sub>50</sub> = 251 nM) and presented a pronounced metabolic turnover in RLM. In contrast to previous SAR trends,<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> the increased lipohilicity of <b>33</b> and <b>34</b> relative to <b>19</b> did not result in more potent compounds.</div><div class="NLM_p">A set of compounds (<b>19</b>–<b>24</b>, <b>26</b>–<b>28</b>, and <b>31</b>–<b>33</b>) was then investigated for their ability to inhibit the hERG channel in an electrophysiology patch-clamp study. The inhibition of the hERG channel is an indicator for potential QTc prolongation and potential for serious cardiac arrhythmias. Unfortunately, most of the compounds inhibited the hERG channel in >55% at the highest concentration tested (3 μM). Thus, in the case of 3-cyanopyridones, the more lipohilic molecules (<b>26</b>,<b> 27</b>, and <b>32</b>) showed higher hERG inhibitory activity. Interestingly, despite its high lipophilicity (cLogP = 4.25), the 3-chloropyridone derivative <b>33</b> exhibited the lowest hERG inhibition value (51%). However, more detailed in vivo cardiovascular safety studies are required to put the hERG inhibition data into a meaningful context. On the basis of the described profile, compounds <b>18</b> and <b>33</b> were progressed to in vivo pharmacokinetics studies to further understand the potential of the series.</div><div class="NLM_p">Thus, <b>19</b> and <b>33</b> were assessed for their ability to cross the blood–brain barrier (BBB) after a subcutaneous dose of 10 mg/kg in mice. As shown in Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a>, compound <b>33</b> displayed a higher brain-to-plasma (B/P) ratio of 0.9 vs 0.3 for <b>19</b>. Given the requirement for adequate BBB penetration, further exploration of 3-cyanopyridones was halted while we instead sought to fine tune the hERG interaction of the 3-chloropyridone lead <b>33</b>. Two compounds with different alkyl chains attached to the pyridone nitrogen were synthesized (<b>35</b> and <b>36</b>), and their data are shown in Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>. Thus, compounds <b>35</b> and <b>36</b>, having an iso-butyl or butyl chain, respectively, showed comparable potency (<b>35</b>: EC<sub>50</sub> = 195 nM and <b>36</b>: EC<sub>50</sub> = 147 nM) and metabolic stability to that of <b>33</b>. More interestingly, both compounds had reduced hERG inhibition (<b>35</b>: 24%; <b>36</b>: 43% at 3 μM).</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Functional Activity, Metabolic Stability Data, Calculated LogP, and hERG Inhibition Data of Representative Set of Aryl-Modified mGlu2 Receptor PAMs <b>33</b>, <b>35</b>, and <b>36</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-15/jm500496m/production/images/medium/jm-2014-00496m_0014.gif" alt="" id="fx8" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-15/jm500496m/production/images/medium/jm-2014-00496m_0015.gif" alt="" id="fx9" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup>Table a</sup><p class="last">Values represent the mean for at least two experiments.</p></div><div class="footnote" id="t4fn2"><sup>Table b</sup><p class="last">CI = confidence interval.</p></div><div class="footnote" id="t4fn3"><sup>Table c</sup><p class="last">HLM and RLM data refer to the percent of compound metabolized after 15 min at 5 μM concentration.</p></div><div class="footnote" id="t4fn4"><sup>Table d</sup><p class="last">cLogP calculated with Biobyte software.</p></div><div class="footnote" id="t4fn5"><sup>Table e</sup><p class="last">Experiments were performed using HEK293 cells stably transfected with the hERG potassium channel. Whole-cell currents were recorded with an automated patch-clamp system (PatchXpress 7000A). Three concentrations of compound were tested (0.1, 0.3, and 3 μM; <i>n</i> = 3) and compared to vehicle (0.1% DMSO; <i>n</i> = 3). Data are presented as the percent inhibition at the highest concentration tested (3 μM).</p></div></div><div></div></div><div class="NLM_p">Because of their overall favorable attributes, compounds <b>35</b> and <b>36</b> along with <b>19</b> and <b>33</b> were investigated further to ascertain their drug-like properties as well as in vivo activity. Overall, the four compounds exhibited relatively comparable rat PK data (Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a>). After intravenous (i.v.) administration, all compounds presented low-to-moderate plasma clearance (Cl), with compounds <b>33</b> and <b>36</b> having higher values. When dosed orally (p.o.), plasma concentrations declined in comparable magnitude for all of the compounds with relatively short half-lives (<i>T</i><sub>1/2</sub> between 2.1 and 3.5 h). The mean maximum plasma concentrations (<i>C</i><sub>max</sub>) were reached at 0.5–0.7 h postdose and were in the range of ∼900 to ∼1400 ng h/mL, indicating a fast absorption rate. Plasma exposure (AUC<sub>0–inf</sub>) was relatively good for all compounds, ranging between ∼2000 and ∼4350 ng h/mL, and this resulted in moderate absolute oral bioavailabilities (F %) between 25 and 51%. As expected, B/P ratios observed of compounds <b>35</b> and <b>36</b> were comparable to that of compound <b>33</b>, previously discussed.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. PK Data for Compounds <b>19</b>, <b>33</b>, <b>35</b>, and <b>36</b> after Oral and i.v. Administration in Male Sprague–Dawley Rats<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a> and in Vivo Activity in the swEEG Model in Rats</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center" char="±">Cl (mL, min<sup>–1</sup> kg<sup>–1</sup>)<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center" char="±"><i>T</i><sub>1/2</sub> (h)<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center" char="±"><i>T</i><sub>max</sub> (h)<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center" char="±">AUC<sub>0–inf</sub> (ng h/mL)<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center" char="±"><i>C</i><sub>max</sub> (ng/mL)<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">F (%)</th><th class="colsep0 rowsep0" align="center">B/P<a class="ref internalNav" href="#t5fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center">swEEG<a class="ref internalNav" href="#t5fn4" aria-label="d">d</a> LAD/LAC</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19</b></td><td class="colsep0 rowsep0" align="char" char="±">18 ± 8.0</td><td class="colsep0 rowsep0" align="char" char="±">2.1 ± 0.1</td><td class="colsep0 rowsep0" align="char" char="±">0.5 ± 0.0</td><td class="colsep0 rowsep0" align="char" char="±">4350 ± 895</td><td class="colsep0 rowsep0" align="char" char="±">1407 ± 391</td><td class="colsep0 rowsep0" align="left">51</td><td class="colsep0 rowsep0" align="left">0.3</td><td class="colsep0 rowsep0" align="left">3/420</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>33</b></td><td class="colsep0 rowsep0" align="char" char="±">24 ± 4.0</td><td class="colsep0 rowsep0" align="char" char="±">3.5 ± 0.3</td><td class="colsep0 rowsep0" align="char" char="±">0.5 ± 0.0</td><td class="colsep0 rowsep0" align="char" char="±">2312 ± 516</td><td class="colsep0 rowsep0" align="char" char="±">986 ± 154</td><td class="colsep0 rowsep0" align="left">34</td><td class="colsep0 rowsep0" align="left">0.9</td><td class="colsep0 rowsep0" align="left">>10/>986</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>35</b></td><td class="colsep0 rowsep0" align="char" char="±">13 ± 4.0</td><td class="colsep0 rowsep0" align="char" char="±">2.6 ± 0.5</td><td class="colsep0 rowsep0" align="char" char="±">0.7 ± 0.3</td><td class="colsep0 rowsep0" align="char" char="±">3455 ± 734</td><td class="colsep0 rowsep0" align="char" char="±">1357 ± 214</td><td class="colsep0 rowsep0" align="left">25</td><td class="colsep0 rowsep0" align="left">0.8</td><td class="colsep0 rowsep0" align="left">3/407</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>36</b></td><td class="colsep0 rowsep0" align="char" char="±">23 ± 1.0</td><td class="colsep0 rowsep0" align="char" char="±">2.3 ± 0.5</td><td class="colsep0 rowsep0" align="char" char="±">0.5 ± 0.0</td><td class="colsep0 rowsep0" align="char" char="±">2250 ± 417</td><td class="colsep0 rowsep0" align="char" char="±">938 ± 300</td><td class="colsep0 rowsep0" align="left">31</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">3/281</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup>a</sup><p class="last">Study in male Sprague–Dawley rats dosed at 10 mg/kg p.o. and 2.5 mg/kg iv, formulated in 20% HP-β-CD + HCl solution at pH 4.</p></div><div class="footnote" id="t5fn2"><sup>b</sup><p class="last">Values are the mean of three animals ± SEM.</p></div><div class="footnote" id="t5fn3"><sup>c</sup><p class="last">Ratios calculated after 1 h of a single dose at 10 mg/kg sc in 1 mg/mL in 20% HP-β-CD + HCl solution at pH 4 in the Swiss mouse.</p></div><div class="footnote" id="t5fn4"><sup>d</sup><p class="last">Compound given orally. LAD stands for lowest active dose expressed in mg/kg. LAC stands for lowest active concentration in plasma, at active doses estimated on the basis of <i>C</i><sub>max</sub> expressed in ng/mL.</p></div></div></div><div class="NLM_p">As in previously reported series, the in vivo pharmacological activity of the compounds was investigated in the sleep–wake EEG (swEEG) paradigm.<a onclick="showRef(event, 'ref29 ref31 ref32'); return false;" href="javascript:void(0);" class="ref ref29 ref31 ref32">(29, 31, 32)</a> It has been previously shown that selective activation or positive allosteric modulation of the mGlu2 receptor in vivo affects the sleep–wake architecture in rats and mice.<a onclick="showRef(event, 'ref48 ref49'); return false;" href="javascript:void(0);" class="ref ref48 ref49">(48, 49)</a> After acute p.o. administration of a 3 mg/kg dose, compounds <b>19</b>, <b>35</b>, and <b>36</b>, but not <b>33</b>, significantly decreased the amount of REM sleep in rats during the first 4 h without clear effects on the other sleep–wake stages (see <b>36</b> in Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>, bottom right panel, as a representative example). The active dose of 3 mg/kg p.o. corresponded to plasma concentrations of ∼420, 407, and 281 ng/mL for compounds <b>19</b>, <b>35</b>, and <b>36</b>, respectively.</div><figure id="fig2" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-15/jm500496m/production/images/medium/jm-2014-00496m_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-15/jm500496m/production/images/large/jm-2014-00496m_0002.jpeg" id="fx10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Effect of <b>36</b> or vehicle (20% CD + 1HCl) on sleep–wake organization in rats during 20 consecutive hours and after a single oral dose. Mean percentage of occurrence per 30 min period is indicated for each sleep–wake state. Shaded area indicates dark period. Small bar charts indicate amounts of vigilance states in minutes (±SEM, <i>n</i> = 8 for each group) during the first 4 h postadministration. Dots on the lines of the graph indicate <i>p</i> < 0.05 versus vehicle (Wilcoxon–Mann–Whitney rank sum); * indicates <i>p</i> < 0.05: Wilcoxon–Mann–Whitney rank sum tests compared to vehicle values.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-15/jm500496m/production/images/large/jm-2014-00496m_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500496m&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Compound <b>36</b> showed the best overall in vitro and in vivo profile among all of the analogues prepared, which prompted us to select it for an extensive characterization. A general profile of <b>36</b> is presented in Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a>. Compound <b>36</b> did not have significant activity against other mGlu receptor subtypes<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> with ≥30-fold selectivity, exhibiting also ≥100-fold selectivity versus a panel of diverse targets<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> with only mild antagonist effect for the 5HT<sub>2A</sub> receptor (<i>K</i><sub>b</sub> = 1.1 μM). Further characterization of the 5HT<sub>2A</sub> interaction will be described in more detail in a separate publication.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Overview of <b>36</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-15/jm500496m/production/images/medium/jm-2014-00496m_0017.gif" alt="" id="GRAPHIC-d55e2165-autogenerated" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col></colgroup><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">physicochemical properties</td><td class="colsep0 rowsep0" align="left">MW = 344</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Experimental p<i>K</i><sub>a</sub> < 2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Experimental logP = 4.6 at pH 6.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">in vitro pharmacology</td><td class="colsep0 rowsep0" align="left">mGlu2 PAM EC<sub>50</sub> = 147 ± 42 nM; <i>E</i><sub>max</sub> = 273 ± 32%</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">mGlu2 PAM binding IC<sub>50</sub> ∼ 68 ± 29 nM</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Selectivity (mGlu 1.3–8; CEREP) ≥ 30-fold vs mGlu2 PAM but 5HT<sub>2A</sub> (∼10-fold)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ADME profile</td><td class="colsep0 rowsep0" align="left">Solubility <0.001 mg/mL in water and 2.2 mg/mL 20% HP-β-CD at pH 4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Plasma Protein Binding (%) = 99.5 (h), 99.6 (r), 99.2 (ms), 99.4 (dog)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Permeability (Caco-2 monolayers): High (AB/BA <i>P</i><sub>app</sub> × 10 cm s<sup>–1</sup> = 12/6)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">CYP450 inh. = 1A2, 2D6, 3A4 (>18 μM), 2C9 (6 μM), 2C19 (7 μM)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">rat PK: 2.5 mg/kg i.v.; 10 mg/kg p.o.</td><td class="colsep0 rowsep0" align="left">Cl = 23 mL/min/kg; <i>V</i><sub>dss</sub> = 2.3 L/kg; <i>T</i><sub>max</sub> = 0.5 h; <i>T</i><sub>1/2</sub> = 2.3 h</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">AUC<sub>0–inf</sub> = 2250 ng h/mL; <i>C</i><sub>max</sub> = 938 ng/mL; F (%) = 31; B/P ratio = 1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">dog PK: 1 mg/kg i.v.; 2.5 mg/kg p.o.</td><td class="colsep0 rowsep0" align="left">Cl = 23 mL/min/kg; <i>V</i><sub>dss</sub> = 1.8 L/kg; <i>T</i><sub>max</sub> = 0.5 h; <i>T</i><sub>1/2</sub> = 3.7 h</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">AUC<sub>0–inf</sub> = 743 ng.h/mL; <i>C</i><sub>max</sub> = 373 ng/mL; F (%) = 20</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">swEEG rat p.o.</td><td class="colsep0 rowsep0" align="left">LAD = 3 mg/kg (free plasma conc. ∼ 0.9 ng/mL)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CV safety</td><td class="colsep0 rowsep0" align="left">hERG PC<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a>; rabbit Purkinje fiber; anesthetized guinea-pig, and anesthetized dog; all margin ≥38<a class="ref internalNav" href="#t6fn2" aria-label="b">b</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">genotoxicity</td><td class="colsep0 rowsep0" align="left">Ames TA98<a class="ref internalNav" href="#t6fn4" aria-label="c">c</a>: clean up to 125 mg/mL</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">In vitro Micronucleus<a class="ref internalNav" href="#t6fn3" aria-label="d">d</a>: clean up to 150 μg/mL</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup>a</sup><p class="last">Experiments were performed using HEK293 cells stably transfected with the hERG potassium channel. Whole-cell currents were recorded with an automated patch-clamp system (PatchXpress7000A). Three concentrations of compound were tested (0.1, 0.3, and 3 μM; <i>n</i> = 3) and compared with vehicle (0.1% DMSO; <i>n</i> = 3). Data are presented as the percent inhibition at the highest concentration tested (3 μM).</p></div><div class="footnote" id="t6fn2"><sup>b</sup><p class="last">Based on efficacy free concentration in sw-EEG model (∼0.9 ng/mL).</p></div><div class="footnote" id="t6fn4"><sup>c</sup><p class="last">In vitro bacterial reverse mutation assay in <i>Salmonella typhimurium</i> TA98.</p></div><div class="footnote" id="t6fn3"><sup>d</sup><p class="last">Study conducted in human lymphoblastoid TK6 cell line in the presence or absence of metabolic activation (rat liver S9).</p></div></div></div><div class="NLM_p">Radioligand binding studies were performed using [<sup>3</sup>H]<b>19</b> as an allosteric mGlu2 receptor radioligand<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> and confirmed that <b>36</b> binds to an allosteric site with high affinity (IC<sub>50</sub> = 68 nM)</div><div class="NLM_p last">Compound <b>36</b> showed low aqueous solubility (<0.001 mg/mL), which was not influenced by the pH; nevertheless, the solubility of <b>36</b> increased in complexation with cyclodextrins and thus with 20% HP-β-CD it reached 2.20 mg/mL at pH 4.16. Caco-2 data showed high permeability with no indication for an efflux mechanism such as P-gp. Elimination half-lives were moderate across different species. Volume of distribution across species was equal to or a little higher than total body water (0.8–1.8 L/kg), indicative of compound distribution outside of the plasma. Oral bioavailability was low to moderate across mouse, rat, dog and monkey (6–31%). The predicted in vitro hepatic clearance for the rat, dog, monkey, and human suggested that phase 1 metabolism via the CYP450 enzymes contributes largely to the in vivo plasma clearance of the compound. The calculated hepatic clearance corresponded to ∼45–55% of the hepatic blood flow across the species. Compound <b>36</b> does not inhibit CYP450 enzymes significantly and is predominantly metabolized by CYP 3A4. Plasma protein binding was consistently high across the species. Compound <b>36</b> showed good safety margins in various cardiovascular studies and no indication of genotoxicity or cytotoxicity.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i15">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_36687" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_36687" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Further optimization of the 1,4-disubstituted cyanopyridone series of mGlu2 receptor PAMs was performed. Strategic exploration of the SAR led to a novel generation of pyridones with a more optimal balance between potency, PK, and CV safety. Our lead optimization efforts have led to the discovery of <b>36</b> as a potent, selective mGlu2 receptor PAM, which is orally bioavailable and safe. In an exploratory phase 2a study in schizophrenia, not powered to determine statistical significance of effects but rather used as a signal generation study, <b>36</b> met the primary objectives of safety and tolerability and also demonstrated an effect in patients with residual negative symptoms. Further evaluation of this signal in a formal proof-of-concept study is warranted in patients with residual negative symptoms. In contrast, in patients with MDD with significant anxiety symptoms, <b>36</b> failed to meet the criterion for efficacy signal. Despite this lack of signal on the primary outcome measure, treatment with <b>36</b> showed mixed and modest efficacy signals on several anxiety measures and on all depression measures.</div><div class="NLM_p last">The data collected from the clinical trials with <b>36</b> undoubtedly provides valuable information and should help to better assess the potential of the mGlu2 receptor as a viable target for the treatment of CNS disorders. To that end, finding the right patient population that may be benefit from treatment with an mGlu2 modulator is still a challenge that must be addressed.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i16">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_71455" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_71455" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> Chemistry</h3><div class="NLM_p">Unless otherwise noted, all reagents and solvents were obtained from commercial suppliers and used without further purification. Synthesis of intermediates <b>39a</b>,<b>c</b>,<b>d</b>,<b>e</b>, <b>40a</b>,<b>c</b>,<b>d</b>,<b>e</b>, and <b>41a</b>,<b>c</b>,<b>d</b>,<b>e</b> and final compound <b>5</b> were previously described.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> Thin-layer chromatography (TLC) was carried out on silica gel 60 F254 plates (Merck). Flash column chromatography was performed on silica gel (particle size 60 Å, mesh = 230–400 (Merck)) using standard techniques. Microwave-assisted reactions were performed in a single-mode reactor, Biotage Initiator Sixty microwave reactor (Biotage), or in a multimode reactor, MicroSYNTH Labstation (Milestone, Inc.). Nuclear magnetic resonance (NMR) spectra were recorded with either a Bruker DPX-400 or a Bruker AV-500 spectrometer (broaduker AG) with standard pulse sequences, operating at 400 and 500 MHz, respectively, using CDCl<sub>3</sub> and DMSO-<i>d</i><sub>6</sub> as solvents. Chemical shifts (δ) are reported in parts per million (ppm) downfield from tetramethylsilane (δ = 0). Coupling constants are reported in Hertz. Splitting patterns are defined by s (singlet), d (doublet), dd (double doublet), t (triplet), q (quartet), quin (quintet), sex (sextet), sep (septet), or m (multiplet). Liquid chromatography combined with mass spectrometry (LC–MS) was performed on a HP 1100 HPLC system (Agilent Technologies) comprising a quaternary or binary pump with degasser, an autosampler, a column oven, a diode-array detector (DAD), and a column. Flow from the column was split to a MS spectrometer. The MS detector was configured either with an electrospray ionization source or an ESCI dual ionization source (electrospray combined with atmospheric pressure chemical ionization). Nitrogen was used as the nebulizer gas. Data acquisition was performed with MassLynx-Openlynx software or with Chemsation-Agilent Data Browser software. Gas chromatography combined with mass spectrometry (GC–MS) was performed using a 6890 series gas chromatograph (Agilent Technologies) system comprising a 7683 series injector and autosampler, a column oven, and a J&W HP-5MS coupled to a 5973N MSD mass selective detector (single quadrupole, Agilent Technologies). The MS detector was configured with an electronic impact ionization source/chemical ionization source (EI/CI). EI low-resolution mass spectra were acquired by scanning from 50 to 550 at a rate of 14.29 scans/s. The source temperature was maintained at 230 °C. Helium was used as the nebulizer gas. Data acquisition was performed with Chemstation-Open Action software. Melting point (mp) values are peak values obtained with experimental uncertainties that are commonly associated with this analytical method and were determined in open capillary tubes on a Mettler FP62 apparatus with a temperature gradient of 10 °C/min. Maximum temperature was 300 °C.</div><div class="NLM_p last">Purities of all new compounds were determined by analytical reverse-phase RP-HPLC using the area percentage method on the UV trace recorded at a wavelength of 254 nm and were found to have ≥95% purity, unless otherwise specified.</div></div><div id="sec5_1_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> 1-Isopentyl-2-oxo-4-phenethyl-1,2-dihydropyridine-3-carbonitrile (<b>6</b>)</h3><div class="NLM_p last">A mixture of 1-isopentyl-2-oxo-4-(2-phenylethynyl)-1,2-dihydropyridine-3-carbonitrile <b>39d</b> (45 mg, 0.2 mmol) and 10% Pd/C (0.01 g, catalyst) in MeOH (5 mL) was hydrogenated for 3 h at room temperature. The catalyst was filtered off under nitrogen atmosphere, and the filtrate solvent was evaporated. The crude was purified by flash column chromatography (silica gel, MeOH in CH<sub>2</sub>Cl<sub>2</sub>, 0:100 to 4:96). Desired fractions were collected, and the solvent was evaporated. The residue was further purified by preparative reverse phase HPLC (C18 XSelect 19 × 100 mm 5 μm, 20–100% CH<sub>3</sub>CN/0.1% NH<sub>4</sub>CO<sub>3</sub>H/NH<sub>4</sub>OH pH 9 solution in water) to yield <b>6</b> (1.6 mg, 4%). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 0.96 (d, <i>J</i> = 6.4 Hz, 6H), 1.58–1.65 (m, 3H), 2.92–3.04 (m, 4H), 3.92–3.97 (m, 2H), 6.04 (d, <i>J</i> = 6.9 Hz, 1H), 7.16–7.24 (m, 3H), 7.27–7.32 (m, 2H), 7.35 (d, <i>J</i> = 6.9 Hz, 1H). LC–MS <i>m</i>/<i>z</i> 295 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> 4-Benzyloxy-1-isopentyl-2-oxo-1,2-dihydropyridine-3-carbonitrile (<b>7</b>)</h3><div class="NLM_p last">Benzyl bromide (88.2 μL, 0.7 mmol) was added to a mixture of <b>40d</b> (102 mg, 0.5 mmol) and CsCO<sub>3</sub> (319 mg, 1 mmol) in CH<sub>3</sub>CN (2 mL) and DMF (1 mL). The reaction mixture was heated in a microwave oven at 130 °C for 20 min. The solid was filtered off through a Celite pad and washed with EtOAc (10 mL). The combined organic filtrates were evaporated in vacuo, and the residue was purified by flash column chromatography (silica gel, silica gel, MeOH in CH<sub>2</sub>Cl<sub>2</sub>, 0:100 to 4:96). Desired fractions were collected, and the solvent was evaporated to yield compound <b>7</b> as a white solid (115 mg, 79%). mp 173.8 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 0.95 (d, <i>J</i> = 5.8 Hz, 6H), 1.54–1.67 (m, 3H), 3.88–3.94 (m, 2H), 5.28 (s, 2H), 6.06 (d, <i>J</i> = 7.7 Hz, 1H), 7.31–7.45 (m, 6H). LC–MS <i>m</i>/<i>z</i> 297 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> 4-[Benzyl(methyl)amino]-1-isopentyl-2-oxo-1,2-dihydropyridine-3-carbonitrile (<b>8</b>)</h3><div class="NLM_p last">A mixture of <b>41d</b> (50 mg, 0.2 mmol), <i>N</i>-methylbenzylamine (28.8 mg, 0.2 mmol), 2-(2′-di-<i>tert</i>-butylphosphine)biphenylpalladium(II) acetate (4.6 mg, 0.01 mmol), K<sub>3</sub>PO<sub>4</sub> (90 mg, 0.4 mmol), and 1,4-dioxane (6 mL) was heated at 85 °C for 6 h. The mixture was cooled to room temperature and filtered through a Celite pad. The solid was washed with more 1,4-dioxane (10 mL). The organic filtrate was evaporated, and the residue was purified by flash column chromatography (silica gel, silica gel, MeOH–NH<sub>3</sub> in CH<sub>2</sub>Cl<sub>2</sub>, 0:100 to 4:96). Desired fractions were collected, and the solvent was evaporated to yield compound <b>8</b> (39 mg, 66%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 0.94 (d, <i>J</i> = 6.2 Hz, 6H), 1.53–1.67 (m, 3H), 3.35 (s, 3H), 3.79–3.86 (m, 2H), 4.73 (s, 2H), 5.77 (d, <i>J</i> = 8.1 Hz, 1H), 7.10 (d, <i>J</i> = 8.1 Hz, 1H), 7.15–7.20 (m, 2H), 7.28–7.34 (m, 1H), 7.34–7.41 (m, 2H). LC–MS <i>m</i>/<i>z</i> 310 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> 4-(3,4-Dihydro-1<i>H</i>-isoquinolin-2-yl)-1-isopentyl-2-oxo-1,2-dihydropyridine-3-carbonitrile (<b>9</b>)</h3><div class="NLM_p last">Starting from <b>41d</b> (120 mg, 0.4 mmol) and 1,2,3,4-tetrahydroisoquinoline following the procedure described for <b>8</b>, compound <b>9</b> was obtained as a white solid (78 mg, 54%). mp > 300. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 0.95 (d, <i>J</i> = 6.4 Hz, 6H), 1.53–1.66 (m, 3H), 3.05 (t, <i>J</i> = 5.9 Hz, 2H), 3.82–3.88 (m, 2H), 3.91 (t, <i>J</i> = 5.9 Hz, 2H), 4.78 (s, 2H), 5.92 (d, <i>J</i> = 8.1 Hz, 1H), 7.12–7.26 (m, 5H). LC–MS <i>m</i>/<i>z</i> 322 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> 1-Isopentyl-2-oxo-4-(4-phenyl-1-piperidyl)-1,2-dihydropyridine-3-carbonitrile (<b>10</b>)</h3><div class="NLM_p last">DIPEA (0.233 mL, 1.34 mmol) was added to a mixture of <b>41d</b> (300 mg, 1.12 mmol) and 4-phenylpiperidine (198 mg, 1.23 mmol) in CH<sub>3</sub>CN (3 mL). The reaction mixture was heated at 150 °C for 10 min in a microwave oven. The solvent was evaporated, and the residue was purified by flash column chromatography (silica gel, silica gel, EtOAc in CH<sub>2</sub>Cl<sub>2</sub>, 0:100 to 20:80). Desired fractions were collected, and the solvent was evaporated to yield compound <b>10</b> (296 mg, 63%) as a colorless oil that solidified upon standing. mp > 300. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 0.96 (d, <i>J</i> = 6.2 Hz, 6H), 1.54–1.68 (m, 3H), 1.84 (qd, <i>J</i> = 12.5, 3.9 Hz, 2H), 1.97–2.05 (m, 2H), 2.82 (tt, <i>J</i> = 12.1, 3.8 Hz, 1H), 3.18–3.27 (m, 2H), 3.82–3.89 (m, 2H), 4.27–4.35 (m, 2H), 5.89 (d, <i>J</i> = 7.9 Hz, 1H), 7.18 (d, <i>J</i> = 7.9 Hz, 1H), 7.20–7.26 (m, 3H), 7.29–7.36 (m, 2H). LC–MS <i>m</i>/<i>z</i> 350 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> Isopentyl-2-oxo-4-(3-phenyl-1-piperidyl)pyridine-3-carbonitrile (<b>11</b>)</h3><div class="NLM_p last">Starting from <b>41d</b> (60 mg, 0.22 mmol) and 3-phenylpiperidine (42.5 mg, 0.26 mmol) and following the procedure described for <b>8</b>, compound <b>11</b> was obtained as a white gummy solid (13 mg, 30%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 0.95 (d, <i>J</i> = 6.4 Hz, 6H), 1.53–1.67 (m, 3H), 1.76–1.88 (m, 2H), 1.90–2.01 (m, 1H), 2.06–2.17 (m, 1H), 2.91 (tt, <i>J</i> = 11.4, 3.7 Hz, 1H), 3.03–3.18 (m, 2H), 3.80–3.87 (m, 2H), 4.12–4.21 (m, 1H), 4.24–4.33 (m, 1H), 5.85 (d, <i>J</i> = 7.9 Hz, 1H), 7.15 (d, <i>J</i> = 7.9 Hz, 1H), 7.22–7.37 (m, 5H). LC–MS <i>m</i>/<i>z</i> 350 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> Isopentyl-2-oxo-4-(1-piperidyl)pyridine-3-carbonitrile (<b>12</b>)</h3><div class="NLM_p last">Starting from <b>41d</b> (110 mg, 0.60 mmol) and piperidine hydrobromide (119.5 mg, 0.72 mmol) and following the procedure described for <b>8</b>, compound <b>12</b> was obtained as a white solid (125 mg, 82%). mp 75.9 °C. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 0.94 (d, <i>J</i> = 6.4 Hz, 6H), 1.53–1.66 (m, 3H), 1.71 (br s, 6H), 3.58–3.67 (m, 4H), 3.81–3.87 (m, 2H), 5.92 (d, <i>J</i> = 7.8 Hz, 1H), 7.25 (d, <i>J</i> = 7.8 Hz, 1H). LC–MS <i>m</i>/<i>z</i> 274 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> Isopentyl-2-oxo-4-(4-phenylpiperazinn-1-yl)pyridine-3-carbonitrile (<b>13</b>)</h3><div class="NLM_p last">Starting from <b>41d</b> (120 mg, 0.40 mmol) and 1-phenylpiperazine (77.87 mg, 0.48 mmol) and following the procedure described for <b>8</b>, compound <b>13</b> was obtained as a white solid (155 mg, 99%). mp > 300 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 0.95 (d, <i>J</i> = 6.0 Hz, 6H), 1.54–1.67 (m, 3H), 3.29–3.37 (m, 4H), 3.79–3.90 (m, 6H), 5.92 (d, <i>J</i> = 7.9 Hz, 1H), 6.87–6.96 (m, 3H), 7.23–7.32 (m, 3H). LC–MS <i>m</i>/<i>z</i> 351 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> Isopentyl-2-oxo-4-[4-(2-pyridyl)piperazin-1-yl]pyridine-3-carbonitrile (<b>14</b>)</h3><div class="NLM_p last">Starting from <b>41d</b> (50 mg, 0.20 mmol) and 1-(2-pyridyl)piperazine (40.8 μL, 0.24 mmol) and following the procedure described for <b>8</b>, compound <b>14</b> was obtained as a white solid (60 mg, 95%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 0.95 (d, <i>J</i> = 6.2 Hz, 6H), 1.54–1.69 (m, 3H), 3.71–3.77 (m, 4H), 3.81–3.89 (m, 6H), 5.91 (d, <i>J</i> = 7.9 Hz, 1H), 6.64 (d, <i>J</i> = 8.5 Hz, 1H), 6.68 (ddd, <i>J</i> = 7.2, 4.9, 0.7 Hz, 1H), 7.25 (d, <i>J</i> = 7.9 Hz, 1H), 7.53 (ddd, <i>J</i> = 8.7, 7.0, 2.1 Hz, 1H), 8.20 (ddd, <i>J</i> = 5.0, 1.9, 0.8 Hz, 1H). LC–MS <i>m</i>/<i>z</i> 352 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> Isopentyl-2-oxo-4-(4-benzylpiperazin-1-yl)pyridine-3-carbonitrile (<b>15</b>)</h3><div class="NLM_p last">Starting from <b>41d</b> (120 mg, 0.40 mmol) and 1-benzylpiperazine (84.60 mg, 0.48 mmol) and following the procedure described for <b>8</b>, compound <b>15</b> was obtained as a white solid (150 mg, 93%). mp 131.6 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 0.94 (d, <i>J</i> = 6.2 Hz, 6H), 1.52–1.66 (m, 3H), 2.53–2.60 (m, 4H), 3.54 (s, 2H), 3.63–3.69 (m, 4H), 3.80–3.86 (m, 2H), 5.85 (d, <i>J</i> = 7.9 Hz, 1H), 7.21 (d, <i>J</i> = 7.9 Hz, 1H), 7.23–7.40 (m, 5H). LC–MS <i>m</i>/<i>z</i> 365 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> Butyl-2-oxo-4-(4-phenyl-1-piperidyl)pyridine-3-carbonitrile (<b>16</b>)</h3><div class="NLM_p last">Starting from <b>41c</b> (1000 mg, 3.92 mmol) and 4-phenylpiperidine (821.6 mg, 5.09 mmol) and following the procedure described for <b>10,</b> compound <b>16</b> was obtained as a cream solid (1.24 g, 94%). mp 138.2 °C. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 0.95 (t, <i>J</i> = 7.4 Hz, 3H), 1.36 (sxt, <i>J</i> = 7.5 Hz, 2H), 1.69 (quin, <i>J</i> = 7.5 Hz, 2H), 1.85 (qd, <i>J</i> = 12.7, 3.3 Hz, 2H), 1.97–2.05 (m, 2H), 2.82 (tt, <i>J</i> = 12.1, 3.5 Hz, 1H), 3.23 (br t, <i>J</i> = 12.7 Hz, 2H), 3.84 (t, <i>J</i> = 7.4 Hz, 2H), 4.28–4.35 (m, 2H), 5.87 (d, <i>J</i> = 8.1 Hz, 1H), 7.16 (d, <i>J</i> = 7.8 Hz, 1H), 7.19–7.25 (m, 3H), 7.29–7.35 (m, 2H). LC–MS <i>m</i>/<i>z</i> 336 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> Isobutyl-2-oxo-4-(4-phenyl-1-piperidyl)pyridine-3-carbonitrile (<b>17</b>)</h3><div class="NLM_p last">Starting from <b>41b</b> (510 mg, 2.0 mmol) and 4-phenylpiperidine (386.9 mg, 2.4 mmol) and following the procedure described for <b>10</b>, compound <b>17</b> was obtained as a white solid (606 mg, 94%). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 0.94 (d, <i>J</i> = 6.6 Hz, 6H), 1.86 (qd, <i>J</i> = 12.7, 3.6 Hz, 2H), 1.98–2.06 (m, 2H), 2.15 (dquin, <i>J</i> = 13.7, 6.8 Hz, 1H), 2.82 (tt, <i>J</i> = 12.0, 3.6 Hz, 1H), 3.19–3.28 (m, 2H), 3.65 (d, <i>J</i> = 7.5 Hz, 2H), 4.29–4.36 (m, 2H), 5.87 (d, <i>J</i> = 8.1 Hz, 1H), 7.13 (d, <i>J</i> = 7.8 Hz, 1H), 7.20–7.26 (m, 3H), 7.29–7.36 (m, 2H). LC–MS <i>m</i>/<i>z</i> 336 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> 1-(Cyclobutylmethyl)-2-oxo-4-(4-phenyl-1-piperidyl)pyridine-3-carbonitrile (<b>18</b>)</h3><div class="NLM_p last">Starting from <b>41e</b> (600 mg, 2.24 mmol) and 4-phenylpiperidine (435 mg, 2.69 mmol) and following the procedure described for <b>10</b>, compound <b>18</b> was obtained as a cream solid (749.4 m g, 96%). mp 158.1 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 1.62–1.98 (m, 10H), 2.63 (quin, <i>J</i> = 7.7 Hz, 1H), 2.86 (tt, <i>J</i> = 12.1, 3.5 Hz, 1H), 3.17–3.27 (m, 2H), 3.81 (d, <i>J</i> = 7.4 Hz, 2H), 4.21–4.29 (m, 2H), 6.16 (d, <i>J</i> = 8.1 Hz, 1H), 7.18–7.23 (m, 1H), 7.24–7.34 (m, 5H). LC–MS <i>m</i>/<i>z</i> 348 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> 1-(Cyclopropylmethyl)-2-oxo-4-(4-phenyl-1-piperidyl)pyridine-3-carbonitrile (<b>19</b>)</h3><div class="NLM_p last">Starting from <b>41a</b> (0.3 g, 1.18 mmol) and following the procedure described for <b>10</b>, compound <b>19</b> was obtained as a solid (285 mg, 73%). mp 128.4. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 0.31–0.42 (m, 2H), 0.55–0.66 (m, 2H), 1.15–1.24 (m, 1H), 1.85 (qd, <i>J</i> = 12.7, 3.8 Hz, 2H), 1.97–2.05 (m, 2H), 2.82 (tt, <i>J</i> = 12.1, 3.8 Hz, 1H), 3.19–3.28 (m, 2H), 3.71 (d, <i>J</i> = 7.2 Hz, 2H), 4.28–4.37 (m, 2H), 5.90 (d, <i>J</i> = 7.8 Hz, 1H), 7.20–7.26 (m, 3H), 7.28–7.36 (m, 3H). LC–MS <i>m</i>/<i>z</i> 334 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> 1-(2-Cyclopropylethyl)-2-oxo-4-(4-phenyl-1-piperidyl)pyridine-3-carbonitrile (<b>20</b>)</h3><div class="NLM_p last">Starting from <b>41f</b> (0.2 g, 0.748 mmol) and following the procedure described for <b>10</b>, compound <b>20</b> was obtained as a solid (200 mg, 77%). mp > 300. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 0.03–0.10 (m, 2H), 0.40–0.52 (m, 2H), 0.59–0.69 (m, 1H), 1.57–1.66 (m, 2H), 1.79–1.90 (m, 2H), 1.97–2.05 (m, 2H), 2.77–2.86 (m, 1H), 3.23 (br t, <i>J</i> = 12.9 Hz, 2H), 3.92 (br t, <i>J</i> = 6.8 Hz, 2H), 4.32 (br d, <i>J</i> = 13.3 Hz, 2H), 5.86 (d, <i>J</i> = 8.1 Hz, 1H), 7.18–7.26 (m, 4H), 7.29–7.36 (m, 2H). LC–MS <i>m</i>/<i>z</i> 348 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> 2-Oxo-4-(4-phenyl-1-piperidyl)-1-(4,4,4-trifluorobutyl)pyridine-3-carbonitrile (<b>21</b>)</h3><div class="NLM_p last">Starting from <b>41g</b> (0.25 g, 0.81 mmol) and following the procedure described for <b>10</b>, compound <b>21</b> was obtained as a solid (300 mg, 95%). mp 113.2 °C. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 1.78 (qd, <i>J</i> = 12.7, 3.8 Hz, 2H), 1.89–2.02 (m, 4H), 2.04–2.16 (m, 2H), 2.77 (tt, <i>J</i> = 12.1, 3.6 Hz, 1H), 3.14–3.23 (m, 2H), 3.85 (br t, <i>J</i> = 7.1 Hz, 2H), 4.27 (br d, <i>J</i> = 13.3 Hz, 2H), 5.85 (d, <i>J</i> = 8.1 Hz, 1H), 7.07 (d, <i>J</i> = 7.8 Hz, 1H), 7.12–7.21 (m, 3H), 7.22–7.29 (m, 2H). LC–MS <i>m</i>/<i>z</i> 390 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> 1-(Cyclopropylmethyl)-4-[4-(2-fluorophenyl)-1-piperidyl]-2-oxo-pyridine-3-carbonitrile (<b>22</b>)</h3><div class="NLM_p last">A solution of <b>48a</b> (0.185 g, 0.52 mmol) in EtOAc (15 mL) was hydrogenated (atmospheric pressure) with Pd/C (37 mg) as a catalyst at room temperature for 4 h. The mixture was filtered through a Celite pad, and the filtrate was evaporated in vacuo. The crude was purified by flash column chromatography (silica gel, MeOH–NH<sub>3</sub> in CH<sub>2</sub>Cl<sub>2</sub>, 0:100 to 2:98) to give <b>22</b> as a pale yellow solid (148.3 mg, 80%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 0.31–0.44 (m, 2H), 0.55–0.68 (m, 2H), 1.16–1.25 (m, 1H), 1.88 (qd, <i>J</i> = 12.4, 3.7 Hz, 2H), 1.97–2.05 (m, 2H), 3.18 (tt, <i>J</i> = 12.0, 3.9 Hz, 1H), 3.26 (td, <i>J</i> = 12.9, 2.4 Hz, 2H), 3.72 (d, <i>J</i> = 7.3 Hz, 2H), 4.29–4.38 (m, 2H), 5.90 (d, <i>J</i> = 8.1 Hz, 1H), 7.01–7.08 (m, 1H), 7.09–7.15 (m, 1H), 7.18–7.26 (m, 2H), 7.30 (d, <i>J</i> = 7.9 Hz, 1H). LC–MS <i>m</i>/<i>z</i> 352 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> 1-(Cyclopropylmethyl)-4-[4-(3-fluorophenyl)-1-piperidyl]-2-oxo-pyridine-3-carbonitrile (<b>23</b>)</h3><div class="NLM_p last">Starting from <b>48b</b> (0.215 g, 0.61 mmol) and following the procedure described for <b>22</b>, compound <b>23</b> was obtained as a pale yellow solid (156 mg, 72%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 0.33–0.46 (m, 2H), 0.56–0.70 (m, 2H), 1.16–1.28 (m, 1H), 1.85 (qd, <i>J</i> = 12.8, 3.8 Hz, 2H), 1.99–2.08 (m, 2H), 2.85 (tt, <i>J</i> = 12.1, 3.7 Hz, 1H), 3.19–3.30 (m, 2H), 3.74 (d, <i>J</i> = 7.0 Hz, 2H), 4.30–4.38 (m, 2H), 5.91 (d, <i>J</i> = 7.9 Hz, 1H), 6.91–6.98 (m, 2H), 7.02 (br d, <i>J</i> = 7.9 Hz, 1H), 7.27–7.35 (m, 1H), 7.32 (d, <i>J</i> = 7.9 Hz, 1H). LC–MS <i>m</i>/<i>z</i> 352 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> 1-(Cyclopropylmethyl)-4-[4-(4-fluorophenyl)-1-piperidyl]-2-oxo-pyridine-3-carbonitrile (<b>24</b>)</h3><div class="NLM_p last">Triethylsilane (1.11 mL, 9.55 mmol) was added to a solution of <b>49</b> (0.351 g, 0.955 mmol) in CF<sub>3</sub>CO<sub>2</sub>H (0.5 mL, 6.49 mmol). The mixture was stirred at room temperature for 18 h and then diluted with CH<sub>2</sub>Cl<sub>2</sub> (15 mL) and washed with 1 N NaOH (2 × 30 mL). The organic layer was separated, dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and concentrated in vacuo. The crude was purified by flash column chromatography (silica gel, MeOH–NH<sub>3</sub> in CH<sub>2</sub>Cl<sub>2</sub>, 0:100 to 2:98) to give <b>24</b> as a white solid (225 mg, 67%). mp 92.3 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 0.26–0.39 (m, 2H), 0.48–0.61 (m, 2H), 1.11–1.21 (m, 1H), 1.75 (qd, <i>J</i> = 12.7, 3.7 Hz, 2H), 1.90–1.98 (m, 2H), 2.78 (tt, <i>J</i> = 12.1, 3.8 Hz, 1H), 3.13–3.23 (m, 2H), 3.67 (d, <i>J</i> = 7.0 Hz, 2H), 4.24–4.32 (m, 2H), 5.94 (d, <i>J</i> = 8.1 Hz, 1H), 6.92–6.99 (m, 2H), 7.10–7.18 (m, 2H), 7.36 (d, <i>J</i> = 7.9 Hz, 1H). LC–MS <i>m</i>/<i>z</i> 352 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_20" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> 4-[4-(2-Chlorophenyl)-1-piperidyl]-1-(cyclopropylmethyl)-2-oxo-pyridine-3-carbonitrile (<b>25</b>)</h3><div class="NLM_p last">A solution of <b>48c</b> (0.68 g, 1.86 mmol) in MeOH (5 mL) and CH<sub>3</sub>CO<sub>2</sub>H (1 mL) was hydrogenated (atmospheric pressure) with PtO<sub>2</sub> (4 mg, 0.018 mmol) as a catalyst at room temperature for 72 h. The mixture was filtered through a Celite pad, and the residue was washed with CH<sub>2</sub>Cl<sub>2</sub>. The filtrate was evaporated in vacuo, and the crude was purified by flash column chromatography (silica gel, silica gel, MeOH in CH<sub>2</sub>Cl<sub>2</sub>, 0:100 to 5:95) to give <b>25</b> as a white solid (289.6 mg, 42%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 0.29–0.39 (m, 2H), 0.41–0.51 (m, 2H), 1.11–1.20 (m, 1H), 1.72 (qd, <i>J</i> = 12.6, 3.6 Hz, 2H), 1.89 (br d, <i>J</i> = 12.4 Hz, 2H), 3.24–3.32 (m, 3H), 3.63 (d, <i>J</i> = 6.9 Hz, 2H), 4.29 (br d, <i>J</i> = 13.6 Hz, 2H), 6.19 (d, <i>J</i> = 8.1 Hz, 1H), 7.25 (td, <i>J</i> = 7.8, 1.7 Hz, 1H), 7.33 (td, <i>J</i> = 7.5, 1.2 Hz, 1H), 7.40 (dd, <i>J</i> = 7.8, 1.7 Hz, 1H), 7.44 (dd, <i>J</i> = 7.9, 1.3 Hz, 1H), 7.71 (d, <i>J</i> = 8.1 Hz, 1H). LC–MS <i>m</i>/<i>z</i> 368 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_21" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> 4-[4-(4-Chlorophenyl)-1-piperidyl]-1-(cyclopropylmethyl)-2-oxo-pyridine-3-carbonitrile (<b>26</b>)</h3><div class="NLM_p last">Starting from <b>41a</b> (0.35 g, 1.38 mmol) and following the procedure described for <b>10</b>, compound <b>26</b> was obtained as a solid (177.42 mg, 35%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 0.15–0.27 (m, 2H), 0.38–0.51 (m, 2H), 0.98–1.10 (m, 1H), 1.65 (qd, <i>J</i> = 12.7, 3.9 Hz, 2H), 1.79–1.87 (m, 2H), 2.64 (tt, <i>J</i> = 12.1, 3.8 Hz, 1H), 3.01–3.11 (m, 2H), 3.56 (d, <i>J</i> = 7.3 Hz, 2H), 4.12–4.19 (m, 2H), 5.73 (d, <i>J</i> = 8.1 Hz, 1H), 6.97–7.03 (m, 2H), 7.11–7.18 (m, 3H). LC–MS <i>m</i>/<i>z</i> 368 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_22" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> 1-(Cyclopropylmethyl)-2-oxo-4-[4-[3-(trifluoromethyl)phenyl]-1-piperidyl]pyridine-3-carbonitrile (<b>27</b>)</h3><div class="NLM_p last">DIPEA (0.72 mL, 4.14 mmol) was added to a mixture of <b>41a</b> (0.35 g, 1.38 mmol) and 4-(3-trifluoromethyl-phenyl)-piperidine (0.41 g, 1.79 mmol) in CH<sub>3</sub>CN (8 mL). The reaction mixture was heated at 170 °C for 35 min in a microwave oven. The mixture was washed with a saturated solution of NH<sub>4</sub>Cl and extracted with CH<sub>2</sub>Cl<sub>2</sub> (2 × 5 mL).The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo. The crude was purified by flash column chromatography (silica gel, silica gel, MeOH–NH<sub>3</sub> in CH<sub>2</sub>Cl<sub>2</sub>, 0:100 to 1:99). Desired fractions were collected, and the solvent was evaporated to yield compound <b>27</b> (0.414 g, 75%) as a white solid. mp 111.9 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 0.31–0.44 (m, 2H), 0.55–0.68 (m, 2H), 1.15–1.27 (m, 1H), 1.87 (qd, <i>J</i> = 12.8, 3.7 Hz, 2H), 2.00–2.09 (m, 2H), 2.90 (tt, <i>J</i> = 12.1, 3.7 Hz, 1H), 3.19–3.30 (m, 2H), 3.73 (d, <i>J</i> = 7.3 Hz, 2H), 4.29–4.39 (m, 2H), 5.91 (d, <i>J</i> = 7.9 Hz, 1H), 7.32 (d, <i>J</i> = 8.1 Hz, 1H), 7.39–7.56 (m, 4H). LC–MS <i>m</i>/<i>z</i> 402 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_23" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> 1-(Cyclopropylmethyl)-4-[4-(2-methoxyphenyl)-1-piperidyl]-2-oxo-pyridine-3-carbonitrile (<b>28</b>)</h3><div class="NLM_p last">Starting from <b>41a</b> (0.35 g, 1.38 mmol) and 4-(2-methoxy-phenyl)-piperidine (0.342 g, 1.79 mmol) following the procedure described for <b>27</b>, compound <b>28</b> was obtained as a white solid (0.319 g, 64%). mp 148.1 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 0.30–0.43 (m, 2H), 0.54–0.68 (m, 2H), 1.15–1.25 (m, 1H), 1.81 (qd, <i>J</i> = 12.6, 3.7 Hz, 2H), 1.95–2.03 (m, 2H), 3.21–3.32 (m, 3H), 3.72 (d, <i>J</i> = 7.3 Hz, 2H), 3.85 (s, 3H), 4.29–4.37 (m, 2H), 5.90 (d, <i>J</i> = 8.1 Hz, 1H), 6.88 (dd, <i>J</i> = 8.2, 1.1 Hz, 1H), 6.94 (td, <i>J</i> = 7.5, 1.0 Hz, 1H), 7.17 (dd, <i>J</i> = 7.6, 1.8 Hz, 1H), 7.19–7.25 (m, 1H), 7.29 (d, <i>J</i> = 7.9 Hz, 1H). LC–MS <i>m</i>/<i>z</i> 364 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_24" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> 1-(Cyclopropylmethyl)-4-[4-(4-methoxyphenyl)-1-piperidyl]-2-oxo-pyridine-3-carbonitrile (<b>29</b>)</h3><div class="NLM_p last">Starting from <b>41a</b> (0.35 g, 1.38 mmol) and 4-(4-methoxy-phenyl)-piperidine (0.376 g, 1.66 mmol) following the procedure described for <b>27</b>, compound <b>29</b> was obtained as a white solid (0.284 g, 48%). mp 247.6 °C. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 0.32–0.43 (m, 2H), 0.56–0.66 (m, 2H), 1.16–1.25 (m, 1H), 1.81 (qd, <i>J</i> = 12.7, 3.6 Hz, 2H), 1.99 (br d, <i>J</i> = 12.1 Hz, 2H), 2.78 (tt, <i>J</i> = 12.1, 3.5 Hz, 1H), 3.22 (br t, <i>J</i> = 12.9 Hz, 2H), 3.72 (d, <i>J</i> = 7.2 Hz, 2H), 3.80 (s, 3H), 4.32 (br d, <i>J</i> = 13.3 Hz, 2H), 5.90 (d, <i>J</i> = 7.8 Hz, 1H), 6.87 (d, <i>J</i> = 8.7 Hz, 2H), 7.15 (d, <i>J</i> = 8.7 Hz, 2H), 7.30 (d, <i>J</i> = 7.8 Hz, 1H). LC–MS <i>m</i>/<i>z</i> 364 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_25" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42"> 1-(Cyclopropylmethyl)-4-[4-(2,4-difluorophenyl)-1-piperidyl]-2-oxo-pyridine-3-carbonitrile (<b>30</b>)</h3><div class="NLM_p last"><b>48c</b> (0.9 g, 2.67 mmol) and 10% Pd/C (0.0028 g, 0.026 mmol) in MeOH (15 mL) were hydrogenated for 16 h. The crude was filtered over Celite and washed with MeOH, and the solution was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The crude was purified by flash column chromatography (silica gel, silica gel, MeOH–NH<sub>3</sub> in CH<sub>2</sub>Cl<sub>2</sub>, 0:100 to 1:99). Desired fractions were collected, and the solvent was evaporated to yield compound <b>30</b> (0.614 g, 62%) as a white solid. mp 111.9 °C. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 0.31–0.37 (m, 2H), 0.43–0.48 (m, 2H), 1.11–1.20 (m, 1H), 1.74 (qd, <i>J</i> = 12.4, 3.2 Hz, 2H), 1.81–1.88 (m, 2H), 3.14 (tt, <i>J</i> = 12.1, 3.8 Hz, 1H), 3.22–3.29 (m, 2H), 3.63 (d, <i>J</i> = 7.2 Hz, 2H), 4.26 (br d, <i>J</i> = 13.6 Hz, 2H), 6.18 (d, <i>J</i> = 7.8 Hz, 1H), 7.04 (td, <i>J</i> = 8.5, 2.3 Hz, 1H), 7.17–7.23 (m, 1H), 7.40 (td, <i>J</i> = 8.5, 6.9 Hz, 1H), 7.71 (d, <i>J</i> = 8.1 Hz, 1H). LC–MS <i>m</i>/<i>z</i> 370 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_26" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43"> 1-(Cyclopropylmethyl)-4-[4-(2,6-difluorophenyl)-1-piperidyl]-2-oxo-pyridine-3-carbonitrile (<b>31</b>)</h3><div class="NLM_p last">Starting from <b>41a</b> (0.35 g, 1.38 mmol) and 4-(2,6-difluoro-phenyl)-piperidine acetate (0.426 g, 1.65 mmol) following the procedure described for <b>27</b>, compound <b>31</b> was obtained as a white solid (0.184 g, 31%). mp 144.2 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 0.30–0.44 (m, 2H), 0.54–0.69 (m, 2H), 1.13–1.27 (m, 1H), 1.87 (br d, <i>J</i> = 12.5 Hz, 2H), 2.16–2.30 (m, 2H), 3.16–3.37 (m, 3H), 3.72 (d, <i>J</i> = 7.2 Hz, 2H), 4.34 (br d, <i>J</i> = 13.6 Hz, 2H), 5.90 (d, <i>J</i> = 7.9 Hz, 1H), 6.81–6.90 (m, 2H), 7.10–7.24 (m, 1H), 7.30 d, <i>J</i> = 7.9 Hz, 1H). LC–MS <i>m</i>/<i>z</i> 370 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_27" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44"> 1-(Cyclopropylmethyl)-4-[4-(3,5-difluorophenyl)-1-piperidyl]-2-oxo-pyridine-3-carbonitrile (<b>32</b>)</h3><div class="NLM_p last">Starting from <b>41a</b> (0.35 g, 1.38 mmol) and 4-(3,5-difluoro-phenyl)-piperidine (0.3 g, 1.52 mmol) following the procedure described for <b>27</b>, compound <b>32</b> was obtained as a white solid (0.28 g, 50%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 0.29–0.39 (m, 2H), 0.41–0.51 (m, 2H), 1.10–1.19 (m, 1H), 1.70 (qd, <i>J</i> = 12.6, 3.6 Hz, 2H), 1.86–1.94 (m, 2H), 2.93 (tt, <i>J</i> = 12.0, 3.5 Hz, 1H), 3.17–3.25 (m, 2H), 3.63 (d, <i>J</i> = 7.2 Hz, 2H), 4.27 (br d, <i>J</i> = 13.3 Hz, 2H), 6.18 (d, <i>J</i> = 8.1 Hz, 1H), 7.04 (d, <i>J</i> = 9.2 Hz, 3H), 7.70 (d, <i>J</i> = 7.8 Hz, 1H). LC–MS <i>m</i>/<i>z</i> 370 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_28" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45"> 3-Chloro-1-(cyclopropylmethyl)-4-(4-phenyl-1-piperidyl)pyridin-2-one (<b>33</b>)</h3><div class="NLM_p last">NCS (0.81 g, 6.09 mmol) was added to a mixture of <b>50a</b> (1.89 g, 6.15 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (300 mL). The reaction mixture was stirred for 10 min at room temperature. The mixture was washed with a saturated solution of NaHCO<sub>3</sub> and extracted with CH<sub>2</sub>Cl<sub>2</sub> (2 × 10 mL). The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo. The crude was purified by flash column chromatography (silica gel, silica gel, MeOH–NH<sub>3</sub> in CH<sub>2</sub>Cl<sub>2</sub>, 0:100 to 3:97). Desired fractions were collected, and the solvent was evaporated to yield compound <b>33</b> (1.88 g, 85%) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 0.31–0.45 (m, 2H), 0.53–0.67 (m, 2H), 1.20–1.31 (m, 1H), 1.85–1.99 (m, 4H), 2.64–2.76 (m, 1H), 2.86–2.99 (m, 2H), 3.77–3.87 (m, 2H), 3.81 (d, <i>J</i> = 7.2 Hz, 2H), 6.05 (d, <i>J</i> = 7.6 Hz, 1H), 7.19–7.29 (m, 4H), 7.29–7.37 (m, 2H). LC–MS <i>m</i>/<i>z</i> 343 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_29" class="NLM_sec NLM_sec_level_2"><div id="ac_i46" class="anchor-spacer"></div><h3 class="article-section__title" id="_i46"> 3-Trifluoromethyl-1-(cyclopropylmethyl)-4-(4-phenyl-1-piperidyl)pyridin-2-one (<b>34</b>)</h3><div class="NLM_p last">To a solution of <b>46</b> (0.3 g, 1.01 mmol) in toluene (7 mL) were added 4-phenylpiperidine (0.33 g, 2.02 mmol), Pd(OAc)<sub>2</sub> (0.012 g, 0.005 mmol), NaO<sup><i>t</i></sup>Bu (0.24 g, 2.52 mmol), and BINAP (0.05 g, 0.08 mmol). The mixture was heated at 100 °C for 16 h in a sealed tube. The cooled mixture was partitioned between water and EtOAc. The crude was extracted with EtOAc (3 × 5 mL), and the combined organic layers were dried (Na<sub>2</sub>SO<sub>4</sub>) and concentrated in vacuo. The crude was purified by flash column chromatography (silica gel, silica gel, MeOH in CH<sub>2</sub>Cl<sub>2</sub>, 0:100 to 4:96). Compound <b>34</b> was obtained as white solid (0.11 g, 31%). mp 177.2 °C. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 0.33–0.38 (m, 2H), 0.45–0.50 (m, 2H), 1.13–1.22 (m, 1H), 1.64–1.75 (m, 2H), 1.64–1.75 (m, 2H), 1.84 (br d, <i>J</i> = 11.0 Hz, 2H), 2.73–2.80 (m, 1H), 3.14 (br t, <i>J</i> = 12.1 Hz, 2H), 3.59 (br d, <i>J</i> = 13.0 Hz, 2H), 3.65 (d, <i>J</i> = 7.2 Hz, 2H), 6.21 (d, <i>J</i> = 7.8 Hz, 1H), 7.19–7.23 (m, 1H), 7.24–7.29 (m, 2H), 7.73 (d, <i>J</i> = 7.8 Hz, 1H). LC–MS <i>m</i>/<i>z</i> 377 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_30" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47"> 3-Chloro-1-isobutyl-4-(4-phenyl-1-piperidyl)pyridin-2-one (<b>35</b>)</h3><div class="NLM_p last">Starting from <b>50b</b> (0.35 g, 1.38 mmol) and <i>N</i>-chlorosuccinimide (0.62 g, 4.65 mmol) following the procedure described for <b>33</b>, compound <b>35</b> was obtained as a white solid (1.42 g, 83%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 0.94 (d, <i>J</i> = 6.7 Hz, 6H), 1.86–1.99 (m, 4H), 2.21 (dquin, <i>J</i> = 13.7, 6.9 Hz, 1H), 2.65–2.76 (m, 1H), 2.88–2.97 (m, 2H), 3.74 (d, <i>J</i> = 7.4 Hz, 2H), 3.80–3.87 (m, 2H), 6.02 (d, <i>J</i> = 7.6 Hz, 1H), 7.07 (d, <i>J</i> = 7.6 Hz, 1H), 7.20–7.29 (m, 3H), 7.31–7.38 (m, 2H). LC–MS <i>m</i>/<i>z</i> 345 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_31" class="NLM_sec NLM_sec_level_2"><div id="ac_i48" class="anchor-spacer"></div><h3 class="article-section__title" id="_i48"> 3-Chloro-1-butyl-4-(4-phenyl-1-piperidyl)pyridin-2-one (<b>36</b>)</h3><div class="NLM_p last">Starting from <b>50c</b> (0.43 g, 1.40 mmol) and <i>N</i>-chlorosuccinimide (0.19 g, 1.4 mmol) following the procedure described for <b>33</b>, compound <b>36</b> was obtained as a white solid (0.39 g, 82%). mp 149.4 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 0.95 (t, <i>J</i> = 7.3 Hz, 3H), 1.31–1.42 (m, 2H), 1.68–1.78 (m, 2H), 1.85–1.98 (m, 4H), 2.64–2.73 (m, 1H), 2.87–2.98 (m, 2H), 3.82 (brd, <i>J</i> = 12.1 Hz, 2H), 3.93 (t, <i>J</i> = 7.3, 2H), 6.03 (d, <i>J</i> = 7.6 Hz, 1H), 7.10 (d, <i>J</i> = 7.6 Hz, 1H), 7.19–7.28 (m, 3H), 7.29–7.37 (m, 2H). LC–MS <i>m</i>/<i>z</i> 345 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_32" class="NLM_sec NLM_sec_level_2"><div id="ac_i49" class="anchor-spacer"></div><h3 class="article-section__title" id="_i49"> 1-Isobutyl-4-methoxy-2-oxo-1,2-dihydropyridine-3-carbonitrile (<b>39b</b>)</h3><div class="NLM_p last">Starting from isobutyl bromide <b>38b</b> (11.5 mL g, 103 mmol) and <b>37</b> (8 g, 53.3 mmol) and following the procedure described for synthesis of <b>39a</b>,<b>c</b>,<b>d</b>,<b>e</b>,<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> compound <b>39b</b> was obtained as a white solid (11.0 g, quantitative). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 0.93 (d, <i>J</i> = 6.7 Hz, 6H), 2.10–2.22 (m, 1H), 3.74 (d, <i>J</i> = 7.4 Hz, 2H), 4.00 (s, 3H), 6.05 (d, <i>J</i> = 7.9 Hz, 1H), 7.44 (d, <i>J</i> = 7.6 Hz, 1H). LC–MS <i>m</i>/<i>z</i> 207 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_33" class="NLM_sec NLM_sec_level_2"><div id="ac_i50" class="anchor-spacer"></div><h3 class="article-section__title" id="_i50"> 1-(2-Cyclopropylethyl)-4-methoxy-2-oxo-1,2-dihydropyridine-3-carbonitrile (<b>39f</b>)</h3><div class="NLM_p last">Starting from 2-cyclopropylethyl bromide <b>38g</b> (2.59 g, 17.3 mmol) and <b>37</b> (7.1 g, 19.0 mmol) and following the procedure as described for synthesis of <b>39a</b>,<b>c</b>,<b>d</b>,<b>e</b>,<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> compound <b>39f</b> was obtained as a white solid (2.63 g, 70%). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 0.00–0.06 (m, 2H), 0.42–0.53 (m, 2H), 0.57–0.66 (m, 1H), 1.64 (quin, <i>J</i> = 6.72 Hz, 2H), 3.99 (s, 3H), 4.01 (t, <i>J</i> = 6.90 Hz, 2H), 6.07 (d, <i>J</i> = 7.80 Hz, 1H), 7.56 (d, <i>J</i> = 7.80 Hz, 1H). LC–MS <i>m</i>/<i>z</i> 219 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_34" class="NLM_sec NLM_sec_level_2"><div id="ac_i51" class="anchor-spacer"></div><h3 class="article-section__title" id="_i51"> 1-(4,4,4-Trifluorobutyl)-4-methoxy--2-oxo-1,2-dihydropyridine-3-carbonitrile (<b>39g</b>)</h3><div class="NLM_p last">Starting from <b>38g</b> (0.107 mL, 0.867 mmol) and following the procedure as described for synthesis of <b>39a</b>,<b>c</b>,<b>d</b>,<b>e</b>,<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> compound <b>39g</b> was obtained as a white solid (0.142 g, 82%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 1.98–2.08 (m, 2H), 2.10–2.24 (m, 2H), 3.99–4.04 (m, 2H), 4.02 (s, 3H), 6.13 (d, <i>J</i> = 7.9 Hz, 1H), 7.52 (d, <i>J</i> = 7.6 Hz, 1H). LC–MS <i>m</i>/<i>z</i> 261 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_35" class="NLM_sec NLM_sec_level_2"><div id="ac_i52" class="anchor-spacer"></div><h3 class="article-section__title" id="_i52"> 1-Isobuthyl-4-hydroxy-2-oxo-1,2-dihydropyridine-3-carbonitrile (<b>40b</b>)</h3><div class="NLM_p last">Starting from <b>39b</b> (10.93 g, 53 mmol) and following the procedure as described for synthesis of <b>40a</b>,<b>c</b>,<b>d</b>,<b>e</b>,<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> compound <b>40b</b> was obtained as a white solid (4.83 g, 47%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 0.83 (d, <i>J</i> = 6.9 Hz, 6H), 1.99 (s, 1H), 3.65 (d, <i>J</i> = 7.4 Hz, 2H), 6.04 (d, <i>J</i> = 7.6 Hz, 1H), 7.79 (d, <i>J</i> = 7.6 Hz, 1H), 12.69 (br s, 1H). LC–MS <i>m</i>/<i>z</i> 193 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_36" class="NLM_sec NLM_sec_level_2"><div id="ac_i53" class="anchor-spacer"></div><h3 class="article-section__title" id="_i53"> 1-(2-Cyclopropylethyl)-4-hydroxy-2-oxo-1,2-dihydropyridine-3-carbonitrile (<b>40f</b>)</h3><div class="NLM_p last">Starting from <b>39f</b> (2.63 g, 12 mmol) and following the procedure described as described for synthesis of <b>39a</b>,<b>c</b>,<b>d</b>,<b>e</b>,<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> compound <b>40f</b> was obtained as a white solid (1.15 g, 47%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ −0.09–0.02 (m, 2H) 0.31–0.42 (m, 2H) 0.56–0.65 (m, 1H) 1.48 (q, <i>J</i> = 7.13 Hz, 2H) 3.89 (t, <i>J</i> = 6.94 Hz, 2H) 6.03 (d, <i>J</i> = 7.80 Hz, 1H) 7.84 (d, <i>J</i> = 7.51 Hz, 1H) 12.61 (br s, 1H). LC–MS <i>m</i>/<i>z</i> 205 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_37" class="NLM_sec NLM_sec_level_2"><div id="ac_i54" class="anchor-spacer"></div><h3 class="article-section__title" id="_i54"> 1-(4,4,4-Trifluorobutyl)-4-hydroxy-2-oxo-1,2-dihydropyridine-3-carbonitrile (<b>40g</b>)</h3><div class="NLM_p last">Starting from <b>39g</b> (6.8 g, 26.1 mmol) and following the procedure as described for synthesis of <b>39a</b>,<b>c</b>,<b>d</b>,<b>e</b>,<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> compound <b>40g</b> was obtained as a white solid (5.9 g, 92%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 1.77–1.87 (m, 2H), 2.19–2.36 (m, 2H), 3.89 (t, <i>J</i> = 7.3 Hz, 2H), 6.06 (d, <i>J</i> = 7.6 Hz, 1H), 7.84 (d, <i>J</i> = 7.6 Hz, 1H), 12.69 (br s, 1H). LC–MS <i>m</i>/<i>z</i> 247 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_38" class="NLM_sec NLM_sec_level_2"><div id="ac_i55" class="anchor-spacer"></div><h3 class="article-section__title" id="_i55"> 4-Bromo-1-isobutyl-2-oxo-1,2-dihydropyridine-3-carbonitrile (<b>41b</b>)</h3><div class="NLM_p last">Starting from <b>40b</b> (4.83 g, 25.1 mmol) and following the procedure as described for synthesis of <b>41a</b>,<b>c</b>,<b>d</b>,<b>e</b>,<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> compound <b>41b</b> was obtained as a white solid (4.21 g, 66%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 0.95 (d, <i>J</i> = 6.7 Hz, 6H), 2.11–2.23 (m, 1H), 3.76 (d, <i>J</i> = 7.4 Hz, 2H), 6.49 (d, <i>J</i> = 7.2 Hz, 1H), 7.33 (d, <i>J</i> = 7.2 Hz, 1H). LC–MS <i>m</i>/<i>z</i> 256 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_39" class="NLM_sec NLM_sec_level_2"><div id="ac_i56" class="anchor-spacer"></div><h3 class="article-section__title" id="_i56"> 4-Bromo-1-(2-cyclopropylethyl)-2-oxo-1,2-dihydropyridine-3-carbonitrile (<b>41f</b>)</h3><div class="NLM_p last">Starting from <b>40f</b> (1.15 g, 5.63 mmol) and following the procedure as described for synthesis of <b>41a</b>,<b>c</b>,<b>d</b>,<b>e</b>,<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> compound <b>41f</b> was obtained as a white solid (1.04 g, 69%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 0.00–0.12 (m, 2H), 0.42–0.55 (m, 2H), 0.57–0.69 (m, 1H), 1.67 (q, <i>J</i> = 7.1 Hz, 2H), 4.04 (t, <i>J</i> = 6.9 Hz, 2H), 6.50 (d, <i>J</i> = 7.2 Hz, 1H), 7.43 (d, <i>J</i> = 7.2 Hz, 1H). LC–MS <i>m</i>/<i>z</i> 268 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_40" class="NLM_sec NLM_sec_level_2"><div id="ac_i57" class="anchor-spacer"></div><h3 class="article-section__title" id="_i57"> 4-Bromo-1-(4,4,4-trifluorobutyl)-2-oxo-1,2-dihydropyridine-3-carbonitrile (<b>41g</b>)</h3><div class="NLM_p last">Starting from <b>40g</b> (5.1 g, 20.7 mmol) and following the procedure as described for synthesis of <b>41a</b>,<b>c</b>,<b>d</b>,<b>e</b>,<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> compound <b>41g</b> was obtained as a white solid (5.2 g, 82%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 2.00–2.11 (m, 2H), 2.12–2.27 (m, 2H), 4.05 (t, <i>J</i> = 7.3 Hz, 2H), 6.58 (d, <i>J</i> = 7.4 Hz, 1H), 7.47 (d, <i>J</i> = 7.2 Hz, 1H). LC–MS <i>m</i>/<i>z</i> 310 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_41" class="NLM_sec NLM_sec_level_2"><div id="ac_i58" class="anchor-spacer"></div><h3 class="article-section__title" id="_i58"> 4-Benzyloxy-1-cyclopropylmethyl-1<i>H</i>-pyridin-2-one (<b>43a</b>)</h3><div class="NLM_p last">Cyclopropylmethyl bromide <b>38a</b> (2.64 mL, 27.33 mmol) and K<sub>2</sub>CO<sub>3</sub> (10.3 g, 74.52 mmol) was added to a solution of <b>42</b> (5 g, 24.84 mmol) in CH<sub>3</sub>CN (200 mL). The mixture was stirred at reflux for 16 h. The cooled mixture was filtered through a Celite pad and concentrated in vacuo. The residue thus obtained was precipitated by treatment with diethyl ether. The resulting solid was filtered off and dried in the vacuum oven (50 °C) to yield <b>43a</b> (6.32 g, 98%). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 0.31–0.41 (m, 2H), 0.53–0.64 (m, 2H), 1.21 (m, <i>J</i> = 7.80 Hz, 1H), 3.74 (d, <i>J</i> = 6.94 Hz, 2H), 4.98 (s, 2H), 5.97 (dd, <i>J</i> = 7.51, 2.60 Hz, 1H), 5.99 (d, <i>J</i> = 2.89 Hz, 1H), 7.25 (d, <i>J</i> = 7.51 Hz, 1H), 7.31–7.42 (m, 5H). LC–MS <i>m</i>/<i>z</i> 258 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_42" class="NLM_sec NLM_sec_level_2"><div id="ac_i59" class="anchor-spacer"></div><h3 class="article-section__title" id="_i59"> 4-Benzyloxy-1-isobutyl-1H-pyridin-2-one (<b>43b</b>)</h3><div class="NLM_p last">Starting from <sup><i>i</i></sup>butyl bromide <b>38b</b> (5.89 mL, 54.66 mmol) and <b>42</b> (10 g, 49.69 mmol) and following the procedure described for <b>43a</b>, compound <b>43b</b> was obtained as a white solid (11.25 g, 88%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 0.93 (d, <i>J</i> = 6.7 Hz, 6H), 2.09–2.21 (m, 1H), 3.67 (d, <i>J</i> = 7.4 Hz, 2H), 4.98 (s, 2H), 5.94 (dd, <i>J</i> = 7.4, 2.8 Hz, 1H), 5.99 (d, <i>J</i> = 2.8 Hz, 1H), 7.08 (d, <i>J</i> = 7.4 Hz, 1H), 7.32–7.43 (m, 5H). LC–MS <i>m</i>/<i>z</i> 258 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_43" class="NLM_sec NLM_sec_level_2"><div id="ac_i60" class="anchor-spacer"></div><h3 class="article-section__title" id="_i60"> 4-Benzyloxy-1-butyl-1<i>H</i>-pyridin-2-one (<b>43c</b>)</h3><div class="NLM_p last">Starting from <sup><i>n</i></sup>butyl bromide <b>38c</b> (8.80 mL, 81.99 mmol) and <b>42</b> (15 g, 74.54 mmol) and following the procedure described for <b>43a</b>, compound <b>43c</b> was obtained as a white solid (13.5 g, 70%). <sup>1</sup>H NMR (360 MHz, CDCl<sub>3</sub>) δ 0.93 (t, <i>J</i> = 7.32 Hz, 3H), 1.28–1.40 (m, 2H), 1.62–1.73 (m, 2H), 3.84 (t, <i>J</i> = 7.32 Hz, 2H), 4.95 (s, 2H), 5.93 (dd, <i>J</i> = 7.32, 2.90 Hz, 1H), 5.97 (d, <i>J</i> = 2.93 Hz, 1H), 7.11 (d, <i>J</i> = 7.32 Hz, 1H), 7.27–7.42 (m, 5H). LC–MS <i>m</i>/<i>z</i> 258 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_44" class="NLM_sec NLM_sec_level_2"><div id="ac_i61" class="anchor-spacer"></div><h3 class="article-section__title" id="_i61"> 4-Benzyloxy-1-cyclopropylmethyl-3-iodo-1<i>H</i>-pyridin-2-one (<b>44</b>)</h3><div class="NLM_p last">NIS (2.64 g, 11.74 mmol) was added to a solution of <b>43a</b> (3 g, 11.74 mmol) in acetic acid (40 mL). The mixture was stirred at room temperature for 1 h. The mixture was concentrated in vacuo. The crude was purified by flash column chromatography (silica gel, silica gel, MeOH in CH<sub>2</sub>Cl<sub>2</sub>, 0:100 to 3:97) to give the desired product <b>44</b> (4.12 g, 92%). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 0.32–0.42 (m, 2H), 0.54–0.65 (m, 2H), 1.19–1.29 (m, 1H), 3.82 (d, <i>J</i> = 7.2 Hz, 2H), 5.24 (s, 2H), 6.00 (d, <i>J</i> = 7.5 Hz, 1H), 7.31–7.37 (m, 2H), 7.38–7.47 (m, 4H). LC–MS <i>m</i>/<i>z</i> 382 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_45" class="NLM_sec NLM_sec_level_2"><div id="ac_i62" class="anchor-spacer"></div><h3 class="article-section__title" id="_i62"> 4-Benzylox-1-cyclopropylmethyl-3-trifluoromethyl-1<i>H</i>-pyridin-2-one (<b>45</b>)</h3><div class="NLM_p last">Methyl 2,2-difluoro-2-(fluorosulfonyl)acetate (0.67 mL, 5.24 mmol) and intermediate <b>44</b> were added to a solution of CuI (0.99 g, 5.24 mmol) in DMF (30 mL). The mixture was heated at 100 °C for 5 h. The cooled mixture was filtered through a Celite pad and concentrated in vacuo. The crude was purified by flash column chromatography (silica gel, DCM) to give the desired product <b>45</b> (0.76 g, 89%). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 0.30–0.41 (m, 2H), 0.56–0.67 (m, 2H), 1.16–1.27 (m, 1H), 3.75 (d, <i>J</i> = 7.2 Hz, 2H), 5.22 (s, 2H), 6.08 (d, <i>J</i> = 7.8 Hz, 1H), 7.31–7.43 (m, 5H), 7.52 (d, <i>J</i> = 7.8 Hz, 1H). LC–MS <i>m</i>/<i>z</i> 324 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_46" class="NLM_sec NLM_sec_level_2"><div id="ac_i63" class="anchor-spacer"></div><h3 class="article-section__title" id="_i63"> 4-Bromo-1-(cyclopropylmethyl)-3-(trifluoromethyl)pyridin-2-one (<b>46</b>)</h3><div class="NLM_p last">A solution of <b>45</b> (2 g, 6.18 mmol) in ethanol (60 mL) was hydrogenated (atmospheric pressure) with Pd/C (400 mg) as a catalyst at room temperature for 2 h. The mixture was filtered through Celite pad, and the filtrate was evaporated in vacuo. The residue was dissolved in DMF (28 mL), and phosphorus oxybromide (3.54 g, 12.36 mmol) was added. The mixture was heated at 100 °C for 1 h. The cooled mixture was partitioned between water and EtOAc. After three extractions with EtOAc, the combined organic layers were dried (Na<sub>2</sub>SO<sub>4</sub>) and concentrated in vacuo. The crude was purified by flash column chromatography (silica gel, DCM) to yield <b>46</b> (0.769 g, 42%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 0.33–0.49 (m, 2H), 0.57–0.73 (m, 2H), 1.18–1.31 (m, 1H), 3.79 (d, <i>J</i> = 7.40 Hz, 2H), 6.51 (d, <i>J</i> = 7.17 Hz, 1H), 7.47 (d, <i>J</i> = 7.17 Hz, 1H). LC–MS <i>m</i>/<i>z</i> 296 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_47" class="NLM_sec NLM_sec_level_2"><div id="ac_i64" class="anchor-spacer"></div><h3 class="article-section__title" id="_i64"> 4-Bromo-1-(cyclopropylmethyl)pyridin-2-one (<b>47a</b>)</h3><div class="NLM_p last">Starting from <b>43a</b> (2.196 g, 8.6 mmol) and following the procedure described for <b>46</b>, compound <b>47a</b> was obtained (1.82 g, 93%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 0.31–0.44 (m, 2H), 0.55–0.69 (m, 2H), 1.16–1.28 (m, 1H), 3.76 (d, <i>J</i> = 7.2 Hz, 2H), 6.34 (dd, <i>J</i> = 7.2, 2.3 Hz, 1H), 6.82 (d, <i>J</i> = 2.1 Hz, 1H), 7.26 (d, <i>J</i> = 7.2 Hz, 1H). LC–MS <i>m</i>/<i>z</i> 228 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_48" class="NLM_sec NLM_sec_level_2"><div id="ac_i65" class="anchor-spacer"></div><h3 class="article-section__title" id="_i65"> 4-Bromo-1-isobutyl-pyridin-2-one (<b>47b</b>)</h3><div class="NLM_p last">Starting from <b>43b</b> (6.78 g, 26.35 mmol) and following the procedure described for <b>46</b>, compound <b>47b</b> was obtained (3.5 g, 58%). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 0.93 (d, <i>J</i> = 6.6 Hz, 6H), 2.10–2.20 (m, 1H), 3.70 (d, <i>J</i> = 7.5 Hz, 2H), 6.33 (dd, <i>J</i> = 7.2, 2.3 Hz, 1H), 6.85 (d, <i>J</i> = 2.0 Hz, 1H), 7.08 (d, <i>J</i> = 7.2 Hz, 1H). LC–MS <i>m</i>/<i>z</i> 230 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_49" class="NLM_sec NLM_sec_level_2"><div id="ac_i66" class="anchor-spacer"></div><h3 class="article-section__title" id="_i66"> 4-Bromo-1-butyl-pyridin-2-one (<b>47c</b>)</h3><div class="NLM_p last">Starting from <b>43c</b> (2.19 g, 8.5 mmol) and following the procedure described for <b>46</b>, compound <b>47c</b> was obtained (1.82 g, 93%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 0.95 (t, <i>J</i> = 7.3 Hz, 3H), 1.36 (dq, <i>J</i> = 15.1, 7.4 Hz, 2H), 1.66–1.75 (m, 2H), 3.89 (t, <i>J</i> = 7.4 Hz, 2H), 6.34 (dd, <i>J</i> = 7.2, 2.1 Hz, 1H), 6.84 (d, <i>J</i> = 2.3 Hz, 1H), 7.14 (d, <i>J</i> = 7.2 Hz, 1H). LC–MS <i>m</i>/<i>z</i> 230 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_50" class="NLM_sec NLM_sec_level_2"><div id="ac_i67" class="anchor-spacer"></div><h3 class="article-section__title" id="_i67"> 1-(Cyclopropylmethyl)-4-[4-(2-fluorophenyl)-3,6-dihydro-2<i>H</i>-pyridin-1-yl]-2-oxo-pyridine-3-carbonitrile (<b>48a</b>)</h3><div class="NLM_p last">Starting from <b>41a</b> (0.23 g, 0.91 mmol) and 4-(2-fluorophenyl)-1,2,3,6-tetrahydropyridine (0.2 g, 1.13 mmol) and following the procedure described for <b>10</b>, compound <b>48a</b> was obtained as a white solid (263 mg, 83%). <sup>1</sup>H NMR (400 MHz,CDCl<sub>3</sub>) δ 0.30–0.43 (m, 2H), 0.53–0.66 (m, 2H), 1.14–1.26 (m, 1H), 2.71–2.78 (m, 2H), 3.72 (d, <i>J</i> = 7.2 Hz, 2H), 3.91 (t, <i>J</i> = 5.5 Hz, 2H), 4.32 (br q, <i>J</i> = 2.6 Hz, 2H), 5.95 (d, <i>J</i> = 8.1 Hz, 1H), 5.98–6.02 (m, 1H), 7.02–7.08 (m, 1H), 7.10–7.15 (m, 1H), 7.22–7.28 (m, 2H), 7.35 (d, <i>J</i> = 7.9 Hz, 1H). LC–MS <i>m</i>/<i>z</i> 350 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_51" class="NLM_sec NLM_sec_level_2"><div id="ac_i68" class="anchor-spacer"></div><h3 class="article-section__title" id="_i68"> 1-(Cyclopropylmethyl)-4-[4-(3-fluorophenyl)-3,6-dihydro-2H-pyridin-1-yl]-2-oxo-pyridine-3-carbonitrile (<b>48b</b>)</h3><div class="NLM_p last">Starting from <b>41a</b> (0.23 g, 0.91 mmol) and 4-(3-fluorophenyl)-1,2,3,6-tetrahydropyridine (0.2 g, 1.13 mmol) and following the procedure described for <b>6</b>, compound <b>48b</b> was obtained as a white solid (246 mg, 77%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 0.30–0.43 (m, 2H), 0.53–0.67 (m, 2H), 1.14–1.25 (m, 1H), 2.71–2.78 (m, 2H), 3.72 (d, <i>J</i> = 7.2 Hz, 2H), 3.93 (t, <i>J</i> = 5.5 Hz, 2H), 4.30 (q, <i>J</i> = 2.7 Hz, 2H), 5.93 (d, <i>J</i> = 8.1 Hz, 1H), 6.09–6.13 (m, 1H), 6.98 (tdd, <i>J</i> = 8.3, 2.5, 0.9 Hz, 1H), 7.08 (dt, <i>J</i> = 10.5, 2.2 Hz, 1H), 7.15–7.19 (m, 1H), 7.31 (td, <i>J</i> = 8.0, 6.0 Hz, 1H), 7.34 (d, <i>J</i> = 8.1 Hz, 1H). LC–MS <i>m</i>/<i>z</i> 350 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_52" class="NLM_sec NLM_sec_level_2"><div id="ac_i69" class="anchor-spacer"></div><h3 class="article-section__title" id="_i69"> 4-[4-(2-Chlorophenyl)-3,6-dihydro-2<i>H</i>-pyridin-1-yl]-1-(cyclopropylmethyl)-2-oxo-pyridine-3-carbonitrile (<b>48c</b>)</h3><div class="NLM_p last">Starting from <b>41a</b> (0.47 g, 1.88 mmol) and 4-(2-chlorophenyl)-1,2,3,6-tetrahydropyridine (0.4 g, 2.07 mmol) and following the procedure described for <b>10</b>, compound <b>48c</b> was obtained as a white solid (680 mg, 100%). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 0.32–0.42 (m, 2H), 0.54–0.65 (m, 2H), 1.16–1.24 (m, 1H), 2.65–2.71 (m, 2H), 3.72 (d, <i>J</i> = 7.2 Hz, 2H), 3.91 (t, <i>J</i> = 5.5 Hz, 2H), 4.31 (br q, <i>J</i> = 2.9 Hz, 2H), 5.72–5.75 (m, 1H), 5.94 (d, <i>J</i> = 7.8 Hz, 1H), 7.16–7.20 (m, 1H), 7.21–7.26 (m, 2H), 7.34 (d, <i>J</i> = 8.1 Hz, 1H), 7.36–7.39 (m, 1H). LC–MS <i>m</i>/<i>z</i> 366 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_53" class="NLM_sec NLM_sec_level_2"><div id="ac_i70" class="anchor-spacer"></div><h3 class="article-section__title" id="_i70"> 1-(Cyclopropylmethyl)-4-[4-(2,4-difluorophenyl)-3,6-dihydro-2<i>H</i>-pyridin-1-yl]-2-oxo-pyridine-3-carbonitrile (<b>48d</b>)</h3><div class="NLM_p last">Starting from <b>41a</b> (0.67 g, 2.67 mmol) and 4-(2,4-difluorophenyl)-1,2,3,6-tetrahydropyridine (0.57 g, 2.94 mmol) and following the procedure described for <b>10</b>, compound <b>48d</b> was obtained as a white solid (900 mg, 92%). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 0.32–0.42 (m, 2H), 0.54–0.65 (m, 2H), 1.15–1.24 (m, 1H), 2.71 (br s, 2H), 3.72 (d, <i>J</i> = 7.2 Hz, 2H), 3.90 (t, <i>J</i> = 5.5 Hz, 2H), 4.30 (br q, <i>J</i> = 2.6 Hz, 2H), 5.93 (d, <i>J</i> = 8.1 Hz, 1H), 5.95–5.98 (m, 1H), 6.81 (ddd, <i>J</i> = 11.2, 8.7, 2.6 Hz, 1H), 6.84–6.89 (m, 1H), 7.23 (td, <i>J</i> = 8.7, 6.4 Hz, 1H), 7.34 (d, <i>J</i> = 7.8 Hz, 1H). LC–MS <i>m</i>/<i>z</i> 368 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_54" class="NLM_sec NLM_sec_level_2"><div id="ac_i71" class="anchor-spacer"></div><h3 class="article-section__title" id="_i71"> 1-(Cyclopropylmethyl)-4-[4-(4-fluorophenyl)-4-hydroxy-1-piperidyl]-2-oxo-pyridine-3-carbonitrile (<b>49</b>)</h3><div class="NLM_p last">To a solution of <b>46</b> (0.77 g, 1.88 mmol) in CH<sub>3</sub>CN (10 mL) were added 4-(4-fluoro-phenyl)-piperidin-4-ol (0.369 g, 1.89 mmol) and DIPEA (0.697 mL, 4 mmol). The mixture was heated under microwave irradiation at 140 °C for 30 min. The cooled mixture was evaporated in vacuo. The residue was taken up in CH<sub>2</sub>Cl<sub>2</sub> and washed with saturated solution of NaHCO<sub>3</sub>. The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated in vacuo. The crude was purified by flash column chromatography (silica gel, silica gel, MeOH–NH<sub>3</sub> in CH<sub>2</sub>Cl<sub>2</sub>, 0:100 to 2:98); compound <b>49</b> was obtained as a white solid (0.53 g, 73%). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 0.32–0.42 (m, 2H), 0.56–0.67 (m, 2H), 1.15–1.24 (m, 1H), 1.60 (br s, 1H), 1.90–1.97 (m, 2H), 2.20 (td, <i>J</i> = 13.2, 4.2 Hz, 2H), 3.66 (td, <i>J</i> = 12.9, 2.2 Hz, 2H), 3.72 (d, <i>J</i> = 6.9 Hz, 2H), 4.09–4.16 (m, 2H), 5.91 (d, <i>J</i> = 8.1 Hz, 1H), 7.07 (br t, <i>J</i> = 8.7 Hz, 2H), 7.30 (d, <i>J</i> = 7.8 Hz, 1H), 7.44–7.51 (m, 2H). LC–MS <i>m</i>/<i>z</i> 368 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_55" class="NLM_sec NLM_sec_level_2"><div id="ac_i72" class="anchor-spacer"></div><h3 class="article-section__title" id="_i72"> 1-(Cyclopropylmethyl)-4-(4-phenyl-1-piperidyl)pyridin-2-one (<b>50a</b>)</h3><div class="NLM_p last">To a solution of <b>47a</b> (0.4 g, 1.58 mmol) in toluene (5 mL) were added 4-phenylpiperidine (0.509 g, 3.16 mmol), Pd(OAc)<sub>2</sub> (0.017 g, 0.079 mmol), NaO<sup><i>t</i></sup>Bu (0.38 g, 3.95 mmol), and BINAP (0.073 g, 0.11 mmol). The mixture was heated at 100 °C for 16 h in a sealed tube. The cooled mixture was partitioned between water and EtOAc. The crude was extracted with EtOAc (3 × 5 mL), and the combined organic layers were dried (Na<sub>2</sub>SO<sub>4</sub>) and concentrated in vacuo. The crude was purified by flash column chromatography (silica gel, silica gel, MeOH–NH<sub>3</sub> in CH<sub>2</sub>Cl<sub>2</sub>, 0:100 to 1:99); compound <b>50a</b> was obtained as brown oil (0.48 g, 98%). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 0.31–0.42 (m, 2H), 0.53–0.64 (m, 2H), 1.19–1.28 (m, 1H), 1.77 (qd, <i>J</i> = 12.7, 3.9 Hz, 2H), 1.89–1.96 (m, 2H), 2.76 (tt, <i>J</i> = 12.1, 3.6 Hz, 1H), 2.96 (td, <i>J</i> = 12.8, 2.2 Hz, 2H), 3.73 (d, <i>J</i> = 7.2 Hz, 2H), 3.90–3.97 (m, 2H), 5.82 (d, <i>J</i> = 2.9 Hz, 1H), 5.98 (dd, <i>J</i> = 7.8, 2.9 Hz, 1H), 7.17–7.26 (m, 4H), 7.30–7.35 (m, 2H). LC–MS <i>m</i>/<i>z</i> 309 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_56" class="NLM_sec NLM_sec_level_2"><div id="ac_i73" class="anchor-spacer"></div><h3 class="article-section__title" id="_i73"> 1-Isobutyl-4-(4-phenyl-1-piperidyl)pyridin-2-one (<b>50b</b>)</h3><div class="NLM_p last">To a solution of <b>47b</b> (2 g, 8.69 mmol) in toluene (35 mL) were added 4-phenylpiperidine (1.962 g, 12.16 mmol), Pd(OAc)<sub>2</sub> (0.098 g, 0.43 mmol), NaO<i><sup>t</sup></i>Bu (2.088 g, 21.72 mmol), and 2,2′-bis (diphenylphosphino)-1,1′-binaphthyl (0.406 g, 0.652 mmol). The mixture was heated at 100 °C for 16 h in a sealed tube. The cooled mixture was partitioned between water and EtOAc. The crude was extracted with EtOAc (3 × 5 mL), and the combined organic layers were dried (Na<sub>2</sub>SO<sub>4</sub>) and concentrated in vacuo. The crude was purified by flash column chromatography (silica gel, silica gel, MeOH in CH<sub>2</sub>Cl<sub>2</sub>, 0:100 to 4:96); compound <b>50b</b> was obtained as a white solid (1.9 g, 65%). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 0.93 (d, <i>J</i> = 6.6 Hz, 6H), 1.76 (qd, <i>J</i> = 12.8, 3.5 Hz, 2H), 1.87–1.94 (m, 2H), 2.11–2.21 (m, 1H), 2.74 (tt, <i>J</i> = 12.1, 3.5 Hz, 1H), 2.94 (td, <i>J</i> = 12.8, 2.5 Hz, 2H), 3.64 (d, <i>J</i> = 7.5 Hz, 2H), 3.88–3.95 (m, 2H), 5.78 (d, <i>J</i> = 2.9 Hz, 1H), 5.93 (dd, <i>J</i> = 7.8, 2.6 Hz, 1H), 7.02 (d, <i>J</i> = 7.5 Hz, 1H), 7.17–7.25 (m, 3H), 7.28–7.34 (m, 2H). LC–MS <i>m</i>/<i>z</i> 311 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_57" class="NLM_sec NLM_sec_level_2"><div id="ac_i74" class="anchor-spacer"></div><h3 class="article-section__title" id="_i74"> 1-Butyl-4-(4-phenyl-1-piperidyl)pyridin-2-one (<b>50c</b>)</h3><div class="NLM_p last">To a solution of <b>47c</b> (2 g, 8.69 mmol) in toluene (75 mL) were added 4-phenylpiperidine (2.1 g, 13.038 mmol), Pd(OAc)<sub>2</sub> (0.98 g,0.435 mmol), NaO<sup><i>t</i></sup>Bu (2.09 g, 21.73 mmol), and BINAP (0.406 g,0.652 mmol). The mixture was heated at 100 °C for 16 h in a sealed tube. The cooled mixture was partitioned between water and EtOAc. The crude was extracted with EtOAc (3 × 5 mL), and the combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated in vacuo. The crude was purified by flash column chromatography (silica gel, silica gel, MeOH–NH<sub>3</sub> in CH<sub>2</sub>Cl<sub>2</sub>, 0:100 to 4:96); compound <b>50c</b> was obtained (1.8 g, 66%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 0.95 (t, <i>J</i> = 7.4 Hz, 3H), 1.31–1.43 (m, 2H), 1.65–1.82 (m, 4H), 1.86–1.95 (m, 2H), 2.74 (tt, <i>J</i> = 12.1, 3.7 Hz, 1H), 2.94 (td, <i>J</i> = 12.8, 2.5 Hz, 2H), 3.84 (t, <i>J</i> = 7.4 Hz, 2H), 3.88–3.95 (m, 2H), 5.79 (d, <i>J</i> = 2.8 Hz, 1H), 5.95 (dd, <i>J</i> = 7.7, 2.9 Hz, 1H), 7.06 (d, <i>J</i> = 7.6 Hz, 1H), 7.17–7.25 (m, 3H), 7.28–7.35 (m, 2H). LC–MS <i>m</i>/<i>z</i> 311 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_58" class="NLM_sec NLM_sec_level_2"><div id="ac_i75" class="anchor-spacer"></div><h3 class="article-section__title" id="_i75"> 1-Isopentyl-2-oxo-4-(2-phenylethynyl)pyridine-3-carbonitrile (<b>51</b>)</h3><div class="NLM_p last">To a solution of <b>41d</b> (0.15 g, 0.6 mmol) in THF (6 mL) were added phenylacetylene (0.064 mL, 0.6 mmol), PdCl<sub>2</sub>(PPh<sub>3</sub>)<sub>2</sub> (0.02 g, 0.028 mmol), Et<sub>3</sub>N (0.0787 mL, 2.2 mmol), and PPh<sub>3</sub> (0.0037 g, 0.014 mmol). The mixture was degassed for 5 min, and then CuI (0.0013 g, 0.007 mmol) was added. The mixture was heated at 90 °C for 10 h in a sealed tube. The mixture was cooled to room temperature and treated with aqueous Na<sub>2</sub>S<sub>2</sub>O<sub>4</sub> and CH<sub>2</sub>Cl<sub>2</sub>. The layers were separated, the organic layer was washed with a saturated aqueous solution of NaHCO<sub>3</sub>, and the combined organic layers were dried (Na<sub>2</sub>SO<sub>4</sub>) and concentrated in vacuo. The crude was purified by automated flash column chromatography over silica gel (silica gel, silica gel, MeOH–NH<sub>3</sub> in CH<sub>2</sub>Cl<sub>2</sub>, 0:100 to 2:98); compound <b>51</b> was obtained (0.097 g, 60%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 0.97 (d, <i>J</i> = 6.2 Hz, 6H), 1.56–1.71 (m, 3H), 3.94–4.01 (m, 2H), 6.36 (d, <i>J</i> = 6.8 Hz, 1H), 7.36–7.47 (m, 3H), 7.53 (d, <i>J</i> = 7.0 Hz, 1H), 7.59–7.65 (m, 2H). LC–MS <i>m</i>/<i>z</i> 291 [M + H]<sup>+</sup>.</div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i76" class="anchor-spacer"></div><h3 class="article-section__title" id="_i76"> Biology</h3></div><div id="sec5_2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i77" class="anchor-spacer"></div><h3 class="article-section__title" id="_i77"> Membrane Preparation</h3><div class="NLM_p last">CHO cells expressing the human mGlu2 receptor were grown until they were 80% confluent, washed in ice-cold phosphate buffered saline, and stored at −20 °C until membrane preparation. After thawing, cells were suspended in 50 mM Tris-HCl, pH 7.4, and collected through centrifugation for 10 min at 23 500<i>g</i> at 4 °C. Cells were lysed in 5 mM hypotonic Tris-HCl, pH 7.4, and after recentrifugation for 20 min at 30 000<i>g</i> at 4 °C, the pellet was homogenized with an Ultra Turrax homogenizer in 50 mM Tris-HCl, pH 7.4. Protein concentrations were measured by the Bio-Rad protein assay using bovine serum albumin as standard.</div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i78" class="anchor-spacer"></div><h3 class="article-section__title" id="_i78"> [<sup>35</sup>S]GTPγS Binding Assay</h3><div class="NLM_p last">For [<sup>35</sup>S]GTPγS measurements, compound and glutamate were diluted in buffer containing 10 mM HEPES acid, 10 mM HEPES salt, pH 7.4, containing 100 mM NaCl, 3 mM MgCl<sub>2</sub>, and 10 μM GDP. Membranes were thawed on ice and diluted in the same buffer, supplemented with 14 μg/mL saponin (final assay concentration of 2 μg/mL saponin). Final assay mixtures contained 7 μg of membrane protein and were preincubated with compound alone (determination of agonist effects) or together with an EC<sub>20</sub> concentration (4 μM) of glutamate (determination of PAM effects) for 30 min at 30 °C. [<sup>35</sup>S]GTPγS was added at a final concentration of 0.1 nM and incubated for another 30 min at 30 °C. Reactions were terminated by rapid filtration through Unifilter-96 GF/B filter plates (Packard) using a 96-well Packard filtermate harvester. Filters were washed six times with ice-cold 10 mM NaH<sub>2</sub>PO<sub>4</sub>/10 mM Na<sub>2</sub>HPO<sub>4</sub>, pH 7.4, and filter-bound radioactivity was counted in a microplate scintillation and luminescence counter from Packard.</div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i79" class="anchor-spacer"></div><h3 class="article-section__title" id="_i79"> Data Analysis</h3><div class="NLM_p last">Data were processed using an internal software interface and were calculated as the percent of the control agonist challenge. Sigmoid concentration–response curves plotting these percentages versus the log concentration of the test compound were analyzed using nonlinear regression analysis. The EC<sub>50</sub> is the concentration of a compound that causes a half-maximal potentiation of the glutamate response.The pEC<sub>50</sub> values are calculated as the −log EC<sub>50</sub> (wherein EC<sub>50</sub> is expressed in mol L<sup>–1</sup>).</div></div><div id="sec5_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i80" class="anchor-spacer"></div><h3 class="article-section__title" id="_i80"> Patch-Clamp Assay</h3><div class="NLM_p last">Experiments were performed using HEK293 cells stably expressing the hERG potassium channel. Cells were grown at 37 °C and 5% CO<sub>2</sub> in culture flasks in MEM medium supplemented with 10% heat-inactivated fetal bovine serum, 1% <span class="smallcaps smallerCapital">l</span>-glutamine–penicillin–streptomycin solution, 1% nonessential amino acids (100×), 1% sodium pyruvate (100 mM), and 0.8% Geneticin (50 mg/mL). Before use, the cells were subcultured in MEM medium in the absence of 5 mL of <span class="smallcaps smallerCapital">l</span>-glutamine–penicillin–streptomycin. For use in the automated patch-clamp system PatchXpress 7000A (Axon Instruments), cells were harvested to obtain cell suspension of single cells. The extracellular solution contained the following (mM): 150 NaCl, 4 KCl, 1 MgCl<sub>2</sub>, 1.8 CaCl<sub>2</sub>, 10 HEPES, 5 glucose (pH 7.4 with NaOH). The pipette solution contained the following (mM): 120 KCl, 10 HEPES, 5 EGTA, 4 ATP-Mg2, 2 MgCl<sub>2</sub>, 0.5 CaCl<sub>2</sub> (pH 7.2 with KOH). Patch-clamp experiments were performed in the voltage-clamp mode, and whole-cell currents were recorded with an automated patch-clamp assay utilizing the PatchXpress 7000A system (Axon Instruments). Current signals were amplified and digitized by a multiclamp amplifier, stored, and analyzed by using the PatchXpress and DataXpress software and Igor 5.0 (Wavemetrics). The holding potential was −80 mV. The hERG current (K<sup>+</sup>-selective outward current) was determined as the maximal tail current at −40 mV after a 2 s depolarization to +60 mV. The pulse cycling rate was 15 s. Before each test pulse, a short pulse (0.5 s) from the holding potential to −60 mV was given to determine (linear) leak current. After establishment of whole-cell configuration and a stability period, the vehicle was applied for 5 min followed by the test substance at increasing concentrations of 10<sup>–7</sup>, 3 × 10<sup>–7</sup>, and 3 × 10<sup>–6</sup> M. Each concentration of the test substance was applied twice. The effect of each concentration was determined after 5 min as an average current of three sequential voltage pulses. To determine the extent of block, the residual current was compared with vehicle pretreatment.</div></div><div id="sec5_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i81" class="anchor-spacer"></div><h3 class="article-section__title" id="_i81"> Sleep–Wake EEG: Animals, Drug Treatment, and Experimental Procedure</h3><div class="NLM_p last">All in vivo experimental procedures were performed according to the applicable European Communities Council Directive of November 24, 1986 (86/609/EEC) and approved by the Animal Care and Use Committee of Janssen Pharmaceutical Companies of Johnson & Johnson and by the local ethical committee. Male Sprague–Dawley rats (Charles River, France) weighing 250–300 g were used. Animals were chronically implanted with electrodes for recording the cortical electroencephalogram (EEG), electrical neck muscle activity (EMG), and ocular movements (EOG). All animals were housed in individually ventilated cages under environmentally controlled conditions (ambient temperature, 22 °C; humidity, 60%) on a 12 h light/dark cycle (lights on from 12:00 a.m. to 12:00 p.m., illumination intensity of ∼100 lx). The animals had free access to food and tap water. The effects of the tested molecule and vehicle on sleep–wake distribution during the lights-on period were investigated in 16 rats (<i>n</i> = 8 each group). Two EEG recording sessions were performed: the first recording session started at 13:30 h and lasted 20 h following oral administration of saline. The second recording session was performed during the same consecutive circadian time and for the same duration following administration of either vehicle (20% CD + 2H2T) or tested compound. Sleep polysomnographic variables were determined offline as described elsewhere using a sleep stages analyzer, scoring each 2 s epoch before averaging stages over 30 min periods. Sleep–wake state classifications were assigned on the basis of the combination of dynamics of five EEG frequency domains, integrated EMG, EOG, and body activity level: active wake (AW); passive wake (PW); intermediate stage (pre-REM transients); rapid eye movement sleep (REM); light non-REM sleep (lSWS); deep non-REM sleep (dSWS). Different sleep–wake parameters were investigated over 20 h postadministration, and time spent in each vigilance state, sleep parameters, latencies for first REM sleep period and the number of transitions between states were determined.</div></div><div id="sec5_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i82" class="anchor-spacer"></div><h3 class="article-section__title" id="_i82"> Statistical Analysis</h3><div class="NLM_p last">Time spent in each vigilance state (AW, PW, lSWS, dSWS, IS, and REMS) was expressed as a percentage of the recording period. A statistical analysis of the obtained data was carried out by a nonparametric analysis of variance of each 30 min period, followed by a Wilcoxon–Mann–Whitney rank sum test of comparisons with the control group.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id=""></div><div class="testing" data-doi="10.1021/jm500496m" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_67512" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_67512" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">José María Cid</span> - <span class="hlFld-Affiliation affiliation">Neuroscience
Medicinal Chemistry, Janssen Research & Development, Janssen-Cilag S.A., C/Jarama 75, 45007 Toledo, Spain</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#412b222825012835326f2b2f2b6f222e2c"><span class="__cf_email__" data-cfemail="abc1c8c2cfebc2dfd885c1c5c185c8c4c6">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gary Tresadern</span> - <span class="hlFld-Affiliation affiliation">Neuroscience
Medicinal Chemistry, Janssen Research & Development, Janssen-Cilag S.A., C/Jarama 75, 45007 Toledo, Spain</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Guillaume Duvey</span> - <span class="hlFld-Affiliation affiliation">Addex
Therapeutics, 12 Chemin
des Aulx, 1228 Plan-les-Ouates, Geneva, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Robert Lütjens</span> - <span class="hlFld-Affiliation affiliation">Addex
Therapeutics, 12 Chemin
des Aulx, 1228 Plan-les-Ouates, Geneva, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Terry Finn</span> - <span class="hlFld-Affiliation affiliation">Neuroscience
Medicinal Chemistry, Janssen Research & Development, Janssen-Cilag S.A., C/Jarama 75, 45007 Toledo, Spain</span>; 
    <span class="hlFld-Affiliation affiliation">‡Neuroscience Medicinal
Chemistry, §Neuroscience Biology, ∥Discovery ADME/Tox, ⊥Molecular Sciences, #Project Management Office, ∇Translational Sciences, Janssen Research & Development, Turnhoutseweg 30, B-2340, Beerse, Belgium</span>; 
    <span class="hlFld-Affiliation affiliation">Addex
Therapeutics, 12 Chemin
des Aulx, 1228 Plan-les-Ouates, Geneva, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jean-Philippe Rocher</span> - <span class="hlFld-Affiliation affiliation">Neuroscience
Medicinal Chemistry, Janssen Research & Development, Janssen-Cilag S.A., C/Jarama 75, 45007 Toledo, Spain</span>; 
    <span class="hlFld-Affiliation affiliation">‡Neuroscience Medicinal
Chemistry, §Neuroscience Biology, ∥Discovery ADME/Tox, ⊥Molecular Sciences, #Project Management Office, ∇Translational Sciences, Janssen Research & Development, Turnhoutseweg 30, B-2340, Beerse, Belgium</span>; 
    <span class="hlFld-Affiliation affiliation">Addex
Therapeutics, 12 Chemin
des Aulx, 1228 Plan-les-Ouates, Geneva, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sonia Poli</span> - <span class="hlFld-Affiliation affiliation">Neuroscience
Medicinal Chemistry, Janssen Research & Development, Janssen-Cilag S.A., C/Jarama 75, 45007 Toledo, Spain</span>; 
    <span class="hlFld-Affiliation affiliation">‡Neuroscience Medicinal
Chemistry, §Neuroscience Biology, ∥Discovery ADME/Tox, ⊥Molecular Sciences, #Project Management Office, ∇Translational Sciences, Janssen Research & Development, Turnhoutseweg 30, B-2340, Beerse, Belgium</span>; 
    <span class="hlFld-Affiliation affiliation">Addex
Therapeutics, 12 Chemin
des Aulx, 1228 Plan-les-Ouates, Geneva, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Juan Antonio Vega</span> - <span class="hlFld-Affiliation affiliation">Neuroscience
Medicinal Chemistry, Janssen Research & Development, Janssen-Cilag S.A., C/Jarama 75, 45007 Toledo, Spain</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ana Isabel de Lucas</span> - <span class="hlFld-Affiliation affiliation">Neuroscience
Medicinal Chemistry, Janssen Research & Development, Janssen-Cilag S.A., C/Jarama 75, 45007 Toledo, Spain</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Encarnación Matesanz</span> - <span class="hlFld-Affiliation affiliation">Neuroscience
Medicinal Chemistry, Janssen Research & Development, Janssen-Cilag S.A., C/Jarama 75, 45007 Toledo, Spain</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">María Lourdes Linares</span> - <span class="hlFld-Affiliation affiliation">Neuroscience
Medicinal Chemistry, Janssen Research & Development, Janssen-Cilag S.A., C/Jarama 75, 45007 Toledo, Spain</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">José Ignacio Andrés</span> - <span class="hlFld-Affiliation affiliation">Neuroscience
Medicinal Chemistry, Janssen Research & Development, Janssen-Cilag S.A., C/Jarama 75, 45007 Toledo, Spain</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jesús Alcazar</span> - <span class="hlFld-Affiliation affiliation">Neuroscience
Medicinal Chemistry, Janssen Research & Development, Janssen-Cilag S.A., C/Jarama 75, 45007 Toledo, Spain</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">José Manuel Alonso</span> - <span class="hlFld-Affiliation affiliation">Neuroscience
Medicinal Chemistry, Janssen Research & Development, Janssen-Cilag S.A., C/Jarama 75, 45007 Toledo, Spain</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gregor J. Macdonald</span> - <span class="hlFld-Affiliation affiliation">Neuroscience
Medicinal Chemistry, Janssen Research & Development, Janssen-Cilag S.A., C/Jarama 75, 45007 Toledo, Spain</span>; 
    <span class="hlFld-Affiliation affiliation">‡Neuroscience Medicinal
Chemistry, §Neuroscience Biology, ∥Discovery ADME/Tox, ⊥Molecular Sciences, #Project Management Office, ∇Translational Sciences, Janssen Research & Development, Turnhoutseweg 30, B-2340, Beerse, Belgium</span>; 
    <span class="hlFld-Affiliation affiliation">Addex
Therapeutics, 12 Chemin
des Aulx, 1228 Plan-les-Ouates, Geneva, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Daniel Oehlrich</span> - <span class="hlFld-Affiliation affiliation">Neuroscience
Medicinal Chemistry, Janssen Research & Development, Janssen-Cilag S.A., C/Jarama 75, 45007 Toledo, Spain</span>; 
    <span class="hlFld-Affiliation affiliation">‡Neuroscience Medicinal
Chemistry, §Neuroscience Biology, ∥Discovery ADME/Tox, ⊥Molecular Sciences, #Project Management Office, ∇Translational Sciences, Janssen Research & Development, Turnhoutseweg 30, B-2340, Beerse, Belgium</span>; 
    <span class="hlFld-Affiliation affiliation">Addex
Therapeutics, 12 Chemin
des Aulx, 1228 Plan-les-Ouates, Geneva, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hilde Lavreysen</span> - <span class="hlFld-Affiliation affiliation">Neuroscience
Medicinal Chemistry, Janssen Research & Development, Janssen-Cilag S.A., C/Jarama 75, 45007 Toledo, Spain</span>; 
    <span class="hlFld-Affiliation affiliation">‡Neuroscience Medicinal
Chemistry, §Neuroscience Biology, ∥Discovery ADME/Tox, ⊥Molecular Sciences, #Project Management Office, ∇Translational Sciences, Janssen Research & Development, Turnhoutseweg 30, B-2340, Beerse, Belgium</span>; 
    <span class="hlFld-Affiliation affiliation">Addex
Therapeutics, 12 Chemin
des Aulx, 1228 Plan-les-Ouates, Geneva, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Abdelah Ahnaou</span> - <span class="hlFld-Affiliation affiliation">Neuroscience
Medicinal Chemistry, Janssen Research & Development, Janssen-Cilag S.A., C/Jarama 75, 45007 Toledo, Spain</span>; 
    <span class="hlFld-Affiliation affiliation">‡Neuroscience Medicinal
Chemistry, §Neuroscience Biology, ∥Discovery ADME/Tox, ⊥Molecular Sciences, #Project Management Office, ∇Translational Sciences, Janssen Research & Development, Turnhoutseweg 30, B-2340, Beerse, Belgium</span>; 
    <span class="hlFld-Affiliation affiliation">Addex
Therapeutics, 12 Chemin
des Aulx, 1228 Plan-les-Ouates, Geneva, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wilhelmus Drinkenburg</span> - <span class="hlFld-Affiliation affiliation">Neuroscience
Medicinal Chemistry, Janssen Research & Development, Janssen-Cilag S.A., C/Jarama 75, 45007 Toledo, Spain</span>; 
    <span class="hlFld-Affiliation affiliation">‡Neuroscience Medicinal
Chemistry, §Neuroscience Biology, ∥Discovery ADME/Tox, ⊥Molecular Sciences, #Project Management Office, ∇Translational Sciences, Janssen Research & Development, Turnhoutseweg 30, B-2340, Beerse, Belgium</span>; 
    <span class="hlFld-Affiliation affiliation">Addex
Therapeutics, 12 Chemin
des Aulx, 1228 Plan-les-Ouates, Geneva, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Claire Mackie</span> - <span class="hlFld-Affiliation affiliation">Neuroscience
Medicinal Chemistry, Janssen Research & Development, Janssen-Cilag S.A., C/Jarama 75, 45007 Toledo, Spain</span>; 
    <span class="hlFld-Affiliation affiliation">‡Neuroscience Medicinal
Chemistry, §Neuroscience Biology, ∥Discovery ADME/Tox, ⊥Molecular Sciences, #Project Management Office, ∇Translational Sciences, Janssen Research & Development, Turnhoutseweg 30, B-2340, Beerse, Belgium</span>; 
    <span class="hlFld-Affiliation affiliation">Addex
Therapeutics, 12 Chemin
des Aulx, 1228 Plan-les-Ouates, Geneva, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Stefan Pype</span> - <span class="hlFld-Affiliation affiliation">Neuroscience
Medicinal Chemistry, Janssen Research & Development, Janssen-Cilag S.A., C/Jarama 75, 45007 Toledo, Spain</span>; 
    <span class="hlFld-Affiliation affiliation">‡Neuroscience Medicinal
Chemistry, §Neuroscience Biology, ∥Discovery ADME/Tox, ⊥Molecular Sciences, #Project Management Office, ∇Translational Sciences, Janssen Research & Development, Turnhoutseweg 30, B-2340, Beerse, Belgium</span>; 
    <span class="hlFld-Affiliation affiliation">Addex
Therapeutics, 12 Chemin
des Aulx, 1228 Plan-les-Ouates, Geneva, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">David Gallacher</span> - <span class="hlFld-Affiliation affiliation">Neuroscience
Medicinal Chemistry, Janssen Research & Development, Janssen-Cilag S.A., C/Jarama 75, 45007 Toledo, Spain</span>; 
    <span class="hlFld-Affiliation affiliation">‡Neuroscience Medicinal
Chemistry, §Neuroscience Biology, ∥Discovery ADME/Tox, ⊥Molecular Sciences, #Project Management Office, ∇Translational Sciences, Janssen Research & Development, Turnhoutseweg 30, B-2340, Beerse, Belgium</span>; 
    <span class="hlFld-Affiliation affiliation">Addex
Therapeutics, 12 Chemin
des Aulx, 1228 Plan-les-Ouates, Geneva, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Andrés A. Trabanco</span> - <span class="hlFld-Affiliation affiliation">Neuroscience
Medicinal Chemistry, Janssen Research & Development, Janssen-Cilag S.A., C/Jarama 75, 45007 Toledo, Spain</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d55e6038-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i83">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_13337" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_13337" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The authors thank Addex Therapeutics for its collaboration on the mGlu2PAM discovery program, members of the purification and analysis team from Toledo, the biology and ADMET team from Janssen R & D, and Lieve Heylen, Heidi Szel, and Ria Wouters for technical assistance.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i84" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i84"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i85" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i85"> Abbreviations Used</h2><tr><td class="NLM_term">AcOH</td><td class="NLM_def"><p class="first last">acetic acid</p></td></tr><tr><td class="NLM_term">ADME</td><td class="NLM_def"><p class="first last">absorption, distribution, metabolism, excretion</p></td></tr><tr><td class="NLM_term">AUC</td><td class="NLM_def"><p class="first last">area under the curve</p></td></tr><tr><td class="NLM_term">AW</td><td class="NLM_def"><p class="first last">active wake</p></td></tr><tr><td class="NLM_term">BBB</td><td class="NLM_def"><p class="first last">blood–brain barrier</p></td></tr><tr><td class="NLM_term">BINAP</td><td class="NLM_def"><p class="first last">2,2′-bis(diphenylphosphino)-1,1′-binaphthyl</p></td></tr><tr><td class="NLM_term">B/P</td><td class="NLM_def"><p class="first last">brain plasma ratio</p></td></tr><tr><td class="NLM_term">Cl</td><td class="NLM_def"><p class="first last">clearance</p></td></tr><tr><td class="NLM_term"><i>C</i><sub>max</sub></td><td class="NLM_def"><p class="first last">maximum plasma concentrations</p></td></tr><tr><td class="NLM_term">CNS</td><td class="NLM_def"><p class="first last">central nervous system</p></td></tr><tr><td class="NLM_term">CV</td><td class="NLM_def"><p class="first last">cardiovascular</p></td></tr><tr><td class="NLM_term">dSWS</td><td class="NLM_def"><p class="first last">deep non-REM sleep</p></td></tr><tr><td class="NLM_term">DCM</td><td class="NLM_def"><p class="first last">dichloromethane</p></td></tr><tr><td class="NLM_term">DIPEA</td><td class="NLM_def"><p class="first last">diisopropylethylamine</p></td></tr><tr><td class="NLM_term">DMF</td><td class="NLM_def"><p class="first last">dimethylformamide</p></td></tr><tr><td class="NLM_term">DMSO</td><td class="NLM_def"><p class="first last">dimethyl sulfoxide</p></td></tr><tr><td class="NLM_term">EEG</td><td class="NLM_def"><p class="first last">electroencephalogram</p></td></tr><tr><td class="NLM_term">EMG</td><td class="NLM_def"><p class="first last">electrical neck muscle activity</p></td></tr><tr><td class="NLM_term">EOG</td><td class="NLM_def"><p class="first last">ocular movement</p></td></tr><tr><td class="NLM_term">EtOAc</td><td class="NLM_def"><p class="first last">ethyl acetate</p></td></tr><tr><td class="NLM_term">GCMS</td><td class="NLM_def"><p class="first last">gas chromatography mass spectrometry</p></td></tr><tr><td class="NLM_term">GPCR</td><td class="NLM_def"><p class="first last">G-protein-coupled receptor</p></td></tr><tr><td class="NLM_term">h</td><td class="NLM_def"><p class="first last">hours</p></td></tr><tr><td class="NLM_term">HLM</td><td class="NLM_def"><p class="first last">human liver microsome</p></td></tr><tr><td class="NLM_term">HP-β-CD</td><td class="NLM_def"><p class="first last">2-hydroxylpropyl-β-cyclodextrin</p></td></tr><tr><td class="NLM_term">HTS</td><td class="NLM_def"><p class="first last">high-throughput screening</p></td></tr><tr><td class="NLM_term">iGlu</td><td class="NLM_def"><p class="first last">ionotropic glutamate</p></td></tr><tr><td class="NLM_term">iv</td><td class="NLM_def"><p class="first last">intravenous</p></td></tr><tr><td class="NLM_term">LAD</td><td class="NLM_def"><p class="first last">lowest active dose</p></td></tr><tr><td class="NLM_term">LC–MS</td><td class="NLM_def"><p class="first last">liquid chromatography combined with mass spectrometry</p></td></tr><tr><td class="NLM_term">mGlu2</td><td class="NLM_def"><p class="first last">metabotropic glutamate 2</p></td></tr><tr><td class="NLM_term">min</td><td class="NLM_def"><p class="first last">minutes</p></td></tr><tr><td class="NLM_term">lSWS</td><td class="NLM_def"><p class="first last">light non-REM sleep</p></td></tr><tr><td class="NLM_term">MDD</td><td class="NLM_def"><p class="first last">major depressive disorder</p></td></tr><tr><td class="NLM_term">MeOH</td><td class="NLM_def"><p class="first last">methanol</p></td></tr><tr><td class="NLM_term">mp</td><td class="NLM_def"><p class="first last">melting point</p></td></tr><tr><td class="NLM_term">MW</td><td class="NLM_def"><p class="first last">molecular weight</p></td></tr><tr><td class="NLM_term">NCS</td><td class="NLM_def"><p class="first last"><i>N</i>-chlorosuccinimide</p></td></tr><tr><td class="NLM_term">ND</td><td class="NLM_def"><p class="first last">not determined</p></td></tr><tr><td class="NLM_term">NM</td><td class="NLM_def"><p class="first last">not measurable</p></td></tr><tr><td class="NLM_term">NIS</td><td class="NLM_def"><p class="first last"><i>N</i>-iodosuccinimide</p></td></tr><tr><td class="NLM_term">NMDA</td><td class="NLM_def"><p class="first last"><i>N</i>-methyl-<span class="smallcaps smallerCapital">d</span>-aspartate</p></td></tr><tr><td class="NLM_term">NMR</td><td class="NLM_def"><p class="first last">nuclear magnetic resonance</p></td></tr><tr><td class="NLM_term">NOEL</td><td class="NLM_def"><p class="first last">no effect level</p></td></tr><tr><td class="NLM_term">NT</td><td class="NLM_def"><p class="first last">not tested</p></td></tr><tr><td class="NLM_term">PAM</td><td class="NLM_def"><p class="first last">positive allosteric modulator</p></td></tr><tr><td class="NLM_term">PCP</td><td class="NLM_def"><p class="first last">phencyclidine</p></td></tr><tr><td class="NLM_term">PK</td><td class="NLM_def"><p class="first last">pharmacokinetics</p></td></tr><tr><td class="NLM_term">po</td><td class="NLM_def"><p class="first last">per oral</p></td></tr><tr><td class="NLM_term">PW</td><td class="NLM_def"><p class="first last">passive wake</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr><tr><td class="NLM_term">SEM</td><td class="NLM_def"><p class="first last">standard error of mean</p></td></tr><tr><td class="NLM_term">po</td><td class="NLM_def"><p class="first last">oral</p></td></tr><tr><td class="NLM_term">REM</td><td class="NLM_def"><p class="first last">rapid eye movement</p></td></tr><tr><td class="NLM_term">RLM</td><td class="NLM_def"><p class="first last">rat liver microsome</p></td></tr><tr><td class="NLM_term">ROL</td><td class="NLM_def"><p class="first last">REM sleep onset latency</p></td></tr><tr><td class="NLM_term">rt</td><td class="NLM_def"><p class="first last">room temperature</p></td></tr><tr><td class="NLM_term">RP-HPLC</td><td class="NLM_def"><p class="first last">reverse-phase high-performance liquid chromatography</p></td></tr><tr><td class="NLM_term">sc</td><td class="NLM_def"><p class="first last">subcutaneous</p></td></tr><tr><td class="NLM_term">SD</td><td class="NLM_def"><p class="first last">standard deviation</p></td></tr><tr><td class="NLM_term">sw-EEG</td><td class="NLM_def"><p class="first last">sleep–wake electroencephalogram</p></td></tr><tr><td class="NLM_term">TFA</td><td class="NLM_def"><p class="first last">trifluoroacetic acid</p></td></tr><tr><td class="NLM_term">THF</td><td class="NLM_def"><p class="first last">tetrahydrofuran</p></td></tr><tr><td class="NLM_term">TLC</td><td class="NLM_def"><p class="first last">thin-layer chromatography</p></td></tr><tr><td class="NLM_term">TPSA</td><td class="NLM_def"><p class="first last">total polar surface area</p></td></tr><tr><td class="NLM_term"><i>V</i><sub>d</sub></td><td class="NLM_def"><p class="first last">volume of distribution</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i86">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_21265" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_21265" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 51 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Kew, J. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kemp, J. A.</span><span> </span><span class="NLM_article-title">Ionotropic and metabotropic glutamate receptor, structure and pharmacology</span> <span class="citation_source-journal">Psychoharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">182</span><span class="NLM_x">, </span> <span class="NLM_fpage">320</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Fjm500496m&amp;key=10.1007%2Fs00213-005-0152-y" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=182&publication_year=2005&pages=320&author=J.+N.+Kewauthor=J.+A.+Kemp&title=Ionotropic+and+metabotropic+glutamate+receptor%2C+structure+and+pharmacology"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1007%2Fs00213-005-0152-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00213-005-0152-y%26sid%3Dliteratum%253Aachs%26aulast%3DKew%26aufirst%3DJ.%2BN.%26aulast%3DKemp%26aufirst%3DJ.%2BA.%26atitle%3DIonotropic%2520and%2520metabotropic%2520glutamate%2520receptor%252C%2520structure%2520and%2520pharmacology%26jtitle%3DPsychoharmacology%26date%3D2005%26volume%3D182%26spage%3D320" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Pin, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galvez, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prezeau, L.</span><span> </span><span class="NLM_article-title">Evolution, structure, and activation mechanism of family 3/C G-protein-coupled receptors</span> <span class="citation_source-journal">Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">98</span><span class="NLM_x">, </span> <span class="NLM_fpage">325</span><span class="NLM_x">–</span> <span class="NLM_lpage">354</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Fjm500496m&amp;key=10.1016%2FS0163-7258%2803%2900038-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Fjm500496m&amp;key=12782243" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Fjm500496m&amp;key=1%3ACAS%3A528%3ADC%252BD3sXktVOqsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2003&pages=325-354&author=J.+P.+Pinauthor=T.+Galvezauthor=L.+Prezeau&title=Evolution%2C+structure%2C+and+activation+mechanism+of+family+3%2FC+G-protein-coupled+receptors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Evolution, structure, and activation mechanism of family 3/C G-protein-coupled receptors</span></div><div class="casAuthors">Pin, Jean-Philippe; Galvez, Thierry; Prezeau, Laurent</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">325-354</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">A review.  G-protein-coupled receptors (GPCRs) represent one of the largest gene families in the animal genome.  These receptors can be classified into several groups based on the sequence similarity of their common heptahelical domain.  The family 3 (or C) GPCRs are receptors for the main neurotransmitters glutamate and γ-aminobutyric acid, for Ca2+, for sweet and amino acid taste compds., and for some pheromone mols., as well as for odorants in fish.  Although none of these family 3 receptors have been found in plants, members have been identified in ancient organisms, such as slime molds (Dictyostelium) and sponges.  Like any other GPCRs, family 3 receptors possess a transmembrane heptahelical domain responsible for G-protein activation.  However, most of these identified receptors also possess a large extracellular domain that is responsible for ligand recognition, is structurally similar to bacterial periplasmic proteins involved in the transport of small mols., and is called a Venus Flytrap module.  The recent resoln. of the structure of this binding domain in one of these receptors, the metabotropic glutamate 1 receptor, together with the recent demonstration that these receptors are dimers, revealed a unique mechanism of activation for these GPCRs.  Such data open new possibilities in the development of drugs aimed at modulating these receptors, and raise a no. of interesting questions on the activation mechanism of the other GPCRs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqNRDDmZSLFrVg90H21EOLACvtfcHk0ljQht_ArwebVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXktVOqsb8%253D&md5=33ed658debc421c5dbd63a8b6dbf56b1</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2FS0163-7258%2803%2900038-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0163-7258%252803%252900038-X%26sid%3Dliteratum%253Aachs%26aulast%3DPin%26aufirst%3DJ.%2BP.%26aulast%3DGalvez%26aufirst%3DT.%26aulast%3DPrezeau%26aufirst%3DL.%26atitle%3DEvolution%252C%2520structure%252C%2520and%2520activation%2520mechanism%2520of%2520family%25203%252FC%2520G-protein-coupled%2520receptors%26jtitle%3DPharmacol.%2520Ther.%26date%3D2003%26volume%3D98%26spage%3D325%26epage%3D354" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Brauner-Osborne, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wellendorph, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jensen, A. A.</span><span> </span><span class="NLM_article-title">Structure, pharmacology and therapeutic prospects of family C G-protein coupled receptors</span> <span class="citation_source-journal">Curr. Drug Targets</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">169</span><span class="NLM_x">–</span> <span class="NLM_lpage">184</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm500496m&amp;key=10.2174%2F138945007779315614" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Fjm500496m&amp;key=17266540" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm500496m&amp;key=1%3ACAS%3A280%3ADC%252BD2s%252FmtF2kuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2007&pages=169-184&author=H.+Brauner-Osborneauthor=P.+Wellendorphauthor=A.+A.+Jensen&title=Structure%2C+pharmacology+and+therapeutic+prospects+of+family+C+G-protein+coupled+receptors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Structure, pharmacology and therapeutic prospects of family C G-protein coupled receptors</span></div><div class="casAuthors">Brauner-Osborne Hans; Wellendorph Petrine; Jensen Anders A</div><div class="citationInfo"><span class="NLM_cas:title">Current drug targets</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">169-84</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Family C of G-protein coupled receptors (GPCRs) from humans is constituted by eight metabotropic glutamate (mGlu(1-8)) receptors, two heterodimeric gamma-aminobutyric acid(B) (GABA(B)) receptors, a calcium-sensing receptor (CaR), three taste (T1R) receptors, a promiscuous L-alpha-amino acid receptor (GPRC6A), and five orphan receptors.  Aside from the orphan receptors, the family C GPCRs are characterised by a large amino-terminal domain, which bind the endogenous orthosteric agonists.  Recently, a number of allosteric modulators binding to the seven transmembrane domains of the receptors have also been reported.  Family C GPCRs regulate a number of important physiological functions and are thus intensively pursued as drug targets.  So far, two drugs acting at family C receptors (the GABA(B) agonist baclofen and the positive allosteric CaR modulator cinacalcet) have been marketed.  Cinacalcet is the first allosteric GPCR modulator to enter the market, which demonstrates that the therapeutic principle of allosteric modulation can also be extended to this important drug target class.  In this review we outline the structure and function of family C GPCRs with particular focus on the ligand binding sites, and we present the most important pharmacological agents and the therapeutic prospects of the receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRMO1HRaArq6WxpATR2EQURfW6udTcc2eYx2irSuco1d7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2s%252FmtF2kuw%253D%253D&md5=242ec346ee4fd59c033b5574983fd164</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.2174%2F138945007779315614&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138945007779315614%26sid%3Dliteratum%253Aachs%26aulast%3DBrauner-Osborne%26aufirst%3DH.%26aulast%3DWellendorph%26aufirst%3DP.%26aulast%3DJensen%26aufirst%3DA.%2BA.%26atitle%3DStructure%252C%2520pharmacology%2520and%2520therapeutic%2520prospects%2520of%2520family%2520C%2520G-protein%2520coupled%2520receptors%26jtitle%3DCurr.%2520Drug%2520Targets%26date%3D2007%26volume%3D8%26spage%3D169%26epage%3D184" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Lavreysen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dautzenberg, F.</span><span> </span><span class="NLM_article-title">Therapeutic potential of group III metabotropic glutamate receptors</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">671</span><span class="NLM_x">–</span> <span class="NLM_lpage">684</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Fjm500496m&amp;key=10.2174%2F092986708783885246" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Fjm500496m&amp;key=18336281" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm500496m&amp;key=1%3ACAS%3A528%3ADC%252BD1cXnsVyitrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2008&pages=671-684&author=H.+Lavreysenauthor=F.+Dautzenberg&title=Therapeutic+potential+of+group+III+metabotropic+glutamate+receptors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic potential of group III metabotropic glutamate receptors</span></div><div class="casAuthors">Lavreysen, Hilde; Dautzenberg, Frank M.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">671-684</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Metabotropic glutamate (mGlu) receptors have received much attention, driven by a strong belief in the potential of these modulatory glutamate receptors as drug targets.  So far, major drug discovery programs have largely focused on group I (mGlu1 and 5) and II (mGlu2 and 3) mGlu receptors, which have been implicated in neuropathol. and various psychiatric disorders.  The four group III representatives (mGlu4, mGlu6, mGlu7 and mGlu8) are less understood, mainly due to the paucity of specific compds.  Recent advances in the identification of selective or specific compds., and the generation of transgenic animals have, however, revealed important insights into the potential role of group III receptors in the pathophysiol. of neurol. and mood disorders.  Activation of the mGlu4 receptor seems to be beneficial for treating Parkinson-like symptoms and a potential role in the treatment of mood disorders is slowly growing.  Similarly, genetic inactivation studies and usage of relatively selective agonists strongly support the involvement of the mGlu8 receptor for anxiety disorders.  In contrast, controversial data have been obtained for the mGlu7 receptor.  While mGlu7 receptor-deficient animals show an anxiolytic profile in several in vivo readouts, the first selective allosteric agonist AMN082 has also been reported to improve anxiety-like behavior despite activating the stress axis.  The least investigated receptor remains the mGlu6 receptor, which is mostly based on its predominant expression in the retina.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGospyk97dw1LbVg90H21EOLACvtfcHk0ljQht_ArwebVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXnsVyitrc%253D&md5=a1c617d857505cdc80f35259f8ddd31d</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.2174%2F092986708783885246&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986708783885246%26sid%3Dliteratum%253Aachs%26aulast%3DLavreysen%26aufirst%3DH.%26aulast%3DDautzenberg%26aufirst%3DF.%26atitle%3DTherapeutic%2520potential%2520of%2520group%2520III%2520metabotropic%2520glutamate%2520receptors%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2008%26volume%3D15%26spage%3D671%26epage%3D684" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Niswender, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conn, P. J.</span><span> </span><span class="NLM_article-title">Metabotropic glutamate receptors: physiology, pharmacology, and disease</span> <span class="citation_source-journal">Annu. Rev. Pharmacol. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">295</span><span class="NLM_x">–</span> <span class="NLM_lpage">322</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Fjm500496m&amp;key=10.1146%2Fannurev.pharmtox.011008.145533" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Fjm500496m&amp;key=20055706" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Fjm500496m&amp;key=1%3ACAS%3A528%3ADC%252BC3cXisVelurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2010&pages=295-322&author=C.+M.+Niswenderauthor=P.+J.+Conn&title=Metabotropic+glutamate+receptors%3A+physiology%2C+pharmacology%2C+and+disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Metabotropic glutamate receptors: physiology, pharmacology, and disease</span></div><div class="casAuthors">Niswender, Colleen M.; Conn, P. Jeffrey</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Pharmacology and Toxicology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">295-322</span>CODEN:
                <span class="NLM_cas:coden">ARPTDI</span>;
        ISSN:<span class="NLM_cas:issn">0362-1642</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  The metabotropic glutamate receptors (mGluRs) are family C G-protein-coupled receptors that participate in the modulation of synaptic transmission and neuronal excitability throughout the central nervous system.  The mGluRs bind glutamate within a large extracellular domain and transmit signals through the receptor protein to intracellular signaling partners.  A great deal of progress was made in detg. the mechanisms by which mGluRs are activated, proteins with which they interact, and orthosteric and allosteric ligands that can modulate receptor activity.  The widespread expression of mGluRs makes these receptors particularly attractive drug targets, and recent studies continue to validate the therapeutic utility of mGluR ligands in neurol. and psychiatric disorders such as Alzheimer's disease, Parkinson's disease, anxiety, depression, and schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9idcZk-YH9LVg90H21EOLACvtfcHk0lgtFz-yHEldxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXisVelurg%253D&md5=4e7c2fa7dec6b3e3227e32fb7653423b</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1146%2Fannurev.pharmtox.011008.145533&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.pharmtox.011008.145533%26sid%3Dliteratum%253Aachs%26aulast%3DNiswender%26aufirst%3DC.%2BM.%26aulast%3DConn%26aufirst%3DP.%2BJ.%26atitle%3DMetabotropic%2520glutamate%2520receptors%253A%2520physiology%252C%2520pharmacology%252C%2520and%2520disease%26jtitle%3DAnnu.%2520Rev.%2520Pharmacol.%2520Toxicol.%26date%3D2010%26volume%3D50%26spage%3D295%26epage%3D322" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Wright, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salhoff, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kingston, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calligaro, D. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Monn, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schoepp, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marek, G. J.</span><span> </span><span class="NLM_article-title">CNS distribution of metabotropic glutamate 2 and 3 receptors: transgenic mice and [3H]LY459477 autoradiography</span> <span class="citation_source-journal">Neuropharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">89</span><span class="NLM_x">–</span> <span class="NLM_lpage">98</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Fjm500496m&amp;key=10.1016%2Fj.neuropharm.2012.01.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Fjm500496m&amp;key=22313530" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Fjm500496m&amp;key=1%3ACAS%3A528%3ADC%252BC38XisFKnt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2013&pages=89-98&author=R.+A.+Wrightauthor=B.+G.+Johnsonauthor=C.+Zhangauthor=C.+Salhoffauthor=A.+E.+Kingstonauthor=D.+O.+Calligaroauthor=J.+A.+Monnauthor=D.+D.+Schoeppauthor=G.+J.+Marek&title=CNS+distribution+of+metabotropic+glutamate+2+and+3+receptors%3A+transgenic+mice+and+%5B3H%5DLY459477+autoradiography"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">CNS distribution of metabotropic glutamate 2 and 3 receptors: Transgenic mice and [3H]LY459477 autoradiography</span></div><div class="casAuthors">Wright, Rebecca A.; Johnson, Bryan G.; Zhang, Ce; Salhoff, Craig; Kingston, Ann E.; Calligaro, David O.; Monn, James A.; Schoepp, Darryle D.; Marek, Gerard J.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">89-98</span>CODEN:
                <span class="NLM_cas:coden">NEPHBW</span>;
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Group II metabotropic glutamate (mGlu) receptor agonists were efficacious in randomized clin. research trials for schizophrenia and generalized anxiety disorder.  The regional quantification of mGlu2 and mGlu3 receptors remains unknown.  A selective and structurally novel mGlu2/3 receptor agonist, 2-amino-4-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (LY 459477) was tritiated and the distribution of mGlu2 and mGlu3 receptors was studied in transgenic mice lacking either mGlu2, mGlu3 or both receptors.  LY 459477 is an agonist with 1-2 nM potency for rodent and human mGlu2 and mGlu3 receptors.  The functional selectivity of LY 459477 was demonstrated by over 640-fold selectivity and the displacement binding selectivity was greater than 320-fold for all glutamate receptors except mGlu6 (∼230-fold).  More than 1000-fold selectivity was demonstrated for all non-glutamate receptors known to be targeted by antipsychotic drugs.  Like atypical antipsychotic drugs, LY 459477 reversed in vitro electrophysiol. effects of a serotonergic hallucinogen and behavioral effects of phencyclidine or amphetamine.  There was virtually no binding of [3H]LY459477 to any brain region in mice with a deletion of both mGlu2 and mGlu3 receptors.  Regions enriched in mGlu2 receptors included the medial prefrontal cortex, select hippocampal regions, the medial mammillary nucleus, the medial habenula, and the cerebellar granular cell layer.  Regions enriched in mGlu3 receptors were the dorsolateral entorhinal cortex, the hippocampal CA1 field, the piriform cortex, the substantia nigra, the thalamic reticular nucleus, and primary sensory thalamic nuclei.  These findings suggest [3H]LY 459477 should be a useful tool to further define the role of mGlu2 and mGlu3 receptors throughout the brain with respect to major neuropsychiatric syndromes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqnwwF-vjfXbVg90H21EOLACvtfcHk0lgtFz-yHEldxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XisFKnt7g%253D&md5=b917b3e90d301fe96be384030305fab6</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2012.01.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2012.01.019%26sid%3Dliteratum%253Aachs%26aulast%3DWright%26aufirst%3DR.%2BA.%26aulast%3DJohnson%26aufirst%3DB.%2BG.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DSalhoff%26aufirst%3DC.%26aulast%3DKingston%26aufirst%3DA.%2BE.%26aulast%3DCalligaro%26aufirst%3DD.%2BO.%26aulast%3DMonn%26aufirst%3DJ.%2BA.%26aulast%3DSchoepp%26aufirst%3DD.%2BD.%26aulast%3DMarek%26aufirst%3DG.%2BJ.%26atitle%3DCNS%2520distribution%2520of%2520metabotropic%2520glutamate%25202%2520and%25203%2520receptors%253A%2520transgenic%2520mice%2520and%2520%255B3H%255DLY459477%2520autoradiography%26jtitle%3DNeuropharmacology%26date%3D2013%26volume%3D66%26spage%3D89%26epage%3D98" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Schoepp, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marek, G. J.</span><span> </span><span class="NLM_article-title">Preclinical pharmacology of mGluR2/3 receptor agonists: novel agents for schizophrenia?</span> <span class="citation_source-journal">Curr. Drug Targets: CNS Neurol. Disord.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">215</span><span class="NLM_x">–</span> <span class="NLM_lpage">225</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Fjm500496m&amp;key=10.2174%2F1568007024606177" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Fjm500496m&amp;key=12769628" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Fjm500496m&amp;key=1%3ACAS%3A528%3ADC%252BD38XjvV2nu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2002&pages=215-225&author=D.+D.+Schoeppauthor=G.+J.+Marek&title=Preclinical+pharmacology+of+mGluR2%2F3+receptor+agonists%3A+novel+agents+for+schizophrenia%3F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical pharmacology of mGlu2/3 receptor agonists: novel agents for schizophrenia?</span></div><div class="casAuthors">Schoepp, Darryle D.; Marek, Gerard J.</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Targets: CNS & Neurological Disorders</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">215-225</span>CODEN:
                <span class="NLM_cas:coden">CDTCCC</span>;
        ISSN:<span class="NLM_cas:issn">1568-007X</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Agonists for mGlu2/3 receptors decrease the evoked release of glutamate at certain (ie. forebrain / limbic) glutamatergic synapses, indicating that the functional role of mGlu2 and/or mGlu3 receptors is to suppress glutamate excitations.  This offers a mechanism for dampening glutamate excitation under pathol. states resulting from excessive glutamate release.  Based, in part, on the psychotomimetic actions of phencyclidine (PCP)-like drugs, excessive or pathol. glutamate release has been implicated in a no. of clin. conditions including psychosis.  With this in mind, the pharmacol. of multiple mGlu2/3 receptor agonists have been investigated in PCP treated rats.  Agonists for mGlu2/3 receptors such as LY354740 and LY379268 have been shown to block certain behavioral responses to PCP in rats.  The effects of mGlu2/3 agonists on PCP-induced behaviors are blocked by a low doses of a selective mGlu2/3 receptor antagonist, indicating that these actions are mediated via mGlu2/3 receptors.  In addn., mGlu2/3 agonists potently suppress glutamate release in rat prefrontal cortex, as reflected by excitatory post-synaptic potentials (EPSPs) induced by serotonin (5-HT) acting on 5HT2A receptors.  These actions of LY354740 and LY379268 are also blocked by a selective mGlu2/3 antagonist.  Atypical antipsychotic drugs such as clozapine also suppress 5-HT-induced EPSPs in this brain region, thus suggesting a common pathway for the actions of atypical antipsychotic drugs and mGlu2/3 receptor agonists.  As glutamatergic dysfunction has been implicated in psychotic states and possibly in the etiol. of schizophrenia, clin. studies with mGlu2/3 agonists may be warranted to further explore the validity of the glutamatergic hypothesis of schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPEl6C2-lj4rVg90H21EOLACvtfcHk0lgtFz-yHEldxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XjvV2nu7o%253D&md5=7b0d86049ef459f8bc419e63cfd6b653</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.2174%2F1568007024606177&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568007024606177%26sid%3Dliteratum%253Aachs%26aulast%3DSchoepp%26aufirst%3DD.%2BD.%26aulast%3DMarek%26aufirst%3DG.%2BJ.%26atitle%3DPreclinical%2520pharmacology%2520of%2520mGluR2%252F3%2520receptor%2520agonists%253A%2520novel%2520agents%2520for%2520schizophrenia%253F%26jtitle%3DCurr.%2520Drug%2520Targets%253A%2520CNS%2520Neurol.%2520Disord.%26date%3D2002%26volume%3D1%26spage%3D215%26epage%3D225" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Moghaddam, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adams, B. W.</span><span> </span><span class="NLM_article-title">Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">281</span><span class="NLM_x">, </span> <span class="NLM_fpage">477</span><span class="NLM_x">–</span> <span class="NLM_lpage">484</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=281&publication_year=1998&pages=477-484&author=B.+Moghaddamauthor=B.+W.+Adams&title=Reversal+of+phencyclidine+effects+by+a+group+II+metabotropic+glutamate+receptor+agonist+in+rats"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMoghaddam%26aufirst%3DB.%26aulast%3DAdams%26aufirst%3DB.%2BW.%26atitle%3DReversal%2520of%2520phencyclidine%2520effects%2520by%2520a%2520group%2520II%2520metabotropic%2520glutamate%2520receptor%2520agonist%2520in%2520rats%26jtitle%3DScience%26date%3D1998%26volume%3D281%26spage%3D477%26epage%3D484" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Cartmell, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Monn, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schoepp, D. D.</span><span> </span><span class="NLM_article-title">The metabotropic glutamate 2/3 receptor agonists LY354740 and LY379268 selectively attenuate phencyclidine versus d-amphetamine motor behaviors in rats</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">291</span><span class="NLM_x">, </span> <span class="NLM_fpage">161</span><span class="NLM_x">–</span> <span class="NLM_lpage">170</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Fjm500496m&amp;key=10490900" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Fjm500496m&amp;key=1%3ACAS%3A528%3ADyaK1MXmtlaks7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=291&publication_year=1999&pages=161-170&author=J.+Cartmellauthor=J.+A.+Monnauthor=D.+D.+Schoepp&title=The+metabotropic+glutamate+2%2F3+receptor+agonists+LY354740+and+LY379268+selectively+attenuate+phencyclidine+versus+d-amphetamine+motor+behaviors+in+rats"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">The metabotropic glutamate 2/3 receptor agonists LY354740 and LY379268 selectively attenuate phencyclidine versus d-amphetamine motor behaviors in rats</span></div><div class="casAuthors">Cartmell, Jayne; Monn, James A.; Schoepp, Darryle D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">291</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">161-170</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Previous animal studies have indicated that drugs targeted at metabotropic glutamate (mGlu) receptors may be useful for treatment of psychosis.  In this article, the effects of the novel, potent, and selective mGlu2/3 receptor agonists LY354740 and LY379268, and the clin. effective agents clozapine and haloperidol, were investigated using phencyclidine (PCP; 5 mg/kg)- vs. d-amphetamine (AMP; 3 mg/kg)-evoked motor activities.  LY354740 (1-10 mg/kg s.c.), LY379268 (0.3-3 mg/kg s.c.), clozapine (1-10 mg/kg s.c.), and haloperidol (0.03-1 mg/kg s.c.) reversed the increases in ambulations, fine motor (nonambulatory) movements, and decreased time at rest evoked by PCP.  Furthermore, the inhibitions of the PCP response by the mGlu2/3 agonist LY379268, but not by clozapine, were completely reversed by the selective mGlu2/3 receptor antagonist LY341495.  Doses of LY354740 and LY379268 that blocked the effects on PCP had no effects on rotorod performance, and (with the exception of rearing behavior) had minimal effects on AMP-evoked motor activities.  Clozapine blocked AMP-induced rearing but enhanced AMP-induced ambulations and fine movements at the lower doses (1 and 3 mg/kg).  Unlike the mGlu2/3 agonists, the highest dose of clozapine tested (10 mg/kg) impaired animals on the rotorod.  Haloperidol potently blocked all PCP and AMP effects, but only at doses assocd. with motor impairment.  These data demonstrate that mGlu2/3 receptor agonists act via a unique mechanism to selectively block PCP-induced behaviors.  Moreover, the marked mGlu2/3 receptor-mediated inhibitions of PCP-evoked behaviors by LY354740 and LY379268, with minimal effects on AMP, may indicate potential antipsychotic effects in humans in the absence of dopamine mediated extrapyramidal side effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpj6C09T4kWFLVg90H21EOLACvtfcHk0lgftBIeZ6G_oA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXmtlaks7g%253D&md5=93425a0c85f8dfbea2a7cd5323e645c2</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCartmell%26aufirst%3DJ.%26aulast%3DMonn%26aufirst%3DJ.%2BA.%26aulast%3DSchoepp%26aufirst%3DD.%2BD.%26atitle%3DThe%2520metabotropic%2520glutamate%25202%252F3%2520receptor%2520agonists%2520LY354740%2520and%2520LY379268%2520selectively%2520attenuate%2520phencyclidine%2520versus%2520d-amphetamine%2520motor%2520behaviors%2520in%2520rats%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1999%26volume%3D291%26spage%3D161%26epage%3D170" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Patil, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martenyi, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lowe, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jackson, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andreev, B. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Avedisova, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bardenstein, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gurovich, I. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morozova, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mosolov, S. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neznanov, N. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reznik, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smulevich, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tochilov, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Monn, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schoepp, D. D.</span><span> </span><span class="NLM_article-title">Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial</span> <span class="citation_source-journal">Nat. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">1102</span><span class="NLM_x">–</span> <span class="NLM_lpage">1107</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Fjm500496m&amp;key=10.1038%2Fnm1632" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Fjm500496m&amp;key=17767166" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Fjm500496m&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVSgtrvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2007&pages=1102-1107&author=S.+T.+Patilauthor=L.+Zhangauthor=F.+Martenyiauthor=S.+L.+Loweauthor=K.+A.+Jacksonauthor=B.+V.+Andreevauthor=A.+S.+Avedisovaauthor=L.+M.+Bardensteinauthor=I.+Y.+Gurovichauthor=M.+A.+Morozovaauthor=S.+N.+Mosolovauthor=N.+G.+Neznanovauthor=A.+M.+Reznikauthor=A.+B.+Smulevichauthor=V.+A.+Tochilovauthor=B.+G.+Johnsonauthor=J.+A.+Monnauthor=D.+D.+Schoepp&title=Activation+of+mGlu2%2F3+receptors+as+a+new+approach+to+treat+schizophrenia%3A+a+randomized+Phase+2+clinical+trial"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial</span></div><div class="casAuthors">Patil, Sandeep T.; Zhang, Lu; Martenyi, Ferenc; Lowe, Stephen L.; Jackson, Kimberley A.; Andreev, Boris V.; Avedisova, Alla S.; Bardenstein, Leonid M.; Gurovich, Issak Y.; Morozova, Margarita A.; Mosolov, Sergey N.; Neznanov, Nikolai G.; Reznik, Alexander M.; Smulevich, Anatoly B.; Tochilov, Vladimir A.; Johnson, Bryan G.; Monn, James A.; Schoepp, Darryle D.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1102-1107</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Schizophrenia is a chronic, complex and heterogeneous mental disorder, with pathol. features of disrupted neuronal excitability and plasticity within limbic structures of the brain.  These pathol. features manifest behaviorally as pos. symptoms (including hallucinations, delusions and thought disorder), neg. symptoms (such as social withdrawal, apathy and emotional blunting) and other psychopathol. symptoms (such as psychomotor retardation, lack of insight, poor attention and impulse control).  Altered glutamate neurotransmission has for decades been linked to schizophrenia, but all commonly prescribed antipsychotics act on dopamine receptors.  LY404039 is a selective agonist for metabotropic glutamate 2/3 (mGlu2/3) receptors and has shown antipsychotic potential in animal studies.  With data from rodents, we provide new evidence that mGlu2/3 receptor agonists work by a distinct mechanism different from that of olanzapine.  To clin. test this mechanism, an oral prodrug of LY404039 (LY2140023) was evaluated in schizophrenic patients with olanzapine as an active control in a randomized, three-armed, double-blind, placebo-controlled study.  Treatment with LY2140023, like treatment with olanzapine, was safe and well-tolerated; treated patients showed statistically significant improvements in both pos. and neg. symptoms of schizophrenia compared to placebo (P < 0.001 at week 4).  Notably, patients treated with LY2140023 did not differ from placebo-treated patients with respect to prolactin elevation, extrapyramidal symptoms or wt. gain.  These data suggest that mGlu2/3 receptor agonists have antipsychotic properties and may provide a new alternative for the treatment of schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYtB0jdSzAQrVg90H21EOLACvtfcHk0lgftBIeZ6G_oA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVSgtrvF&md5=afab88e888cba7e72e14c4e949f894d7</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2Fnm1632&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm1632%26sid%3Dliteratum%253Aachs%26aulast%3DPatil%26aufirst%3DS.%2BT.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DMartenyi%26aufirst%3DF.%26aulast%3DLowe%26aufirst%3DS.%2BL.%26aulast%3DJackson%26aufirst%3DK.%2BA.%26aulast%3DAndreev%26aufirst%3DB.%2BV.%26aulast%3DAvedisova%26aufirst%3DA.%2BS.%26aulast%3DBardenstein%26aufirst%3DL.%2BM.%26aulast%3DGurovich%26aufirst%3DI.%2BY.%26aulast%3DMorozova%26aufirst%3DM.%2BA.%26aulast%3DMosolov%26aufirst%3DS.%2BN.%26aulast%3DNeznanov%26aufirst%3DN.%2BG.%26aulast%3DReznik%26aufirst%3DA.%2BM.%26aulast%3DSmulevich%26aufirst%3DA.%2BB.%26aulast%3DTochilov%26aufirst%3DV.%2BA.%26aulast%3DJohnson%26aufirst%3DB.%2BG.%26aulast%3DMonn%26aufirst%3DJ.%2BA.%26aulast%3DSchoepp%26aufirst%3DD.%2BD.%26atitle%3DActivation%2520of%2520mGlu2%252F3%2520receptors%2520as%2520a%2520new%2520approach%2520to%2520treat%2520schizophrenia%253A%2520a%2520randomized%2520Phase%25202%2520clinical%2520trial%26jtitle%3DNat.%2520Med.%26date%3D2007%26volume%3D13%26spage%3D1102%26epage%3D1107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Kinon, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Millen, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osuntokun, O. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kollack-Walker, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kimberley, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ludmila, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Natalia, J.</span><span> </span><span class="NLM_article-title">A multicenter, inpatient, phase 2, double-blind, placebo-controled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia</span> <span class="citation_source-journal">J. Clin. Psychopharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">349</span><span class="NLM_x">–</span> <span class="NLM_lpage">355</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Fjm500496m&amp;key=10.1097%2FJCP.0b013e318218dcd5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Fjm500496m&amp;key=21508856" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Fjm500496m&amp;key=1%3ACAS%3A528%3ADC%252BC3MXltlyrtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2011&pages=349-355&author=B.+J.+Kinonauthor=L.+Zhangauthor=B.+A.+Millenauthor=O.+O.+Osuntokunauthor=J.+E.+Williamsauthor=S.+Kollack-Walkerauthor=J.+Kimberleyauthor=K.+Ludmilaauthor=J.+Natalia&title=A+multicenter%2C+inpatient%2C+phase+2%2C+double-blind%2C+placebo-controled+dose-ranging+study+of+LY2140023+monohydrate+in+patients+with+DSM-IV+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia</span></div><div class="casAuthors">Kinon, Bruce J.; Zhang, Lu; Millen, Brian A.; Osuntokun, Olawale O.; Williams, Judy E.; Kollack-Walker, Sara; Jackson, Kimberley; Kryzhanovskaya, Ludmila; Jarkova, Natalia</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Psychopharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">349-355</span>CODEN:
                <span class="NLM_cas:coden">JCPYDR</span>;
        ISSN:<span class="NLM_cas:issn">0271-0749</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">The primary objective of this study was to test the hypothesis that 1 or more dose levels of LY2140023 monohydrate, an oral prodrug of the potent metabotropic glutamate (mGlu) 2/3 receptor agonist LY404039, given to patients with schizophrenia for 4 wk would demonstrate significantly greater efficacy than placebo.  The HBBI study was a multicenter, randomized, double-blind, parallel, placebo- and active-controlled trial.  Male and female patients aged 18 to 65 years who met the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria for schizophrenia were randomized in a 2:2:2:2:2:1 ratio to receive 5-, 20-, 40-, or 80-mg LY2140023 monohydrate twice daily, placebo twice daily, or placebo (am) and 15 mg of olanzapine (pm) daily.  Efficacy was defined as the change from baseline on the Pos. and Neg. Syndrome Scale (PANSS) total score assessed at 4 wk.  The primary anal. did not show that any of the 4 LY2140023 monohydrate doses were more efficacious than placebo as measured by the PANSS total score.  Similarly, olanzapine did not significantly sep. from placebo.  A higher-than-anticipated treatment effect (14.6-point improvement) in the placebo group was obsd. on PANSS total score.  LY2140023 monohydrate was generally well tolerated, although 4 patients reported the serious adverse event of convulsion.  LY2140023 monohydrate-treated patients showed little change in dopamine-related adverse events and wt.  The results of the HBBI study are considered to be inconclusive because LY2140023 monohydrate and the active control olanzapine did not sep. from placebo in the treatment of patients with acutely exacerbated schizophrenia.  Addnl. efficacy, safety, and tolerability testing are needed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvjveJZO8DRLVg90H21EOLACvtfcHk0lgftBIeZ6G_oA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXltlyrtLg%253D&md5=e7e675c1bc334c0d49f9a72783dca976</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1097%2FJCP.0b013e318218dcd5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FJCP.0b013e318218dcd5%26sid%3Dliteratum%253Aachs%26aulast%3DKinon%26aufirst%3DB.%2BJ.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DMillen%26aufirst%3DB.%2BA.%26aulast%3DOsuntokun%26aufirst%3DO.%2BO.%26aulast%3DWilliams%26aufirst%3DJ.%2BE.%26aulast%3DKollack-Walker%26aufirst%3DS.%26aulast%3DKimberley%26aufirst%3DJ.%26aulast%3DLudmila%26aufirst%3DK.%26aulast%3DNatalia%26aufirst%3DJ.%26atitle%3DA%2520multicenter%252C%2520inpatient%252C%2520phase%25202%252C%2520double-blind%252C%2520placebo-controled%2520dose-ranging%2520study%2520of%2520LY2140023%2520monohydrate%2520in%2520patients%2520with%2520DSM-IV%2520schizophrenia%26jtitle%3DJ.%2520Clin.%2520Psychopharmacol.%26date%3D2011%26volume%3D31%26spage%3D349%26epage%3D355" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Kinon, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gómez, J. C.</span><span> </span><span class="NLM_article-title">Clinical development of pomaglumetad methionil: a non-dopaminergic treatment for schizophrenia</span> <span class="citation_source-journal">Neuropharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">82</span><span class="NLM_x">–</span> <span class="NLM_lpage">86</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2013&pages=82-86&author=B.+J.+Kinonauthor=J.+C.+G%C3%B3mez&title=Clinical+development+of+pomaglumetad+methionil%3A+a+non-dopaminergic+treatment+for+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKinon%26aufirst%3DB.%2BJ.%26aulast%3DG%25C3%25B3mez%26aufirst%3DJ.%2BC.%26atitle%3DClinical%2520development%2520of%2520pomaglumetad%2520methionil%253A%2520a%2520non-dopaminergic%2520treatment%2520for%2520schizophrenia%26jtitle%3DNeuropharmacology%26date%3D2013%26volume%3D66%26spage%3D82%26epage%3D86" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span>Lilly Stops Phase III development of pomaglumetad methionil for the treatment of schizophrenia based on efficacy results; <span class="NLM_publisher-name">Eli Lilly and Co.</span>: <span class="NLM_publisher-loc">Indianapolis, IN</span>,<span class="NLM_x"> </span><span class="NLM_year">2012</span><span class="NLM_x">; </span><a href="https://investor.lilly.com/releasedetail.cfm?ReleaseID=703018" class="extLink">https://investor.lilly.com/releasedetail.cfm?ReleaseID=703018</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Lilly+Stops+Phase+III+development+of+pomaglumetad+methionil+for+the+treatment+of+schizophrenia+based+on+efficacy+results%3B+Eli+Lilly+and+Co.%3A+Indianapolis%2C+IN%2C+2012%3B+https%3A%2F%2Finvestor.lilly.com%2Freleasedetail.cfm%3FReleaseID%3D703018."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dreport%26sid%3Dliteratum%253Aachs%26jtitle%3DLilly%2520Stops%2520Phase%2520III%2520development%2520of%2520pomaglumetad%2520methionil%2520for%2520the%2520treatment%2520of%2520schizophrenia%2520based%2520on%2520efficacy%2520results%26pub%3DEli%2520Lilly%2520and%2520Co%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Schoepp, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wright, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levine, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaydos, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Potter, W. Z.</span><span> </span><span class="NLM_article-title">LY354740, an mGlu2/3 receptor agonist as a novel approach to treat anxiety/stress</span> <span class="citation_source-journal">Stress</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">189</span><span class="NLM_x">–</span> <span class="NLM_lpage">197</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Fjm500496m&amp;key=10.1080%2F1025389031000146773" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Fjm500496m&amp;key=13129812" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Fjm500496m&amp;key=1%3ACAS%3A528%3ADC%252BD3sXntFCmur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2003&pages=189-197&author=D.+D.+Schoeppauthor=R.+A.+Wrightauthor=L.+R.+Levineauthor=B.+Gaydosauthor=W.+Z.+Potter&title=LY354740%2C+an+mGlu2%2F3+receptor+agonist+as+a+novel+approach+to+treat+anxiety%2Fstress"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">LY354740, an mGlu2/3 receptor agonist as a novel approach to treat anxiety/stress</span></div><div class="casAuthors">Schoepp, Darryle D.; Wright, Rebecca A.; Levine, Louise R.; Gaydos, Brenda; Potter, William Z.</div><div class="citationInfo"><span class="NLM_cas:title">Stress (Abingdon, United Kingdom)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">189-197</span>CODEN:
                <span class="NLM_cas:coden">STREFR</span>;
        ISSN:<span class="NLM_cas:issn">1025-3890</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  Metabotropic glutamate (mGlu) receptors, which include mGlu1-8 receptors, are a heterogeneous family of G-protein coupled receptors (GPCRs) that function to modulate neuronal excitation and plasticity via pre-synaptic, post-synaptic and glial mechanisms.  Agonists for group II mGlu receptors (mGlu2 and mGlu3), such as LY354740, have been shown to suppress enhanced glutamatergic excitations in brain synapses known to be involved in the expression of fear/anxiety in animals and humans.  Systemic administration of LY354740 increases open-arm time in the elevated plus maze in mice under conditions of moderate to severe stress, blocks the expression but not development of fear-potentiated startle in rats, prevents lactate-induced panic-like responses in panic-prone rats, and attenuates certain physiol., behavioral, and neurochem. consequences of acute stress in rodents.  In these preclin. models, LY354740 does not produce the side-effects (e.g. sedation) that are assocd. with other anxiolytic agents such as benzodiazepines.  Early clin. results with LY354740 have demonstrated safety and efficacy in a human anxiety model (panic provocation induced by CO2 challenge).  Collectively, these data indicate mGlu2/3 receptor agonists such as LY354740 represent a promising new approach for treatment of anxiety and stress-related disorders in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfLnHWtpR8orVg90H21EOLACvtfcHk0ljXypXSi_H7bg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXntFCmur4%253D&md5=7928235c6b07bb4a8f83c6f635986a1a</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1080%2F1025389031000146773&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F1025389031000146773%26sid%3Dliteratum%253Aachs%26aulast%3DSchoepp%26aufirst%3DD.%2BD.%26aulast%3DWright%26aufirst%3DR.%2BA.%26aulast%3DLevine%26aufirst%3DL.%2BR.%26aulast%3DGaydos%26aufirst%3DB.%26aulast%3DPotter%26aufirst%3DW.%2BZ.%26atitle%3DLY354740%252C%2520an%2520mGlu2%252F3%2520receptor%2520agonist%2520as%2520a%2520novel%2520approach%2520to%2520treat%2520anxiety%252Fstress%26jtitle%3DStress%26date%3D2003%26volume%3D6%26spage%3D189%26epage%3D197" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Woolley, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pemberton, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bate, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corti, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, D. N. C.</span><span> </span><span class="NLM_article-title">The mGlu2 but not the mGlu3 receptor mediates the actions of the mGluR2/3 agonist, LY379268, in mouse models predictive of antipsychotic activity</span> <span class="citation_source-journal">Psychopharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">196</span><span class="NLM_x">, </span> <span class="NLM_fpage">431</span><span class="NLM_x">–</span> <span class="NLM_lpage">440</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=196&publication_year=2008&pages=431-440&author=M.+L.+Woolleyauthor=D.+J.+Pembertonauthor=S.+Bateauthor=C.+Cortiauthor=D.+N.+C.+Jones&title=The+mGlu2+but+not+the+mGlu3+receptor+mediates+the+actions+of+the+mGluR2%2F3+agonist%2C+LY379268%2C+in+mouse+models+predictive+of+antipsychotic+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWoolley%26aufirst%3DM.%2BL.%26aulast%3DPemberton%26aufirst%3DD.%2BJ.%26aulast%3DBate%26aufirst%3DS.%26aulast%3DCorti%26aufirst%3DC.%26aulast%3DJones%26aufirst%3DD.%2BN.%2BC.%26atitle%3DThe%2520mGlu2%2520but%2520not%2520the%2520mGlu3%2520receptor%2520mediates%2520the%2520actions%2520of%2520the%2520mGluR2%252F3%2520agonist%252C%2520LY379268%252C%2520in%2520mouse%2520models%2520predictive%2520of%2520antipsychotic%2520activity%26jtitle%3DPsychopharmacology%26date%3D2008%26volume%3D196%26spage%3D431%26epage%3D440" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Fell, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Svensson, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schoepp, D. D.</span><span> </span><span class="NLM_article-title">Evidence for the role of mGlu2 not mGlu3 receptors in the preclinical antipsychotic pharmacology of the mGlu2/3 receptor agonist LY404039</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">326</span><span class="NLM_x">, </span> <span class="NLM_fpage">209</span><span class="NLM_x">–</span> <span class="NLM_lpage">217</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Fjm500496m&amp;key=10.1124%2Fjpet.108.136861" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Fjm500496m&amp;key=18424625" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Fjm500496m&amp;key=1%3ACAS%3A528%3ADC%252BD1cXotlyltrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=326&publication_year=2008&pages=209-217&author=M.+J.+Fellauthor=K.+A.+Svenssonauthor=B.+G.+Johnsonauthor=D.+D.+Schoepp&title=Evidence+for+the+role+of+mGlu2+not+mGlu3+receptors+in+the+preclinical+antipsychotic+pharmacology+of+the+mGlu2%2F3+receptor+agonist+LY404039"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Evidence for the role of metabotropic glutamate (mGlu)2 not mGlu3 receptors in the preclinical antipsychotic pharmacology of the mGlu2/3 receptor agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]hexane-4,6-dicarboxylic acid (LY404039)</span></div><div class="casAuthors">Fell, Matthew J.; Svensson, Kjell A.; Johnson, Bryan G.; Schoepp, Darryle D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">326</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">209-217</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">(-)-(1R,4S,5S,6S)-4-Amino-2-sulfonylbicyclo[3.1.0]hexane-4,6-dicarboxylic acid (LY404039) is a potent and selective group II metabotropic glutamate [(mGlu)2 and mGlu3] receptor agonist for which its prodrug LY2140023 [(1R,4S,5S,6S)-2-thiabicyclo[3.1.0]-hexane-4,6-dicarboxylic acid,4-[(2S)-2-amino-4-(methylthio)-1-oxobutyl]amino-, 2,2-dioxide monohydrate] has recently been shown to have efficacy in the treatment of the pos. and neg. symptoms of schizophrenia.  In this article, we use mGlu receptor-deficient mice to investigate the relative contribution of mGlu2 and mGlu3 receptors in mediating the antipsychotic profile of LY404039 in the phencyclidine (PCP) and d-amphetamine (AMP) models of psychosis.  To further explore the mechanism of action of LY404039, we compared the drugs' ability to block PCP-induced hyperlocomotion to that of atypical antipsychotics in wild-type and mice lacking mGlu2/3 receptors.  In wild-type animals, LY404039 (3-30 mg/kg i.p.) significantly reversed AMP (5 mg/kg, i.p.)-induced increases in ambulations, distance traveled, and reduced time spent at rest.  LY404039 reversed PCP (7.5 mg/kg i.p.)-evoked behaviors at 10 mg/kg.  The antipsychotic-like effects of LY404039 (10 mg/kg i.p.) on PCP and AMP-evoked behavioral activation were absent in mGlu2 and mGlu2/3 but not in mGlu3 receptor-deficient mice, indicating that the activation of mGlu2 and not mGlu3 receptors is responsible for the antipsychotic-like effects of the mGlu2/3 receptor agonist LY404039.  In contrast, the atypical antipsychotic drugs clozapine and risperidone inhibited PCP-evoked behaviors in both wild-type and mGlu2/3 receptor-deficient mice.  These data demonstrate that the antipsychotic-like effects of the mGlu2/3 receptor agonist LY404039 in psychostimulant models of psychosis are mechanistically distinct from those of atypical antipsychotic drugs and are dependent on functional mGlu2 and not mGlu3 receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQQM2jpXbmkLVg90H21EOLACvtfcHk0ljXypXSi_H7bg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXotlyltrw%253D&md5=795527aeddef2ee2829f2ae2c6803b6e</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1124%2Fjpet.108.136861&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.108.136861%26sid%3Dliteratum%253Aachs%26aulast%3DFell%26aufirst%3DM.%2BJ.%26aulast%3DSvensson%26aufirst%3DK.%2BA.%26aulast%3DJohnson%26aufirst%3DB.%2BG.%26aulast%3DSchoepp%26aufirst%3DD.%2BD.%26atitle%3DEvidence%2520for%2520the%2520role%2520of%2520mGlu2%2520not%2520mGlu3%2520receptors%2520in%2520the%2520preclinical%2520antipsychotic%2520pharmacology%2520of%2520the%2520mGlu2%252F3%2520receptor%2520agonist%2520LY404039%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2008%26volume%3D326%26spage%3D209%26epage%3D217" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Galici, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Echemendia, N. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguez, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conn, P. J.</span><span> </span><span class="NLM_article-title">A selective allosteric potentiator of metabotropic glutamate (mGlu) 2 receptors has effects similar to an orthosteric mGlu2/3 receptor agonist in mouse models predictive of antipsychotic activity</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">315</span><span class="NLM_x">, </span> <span class="NLM_fpage">1181</span><span class="NLM_x">–</span> <span class="NLM_lpage">1187</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Fjm500496m&amp;key=10.1124%2Fjpet.105.091074" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Fjm500496m&amp;key=16123306" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Fjm500496m&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlalurjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=315&publication_year=2005&pages=1181-1187&author=R.+Galiciauthor=N.+G.+Echemendiaauthor=A.+L.+Rodriguezauthor=P.+J.+Conn&title=A+selective+allosteric+potentiator+of+metabotropic+glutamate+%28mGlu%29+2+receptors+has+effects+similar+to+an+orthosteric+mGlu2%2F3+receptor+agonist+in+mouse+models+predictive+of+antipsychotic+activity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">A selective allosteric potentiator of metabotropic glutamate (mGlu) 2 receptors has effects similar to an orthosteric mGlu2/3 receptor agonist in mouse models predictive of antipsychotic activity</span></div><div class="casAuthors">Galici, Ruggero; Echemendia, Nicholas G.; Rodriguez, Alice L.; Conn, P. Jeffrey</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">315</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1181-1187</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Recent studies suggest that agonists of group II metabotropic glutamate (mGlu) receptors (mGlu2/3) have potential utility as novel therapeutic agents for treatment of psychiatric disorders such as anxiety and schizophrenia.  Agonists of mGlu2/3 receptors block amphetamine- and phencyclidine (PCP)-induced hyperlocomotor activity in rodents, two actions that may predict potential antipsychotic activity of these compds.  We now report that LY487379 [N-(4-(2-methoxyphenoxy)phenyl)-N-(2,2,2-trifluoroethylsulfonyl)pyrid-3-ylmethylamine],a recently described selective allosteric potentiator of mGlu2 receptor, has behavioral effects similar to mGlu2/3 receptor agonists.  LY487379 and LY379268 [(-)-2-oxa-4-aminobicyclo[3.1.0]hexane-4,6-dicarboxylate], an ortho-steric mGlu2/3 receptor agonist, induced similar dose-dependent redns. in PCP- and amphetamine-induced hyperlocomotor activity in C57BL6/J mice at doses that did not significantly alter spontaneous locomotor activity.  These effects were blocked by the mGlu2/3 receptor antagonist LY341495 [(2S)-2-amino-2-[(1S,2S)-2-carboxycycloprop-1-yl]-3-(xanth-9-yl) propanoic acid].  LY487379 had a short duration of action compared with LY379268.  Furthermore, unlike the mGlu2/3 agonist, LY487379 reversed amphetamine-induced disruption of prepulse inhibition of the acoustic startle reflex.  When LY379268 was given chronically, it failed to block amphetamine- and PCP-induced hyperlocomotor activity.  The finding that the effects of an orthosteric mGlu2/3 receptor agonist in these models can be mimicked by a selective allosteric potentiator of mGlu2 suggests that these effects are mediated by the mGlu2 receptor subtype.  Furthermore, these data raise the possibility that a selective allosteric potentiator of mGlu2 receptor could have utility as a novel approach for the treatment of schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvwi3qgWI8frVg90H21EOLACvtfcHk0lgeAkuVaF7FmQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlalurjJ&md5=93effc12fc976519477f1cf4a36e84f5</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1124%2Fjpet.105.091074&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.105.091074%26sid%3Dliteratum%253Aachs%26aulast%3DGalici%26aufirst%3DR.%26aulast%3DEchemendia%26aufirst%3DN.%2BG.%26aulast%3DRodriguez%26aufirst%3DA.%2BL.%26aulast%3DConn%26aufirst%3DP.%2BJ.%26atitle%3DA%2520selective%2520allosteric%2520potentiator%2520of%2520metabotropic%2520glutamate%2520%2528mGlu%2529%25202%2520receptors%2520has%2520effects%2520similar%2520to%2520an%2520orthosteric%2520mGlu2%252F3%2520receptor%2520agonist%2520in%2520mouse%2520models%2520predictive%2520of%2520antipsychotic%2520activity%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2005%26volume%3D315%26spage%3D1181%26epage%3D1187" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Conn, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christopoulos, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindsley, C. W.</span><span> </span><span class="NLM_article-title">Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders</span> <span class="citation_source-journal">Nat. Rev. Drug. Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">41</span><span class="NLM_x">–</span> <span class="NLM_lpage">54</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Fjm500496m&amp;key=10.1038%2Fnrd2760" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Fjm500496m&amp;key=19116626" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Fjm500496m&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsFCkurfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=41-54&author=P.+J.+Connauthor=A.+Christopoulosauthor=C.+W.+Lindsley&title=Allosteric+modulators+of+GPCRs%3A+a+novel+approach+for+the+treatment+of+CNS+disorders"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders</span></div><div class="casAuthors">Conn, P. Jeffrey; Christopoulos, Arthur; Lindsley, Craig W.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">41-54</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Despite G-protein-coupled receptors (GPCRs) being among the most fruitful targets for marketed drugs, intense discovery efforts for several GPCR subtypes have failed to deliver selective drug candidates.  Historically, drug discovery programs for GPCR ligands have been dominated by efforts to develop agonists and antagonists that act at orthosteric sites for endogenous ligands.  However, in recent years, there have been tremendous advances in the discovery of novel ligands for GPCRs that act at allosteric sites to regulate receptor function.  These compds. provide high selectivity, novel modes of efficacy and may lead to novel therapeutic agents for the treatment of multiple psychiatric and neurol. human disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmn5h5XCcPKbVg90H21EOLACvtfcHk0lgeAkuVaF7FmQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsFCkurfF&md5=e109e94fe3e2c1fcfd480dc84c6609f7</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1038%2Fnrd2760&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2760%26sid%3Dliteratum%253Aachs%26aulast%3DConn%26aufirst%3DP.%2BJ.%26aulast%3DChristopoulos%26aufirst%3DA.%26aulast%3DLindsley%26aufirst%3DC.%2BW.%26atitle%3DAllosteric%2520modulators%2520of%2520GPCRs%253A%2520a%2520novel%2520approach%2520for%2520the%2520treatment%2520of%2520CNS%2520disorders%26jtitle%3DNat.%2520Rev.%2520Drug.%2520Discovery%26date%3D2009%26volume%3D8%26spage%3D41%26epage%3D54" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Pin, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parmentier, M.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prezeau, L.</span><span> </span><span class="NLM_article-title">Positive allosteric modulators for g-aminobutyric acidB receptors open new routes for the development of drugs targeting family 3 G-protein-coupled receptors</span> <span class="citation_source-journal">Mol. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">881</span><span class="NLM_x">–</span> <span class="NLM_lpage">884</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2001&pages=881-884&author=J.+P.+Pinauthor=M.-L.+Parmentierauthor=L.+Prezeau&title=Positive+allosteric+modulators+for+g-aminobutyric+acidB+receptors+open+new+routes+for+the+development+of+drugs+targeting+family+3+G-protein-coupled+receptors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPin%26aufirst%3DJ.%2BP.%26aulast%3DParmentier%26aufirst%3DM.-L.%26aulast%3DPrezeau%26aufirst%3DL.%26atitle%3DPositive%2520allosteric%2520modulators%2520for%2520g-aminobutyric%2520acidB%2520receptors%2520open%2520new%2520routes%2520for%2520the%2520development%2520of%2520drugs%2520targeting%2520family%25203%2520G-protein-coupled%2520receptors%26jtitle%3DMol.%2520Pharmacol.%26date%3D2001%26volume%3D60%26spage%3D881%26epage%3D884" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Gjoni, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Urwyler, S.</span><span> </span><span class="NLM_article-title">Receptor activation involving positive allosteric modulation, unlike full agonism, does not result in GABAB receptor desensitization</span> <span class="citation_source-journal">Neuropharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">1293</span><span class="NLM_x">–</span> <span class="NLM_lpage">1299</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2008&pages=1293-1299&author=T.+Gjoniauthor=S.+Urwyler&title=Receptor+activation+involving+positive+allosteric+modulation%2C+unlike+full+agonism%2C+does+not+result+in+GABAB+receptor+desensitization"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGjoni%26aufirst%3DT.%26aulast%3DUrwyler%26aufirst%3DS.%26atitle%3DReceptor%2520activation%2520involving%2520positive%2520allosteric%2520modulation%252C%2520unlike%2520full%2520agonism%252C%2520does%2520not%2520result%2520in%2520GABAB%2520receptor%2520desensitization%26jtitle%3DNeuropharmacology%26date%3D2008%26volume%3D55%26spage%3D1293%26epage%3D1299" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Trabanco, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cid, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lavreysen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macdonald, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tresadern, G.</span><span> </span><span class="NLM_article-title">Progress in the development of positive allosteric modulators of the metabotropic glutamate receptor 2</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">47</span><span class="NLM_x">–</span> <span class="NLM_lpage">68</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Fjm500496m&amp;key=10.2174%2F092986711793979706" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Fjm500496m&amp;key=21110815" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Fjm500496m&amp;key=1%3ACAS%3A528%3ADC%252BC3MXkslahs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2011&pages=47-68&author=A.+A.+Trabancoauthor=J.+M.+Cidauthor=H.+Lavreysenauthor=G.+J.+Macdonaldauthor=G.+Tresadern&title=Progress+in+the+development+of+positive+allosteric+modulators+of+the+metabotropic+glutamate+receptor+2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Progress in the development of positive allosteric modulators of the metabotropic glutamate receptor 2</span></div><div class="casAuthors">Trabanco, A. A.; Cid, J. M.; Lavreysen, H.; MacDonald, G. J.; Tresadern, G.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">47-68</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The metabotropic glutamate type 2 (mGlu2) receptor is a G-protein coupled receptor (GPCR) expressed on presynaptic nerve terminals where it neg. modulates glutamate and GABA release.  Mixed mGlu2/mGlu3 orthosteric agonists such as LY354740 have shown activity in a range of preclin. animal models of anxiety and schizophrenia.  Clin. work with LY354740 demonstrated activity in a CO2 inhalation study suggesting application in the treatment of anxiety related disorders.  Subsequently, a related prodrug LY2140023 demonstrated improvements in pos. and neg. symptoms in patients suffering from schizophrenia.  These mols. exhibit combined mGlu2/mGlu3 activity although there is evidence from knock-out studies that preclin. anti-psychotic effects may be mediated via the mGlu2 receptor.  An alternative avenue for modulating GPCRs is to act via allosteric mechanisms, binding at a different site from the orthosteric agonist.  Since the first discovery of mGlu2 pos. allosteric modulators (PAMs) such as 2,2,2-TEMPS and BINA, multiple families of mGlu2 modulators have been reported and several have entered into clin. development.  This review focuses on recent advances in the development of novel mGlu2 PAMs by anal. of compds. disclosed in research articles and patent literature between 2007 and 2010.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkHtOXKWJY9rVg90H21EOLACvtfcHk0lgeAkuVaF7FmQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXkslahs7g%253D&md5=b4059bdfb0001b97cde8ec0e30032a48</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.2174%2F092986711793979706&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986711793979706%26sid%3Dliteratum%253Aachs%26aulast%3DTrabanco%26aufirst%3DA.%2BA.%26aulast%3DCid%26aufirst%3DJ.%2BM.%26aulast%3DLavreysen%26aufirst%3DH.%26aulast%3DMacdonald%26aufirst%3DG.%2BJ.%26aulast%3DTresadern%26aufirst%3DG.%26atitle%3DProgress%2520in%2520the%2520development%2520of%2520positive%2520allosteric%2520modulators%2520of%2520the%2520metabotropic%2520glutamate%2520receptor%25202%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2011%26volume%3D18%26spage%3D47%26epage%3D68" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Trabanco, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cid, J. M.</span><span> </span><span class="NLM_article-title">mGluR2 positive allosteric modulators (PAMs): a patent review (2009–present)</span> <span class="citation_source-journal">Expert Opin. Ther. Patents</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">629</span><span class="NLM_x">–</span> <span class="NLM_lpage">647</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Fjm500496m&amp;key=10.1517%2F13543776.2013.777043" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Fjm500496m&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmt1Sjtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=629-647&author=A.+A.+Trabancoauthor=J.+M.+Cid&title=mGluR2+positive+allosteric+modulators+%28PAMs%29%3A+a+patent+review+%282009%E2%80%93present%29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">mGluR2 positive allosteric modulators: a patent review (2009 - present)</span></div><div class="casAuthors">Trabanco, Andres A.; Cid, Jose Maria</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">629-647</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: The mGlu2 receptor, which belongs to the group II subfamily of metabotropic glutamate receptors (mGlu) along with the mGlu3 receptor, has proven to be of particular importance in neuropharmacol.  Preferentially expressed on presynaptic nerve terminals, the mGlu2 receptor neg. modulates glutamate and GABA release and is widely distributed in the brain.  High levels of mGlu2 receptors are seen in brain areas such as prefrontal cortex, hippocampus and amygdala where glutamate hyperfunction may be implicated in disorders and diseases such as anxiety and schizophrenia.  Given the promise offered by mGlu2/3 receptor activation, there is increased interest in identifying small mols. which activate the receptor.  A preferred approach is via pos. allosteric modulators (PAMs) which bind at an alternative site to agonists.Areas covered: This review covers the patent applications which were published between Apr. 2009 and Dec. 2012 on PAMs of the mGlu2, and it is a continuation of an earlier review published in this journal.Expert opinion: Advances in medicinal chem. and pharmacol. have set the stage in the field of mGlu2 receptor PAMs.  Compds. currently advancing in clin. trials will soon establish the therapeutic potential of this allosteric approach.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsVxJNadzKPbVg90H21EOLACvtfcHk0ljNduq0tUhMXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmt1Sjtr4%253D&md5=af828df2b2c206094dd373bb93e37363</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1517%2F13543776.2013.777043&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543776.2013.777043%26sid%3Dliteratum%253Aachs%26aulast%3DTrabanco%26aufirst%3DA.%2BA.%26aulast%3DCid%26aufirst%3DJ.%2BM.%26atitle%3DmGluR2%2520positive%2520allosteric%2520modulators%2520%2528PAMs%2529%253A%2520a%2520patent%2520review%2520%25282009%25E2%2580%2593present%2529%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Patents%26date%3D2013%26volume%3D23%26spage%3D629%26epage%3D647" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Lorrain, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schaffhauser, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, U. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baccei, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Correa, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowe, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguez, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varney, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pinkerton, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vernier, J.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bristow, L. J.</span><span> </span><span class="NLM_article-title">Group II mGlu receptor activation suppresses norepinephrine release in the ventral hippocampus and locomotor responses to acute ketamine challenge</span> <span class="citation_source-journal">Neuropsychopharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">1622</span><span class="NLM_x">–</span> <span class="NLM_lpage">1632</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Fjm500496m&amp;key=10.1038%2Fsj.npp.1300238" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Fjm500496m&amp;key=12825094" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Fjm500496m&amp;key=1%3ACAS%3A528%3ADC%252BD3sXmsFeisLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2003&pages=1622-1632&author=D.+S.+Lorrainauthor=H.+Schaffhauserauthor=U.+C.+Campbellauthor=C.+S.+Bacceiauthor=L.+D.+Correaauthor=B.+Roweauthor=D.+E.+Rodriguezauthor=J.+J.+Andersonauthor=M.+A.+Varneyauthor=A.+B.+Pinkertonauthor=J.-M.+Vernierauthor=L.+J.+Bristow&title=Group+II+mGlu+receptor+activation+suppresses+norepinephrine+release+in+the+ventral+hippocampus+and+locomotor+responses+to+acute+ketamine+challenge"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Group II mGlu receptor activation suppresses norepinephrine release in the ventral hippocampus and locomotor responses to acute ketamine challenge</span></div><div class="casAuthors">Lorrain, Daniel S.; Schaffhauser, Herve; Campbell, Una C.; Baccei, Christopher S.; Correa, Lucia D.; Rowe, Blake; Rodriguez, Dana E.; Anderson, Jeffery J.; Varney, Mark A.; Pinkerton, Anthony B.; Vernier, Jean-Michel; Bristow, Linda J.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1622-1632</span>CODEN:
                <span class="NLM_cas:coden">NEROEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-133X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Group II mGlu receptor agonists (eg LY379268 and LY354740) have been shown to reverse many of the behavioral responses to PCP as well as glutamate release elicited by PCP and ketamine.  In the present set of expts., the authors used in vivo microdialysis to show that, in addn. to reversing PCP- and ketamine-evoked glutamate release, group II mGlu receptor stimulation also prevents ketamine-evoked norepinephrine (NE) release.  Pretreating animals with the mixed 2/3 metabotropic glutamate (mGlu2/3) receptor agonist LY379268 (0.3-10 mg/kg) dose-dependently inhibited ketamine (25 mg/kg)-evoked NE release in the ventral hippocampus (VHipp).  Ketamine hyperactivity was also reduced in a similar dose range.  Following the authors' initial observation on NE release, they conducted a series of microinjection expts. to reveal that the inhibitory effects of LY379268 on VHipp NE release may be linked to glutamate transmission within the medial prefrontal cortex.  Finally, the authors were able to mimic the inhibitory effects of LY379268 on ketamine-evoked NE release by using a novel mGlu2 receptor selective pos. modulator.  (+/-) 2,2,2-Trifluoroethyl [3-(1-methyl-butoxy)-phenyl]-pyridin-3-ylmethyl-sulfonamide (2,2,2-TEMPS, characterized through in vitro GTPγS binding) at a dose of 100 mg/kg significantly reduced the NE response.  Together, these results demonstrate a novel means to suppress noradrenergic neurotransmission (i.e. by activating mGlu2 receptors) and may, therefore, have important implications for neuropsychiatric disorders in which aberrant activation of the noradrenergic system is thought to be involved.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1EmzIVF7NI7Vg90H21EOLACvtfcHk0ljNduq0tUhMXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXmsFeisLY%253D&md5=b17d585f28f71d8ef7d52cdcac2697f5</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1038%2Fsj.npp.1300238&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.npp.1300238%26sid%3Dliteratum%253Aachs%26aulast%3DLorrain%26aufirst%3DD.%2BS.%26aulast%3DSchaffhauser%26aufirst%3DH.%26aulast%3DCampbell%26aufirst%3DU.%2BC.%26aulast%3DBaccei%26aufirst%3DC.%2BS.%26aulast%3DCorrea%26aufirst%3DL.%2BD.%26aulast%3DRowe%26aufirst%3DB.%26aulast%3DRodriguez%26aufirst%3DD.%2BE.%26aulast%3DAnderson%26aufirst%3DJ.%2BJ.%26aulast%3DVarney%26aufirst%3DM.%2BA.%26aulast%3DPinkerton%26aufirst%3DA.%2BB.%26aulast%3DVernier%26aufirst%3DJ.-M.%26aulast%3DBristow%26aufirst%3DL.%2BJ.%26atitle%3DGroup%2520II%2520mGlu%2520receptor%2520activation%2520suppresses%2520norepinephrine%2520release%2520in%2520the%2520ventral%2520hippocampus%2520and%2520locomotor%2520responses%2520to%2520acute%2520ketamine%2520challenge%26jtitle%3DNeuropsychopharmacology%26date%3D2003%26volume%3D28%26spage%3D1622%26epage%3D1632" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Johnson, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baez, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jagdmann, G. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Britton, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Large, T. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Callagaro, D. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tizzano, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Monn, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schoepp, D. D.</span><span> </span><span class="NLM_article-title">Discovery of allosteric potentiators for the metabotropic glutamate 2 receptor: synthesis and subtype selectivity of <i>N</i>-(4-(2-methoxyphenoxy)phenyl)-<i>N</i>-(2,2,2-trifluoroethylsulfonyl)pyrid-3-ylmethylamine</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">3189</span><span class="NLM_x">–</span> <span class="NLM_lpage">3192</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm034015u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=3189-3192&author=M.+P.+Johnsonauthor=M.+Baezauthor=G.+E.+Jagdmannauthor=T.+C.+Brittonauthor=T.+H.+Largeauthor=D.+O.+Callagaroauthor=J.+P.+Tizzanoauthor=J.+A.+Monnauthor=D.+D.+Schoepp&title=Discovery+of+allosteric+potentiators+for+the+metabotropic+glutamate+2+receptor%3A+synthesis+and+subtype+selectivity+of+N-%284-%282-methoxyphenoxy%29phenyl%29-N-%282%2C2%2C2-trifluoroethylsulfonyl%29pyrid-3-ylmethylamine"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Fjm034015u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm034015u%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DM.%2BP.%26aulast%3DBaez%26aufirst%3DM.%26aulast%3DJagdmann%26aufirst%3DG.%2BE.%26aulast%3DBritton%26aufirst%3DT.%2BC.%26aulast%3DLarge%26aufirst%3DT.%2BH.%26aulast%3DCallagaro%26aufirst%3DD.%2BO.%26aulast%3DTizzano%26aufirst%3DJ.%2BP.%26aulast%3DMonn%26aufirst%3DJ.%2BA.%26aulast%3DSchoepp%26aufirst%3DD.%2BD.%26atitle%3DDiscovery%2520of%2520allosteric%2520potentiators%2520for%2520the%2520metabotropic%2520glutamate%25202%2520receptor%253A%2520synthesis%2520and%2520subtype%2520selectivity%2520of%2520N-%25284-%25282-methoxyphenoxy%2529phenyl%2529-N-%25282%252C2%252C2-trifluoroethylsulfonyl%2529pyrid-3-ylmethylamine%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D3189%26epage%3D3192" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Pinkerton, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vernier, J.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schaffhauser, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowe, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, U. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguez, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lorrain, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baccei, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daggett, L. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bristow, L. J.</span><span> </span><span class="NLM_article-title">Phenyl-tetrazolyl acetophenones: discovery of positive allosteric potentiators for the metabotropic glutamate 2 receptor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">4595</span><span class="NLM_x">–</span> <span class="NLM_lpage">4599</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm040088h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=4595-4599&author=A.+B.+Pinkertonauthor=J.-M.+Vernierauthor=H.+Schaffhauserauthor=B.+A.+Roweauthor=U.+C.+Campbellauthor=D.+E.+Rodriguezauthor=D.+S.+Lorrainauthor=C.+S.+Bacceiauthor=L.+P.+Daggettauthor=L.+J.+Bristow&title=Phenyl-tetrazolyl+acetophenones%3A+discovery+of+positive+allosteric+potentiators+for+the+metabotropic+glutamate+2+receptor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fjm040088h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm040088h%26sid%3Dliteratum%253Aachs%26aulast%3DPinkerton%26aufirst%3DA.%2BB.%26aulast%3DVernier%26aufirst%3DJ.-M.%26aulast%3DSchaffhauser%26aufirst%3DH.%26aulast%3DRowe%26aufirst%3DB.%2BA.%26aulast%3DCampbell%26aufirst%3DU.%2BC.%26aulast%3DRodriguez%26aufirst%3DD.%2BE.%26aulast%3DLorrain%26aufirst%3DD.%2BS.%26aulast%3DBaccei%26aufirst%3DC.%2BS.%26aulast%3DDaggett%26aufirst%3DL.%2BP.%26aulast%3DBristow%26aufirst%3DL.%2BJ.%26atitle%3DPhenyl-tetrazolyl%2520acetophenones%253A%2520discovery%2520of%2520positive%2520allosteric%2520potentiators%2520for%2520the%2520metabotropic%2520glutamate%25202%2520receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D4595%26epage%3D4599" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Fell, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Witkin, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Falcone, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Katner, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perry, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hart, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rorick-Kehn, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Overshiner, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rasmussen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaney, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benvenga, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marlow, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thompson, L. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lueck, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wafford, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seidel, W. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edgar, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quests, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Felder, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heinz, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nikolayev, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuo, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mayhugh, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khilevich, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ebert, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eckstein, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ackermann, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swanson, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Catlow, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dean, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jackson, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tauscher-Wisniewski, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marek, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schkeryantz, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Svensson, K. A.</span><span> </span><span class="NLM_article-title"><i>N</i>-(4-((2-(Trifluoromethyl)-3-hydroxy-4-(isobutyryl)phenoxy)methyl) benzyl)-1-methyl-1<i>H</i>-imidazole-4-carboxamide (THIIC), a novel metabotropic glutamate 2 potentiator with potential anxiolytic/antidepressant properties: in vivo profiling suggests a link between behavioral and central nervous system neurochemical change</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">336</span><span class="NLM_x">, </span> <span class="NLM_fpage">165</span><span class="NLM_x">–</span> <span class="NLM_lpage">177</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Fjm500496m&amp;key=10.1124%2Fjpet.110.172957" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Fjm500496m&amp;key=20947638" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Fjm500496m&amp;key=1%3ACAS%3A528%3ADC%252BC3MXls1erug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=336&publication_year=2011&pages=165-177&author=M.+J.+Fellauthor=J.+M.+Witkinauthor=J.+F.+Falconeauthor=J.+S.+Katnerauthor=K.+W.+Perryauthor=J.+Hartauthor=L.+Rorick-Kehnauthor=C.+D.+Overshinerauthor=K.+Rasmussenauthor=S.+F.+Chaneyauthor=M.+J.+Benvengaauthor=X.+Liauthor=D.+L.+Marlowauthor=L.+K.+Thompsonauthor=S.+K.+Lueckauthor=K.+A.+Waffordauthor=W.+F.+Seidelauthor=D.+M.+Edgarauthor=A.+T.+Questsauthor=C.+C.+Felderauthor=X.+Wangauthor=B.+A.+Heinzauthor=A.+Nikolayevauthor=M.+S.+Kuoauthor=D.+Mayhughauthor=A.+Khilevichauthor=D.+Zhangauthor=P.+J.+Ebertauthor=J.+A.+Ecksteinauthor=B.+L.+Ackermannauthor=S.+P.+Swansonauthor=J.+T.+Catlowauthor=R.+A.+Deanauthor=K.+Jacksonauthor=S.+Tauscher-Wisniewskiauthor=G.+J.+Marekauthor=J.+M.+Schkeryantzauthor=K.+A.+Svensson&title=N-%284-%28%282-%28Trifluoromethyl%29-3-hydroxy-4-%28isobutyryl%29phenoxy%29methyl%29+benzyl%29-1-methyl-1H-imidazole-4-carboxamide+%28THIIC%29%2C+a+novel+metabotropic+glutamate+2+potentiator+with+potential+anxiolytic%2Fantidepressant+properties%3A+in+vivo+profiling+suggests+a+link+between+behavioral+and+central+nervous+system+neurochemical+change"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">N-(4-((2-(trifluoromethyl)-3-hydroxy-4-(isobutyryl)phenoxy)methyl)benzyl)-1-methyl-1H-imidazole-4-carboxamide (THIIC), a novel metabotropic glutamate 2 potentiator with potential anxiolytic/antidepressant properties: in vivo profiling suggests a link between behavioral and central nervous system neurochemical changes</span></div><div class="casAuthors">Fell, Matthew J.; Witkin, Jeffrey M.; Falcone, Julie F.; Katner, Jason S.; Perry, Kenneth W.; Hart, John; Rorick-Kehn, Linda; Overshiner, Carl D.; Rasmussen, Kurt; Chaney, Stephen F.; Benvenga, Mark J.; Li, Xia; Marlow, Deanna L.; Thompson, Linda K.; Luecke, Susan K.; Wafford, Keith A.; Seidel, Wesley F.; Edgar, Dale M.; Quets, Anne T.; Felder, Christian C.; Wang, XuShan; Heinz, Beverly A.; Nikolayev, Alexander; Kuo, Ming-Shang; Mayhugh, Daniel; Khilevich, Albert; Zhang, Deyi; Ebert, Philip J.; Eckstein, James A.; Ackermann, Bradley L.; Swanson, Steven P.; Catlow, John T.; Dean, Robert A.; Jackson, Kimberley; Tauscher-Wisniewski, Sitra; Marek, Gerard J.; Schkeryantz, Jeffrey M.; Svensson, Kjell A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">336</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">165-177</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The normalization of excessive glutamatergic neurotransmission through the activation of metabotropic glutamate 2 (mGlu2) receptors may have therapeutic potential in a variety of psychiatric disorders, including anxiety/depression and schizophrenia.  Here, we characterize the pharmacol. properties of N-(4-((2-(trifluoromethyl)-3-hydroxy-4-(isobutyryl)phenoxy)methyl)benzyl)-1-methyl-1H-imidazole-4-carboxamide (THIIC), a structurally novel, potent, and selective allosteric potentiator of human and rat mGlu2 receptors (EC50 = 23 and 13 nM, resp.).  THIIC produced anxiolytic-like efficacy in the rat stress-induced hyperthermia assay and the mouse stress-induced elevation of cerebellar cGMP and marble-burying assays.  THIIC also produced robust activity in three assays that detect antidepressant-like activity, including the mouse forced-swim test, the rat differential reinforcement of low rate 72-s assay, and the rat dominant-submissive test, with a maximal response similar to that of impiramine.  Effects of THIIC in the forced-swim test and marble burying were deleted in mGlu2 receptor null mice.  Anal. of sleep EEG showed that THIIC had a sleep-promoting profile with increased non-rapid eye movement (REM) and decreased REM sleep.  THIIC also decreased the dark phase increase in extracellular histamine in the medial prefrontal cortex and decreased levels of the histamine metabolite tele-methylhistamine (t-MeHA) in rat cerebrospinal fluid.  Collectively, these results indicate that the novel mGlu2-pos. allosteric modulator THIIC has robust activity in models used to predict anxiolytic/antidepressant efficacy, substantiating, at least with this mol., differentiation in the biol. impact of mGlu2 potentiation vs. mGlu2/3 orthosteric agonism.  In addn., we provide evidence that sleep EEG and CSF t-MeHA might function as viable biomarker approaches to facilitate the translational development of THIIC and other mGlu2 potentiators.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocfm6DC8ijJrVg90H21EOLACvtfcHk0ljmDd02qnzM9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXls1erug%253D%253D&md5=ab138f946460f041067c5330a1b5217a</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1124%2Fjpet.110.172957&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.110.172957%26sid%3Dliteratum%253Aachs%26aulast%3DFell%26aufirst%3DM.%2BJ.%26aulast%3DWitkin%26aufirst%3DJ.%2BM.%26aulast%3DFalcone%26aufirst%3DJ.%2BF.%26aulast%3DKatner%26aufirst%3DJ.%2BS.%26aulast%3DPerry%26aufirst%3DK.%2BW.%26aulast%3DHart%26aufirst%3DJ.%26aulast%3DRorick-Kehn%26aufirst%3DL.%26aulast%3DOvershiner%26aufirst%3DC.%2BD.%26aulast%3DRasmussen%26aufirst%3DK.%26aulast%3DChaney%26aufirst%3DS.%2BF.%26aulast%3DBenvenga%26aufirst%3DM.%2BJ.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DMarlow%26aufirst%3DD.%2BL.%26aulast%3DThompson%26aufirst%3DL.%2BK.%26aulast%3DLueck%26aufirst%3DS.%2BK.%26aulast%3DWafford%26aufirst%3DK.%2BA.%26aulast%3DSeidel%26aufirst%3DW.%2BF.%26aulast%3DEdgar%26aufirst%3DD.%2BM.%26aulast%3DQuests%26aufirst%3DA.%2BT.%26aulast%3DFelder%26aufirst%3DC.%2BC.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DHeinz%26aufirst%3DB.%2BA.%26aulast%3DNikolayev%26aufirst%3DA.%26aulast%3DKuo%26aufirst%3DM.%2BS.%26aulast%3DMayhugh%26aufirst%3DD.%26aulast%3DKhilevich%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DEbert%26aufirst%3DP.%2BJ.%26aulast%3DEckstein%26aufirst%3DJ.%2BA.%26aulast%3DAckermann%26aufirst%3DB.%2BL.%26aulast%3DSwanson%26aufirst%3DS.%2BP.%26aulast%3DCatlow%26aufirst%3DJ.%2BT.%26aulast%3DDean%26aufirst%3DR.%2BA.%26aulast%3DJackson%26aufirst%3DK.%26aulast%3DTauscher-Wisniewski%26aufirst%3DS.%26aulast%3DMarek%26aufirst%3DG.%2BJ.%26aulast%3DSchkeryantz%26aufirst%3DJ.%2BM.%26aulast%3DSvensson%26aufirst%3DK.%2BA.%26atitle%3DN-%25284-%2528%25282-%2528Trifluoromethyl%2529-3-hydroxy-4-%2528isobutyryl%2529phenoxy%2529methyl%2529%2520benzyl%2529-1-methyl-1H-imidazole-4-carboxamide%2520%2528THIIC%2529%252C%2520a%2520novel%2520metabotropic%2520glutamate%25202%2520potentiator%2520with%2520potential%2520anxiolytic%252Fantidepressant%2520properties%253A%2520in%2520vivo%2520profiling%2520suggests%2520a%2520link%2520between%2520behavioral%2520and%2520central%2520nervous%2520system%2520neurochemical%2520change%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2011%26volume%3D336%26spage%3D165%26epage%3D177" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Johnson, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fitz, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engleman, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Svensson, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schkeryantz, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shekhar, A.</span><span> </span><span class="NLM_article-title">Group II metabotropic glutamate receptor type 2 allosteric potentiators prevent sodium lactate-induced panic-like response in panic-vulnerable rats</span> <span class="citation_source-journal">J. Psychopharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">152</span><span class="NLM_x">–</span> <span class="NLM_lpage">61</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Fjm500496m&amp;key=10.1177%2F0269881112454230" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Fjm500496m&amp;key=22914798" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Fjm500496m&amp;key=1%3ACAS%3A280%3ADC%252BC38bgsFehtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2013&pages=152-61&author=P.+L.+Johnsonauthor=S.+D.+Fitzauthor=E.+A.+Englemanauthor=K.+A.+Svenssonauthor=J.+M.+Schkeryantzauthor=A.+Shekhar&title=Group+II+metabotropic+glutamate+receptor+type+2+allosteric+potentiators+prevent+sodium+lactate-induced+panic-like+response+in+panic-vulnerable+rats"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Group II metabotropic glutamate receptor type 2 allosteric potentiators prevent sodium lactate-induced panic-like response in panic-vulnerable rats</span></div><div class="casAuthors">Johnson Philip L; Fitz Stephanie D; Engleman Eric A; Svensson Kjell A; Schkeryantz Jeffrey M; Shekhar Anantha</div><div class="citationInfo"><span class="NLM_cas:title">Journal of psychopharmacology (Oxford, England)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">152-61</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Rats with chronic inhibition of GABA synthesis by infusion of l-allyglycine, a glutamic acid decarboxylase inhibitor, into their dorsomedial/perifornical hypothalamus are anxious and exhibit panic-like cardio-respiratory responses to treatment with intravenous (i.v.) sodium lactate (NaLac) infusions, in a manner similar to what occurs in patients with panic disorder.  We previously showed that either NMDA receptor antagonists or metabotropic glutamate receptor type 2/3 receptor agonists can block such a NaLac response, suggesting that a glutamate mechanism is contributing to this panic-like state.  Using this animal model of panic, we tested the efficacy of CBiPES and THIIC, which are selective group II metabotropic glutamate type 2 receptor allosteric potentiators (at 10-30 mg/kg i.p.), in preventing NaLac-induced panic-like behavioral and cardiovascular responses.  The positive control was alprazolam (3mg/kg i.p.), a clinically effective anti-panic benzodiazepine.  As predicted, panic-prone rats given a NaLac challenge displayed NaLac-induced panic-like cardiovascular (i.e. tachycardia and hypertensive) responses and "anxiety" (i.e. decreased social interaction time) and "flight" (i.e. increased locomotion) -associated behaviors; however, systemic injection of the panic-prone rats with CBiPES, THIIC or alprazolam prior to the NaLac dose blocked all NaLac-induced panic-like behaviors and cardiovascular responses.  These data suggested that in a rat animal model, selective group II metabotropic glutamate type 2 receptor allosteric potentiators show an anti-panic efficacy similar to alprazolam.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSZyMXZ3JfLnYqdXsLcGTEUfW6udTcc2eabfXKndssKS7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38bgsFehtA%253D%253D&md5=531af9f63a70e174839cee84c4cbe39d</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1177%2F0269881112454230&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0269881112454230%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DP.%2BL.%26aulast%3DFitz%26aufirst%3DS.%2BD.%26aulast%3DEngleman%26aufirst%3DE.%2BA.%26aulast%3DSvensson%26aufirst%3DK.%2BA.%26aulast%3DSchkeryantz%26aufirst%3DJ.%2BM.%26aulast%3DShekhar%26aufirst%3DA.%26atitle%3DGroup%2520II%2520metabotropic%2520glutamate%2520receptor%2520type%25202%2520allosteric%2520potentiators%2520prevent%2520sodium%2520lactate-induced%2520panic-like%2520response%2520in%2520panic-vulnerable%2520rats%26jtitle%3DJ.%2520Psychopharmacol.%26date%3D2013%26volume%3D27%26spage%3D152%26epage%3D61" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Cid, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duvey, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cluzeau, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nhem, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macary, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raux, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poirier, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muller, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolea, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finn, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Urios, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Epping-Jordan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chamelot, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Derouet, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Girard, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacDonald, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vega, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Lucas, A. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matesanz, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lavreysen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Linares, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oehlrich, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oyarzabal, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tresadern, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trabanco, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andres, J. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le Poul, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Imogai, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lutjens, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rocher, J.-P.</span><span> </span><span class="NLM_article-title">Discovery of 1,5-disubstituted pyridones: a new class of positive allosteric modulators of the metabotropic glutamate 2 receptor</span> <span class="citation_source-journal">ACS Chem. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">788</span><span class="NLM_x">–</span> <span class="NLM_lpage">795</span></span><div class="citationLinks">[<a href="/doi/10.1021/cn1000638" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Fjm500496m&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVGgsbzO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2010&pages=788-795&author=J.+M.+Cidauthor=G.+Duveyauthor=P.+Cluzeauauthor=V.+Nhemauthor=K.+Macaryauthor=A.+Rauxauthor=N.+Poirierauthor=J.+Mullerauthor=C.+Boleaauthor=T.+Finnauthor=I.+Uriosauthor=M.+Epping-Jordanauthor=E.+Chamelotauthor=F.+Derouetauthor=F.+Girardauthor=G.+J.+MacDonaldauthor=J.+A.+Vegaauthor=A.+I.+de+Lucasauthor=E.+Matesanzauthor=H.+Lavreysenauthor=M.+L.+Linaresauthor=D.+Oehlrichauthor=J.+Oyarzabalauthor=G.+Tresadernauthor=A.+A.+Trabancoauthor=J.+I.+Andresauthor=E.+Le+Poulauthor=H.+Imogaiauthor=R.+Lutjensauthor=J.-P.+Rocher&title=Discovery+of+1%2C5-disubstituted+pyridones%3A+a+new+class+of+positive+allosteric+modulators+of+the+metabotropic+glutamate+2+receptor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 1,5-Disubstituted Pyridones: A New Class of Positive Allosteric Modulators of the Metabotropic Glutamate 2 Receptor</span></div><div class="casAuthors">Cid, Jose Maria; Duvey, Guillaume; Cluzeau, Philippe; Nhem, Vanthea; Macary, Karim; Raux, Alexandre; Poirier, Nicolas; Muller, Jessica; Bolea, Christelle; Finn, Terry; Urios, Isabelle; Epping-Jordan, Mark; Chamelot, Emilie; Derouet, Francis; Girard, Francoise; MacDonald, Gregor J.; Vega, Juan Antonio; de Lucas, Ana Isabel; Matesanz, Encarnacion; Lavreysen, Hilde; Linares, Maria Lourdes; Oehlrich, Daniel; Oyarzabal, Julen; Tresadern, Gary; Trabanco, Andres A.; Andres, Jose Ignacio; Le Poul, Emmanuel; Imogai, Hassan; Lutjens, Robert; Rocher, Jean-Philippe</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">788-795</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of 1,5-disubstituted pyridones was identified as pos. allosteric modulators (PAMs) of the metabotropic glutamate receptor 2 (mGluR2) via high throughput screening (HTS).  Subsequent SAR exploration led to the identification of several compds. with improved in vitro activity.  Lead compd. 8 (I) was further profiled and found to attenuate the increase in PCP induced locomotor activity in mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-saUfhQDgzLVg90H21EOLACvtfcHk0li0TuslDstD6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVGgsbzO&md5=85204e53809a7efcbd7d9fb5f04a3601</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fcn1000638&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcn1000638%26sid%3Dliteratum%253Aachs%26aulast%3DCid%26aufirst%3DJ.%2BM.%26aulast%3DDuvey%26aufirst%3DG.%26aulast%3DCluzeau%26aufirst%3DP.%26aulast%3DNhem%26aufirst%3DV.%26aulast%3DMacary%26aufirst%3DK.%26aulast%3DRaux%26aufirst%3DA.%26aulast%3DPoirier%26aufirst%3DN.%26aulast%3DMuller%26aufirst%3DJ.%26aulast%3DBolea%26aufirst%3DC.%26aulast%3DFinn%26aufirst%3DT.%26aulast%3DUrios%26aufirst%3DI.%26aulast%3DEpping-Jordan%26aufirst%3DM.%26aulast%3DChamelot%26aufirst%3DE.%26aulast%3DDerouet%26aufirst%3DF.%26aulast%3DGirard%26aufirst%3DF.%26aulast%3DMacDonald%26aufirst%3DG.%2BJ.%26aulast%3DVega%26aufirst%3DJ.%2BA.%26aulast%3Dde%2BLucas%26aufirst%3DA.%2BI.%26aulast%3DMatesanz%26aufirst%3DE.%26aulast%3DLavreysen%26aufirst%3DH.%26aulast%3DLinares%26aufirst%3DM.%2BL.%26aulast%3DOehlrich%26aufirst%3DD.%26aulast%3DOyarzabal%26aufirst%3DJ.%26aulast%3DTresadern%26aufirst%3DG.%26aulast%3DTrabanco%26aufirst%3DA.%2BA.%26aulast%3DAndres%26aufirst%3DJ.%2BI.%26aulast%3DLe%2BPoul%26aufirst%3DE.%26aulast%3DImogai%26aufirst%3DH.%26aulast%3DLutjens%26aufirst%3DR.%26aulast%3DRocher%26aufirst%3DJ.-P.%26atitle%3DDiscovery%2520of%25201%252C5-disubstituted%2520pyridones%253A%2520a%2520new%2520class%2520of%2520positive%2520allosteric%2520modulators%2520of%2520the%2520metabotropic%2520glutamate%25202%2520receptor%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2010%26volume%3D1%26spage%3D788%26epage%3D795" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Cid, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duvey, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tresadern, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nhem, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Funary, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cluzeau, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vega, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Lucas, A. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matesanz, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alonso, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Linares, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andres, J. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poli, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lutjens, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Imogai, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rocher, J.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacDonald, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oehlrich, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lavreysen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahnaou, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drinkenburg, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mackie, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trabanco, A. A.</span><span> </span><span class="NLM_article-title">Discovery of 1,4-disubstituted 3-cyano-2-pyridones: a new class of positive allosteric modulators of the metabotropic glutamate 2 receptor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">2388</span><span class="NLM_x">–</span> <span class="NLM_lpage">2405</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm2016864" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=2388-2405&author=J.+M.+Cidauthor=G.+Duveyauthor=G.+Tresadernauthor=V.+Nhemauthor=R.+Funaryauthor=P.+Cluzeauauthor=J.+A.+Vegaauthor=A.+I.+de+Lucasauthor=E.+Matesanzauthor=J.+M.+Alonsoauthor=M.+L.+Linaresauthor=J.+I.+Andresauthor=S.+Poliauthor=R.+Lutjensauthor=H.+Imogaiauthor=J.-P.+Rocherauthor=G.+J.+MacDonaldauthor=D.+Oehlrichauthor=H.+Lavreysenauthor=A.+Ahnaouauthor=W.+Drinkenburgauthor=C.+Mackieauthor=A.+A.+Trabanco&title=Discovery+of+1%2C4-disubstituted+3-cyano-2-pyridones%3A+a+new+class+of+positive+allosteric+modulators+of+the+metabotropic+glutamate+2+receptor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Fjm2016864&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2016864%26sid%3Dliteratum%253Aachs%26aulast%3DCid%26aufirst%3DJ.%2BM.%26aulast%3DDuvey%26aufirst%3DG.%26aulast%3DTresadern%26aufirst%3DG.%26aulast%3DNhem%26aufirst%3DV.%26aulast%3DFunary%26aufirst%3DR.%26aulast%3DCluzeau%26aufirst%3DP.%26aulast%3DVega%26aufirst%3DJ.%2BA.%26aulast%3Dde%2BLucas%26aufirst%3DA.%2BI.%26aulast%3DMatesanz%26aufirst%3DE.%26aulast%3DAlonso%26aufirst%3DJ.%2BM.%26aulast%3DLinares%26aufirst%3DM.%2BL.%26aulast%3DAndres%26aufirst%3DJ.%2BI.%26aulast%3DPoli%26aufirst%3DS.%26aulast%3DLutjens%26aufirst%3DR.%26aulast%3DImogai%26aufirst%3DH.%26aulast%3DRocher%26aufirst%3DJ.-P.%26aulast%3DMacDonald%26aufirst%3DG.%2BJ.%26aulast%3DOehlrich%26aufirst%3DD.%26aulast%3DLavreysen%26aufirst%3DH.%26aulast%3DAhnaou%26aufirst%3DA.%26aulast%3DDrinkenburg%26aufirst%3DW.%26aulast%3DMackie%26aufirst%3DC.%26aulast%3DTrabanco%26aufirst%3DA.%2BA.%26atitle%3DDiscovery%2520of%25201%252C4-disubstituted%25203-cyano-2-pyridones%253A%2520a%2520new%2520class%2520of%2520positive%2520allosteric%2520modulators%2520of%2520the%2520metabotropic%2520glutamate%25202%2520receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D2388%26epage%3D2405" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Tresadern, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cid, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacDonald, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vega, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Lucas, A. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matesanz, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Linares, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oehlrich, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lavreysen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Biesmans, Ilse</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trabanco, A. A.</span><span> </span><span class="NLM_article-title">Scaffold hopping from pyridones to imidazo[1,2-a]pyridines. new positive allosteric modulators of metabotropic glutamate 2 receptor</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">175</span><span class="NLM_x">–</span> <span class="NLM_lpage">179</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=175-179&author=G.+Tresadernauthor=J.+M.+Cidauthor=G.+J.+MacDonaldauthor=J.+A.+Vegaauthor=A.+I.+de+Lucasauthor=A.+Garciaauthor=E.+Matesanzauthor=M.+L.+Linaresauthor=D.+Oehlrichauthor=H.+Lavreysenauthor=Ilse+Biesmansauthor=A.+A.+Trabanco&title=Scaffold+hopping+from+pyridones+to+imidazo%5B1%2C2-a%5Dpyridines.+new+positive+allosteric+modulators+of+metabotropic+glutamate+2+receptor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTresadern%26aufirst%3DG.%26aulast%3DCid%26aufirst%3DJ.%2BM.%26aulast%3DMacDonald%26aufirst%3DG.%2BJ.%26aulast%3DVega%26aufirst%3DJ.%2BA.%26aulast%3Dde%2BLucas%26aufirst%3DA.%2BI.%26aulast%3DGarcia%26aufirst%3DA.%26aulast%3DMatesanz%26aufirst%3DE.%26aulast%3DLinares%26aufirst%3DM.%2BL.%26aulast%3DOehlrich%26aufirst%3DD.%26aulast%3DLavreysen%26aufirst%3DH.%26aulast%3DBiesmans%26aufirst%3DIlse%26aulast%3DTrabanco%26aufirst%3DA.%2BA.%26atitle%3DScaffold%2520hopping%2520from%2520pyridones%2520to%2520imidazo%255B1%252C2-a%255Dpyridines.%2520new%2520positive%2520allosteric%2520modulators%2520of%2520metabotropic%2520glutamate%25202%2520receptor%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D175%26epage%3D179" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Trabanco, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tresadern, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacDonald, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vega, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Lucas, A. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matesanz, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Linares, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alonso de Diego, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alonso, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oehlrich, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahnaou, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drinkenburg, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mackie, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andres, J. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lavreysen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cid, J. M.</span><span> </span><span class="NLM_article-title">Imidazo[1,2-a]pyridines: orally active positive allosteric modulators of the metabotropic glutamate 2 receptor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">2688</span><span class="NLM_x">–</span> <span class="NLM_lpage">2701</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm201561r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=2688-2701&author=A.+A.+Trabancoauthor=G.+Tresadernauthor=G.+J.+MacDonaldauthor=J.+A.+Vegaauthor=A.+I.+de+Lucasauthor=E.+Matesanzauthor=A.+Garciaauthor=M.+L.+Linaresauthor=S.+A.+Alonso+de+Diegoauthor=J.+M.+Alonsoauthor=D.+Oehlrichauthor=A.+Ahnaouauthor=W.+Drinkenburgauthor=C.+Mackieauthor=J.+I.+Andresauthor=H.+Lavreysenauthor=J.+M.+Cid&title=Imidazo%5B1%2C2-a%5Dpyridines%3A+orally+active+positive+allosteric+modulators+of+the+metabotropic+glutamate+2+receptor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Fjm201561r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201561r%26sid%3Dliteratum%253Aachs%26aulast%3DTrabanco%26aufirst%3DA.%2BA.%26aulast%3DTresadern%26aufirst%3DG.%26aulast%3DMacDonald%26aufirst%3DG.%2BJ.%26aulast%3DVega%26aufirst%3DJ.%2BA.%26aulast%3Dde%2BLucas%26aufirst%3DA.%2BI.%26aulast%3DMatesanz%26aufirst%3DE.%26aulast%3DGarcia%26aufirst%3DA.%26aulast%3DLinares%26aufirst%3DM.%2BL.%26aulast%3DAlonso%2Bde%2BDiego%26aufirst%3DS.%2BA.%26aulast%3DAlonso%26aufirst%3DJ.%2BM.%26aulast%3DOehlrich%26aufirst%3DD.%26aulast%3DAhnaou%26aufirst%3DA.%26aulast%3DDrinkenburg%26aufirst%3DW.%26aulast%3DMackie%26aufirst%3DC.%26aulast%3DAndres%26aufirst%3DJ.%2BI.%26aulast%3DLavreysen%26aufirst%3DH.%26aulast%3DCid%26aufirst%3DJ.%2BM.%26atitle%3DImidazo%255B1%252C2-a%255Dpyridines%253A%2520orally%2520active%2520positive%2520allosteric%2520modulators%2520of%2520the%2520metabotropic%2520glutamate%25202%2520receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D2688%26epage%3D2701" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Cid, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tresadern, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vega, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Lucas, A. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matesanz, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iturrino, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Linares, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andres, J. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacDonald, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohelrich, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lavreysen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Megens, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahnaou, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drinkenburg, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mackie, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pype, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallacher, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trabanco, A. A.</span><span> </span><span class="NLM_article-title">Discovery of 3-cyclopropylmethyl-7-(4-phenylpiperidin-1-yl)-8-trifluoromethyl-1,2,4-triazolo[4,3-<i>a</i>]pyridine (JNJ-42153605): a positive allosteric modulator of the metabotropic glutamate 2 receptor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">8770</span><span class="NLM_x">–</span> <span class="NLM_lpage">8789</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm3010724" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=8770-8789&author=J.+M.+Cidauthor=G.+Tresadernauthor=J.+A.+Vegaauthor=A.+I.+de+Lucasauthor=E.+Matesanzauthor=L.+Iturrinoauthor=M.+L.+Linaresauthor=A.+Garciaauthor=J.+I.+Andresauthor=G.+J.+MacDonaldauthor=G.+Ohelrichauthor=H.+Lavreysenauthor=A.+Megensauthor=A.+Ahnaouauthor=W.+Drinkenburgauthor=C.+Mackieauthor=S.+Pypeauthor=D.+Gallacherauthor=A.+A.+Trabanco&title=Discovery+of+3-cyclopropylmethyl-7-%284-phenylpiperidin-1-yl%29-8-trifluoromethyl-1%2C2%2C4-triazolo%5B4%2C3-a%5Dpyridine+%28JNJ-42153605%29%3A+a+positive+allosteric+modulator+of+the+metabotropic+glutamate+2+receptor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Fjm3010724&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3010724%26sid%3Dliteratum%253Aachs%26aulast%3DCid%26aufirst%3DJ.%2BM.%26aulast%3DTresadern%26aufirst%3DG.%26aulast%3DVega%26aufirst%3DJ.%2BA.%26aulast%3Dde%2BLucas%26aufirst%3DA.%2BI.%26aulast%3DMatesanz%26aufirst%3DE.%26aulast%3DIturrino%26aufirst%3DL.%26aulast%3DLinares%26aufirst%3DM.%2BL.%26aulast%3DGarcia%26aufirst%3DA.%26aulast%3DAndres%26aufirst%3DJ.%2BI.%26aulast%3DMacDonald%26aufirst%3DG.%2BJ.%26aulast%3DOhelrich%26aufirst%3DG.%26aulast%3DLavreysen%26aufirst%3DH.%26aulast%3DMegens%26aufirst%3DA.%26aulast%3DAhnaou%26aufirst%3DA.%26aulast%3DDrinkenburg%26aufirst%3DW.%26aulast%3DMackie%26aufirst%3DC.%26aulast%3DPype%26aufirst%3DS.%26aulast%3DGallacher%26aufirst%3DD.%26aulast%3DTrabanco%26aufirst%3DA.%2BA.%26atitle%3DDiscovery%2520of%25203-cyclopropylmethyl-7-%25284-phenylpiperidin-1-yl%2529-8-trifluoromethyl-1%252C2%252C4-triazolo%255B4%252C3-a%255Dpyridine%2520%2528JNJ-42153605%2529%253A%2520a%2520positive%2520allosteric%2520modulator%2520of%2520the%2520metabotropic%2520glutamate%25202%2520receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D8770%26epage%3D8789" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Kent, J.; Anghelescu, I.-G.; Kezic, I.; Daly, E.; Ceusters, M.; De Smedt, H.; Van Nueten, L.; De Boer, P.</span>Safety, tolerability and potential therapeutic efficacy of a novel glutamate modulator as adjunctive treatment in patients with schizophrenia, <span class="NLM_conf-name">166th Annual Meeting of the American Psychiatric Association</span>, <span class="NLM_conf-loc">San Francisco, CA</span>, <span class="NLM_conf-date">May 18–22</span>,<span class="NLM_x"> </span><span class="NLM_year">2013</span><span class="NLM_x">; </span>Abstract, 3160-P.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&conference=166th+Annual+Meeting+of+the+American+Psychiatric+Association&author=J.+Kent&author=I.-G.+Anghelescu&author=I.+Kezic&author=E.+Daly&author=M.+Ceusters&author=H.+De+Smedt&author=L.+Van+Nueten&author=P.+De+Boer&title=Safety%2C+tolerability+and+potential+therapeutic+efficacy+of+a+novel+glutamate+modulator+as+adjunctive+treatment+in+patients+with+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DKent%26aufirst%3DJ.%26jtitle%3DSafety%252C%2520tolerability%2520and%2520potential%2520therapeutic%2520efficacy%2520of%2520a%2520novel%2520glutamate%2520modulator%2520as%2520adjunctive%2520treatment%2520in%2520patients%2520with%2520schizophrenia%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span>Investigation of the safety, tolerability and potential therapeutic effects of JNJ-40411813 in patients with schizophrenia. <a href="http://clinicaltrials.gov/show/NCT01323205" class="extLink">http://clinicaltrials.gov/show/NCT01323205</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Investigation+of+the+safety%2C+tolerability+and+potential+therapeutic+effects+of+JNJ-40411813+in+patients+with+schizophrenia.+http%3A%2F%2Fclinicaltrials.gov%2Fshow%2FNCT01323205."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Hopkins, C. R.</span><span> </span><span class="NLM_article-title">Is there a path forward for mGlu2 positive allosteric modulators for the treatment of schizophrenia?</span> <span class="citation_source-journal">ACS Chem. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">211</span><span class="NLM_x">–</span> <span class="NLM_lpage">213</span></span><div class="citationLinks">[<a href="/doi/10.1021/cn400023y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Fjm500496m&amp;key=1%3ACAS%3A528%3ADC%252BC3sXitlCju7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=211-213&author=C.+R.+Hopkins&title=Is+there+a+path+forward+for+mGlu2+positive+allosteric+modulators+for+the+treatment+of+schizophrenia%3F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Is There a Path Forward for mGlu2 Positive Allosteric Modulators for the Treatment of Schizophrenia?</span></div><div class="casAuthors">Hopkins, Corey R.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">211-213</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Two recent Phase II results show opposing outcomes for the potential of activators of mGlu2 in the treatment of schizophrenia.  The first outcome revealed that Eli Lilly's mGlu2/3 agonist, pomaglumetad methionil (LY2140023), failed to meet the primary efficacy end point.  The second report showed the mGlu2 pos. allosteric modulator (PAM) from Addex (ADX71149) in conjunction with Janssen Research & Development met the primary objectives of safety, tolerability and demonstrated an effect on neg. symptoms in patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlDn7Grx63q7Vg90H21EOLACvtfcHk0lhF8Xxu15yy3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXitlCju7o%253D&md5=0f37080968935b34a0b2a56f30168367</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Fcn400023y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcn400023y%26sid%3Dliteratum%253Aachs%26aulast%3DHopkins%26aufirst%3DC.%2BR.%26atitle%3DIs%2520there%2520a%2520path%2520forward%2520for%2520mGlu2%2520positive%2520allosteric%2520modulators%2520for%2520the%2520treatment%2520of%2520schizophrenia%253F%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2013%26volume%3D4%26spage%3D211%26epage%3D213" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span>AstraZeneca 2010 financial results. <a href="http://www.astrazeneca.com/Investors/financial-information/Financial-results/2010-Financial-results" class="extLink">http://www.astrazeneca.com/Investors/financial-information/Financial-results/2010-Financial-results</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=AstraZeneca+2010+financial+results.+http%3A%2F%2Fwww.astrazeneca.com%2FInvestors%2Ffinancial-information%2FFinancial-results%2F2010-Financial-results."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Litman, R. E.; Smith, M. A.; Doherty, J.; Cross, A.; Raines, S.; Zukin, S.</span>AZD8524, a positive allosteric modulator at the mGluR2 receptor, does not improve symptoms in schizophrenia: a proof of principle study, <span class="NLM_conf-name">53rd NCDEU: an annual meeting sponsored by ASCP</span>, <span class="NLM_conf-loc">Hollywood, Florida</span>, <span class="NLM_conf-date">May 28–31</span>,<span class="NLM_x"> </span><span class="NLM_year">2013</span><span class="NLM_x">; </span>Poster 83.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&conference=53rd+NCDEU%3A+an+annual+meeting+sponsored+by+ASCP&author=R.+E.+Litman&author=M.+A.+Smith&author=J.+Doherty&author=A.+Cross&author=S.+Raines&author=S.+Zukin&title=AZD8524%2C+a+positive+allosteric+modulator+at+the+mGluR2+receptor%2C+does+not+improve+symptoms+in+schizophrenia%3A+a+proof+of+principle+study"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DLitman%26aufirst%3DR.%2BE.%26jtitle%3DAZD8524%252C%2520a%2520positive%2520allosteric%2520modulator%2520at%2520the%2520mGluR2%2520receptor%252C%2520does%2520not%2520improve%2520symptoms%2520in%2520schizophrenia%253A%2520a%2520proof%2520of%2520principle%2520study%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span>Addex reports top-line data from a successful phase 2a clinical study with ADX71149 in schizophrenia patients. <a href="http://www.addextherapeutics.com/investors/press-releases/news-details/article/addex-reports-top-line-data-from-a-successful-phase-2a-clinical-study-with-adx71149-in-schizophrenia/" class="extLink">http://www.addextherapeutics.com/investors/press-releases/news-details/article/addex-reports-top-line-data-from-a-successful-phase-2a-clinical-study-with-adx71149-in-schizophrenia/</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Addex+reports+top-line+data+from+a+successful+phase+2a+clinical+study+with+ADX71149+in+schizophrenia+patients.+http%3A%2F%2Fwww.addextherapeutics.com%2Finvestors%2Fpress-releases%2Fnews-details%2Farticle%2Faddex-reports-top-line-data-from-a-successful-phase-2a-clinical-study-with-adx71149-in-schizophrenia%2F."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">Lavreysen, H.</span>Discovery and early clinical development of novel mGlu2 receptor PAMs, <span class="NLM_conf-name">American College of Neuropsychopharmacology 52nd Annual Meeting</span>, <span class="NLM_conf-loc">Hollywood, Florida</span>, <span class="NLM_conf-date">Dec 8–12</span>,<span class="NLM_x"> </span><span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&conference=American+College+of+Neuropsychopharmacology+52nd+Annual+Meeting&author=H.+Lavreysen&title=Discovery+and+early+clinical+development+of+novel+mGlu2+receptor+PAMs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DLavreysen%26aufirst%3DH.%26jtitle%3DDiscovery%2520and%2520early%2520clinical%2520development%2520of%2520novel%2520mGlu2%2520receptor%2520PAMs%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span>A study of JNJ-40411813 as supplementary treatment to an antidepressant in adults with depression and anxiety symptoms. <a href="http://clinicaltrials.gov/show/NCT01582815" class="extLink">http://clinicaltrials.gov/show/NCT01582815</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=A+study+of+JNJ-40411813+as+supplementary+treatment+to+an+antidepressant+in+adults+with+depression+and+anxiety+symptoms.+http%3A%2F%2Fclinicaltrials.gov%2Fshow%2FNCT01582815."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span>Addex Reports top-line data from ADX71149 phase 2a study in patients with major depressive disorder (MDD) with significant anxiety symptoms. <a href="http://www.addextherapeutics.com/investors/press-releases/news-details/article/addex-reports-top-line-data-from-adx71149-phase-2a-study-in-patients-with-major-depressive-disorder/" class="extLink">http://www.addextherapeutics.com/investors/press-releases/news-details/article/addex-reports-top-line-data-from-adx71149-phase-2a-study-in-patients-with-major-depressive-disorder/</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Addex+Reports+top-line+data+from+ADX71149+phase+2a+study+in+patients+with+major+depressive+disorder+%28MDD%29+with+significant+anxiety+symptoms.+http%3A%2F%2Fwww.addextherapeutics.com%2Finvestors%2Fpress-releases%2Fnews-details%2Farticle%2Faddex-reports-top-line-data-from-adx71149-phase-2a-study-in-patients-with-major-depressive-disorder%2F."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group">Cid-Nuñez, J. M.; Trabanco-Suarez, A. A.; Macdonald, G. J.; Duvey, G. A. J.; Lütjens, R. J.</span>Preparation of 1,4-disubstituted 3-cyanopyridone derivatives as positive mGluR2 receptor modulators. WO/2008/107480,<span class="NLM_x"> </span><span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=J.+M.+Cid-Nu%C3%B1ez&author=A.+A.+Trabanco-Suarez&author=G.+J.+Macdonald&author=G.+A.+J.+Duvey&author=R.+J.+L%C3%BCtjens&title=Preparation+of+1%2C4-disubstituted+3-cyanopyridone+derivatives+as+positive+mGluR2+receptor+modulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCid-Nu%25C3%25B1ez%26aufirst%3DJ.%2BM.%26jtitle%3DPreparation%2520of%25201%252C4-disubstituted%25203-cyanopyridone%2520derivatives%2520as%2520positive%2520mGluR2%2520receptor%2520modulators%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group">Cid-Nuñez, J. M.; Trabanco-Suárez, A. A.; Macdonald, G. J.; Duvey, G. A. J.; Lütjens, R. J.</span>Preparation of 3-cyano-4-(4-phenylpiperidin-1-yl)-pyridin-2-one derivatives for treating and preventing neurol. and psychiatric diseases associated with glutamate dysfunction. WO/2008/107479,<span class="NLM_x"> </span><span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=J.+M.+Cid-Nu%C3%B1ez&author=A.+A.+Trabanco-Su%C3%A1rez&author=G.+J.+Macdonald&author=G.+A.+J.+Duvey&author=R.+J.+L%C3%BCtjens&title=Preparation+of+3-cyano-4-%284-phenylpiperidin-1-yl%29-pyridin-2-one+derivatives+for+treating+and+preventing+neurol.+and+psychiatric+diseases+associated+with+glutamate+dysfunction"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCid-Nu%25C3%25B1ez%26aufirst%3DJ.%2BM.%26jtitle%3DPreparation%2520of%25203-cyano-4-%25284-phenylpiperidin-1-yl%2529-pyridin-2-one%2520derivatives%2520for%2520treating%2520and%2520preventing%2520neurol.%2520and%2520psychiatric%2520diseases%2520associated%2520with%2520glutamate%2520dysfunction%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group">Cid-Nuñez, J. M.; Trabanco-Suárez, A. A.; Macdonald, G. J.; Duvey, G. A. J.; Lütjens, R. J.; Finn, T. P.</span>Preparation of bipyridinones as positive allosteric modulators of mGluR2 for treating neurological and psychiatric disorders. WO/2009/033704,<span class="NLM_x"> </span><span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=J.+M.+Cid-Nu%C3%B1ez&author=A.+A.+Trabanco-Su%C3%A1rez&author=G.+J.+Macdonald&author=G.+A.+J.+Duvey&author=R.+J.+L%C3%BCtjens&author=T.+P.+Finn&title=Preparation+of+bipyridinones+as+positive+allosteric+modulators+of+mGluR2+for+treating+neurological+and+psychiatric+disorders"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCid-Nu%25C3%25B1ez%26aufirst%3DJ.%2BM.%26jtitle%3DPreparation%2520of%2520bipyridinones%2520as%2520positive%2520allosteric%2520modulators%2520of%2520mGluR2%2520for%2520treating%2520neurological%2520and%2520psychiatric%2520disorders%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="note"><p class="first last">The in vitro [<sup>35</sup>S]GTPγS assay provides two measures of compound activity: pEC<sub>50</sub>, which is defined as the negative logarithm of the concentration at which half-maximal potentiation of glutamate is reached, and the maximal increase in observed glutamate response, the % <i>E</i><sub>MAX</sub>.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="note"><p class="first last">Compound <b>6</b> was incubated with human and rat liver microsomes at 0.4% final solvent concentration (0.16% DMSO and 0.24% CH<sub>3</sub>CN). The study was conducted to identify the main metabolites formed after 0 min (control) and 60 min of incubation time in the presence of an NADPH generating system at 37 °C. Test concentration of <b>6</b> was 5 μM. Samples were compared to the control incubations in which compound was added at termination. Data were acquired on a Waters UPLC/QToF Premier mass spectrometer using a 10 min generic UPLC method and a generic MSe method. Complementary MS/MS experiments were performed when necessary. An Acquity UPLC C18 (2.1 mm × 100 mm, 1.8 μm) column was used. Interpretation of data was performed with Waters Metabolynx software.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group">Lavreysen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langlois, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahnaou, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drinkenburg, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">te Riele, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Biesmans, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van der Linden, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peeters, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Megens, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wintmolders, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cid, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trabanco, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andres, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dautzenberg, F. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lutjens, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macdonald, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atack, J. R.</span><span> </span><span class="NLM_article-title">Pharmacological characterization of JNJ-40068782, a new potent, selective and systemically active positive allosteric modulator of the mGlu2 receptor and its radioligand [3H]JNJ-40068782</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">346</span><span class="NLM_x">, </span> <span class="NLM_fpage">514</span><span class="NLM_x">–</span> <span class="NLM_lpage">527</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Fjm500496m&amp;key=10.1124%2Fjpet.113.204990" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Fjm500496m&amp;key=23766542" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Fjm500496m&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtlCmtbbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=346&publication_year=2013&pages=514-527&author=H.+Lavreysenauthor=X.+Langloisauthor=A.+Ahnaouauthor=W.+Drinkenburgauthor=P.+te+Rieleauthor=I.+Biesmansauthor=I.+Van+der+Lindenauthor=L.+Peetersauthor=A.+Megensauthor=C.+Wintmoldersauthor=J.+Cidauthor=A.+A.+Trabancoauthor=I.+Andresauthor=F.+M.+Dautzenbergauthor=R.+Lutjensauthor=G.+Macdonaldauthor=J.+R.+Atack&title=Pharmacological+characterization+of+JNJ-40068782%2C+a+new+potent%2C+selective+and+systemically+active+positive+allosteric+modulator+of+the+mGlu2+receptor+and+its+radioligand+%5B3H%5DJNJ-40068782"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological characterization of JNJ-40068782, a new potent, selective, and systemically active positive allosteric modulator of the mGlu2 receptor and its radioligand [3H]JNJ-40068782</span></div><div class="casAuthors">Lavreysen, Hilde; Langlois, Xavier; Ahnaou, Abdel; Drinkenburg, Wilhelmus; te Riele, Paula; Biesmans, Ilse; Van der Linden, Ilse; Peeters, Luc; Megens, Anton; Wintmolders, Cindy; Cid, Jose Maria; Trabanco, Andres A.; Andres, Jose Ignacio; Dautzenberg, Frank M.; Lutjens, Robert; MacDonald, Gregor; Atack, John R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">346</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">514-527</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Modulation of the metabotropic glutamate type 2 (mGlu2) receptor is considered a promising target for the treatment of central nervous system diseases such as schizophrenia.  Here, we describe the pharmacol. properties of the novel mGlu2 receptor pos. allosteric modulator (PAM) 3-cyano-1-cyclopropylmethyl-4-(4-phenyl-piperidin-1-yl)-pyridine-2(1H)-one (JNJ-40068782) and its radioligand [3H]JNJ-40068782.  In guanosine 5'-O-(3-[35S]thio)triphosphate binding, JNJ-40068782 produced a leftward and upward shift in the glutamate concn.-effect curve at human recombinant mGlu2 receptors.  The EC50 of JNJ-40068782 for potentiation of an EC20-equivalent concn. of glutamate was 143 nM.  Although JNJ-40068782 did not affect binding of the orthosteric antagonist [3H]2S-2-amino-2-(1S,2S-2-carboxycyclopropyl-1-yl)-3-(xanth-9-yl)propanoic acid (LY-341495), it did potentiate the binding of the agonist [3H](2S,2'R,3'R)-2-(2',3'-dicarboxylcyclopropyl)glycine (DCG-IV), demonstrating that it can allosterically affect binding at the agonist recognition site.  The binding of [3H]JNJ-40068782 to human recombinant mGlu2 receptors in Chinese hamster ovary cells and rat brain receptors was saturable with a KD of ∼10 nM.  In rat brain, the anat. distribution of [3H]JNJ-40068782 was consistent with mGlu2 expression previously described and was most abundant in cortex and hippocampus.  The ability of structurally unrelated PAMs to displace [3H]JNJ-40068782 suggests that PAMs may bind to common determinants within the same site.  It is noteworthy that agonists also increased the binding affinity of [3H]JNJ-40068782.  JNJ-40068782 influenced rat sleep-wake organization by decreasing rapid eye movement sleep with a lowest active dose of 3 mg/kg PO.  In mice, JNJ-40068782 reversed phencyclidine-induced hyperlocomotion with an ED50 of 5.7 mg/kg s.c.  Collectively, the present data demonstrate that JNJ-40068782 has utility in investigating the potential of mGlu2 modulation for the treatment of diseases characterized by disturbed glutamatergic signaling and highlight the value of [3H]JNJ-40068782 in exploring allosteric binding.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9aUNTs3sN4bVg90H21EOLACvtfcHk0lgkC5uIvjIFyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtlCmtbbJ&md5=78f9f2a656c7b36196d91109d4decffc</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1124%2Fjpet.113.204990&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.113.204990%26sid%3Dliteratum%253Aachs%26aulast%3DLavreysen%26aufirst%3DH.%26aulast%3DLanglois%26aufirst%3DX.%26aulast%3DAhnaou%26aufirst%3DA.%26aulast%3DDrinkenburg%26aufirst%3DW.%26aulast%3Dte%2BRiele%26aufirst%3DP.%26aulast%3DBiesmans%26aufirst%3DI.%26aulast%3DVan%2Bder%2BLinden%26aufirst%3DI.%26aulast%3DPeeters%26aufirst%3DL.%26aulast%3DMegens%26aufirst%3DA.%26aulast%3DWintmolders%26aufirst%3DC.%26aulast%3DCid%26aufirst%3DJ.%26aulast%3DTrabanco%26aufirst%3DA.%2BA.%26aulast%3DAndres%26aufirst%3DI.%26aulast%3DDautzenberg%26aufirst%3DF.%2BM.%26aulast%3DLutjens%26aufirst%3DR.%26aulast%3DMacdonald%26aufirst%3DG.%26aulast%3DAtack%26aufirst%3DJ.%2BR.%26atitle%3DPharmacological%2520characterization%2520of%2520JNJ-40068782%252C%2520a%2520new%2520potent%252C%2520selective%2520and%2520systemically%2520active%2520positive%2520allosteric%2520modulator%2520of%2520the%2520mGlu2%2520receptor%2520and%2520its%2520radioligand%2520%255B3H%255DJNJ-40068782%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2013%26volume%3D346%26spage%3D514%26epage%3D527" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group">Feinberg, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, I. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schoepp, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, K.</span><span> </span><span class="NLM_article-title">The selective group mGlu2/3 receptor agonist LY379268 suppresses REM sleep and fast EEG in the rat</span> <span class="citation_source-journal">Pharmacol., Biochem. Behav.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">73</span><span class="NLM_x">, </span> <span class="NLM_fpage">467</span><span class="NLM_x">–</span> <span class="NLM_lpage">74</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2002&pages=467-74&author=I.+Feinbergauthor=I.+G.+Campbellauthor=D.+D.+Schoeppauthor=K.+Anderson&title=The+selective+group+mGlu2%2F3+receptor+agonist+LY379268+suppresses+REM+sleep+and+fast+EEG+in+the+rat"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFeinberg%26aufirst%3DI.%26aulast%3DCampbell%26aufirst%3DI.%2BG.%26aulast%3DSchoepp%26aufirst%3DD.%2BD.%26aulast%3DAnderson%26aufirst%3DK.%26atitle%3DThe%2520selective%2520group%2520mGlu2%252F3%2520receptor%2520agonist%2520LY379268%2520suppresses%2520REM%2520sleep%2520and%2520fast%2520EEG%2520in%2520the%2520rat%26jtitle%3DPharmacol.%252C%2520Biochem.%2520Behav.%26date%3D2002%26volume%3D73%26spage%3D467%26epage%3D74" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group">Ahnaou, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dautzenberg, F. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geys, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Imogai, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibelin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moechars, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steckler, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drinkenburg, W. H.</span><span> </span><span class="NLM_article-title">Modulation of group II metabotropic glutamate receptor (mGlu2) elicits common changes in rat and mice sleep–wake architecture</span> <span class="citation_source-journal">Eur. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">603</span><span class="NLM_x">, </span> <span class="NLM_fpage">62</span><span class="NLM_x">–</span> <span class="NLM_lpage">72</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Fjm500496m&amp;key=10.1016%2Fj.ejphar.2008.11.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Fjm500496m&amp;key=19046965" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Fjm500496m&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFCjsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=603&publication_year=2009&pages=62-72&author=A.+Ahnaouauthor=F.+M.+Dautzenbergauthor=H.+Geysauthor=H.+Imogaiauthor=A.+Gibelinauthor=D.+Moecharsauthor=T.+Stecklerauthor=W.+H.+Drinkenburg&title=Modulation+of+group+II+metabotropic+glutamate+receptor+%28mGlu2%29+elicits+common+changes+in+rat+and+mice+sleep%E2%80%93wake+architecture"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Modulation of group II metabotropic glutamate receptor (mGlu2) elicits common changes in rat and mice sleep-wake architecture</span></div><div class="casAuthors">Ahnaou, Abdellah; Dautzenberg, Frank M.; Geys, Helena; Imogai, Hassan; Gibelin, Antoine; Moechars, Dieder; Steckler, Thomas; Drinkenburg, Wilhelmus H. I. M.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">603</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">62-72</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Compiling pharmacol. evidence implicates metabotropic glutamate mGlu2 receptors in the regulation of emotional states and suggests pos. modulators as a novel therapeutic approach of Anxiety/Depression and Schizophrenia.  Here, we investigated s.c. effects of the metabotropic glutamate mGlu2/3 agonist (LY354740) on sleep-wake architecture in rat.  To confirm the specific effects on rapid eye movement (REM) sleep were mediated via metabotropic glutamate mGlu2 receptors, we characterized the sleep-wake cycles in metabotropic glutamate mGlu2 receptor deficient mice (mGlu2R-/-) and their arousal response to LY354740.  We furthermore examd. effects on sleep behavior in rats of the pos. allosteric modulator, biphenyl-indanone A (BINA) alone and in combination with LY354740 at sub-EDs.  LY354740 (1, 3 and 10 mg/kg) dose-dependently suppressed REM sleep and prolonged its onset latency.  Metabotropic glutamate mGlu2R-/- and their wild type (WT) littermates exhibited similar spontaneous sleep-wake phenotype, while LY354740 (10 mg/kg) significantly affected REM sleep variables in WT but not in the mutant.  In rats, BINA (1, 3, 10, 20, 40 mg/kg) dose-dependently suppressed REM sleep, lengthened its onset latency and slightly enhanced passive waking.  Addnl., combined treatment elicited a synergistic action on REM sleep variables.  Our findings show common changes of REM sleep variables following modulation of metabotropic glutamate mGlu2 receptor and support an active role of this receptor in the regulation of REM sleep.  The synergistic action of BINA on LY354740's effects on sleep pattern implies that pos. modulators would tune the endogenous glutamate tone suggesting potential benefit in the treatment of psychiatric disorders, in which REM sleep overdrive is manifested.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlUXqoXCoqp7Vg90H21EOLACvtfcHk0lgkC5uIvjIFyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFCjsbg%253D&md5=eb1e676deebb6b39aad64cf14a281bf2</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2008.11.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2008.11.018%26sid%3Dliteratum%253Aachs%26aulast%3DAhnaou%26aufirst%3DA.%26aulast%3DDautzenberg%26aufirst%3DF.%2BM.%26aulast%3DGeys%26aufirst%3DH.%26aulast%3DImogai%26aufirst%3DH.%26aulast%3DGibelin%26aufirst%3DA.%26aulast%3DMoechars%26aufirst%3DD.%26aulast%3DSteckler%26aufirst%3DT.%26aulast%3DDrinkenburg%26aufirst%3DW.%2BH.%26atitle%3DModulation%2520of%2520group%2520II%2520metabotropic%2520glutamate%2520receptor%2520%2528mGlu2%2529%2520elicits%2520common%2520changes%2520in%2520rat%2520and%2520mice%2520sleep%25E2%2580%2593wake%2520architecture%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2009%26volume%3D603%26spage%3D62%26epage%3D72" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="note"><p class="first last">Compound <b>36</b> was tested for agonist or antagonist activity on mGlu receptors in fluorescent Ca<sup>2+</sup> assays using HEK293 cells expressing human mGlu1, mGlu3, and mGlu5 receptors or [<sup>35</sup>S]GTPgS assays using L929 cells expressing human mGlu4 or CHO cells expressing rat mGlu6 receptors.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="note"><p class="first last">The CEREP selectivity screen was performed on the following targets: 5HT1A, 5HT2A, 5HT3, 5HT5A, 5HT6, 5HT7, A1, A2A, A3, AT1, Beta1, BK2, CCKA, CCR1, D1, D2, DAT, ETA, GAL2, H1, H2, IL8B, CXCR2, M1, M2, M3, MC4, NET, NK2, NK3, NPY1, NPY2, NT1, OP1, OP3, ORL1, V1A, VIP, SST, 5HT1B, α1, α2, BZD, CaCH, CICH, GABA, KCH, NaCH, and SKCaCH.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':[],'ref46':[],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':[],'ref51':[]}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 40 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Ana Isabel de Lucas, Juan Antonio Vega, Encarnación Matesanz, María Lourdes Linares, Aránzazu García Molina, Gary Tresadern, Hilde Lavreysen, Andrés A. Trabanco, <span class="NLM_string-name hlFld-ContribAuthor">José María Cid</span>. </span><span class="cited-content_cbyCitation_article-title">Spiro-oxindole Piperidines and 3-(Azetidin-3-yl)-1H-benzimidazol-2-ones as mGlu2 Receptor PAMs. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>11 </em>
                                    (3)
                                     , 303-308. <a href="https://doi.org/10.1021/acsmedchemlett.9b00350" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.9b00350</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.9b00350&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.9b00350%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DSpiro-oxindole%252BPiperidines%252Band%252B3-%252528Azetidin-3-yl%252529-1H-benzimidazol-2-ones%252Bas%252BmGlu2%252BReceptor%252BPAMs%26aulast%3Dde%2BLucas%26aufirst%3DAna%2BIsabel%26date%3D2020%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D31072019%26date%3D10102019%26date%3D16102019%26date%3D10102019%26volume%3D11%26issue%3D3%26spage%3D303%26epage%3D308" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Maarten
L. J. Doornbos, Xuesong Wang, Sophie C. Vermond, Luc Peeters, Laura Pérez-Benito, Andrés A. Trabanco, Hilde Lavreysen, José María Cid, Laura H. Heitman, Gary Tresadern, <span class="NLM_string-name hlFld-ContribAuthor">Adriaan P. IJzerman</span>. </span><span class="cited-content_cbyCitation_article-title">Covalent Allosteric Probe for the Metabotropic Glutamate Receptor 2: Design, Synthesis, and Pharmacological Characterization. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (1)
                                     , 223-233. <a href="https://doi.org/10.1021/acs.jmedchem.8b00051" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00051</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00051&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b00051%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DCovalent%252BAllosteric%252BProbe%252Bfor%252Bthe%252BMetabotropic%252BGlutamate%252BReceptor%2525C2%2525A02%25253A%252BDesign%25252C%252BSynthesis%25252C%252Band%252BPharmacological%252BCharacterization%26aulast%3DDoornbos%26aufirst%3DMaarten%2BL.%2BJ.%26date%3D2019%26date%3D2018%26date%3D2018%26date%3D12012018%26date%3D07032018%26date%3D01032018%26volume%3D62%26issue%3D1%26spage%3D223%26epage%3D233" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">György Szabó, György I. Túrós, Sándor Kolok, Mónika Vastag, Zsuzsanna Sánta, Miklós Dékány, György I. Lévay, István Greiner, Minami Natsumi, Watanabe Tatsuya, <span class="NLM_string-name hlFld-ContribAuthor">György M. Keserű</span>. </span><span class="cited-content_cbyCitation_article-title">Fragment Based Optimization of Metabotropic Glutamate Receptor 2 (mGluR2) Positive Allosteric Modulators in the Absence of Structural Information. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (1)
                                     , 234-246. <a href="https://doi.org/10.1021/acs.jmedchem.8b00161" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00161</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00161&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b00161%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DFragment%252BBased%252BOptimization%252Bof%252BMetabotropic%252BGlutamate%252BReceptor%252B2%252B%252528mGluR2%252529%252BPositive%252BAllosteric%252BModulators%252Bin%252Bthe%252BAbsence%252Bof%252BStructural%252BInformation%26aulast%3DSzab%25C3%25B3%26aufirst%3DGy%25C3%25B6rgy%26date%3D2019%26date%3D2018%26date%3D2018%26date%3D31012018%26date%3D14032018%26date%3D05032018%26volume%3D62%26issue%3D1%26spage%3D234%26epage%3D246" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gary  Tresadern</span>, <span class="hlFld-ContribAuthor ">Andres A.  Trabanco</span>, <span class="hlFld-ContribAuthor ">Laura  Pérez-Benito</span>, <span class="hlFld-ContribAuthor ">John P.  Overington</span>, <span class="hlFld-ContribAuthor ">Herman W. T.  van Vlijmen</span>, and <span class="hlFld-ContribAuthor ">Gerard J. P.  van Westen</span>  . </span><span class="cited-content_cbyCitation_article-title">Identification of Allosteric Modulators of Metabotropic Glutamate 7 Receptor Using Proteochemometric Modeling. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2017,</strong> <em>57 </em>
                                    (12)
                                     , 2976-2985. <a href="https://doi.org/10.1021/acs.jcim.7b00338" title="DOI URL">https://doi.org/10.1021/acs.jcim.7b00338</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jcim.7b00338&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jcim.7b00338%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DIdentification%252Bof%252BAllosteric%252BModulators%252Bof%252BMetabotropic%252BGlutamate%252B7%252BReceptor%252BUsing%252BProteochemometric%252BModeling%26aulast%3DTresadern%26aufirst%3DGary%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D06062017%26date%3D12122017%26date%3D26122017%26date%3D26112017%26volume%3D57%26issue%3D12%26spage%3D2976%26epage%3D2985" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Enza  Lacivita</span>, <span class="hlFld-ContribAuthor ">Roberto  Perrone</span>, <span class="hlFld-ContribAuthor ">Lucia  Margari</span>, and <span class="hlFld-ContribAuthor ">Marcello  Leopoldo</span>  . </span><span class="cited-content_cbyCitation_article-title">Targets for Drug Therapy for Autism Spectrum Disorder: Challenges and Future Directions. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>60 </em>
                                    (22)
                                     , 9114-9141. <a href="https://doi.org/10.1021/acs.jmedchem.7b00965" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b00965</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b00965&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.7b00965%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DTargets%252Bfor%252BDrug%252BTherapy%252Bfor%252BAutism%252BSpectrum%252BDisorder%25253A%252BChallenges%252Band%252BFuture%252BDirections%26aulast%3DLacivita%26aufirst%3DEnza%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D30062017%26date%3D30102017%26date%3D22112017%26date%3D17102017%26volume%3D60%26issue%3D22%26spage%3D9114%26epage%3D9141" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Maarten L. J.  Doornbos</span>, <span class="hlFld-ContribAuthor ">José María  Cid</span>, <span class="hlFld-ContribAuthor ">Jordi  Haubrich</span>, <span class="hlFld-ContribAuthor ">Alexandro  Nunes</span>, <span class="hlFld-ContribAuthor ">Jasper W.  van de Sande</span>, <span class="hlFld-ContribAuthor ">Sophie C.  Vermond</span>, <span class="hlFld-ContribAuthor ">Thea  Mulder-Krieger</span>, <span class="hlFld-ContribAuthor ">Andrés A.  Trabanco</span>, <span class="hlFld-ContribAuthor ">Abdellah  Ahnaou</span>, <span class="hlFld-ContribAuthor ">Wilhelmus H.  Drinkenburg</span>, <span class="hlFld-ContribAuthor ">Hilde  Lavreysen</span>, <span class="hlFld-ContribAuthor ">Laura H.  Heitman</span>, <span class="hlFld-ContribAuthor ">Adriaan P.  IJzerman</span>, and <span class="hlFld-ContribAuthor ">Gary  Tresadern</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery and Kinetic Profiling of 7-Aryl-1,2,4-triazolo[4,3-a]pyridines: Positive Allosteric Modulators of the Metabotropic Glutamate Receptor 2. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>60 </em>
                                    (15)
                                     , 6704-6720. <a href="https://doi.org/10.1021/acs.jmedchem.7b00669" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b00669</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b00669&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.7b00669%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Band%252BKinetic%252BProfiling%252Bof%252B7-Aryl-1%25252C2%25252C4-triazolo%25255B4%25252C3-a%25255Dpyridines%25253A%252BPositive%252BAllosteric%252BModulators%252Bof%252Bthe%252BMetabotropic%252BGlutamate%252BReceptor%252B2%26aulast%3DDoornbos%26aufirst%3DMaarten%2BL.%2BJ.%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D10052017%26date%3D01082017%26date%3D10082017%26date%3D13072017%26volume%3D60%26issue%3D15%26spage%3D6704%26epage%3D6720" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jose María  Cid</span>, <span class="hlFld-ContribAuthor ">Gary  Tresadern</span>, <span class="hlFld-ContribAuthor ">Juan Antonio  Vega</span>, <span class="hlFld-ContribAuthor ">Ana Isabel  de Lucas</span>, <span class="hlFld-ContribAuthor ">Alcira  del Cerro</span>, <span class="hlFld-ContribAuthor ">Encarnación  Matesanz</span>, <span class="hlFld-ContribAuthor ">María Lourdes  Linares</span>, <span class="hlFld-ContribAuthor ">Aránzazu  García</span>, <span class="hlFld-ContribAuthor ">Laura  Iturrino</span>, <span class="hlFld-ContribAuthor ">Laura  Pérez-Benito</span>, <span class="hlFld-ContribAuthor ">Gregor J.  Macdonald</span>, <span class="hlFld-ContribAuthor ">Daniel  Oehlrich</span>, <span class="hlFld-ContribAuthor ">Hilde  Lavreysen</span>, <span class="hlFld-ContribAuthor ">Luc  Peeters</span>, <span class="hlFld-ContribAuthor ">Marc  Ceusters</span>, <span class="hlFld-ContribAuthor ">Abdellah  Ahnaou</span>, <span class="hlFld-ContribAuthor ">Wilhelmus  Drinkenburg</span>, <span class="hlFld-ContribAuthor ">Claire  Mackie</span>, <span class="hlFld-ContribAuthor ">Marijke  Somers</span>, and <span class="hlFld-ContribAuthor ">Andrés A.  Trabanco</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of 8-Trifluoromethyl-3-cyclopropylmethyl-7-[(4-(2,4-difluorophenyl)-1-piperazinyl)methyl]-1,2,4-triazolo[4,3-a]pyridine (JNJ-46356479), a Selective and Orally Bioavailable mGlu2 Receptor Positive Allosteric Modulator (PAM). </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (18)
                                     , 8495-8507. <a href="https://doi.org/10.1021/acs.jmedchem.6b00913" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b00913</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b00913&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b00913%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252B8-Trifluoromethyl-3-cyclopropylmethyl-7-%25255B%2525284-%2525282%25252C4-difluorophenyl%252529-1-piperazinyl%252529methyl%25255D-1%25252C2%25252C4-triazolo%25255B4%25252C3-a%25255Dpyridine%252B%252528JNJ-46356479%252529%25252C%252Ba%252BSelective%252Band%252BOrally%252BBioavailable%252BmGlu2%252BReceptor%252BPositive%252BAllosteric%252BModulator%252B%252528PAM%252529%26aulast%3DCid%26aufirst%3DJose%2BMar%25C3%25ADa%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D21062016%26date%3D09092016%26date%3D22092016%26date%3D31082016%26volume%3D59%26issue%3D18%26spage%3D8495%26epage%3D8507" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Craig W.  Lindsley</span>, <span class="hlFld-ContribAuthor ">Kyle A.  Emmitte</span>, <span class="hlFld-ContribAuthor ">Corey R.  Hopkins</span>, <span class="hlFld-ContribAuthor ">Thomas M.  Bridges</span>, <span class="hlFld-ContribAuthor ">Karen J.  Gregory</span>, <span class="hlFld-ContribAuthor ">Colleen M.  Niswender</span>, and <span class="hlFld-ContribAuthor ">P. Jeffrey  Conn</span>  . </span><span class="cited-content_cbyCitation_article-title">Practical Strategies and Concepts in GPCR Allosteric Modulator Discovery: Recent Advances with Metabotropic Glutamate Receptors. </span><span class="cited-content_cbyCitation_journal-name">Chemical Reviews</span><span> <strong>2016,</strong> <em>116 </em>
                                    (11)
                                     , 6707-6741. <a href="https://doi.org/10.1021/acs.chemrev.5b00656" title="DOI URL">https://doi.org/10.1021/acs.chemrev.5b00656</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.chemrev.5b00656&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.chemrev.5b00656%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Reviews%26atitle%3DPractical%252BStrategies%252Band%252BConcepts%252Bin%252BGPCR%252BAllosteric%252BModulator%252BDiscovery%25253A%252BRecent%252BAdvances%252Bwith%252BMetabotropic%252BGlutamate%252BReceptors%26aulast%3DLindsley%26aufirst%3DCraig%2BW.%26date%3D2016%26date%3D2016%26date%3D2015%26date%3D06112015%26date%3D16022016%26date%3D08062016%26volume%3D116%26issue%3D11%26spage%3D6707%26epage%3D6741" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Joseph E.  Pero</span>, <span class="hlFld-ContribAuthor ">Michael A.  Rossi</span>, <span class="hlFld-ContribAuthor ">Michael J.  Kelly, III</span>, <span class="hlFld-ContribAuthor ">Hannah D. G. F.  Lehman</span>, <span class="hlFld-ContribAuthor ">Mark E.  Layton</span>, <span class="hlFld-ContribAuthor ">Robert M.  Garbaccio</span>, <span class="hlFld-ContribAuthor ">Julie A.  O’Brien</span>, <span class="hlFld-ContribAuthor ">Brian C.  Magliaro</span>, <span class="hlFld-ContribAuthor ">Jason M.  Uslaner</span>, <span class="hlFld-ContribAuthor ">Sarah L.  Huszar</span>, <span class="hlFld-ContribAuthor ">Kerry L.  Fillgrove</span>, <span class="hlFld-ContribAuthor ">Cuyue  Tang</span>, <span class="hlFld-ContribAuthor ">Yuhsin  Kuo</span>, <span class="hlFld-ContribAuthor ">Leo A.  Joyce</span>, <span class="hlFld-ContribAuthor ">Edward C.  Sherer</span>, and <span class="hlFld-ContribAuthor ">Marlene A.  Jacobson</span>  . </span><span class="cited-content_cbyCitation_article-title">Optimization of Novel Aza-benzimidazolone mGluR2 PAMs with Respect to LLE and PK Properties and Mitigation of CYP TDI. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2016,</strong> <em>7 </em>
                                    (3)
                                     , 312-317. <a href="https://doi.org/10.1021/acsmedchemlett.5b00459" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.5b00459</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.5b00459&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.5b00459%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DOptimization%252Bof%252BNovel%252BAza-benzimidazolone%252BmGluR2%252BPAMs%252Bwith%252BRespect%252Bto%252BLLE%252Band%252BPK%252BProperties%252Band%252BMitigation%252Bof%252BCYP%252BTDI%26aulast%3DPero%26aufirst%3DJoseph%2BE.%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D2015%26date%3D01122015%26date%3D09012016%26date%3D13012016%26date%3D10032016%26date%3D10012016%26volume%3D7%26issue%3D3%26spage%3D312%26epage%3D317" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tengfei  Xu</span>, <span class="hlFld-ContribAuthor ">Yaping  Xue</span>, <span class="hlFld-ContribAuthor ">Jielian  Lu</span>, <span class="hlFld-ContribAuthor ">Chuanfei  Jin</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and biological evaluation of 1-(4-(piperazin-1-yl)phenyl)pyridin-2(1H)-one derivatives as potential SSRIs. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>223 </em>, 113644. <a href="https://doi.org/10.1016/j.ejmech.2021.113644" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113644</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113644&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113644%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252B1-%2525284-%252528piperazin-1-yl%252529phenyl%252529pyridin-2%2525281H%252529-one%252Bderivatives%252Bas%252Bpotential%252BSSRIs%26aulast%3DXu%26aufirst%3DTengfei%26date%3D2021%26volume%3D223%26spage%3D113644" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Juan  Du</span>, <span class="hlFld-ContribAuthor ">Dejian  Wang</span>, <span class="hlFld-ContribAuthor ">Hongcheng  Fan</span>, <span class="hlFld-ContribAuthor ">Chanjuan  Xu</span>, <span class="hlFld-ContribAuthor ">Linhua  Tai</span>, <span class="hlFld-ContribAuthor ">Shuling  Lin</span>, <span class="hlFld-ContribAuthor ">Shuo  Han</span>, <span class="hlFld-ContribAuthor ">Qiuxiang  Tan</span>, <span class="hlFld-ContribAuthor ">Xinwei  Wang</span>, <span class="hlFld-ContribAuthor ">Tuo  Xu</span>, <span class="hlFld-ContribAuthor ">Hui  Zhang</span>, <span class="hlFld-ContribAuthor ">Xiaojing  Chu</span>, <span class="hlFld-ContribAuthor ">Cuiying  Yi</span>, <span class="hlFld-ContribAuthor ">Peng  Liu</span>, <span class="hlFld-ContribAuthor ">Xiaomei  Wang</span>, <span class="hlFld-ContribAuthor ">Yu  Zhou</span>, <span class="hlFld-ContribAuthor ">Jean-Philippe  Pin</span>, <span class="hlFld-ContribAuthor ">Philippe  Rondard</span>, <span class="hlFld-ContribAuthor ">Hong  Liu</span>, <span class="hlFld-ContribAuthor ">Jianfeng  Liu</span>, <span class="hlFld-ContribAuthor ">Fei  Sun</span>, <span class="hlFld-ContribAuthor ">Beili  Wu</span>, <span class="hlFld-ContribAuthor ">Qiang  Zhao</span>. </span><span class="cited-content_cbyCitation_article-title">Structures of human mGlu2 and mGlu7 homo- and heterodimers. </span><span class="cited-content_cbyCitation_journal-name">Nature</span><span> <strong>2021,</strong> <em>594 </em>
                                    (7864)
                                     , 589-593. <a href="https://doi.org/10.1038/s41586-021-03641-w" title="DOI URL">https://doi.org/10.1038/s41586-021-03641-w</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41586-021-03641-w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41586-021-03641-w%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%26atitle%3DStructures%252Bof%252Bhuman%252BmGlu2%252Band%252BmGlu7%252Bhomo-%252Band%252Bheterodimers%26aulast%3DDu%26aufirst%3DJuan%26date%3D2021%26date%3D2021%26volume%3D594%26issue%3D7864%26spage%3D589%26epage%3D593" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shuling  Lin</span>, <span class="hlFld-ContribAuthor ">Shuo  Han</span>, <span class="hlFld-ContribAuthor ">Xiaoqing  Cai</span>, <span class="hlFld-ContribAuthor ">Qiuxiang  Tan</span>, <span class="hlFld-ContribAuthor ">Kexiu  Zhou</span>, <span class="hlFld-ContribAuthor ">Dejian  Wang</span>, <span class="hlFld-ContribAuthor ">Xinwei  Wang</span>, <span class="hlFld-ContribAuthor ">Juan  Du</span>, <span class="hlFld-ContribAuthor ">Cuiying  Yi</span>, <span class="hlFld-ContribAuthor ">Xiaojing  Chu</span>, <span class="hlFld-ContribAuthor ">Antao  Dai</span>, <span class="hlFld-ContribAuthor ">Yan  Zhou</span>, <span class="hlFld-ContribAuthor ">Yan  Chen</span>, <span class="hlFld-ContribAuthor ">Yu  Zhou</span>, <span class="hlFld-ContribAuthor ">Hong  Liu</span>, <span class="hlFld-ContribAuthor ">Jianfeng  Liu</span>, <span class="hlFld-ContribAuthor ">Dehua  Yang</span>, <span class="hlFld-ContribAuthor ">Ming-Wei  Wang</span>, <span class="hlFld-ContribAuthor ">Qiang  Zhao</span>, <span class="hlFld-ContribAuthor ">Beili  Wu</span>. </span><span class="cited-content_cbyCitation_article-title">Structures of Gi-bound metabotropic glutamate receptors mGlu2 and mGlu4. </span><span class="cited-content_cbyCitation_journal-name">Nature</span><span> <strong>2021,</strong> <em>594 </em>
                                    (7864)
                                     , 583-588. <a href="https://doi.org/10.1038/s41586-021-03495-2" title="DOI URL">https://doi.org/10.1038/s41586-021-03495-2</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41586-021-03495-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41586-021-03495-2%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%26atitle%3DStructures%252Bof%252BGi-bound%252Bmetabotropic%252Bglutamate%252Breceptors%252BmGlu2%252Band%252BmGlu4%26aulast%3DLin%26aufirst%3DShuling%26date%3D2021%26date%3D2021%26volume%3D594%26issue%3D7864%26spage%3D583%26epage%3D588" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Eduard  Parellada</span>, <span class="hlFld-ContribAuthor ">Patricia  Gassó</span>. </span><span class="cited-content_cbyCitation_article-title">Glutamate and microglia activation as a driver of dendritic apoptosis: a core pathophysiological mechanism to understand schizophrenia. </span><span class="cited-content_cbyCitation_journal-name">Translational Psychiatry</span><span> <strong>2021,</strong> <em>11 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s41398-021-01385-9" title="DOI URL">https://doi.org/10.1038/s41398-021-01385-9</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41398-021-01385-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41398-021-01385-9%26sid%3Dliteratum%253Aachs%26jtitle%3DTranslational%2520Psychiatry%26atitle%3DGlutamate%252Band%252Bmicroglia%252Bactivation%252Bas%252Ba%252Bdriver%252Bof%252Bdendritic%252Bapoptosis%25253A%252Ba%252Bcore%252Bpathophysiological%252Bmechanism%252Bto%252Bunderstand%252Bschizophrenia%26aulast%3DParellada%26aufirst%3DEduard%26date%3D2021%26date%3D2021%26volume%3D11%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Linjing  Mu</span>, <span class="hlFld-ContribAuthor ">Simon M.  Ametamey</span>. </span><span class="cited-content_cbyCitation_article-title">Current Radioligands for the PET Imaging of Metabotropic Glutamate Receptors. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 427-481. <a href="https://doi.org/10.1007/978-3-030-53176-8_13" title="DOI URL">https://doi.org/10.1007/978-3-030-53176-8_13</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-3-030-53176-8_13&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-3-030-53176-8_13%26sid%3Dliteratum%253Aachs%26atitle%3DCurrent%252BRadioligands%252Bfor%252Bthe%252BPET%252BImaging%252Bof%252BMetabotropic%252BGlutamate%252BReceptors%26aulast%3DMu%26aufirst%3DLinjing%26date%3D2021%26date%3D2020%26spage%3D427%26epage%3D481%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DPET%252Band%252BSPECT%252Bof%252BNeurobiological%252BSystems%26aulast%3DDierckx%26aufirst%3DRudi%2BA.J.O.%26date%3D2021%26volume%3D2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Karen J.  Gregory</span>, <span class="hlFld-ContribAuthor ">Cyril  Goudet</span>, . </span><span class="cited-content_cbyCitation_article-title">International Union of Basic and Clinical Pharmacology. CXI. Pharmacology, Signaling, and Physiology of Metabotropic Glutamate Receptors. </span><span class="cited-content_cbyCitation_journal-name">Pharmacological Reviews</span><span> <strong>2021,</strong> <em>73 </em>
                                    (1)
                                     , 521-569. <a href="https://doi.org/10.1124/pr.119.019133" title="DOI URL">https://doi.org/10.1124/pr.119.019133</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1124/pr.119.019133&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1124%2Fpr.119.019133%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmacological%2520Reviews%26atitle%3DInternational%252BUnion%252Bof%252BBasic%252Band%252BClinical%252BPharmacology.%252BCXI.%252BPharmacology%25252C%252BSignaling%25252C%252Band%252BPhysiology%252Bof%252BMetabotropic%252BGlutamate%252BReceptors%26aulast%3DGregory%26aufirst%3DKaren%2BJ.%26date%3D2021%26date%3D2020%26volume%3D73%26issue%3D1%26spage%3D521%26epage%3D569" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Albert  Martínez-Pinteño</span>, <span class="hlFld-ContribAuthor ">Susana  García-Cerro</span>, <span class="hlFld-ContribAuthor ">Sergi  Mas</span>, <span class="hlFld-ContribAuthor ">Teresa  Torres</span>, <span class="hlFld-ContribAuthor ">Daniel  Boloc</span>, <span class="hlFld-ContribAuthor ">Natalia  Rodríguez</span>, <span class="hlFld-ContribAuthor ">Amalia  Lafuente</span>, <span class="hlFld-ContribAuthor ">Patricia  Gassó</span>, <span class="hlFld-ContribAuthor ">Joan Albert  Arnaiz</span>, <span class="hlFld-ContribAuthor ">Eduard  Parellada</span>. </span><span class="cited-content_cbyCitation_article-title">The positive allosteric modulator of the mGlu2 receptor JNJ-46356479 partially improves neuropathological deficits and schizophrenia-like behaviors in a postnatal ketamine mice model. </span><span class="cited-content_cbyCitation_journal-name">Journal of Psychiatric Research</span><span> <strong>2020,</strong> <em>126 </em>, 8-18. <a href="https://doi.org/10.1016/j.jpsychires.2020.04.005" title="DOI URL">https://doi.org/10.1016/j.jpsychires.2020.04.005</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jpsychires.2020.04.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jpsychires.2020.04.005%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Psychiatric%2520Research%26atitle%3DThe%252Bpositive%252Ballosteric%252Bmodulator%252Bof%252Bthe%252BmGlu2%252Breceptor%252BJNJ-46356479%252Bpartially%252Bimproves%252Bneuropathological%252Bdeficits%252Band%252Bschizophrenia-like%252Bbehaviors%252Bin%252Ba%252Bpostnatal%252Bketamine%252Bmice%252Bmodel%26aulast%3DMart%25C3%25ADnez-Pinte%25C3%25B1o%26aufirst%3DAlbert%26date%3D2020%26volume%3D126%26spage%3D8%26epage%3D18" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">A. I.  Molosh</span>, <span class="hlFld-ContribAuthor ">E. T.  Dustrude</span>, <span class="hlFld-ContribAuthor ">J. L.  Lukkes</span>, <span class="hlFld-ContribAuthor ">S. D.  Fitz</span>, <span class="hlFld-ContribAuthor ">I. F.  Caliman</span>, <span class="hlFld-ContribAuthor ">A. R. R.  Abreu</span>, <span class="hlFld-ContribAuthor ">A. D.  Dietrich</span>, <span class="hlFld-ContribAuthor ">W. A.  Truitt</span>, <span class="hlFld-ContribAuthor ">L.  Ver Donck</span>, <span class="hlFld-ContribAuthor ">M.  Ceusters</span>, <span class="hlFld-ContribAuthor ">J. M.  Kent</span>, <span class="hlFld-ContribAuthor ">P. L.  Johnson</span>, <span class="hlFld-ContribAuthor ">A .  Shekhar</span>. </span><span class="cited-content_cbyCitation_article-title">Panic results in unique molecular and network changes in the amygdala that facilitate fear responses. </span><span class="cited-content_cbyCitation_journal-name">Molecular Psychiatry</span><span> <strong>2020,</strong> <em>25 </em>
                                    (2)
                                     , 442-460. <a href="https://doi.org/10.1038/s41380-018-0119-0" title="DOI URL">https://doi.org/10.1038/s41380-018-0119-0</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41380-018-0119-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41380-018-0119-0%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Psychiatry%26atitle%3DPanic%252Bresults%252Bin%252Bunique%252Bmolecular%252Band%252Bnetwork%252Bchanges%252Bin%252Bthe%252Bamygdala%252Bthat%252Bfacilitate%252Bfear%252Bresponses%26aulast%3DMolosh%26aufirst%3DA.%2BI.%26date%3D2020%26date%3D2018%26volume%3D25%26issue%3D2%26spage%3D442%26epage%3D460" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lingbin  Kong</span>, <span class="hlFld-ContribAuthor ">Rong  Huang</span>, <span class="hlFld-ContribAuthor ">Haodan  He</span>, <span class="hlFld-ContribAuthor ">Yunxiang  Fan</span>, <span class="hlFld-ContribAuthor ">Jun  Lin</span>, <span class="hlFld-ContribAuthor ">Shengjiao  Yan</span>. </span><span class="cited-content_cbyCitation_article-title">Multi-component solvent-free cascade reaction of 2-cyanoacetamides: regioselective synthesis of pyridin-2-ones bearing quaternary centers. </span><span class="cited-content_cbyCitation_journal-name">Green Chemistry</span><span> <strong>2020,</strong> <em>22 </em>
                                    (1)
                                     , 256-264. <a href="https://doi.org/10.1039/C9GC03692J" title="DOI URL">https://doi.org/10.1039/C9GC03692J</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C9GC03692J&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC9GC03692J%26sid%3Dliteratum%253Aachs%26jtitle%3DGreen%2520Chemistry%26atitle%3DMulti-component%252Bsolvent-free%252Bcascade%252Breaction%252Bof%252B2-cyanoacetamides%25253A%252Bregioselective%252Bsynthesis%252Bof%252Bpyridin-2-ones%252Bbearing%252Bquaternary%252Bcenters%26aulast%3DKong%26aufirst%3DLingbin%26date%3D2020%26date%3D2020%26volume%3D22%26issue%3D1%26spage%3D256%26epage%3D264" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">María L.  López-Rodríguez</span>, <span class="hlFld-ContribAuthor ">Bellinda  Benhamú</span>, <span class="hlFld-ContribAuthor ">Henar  Vázquez-Villa</span>. </span><span class="cited-content_cbyCitation_article-title">Allosteric modulators targeting GPCRs. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,, 195-241. <a href="https://doi.org/10.1016/B978-0-12-816228-6.00011-8" title="DOI URL">https://doi.org/10.1016/B978-0-12-816228-6.00011-8</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-816228-6.00011-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-816228-6.00011-8%26sid%3Dliteratum%253Aachs%26atitle%3DAllosteric%252Bmodulators%252Btargeting%252BGPCRs%26aulast%3DL%25C3%25B3pez-Rodr%25C3%25ADguez%26aufirst%3DMar%25C3%25ADa%2BL.%26date%3D2020%26spage%3D195%26epage%3D241%26pub%3DElsevier%26atitle%3DGPCRs%26date%3D2020%26volume%3D289" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Laura  Pérez-Benito</span>, <span class="hlFld-ContribAuthor ">Claudia  Llinas del Torrent</span>, <span class="hlFld-ContribAuthor ">Leonardo  Pardo</span>, <span class="hlFld-ContribAuthor ">Gary  Tresadern</span>. </span><span class="cited-content_cbyCitation_article-title">The computational modeling of allosteric modulation of metabotropic glutamate receptors. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,, 1-33. <a href="https://doi.org/10.1016/bs.apha.2020.02.004" title="DOI URL">https://doi.org/10.1016/bs.apha.2020.02.004</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/bs.apha.2020.02.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fbs.apha.2020.02.004%26sid%3Dliteratum%253Aachs%26atitle%3DThe%252Bcomputational%252Bmodeling%252Bof%252Ballosteric%252Bmodulation%252Bof%252Bmetabotropic%252Bglutamate%252Breceptors%26aulast%3DP%25C3%25A9rez-Benito%26aufirst%3DLaura%26date%3D2020%26spage%3D1%26epage%3D33%26pub%3DElsevier%26atitle%3DFrom%252BStructure%252Bto%252BClinical%252BDevelopment%25253A%252BAllosteric%252BModulation%252Bof%252BG%252BProtein-Coupled%252BReceptors%26date%3D2020%26volume%3D88" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zoltán  Orgován</span>, <span class="hlFld-ContribAuthor ">György G.  Ferenczy</span>, <span class="hlFld-ContribAuthor ">György M.  Keserű</span>. </span><span class="cited-content_cbyCitation_article-title">Fragment-Based Approaches for Allosteric Metabotropic Glutamate Receptor (mGluR) Modulators. </span><span class="cited-content_cbyCitation_journal-name">Current Topics in Medicinal Chemistry</span><span> <strong>2019,</strong> <em>19 </em>
                                    (19)
                                     , 1768-1781. <a href="https://doi.org/10.2174/1568026619666190808150039" title="DOI URL">https://doi.org/10.2174/1568026619666190808150039</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/1568026619666190808150039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F1568026619666190808150039%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Topics%2520in%2520Medicinal%2520Chemistry%26atitle%3DFragment-Based%252BApproaches%252Bfor%252BAllosteric%252BMetabotropic%252BGlutamate%252BReceptor%252B%252528mGluR%252529%252BModulators%26aulast%3DOrgov%25C3%25A1n%26aufirst%3DZolt%25C3%25A1n%26date%3D2019%26volume%3D19%26issue%3D19%26spage%3D1768%26epage%3D1781" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Youwen  Xu</span>, <span class="hlFld-ContribAuthor ">Zizhong  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Imaging metabotropic glutamate receptor system: Application of positron emission tomography technology in drug development. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Research Reviews</span><span> <strong>2019,</strong> <em>39 </em>
                                    (5)
                                     , 1892-1922. <a href="https://doi.org/10.1002/med.21566" title="DOI URL">https://doi.org/10.1002/med.21566</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/med.21566&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fmed.21566%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Research%2520Reviews%26atitle%3DImaging%252Bmetabotropic%252Bglutamate%252Breceptor%252Bsystem%25253A%252BApplication%252Bof%252Bpositron%252Bemission%252Btomography%252Btechnology%252Bin%252Bdrug%252Bdevelopment%26aulast%3DXu%26aufirst%3DYouwen%26date%3D2019%26date%3D2019%26volume%3D39%26issue%3D5%26spage%3D1892%26epage%3D1922" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rhys  Salter</span>, <span class="hlFld-ContribAuthor ">Douglas C.  Beshore</span>, <span class="hlFld-ContribAuthor ">Steven L.  Colletti</span>, <span class="hlFld-ContribAuthor ">Liam  Evans</span>, <span class="hlFld-ContribAuthor ">Yong  Gong</span>, <span class="hlFld-ContribAuthor ">Roy  Helmy</span>, <span class="hlFld-ContribAuthor ">Yong  Liu</span>, <span class="hlFld-ContribAuthor ">Cheri M.  Maciolek</span>, <span class="hlFld-ContribAuthor ">Gary  Martin</span>, <span class="hlFld-ContribAuthor ">Natasa  Pajkovic</span>, <span class="hlFld-ContribAuthor ">Richard  Phipps</span>, <span class="hlFld-ContribAuthor ">James  Small</span>, <span class="hlFld-ContribAuthor ">Jonathan  Steele</span>, <span class="hlFld-ContribAuthor ">Ronald  de Vries</span>, <span class="hlFld-ContribAuthor ">Headley  Williams</span>, <span class="hlFld-ContribAuthor ">Iain J.  Martin</span>. </span><span class="cited-content_cbyCitation_article-title">Microbial biotransformation – an important tool for the study of drug metabolism. </span><span class="cited-content_cbyCitation_journal-name">Xenobiotica</span><span> <strong>2019,</strong> <em>49 </em>
                                    (8)
                                     , 877-886. <a href="https://doi.org/10.1080/00498254.2018.1512018" title="DOI URL">https://doi.org/10.1080/00498254.2018.1512018</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/00498254.2018.1512018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F00498254.2018.1512018%26sid%3Dliteratum%253Aachs%26jtitle%3DXenobiotica%26atitle%3DMicrobial%252Bbiotransformation%252B%2525E2%252580%252593%252Ban%252Bimportant%252Btool%252Bfor%252Bthe%252Bstudy%252Bof%252Bdrug%252Bmetabolism%26aulast%3DSalter%26aufirst%3DRhys%26date%3D2019%26date%3D2018%26volume%3D49%26issue%3D8%26spage%3D877%26epage%3D886" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Claudia  Llinas del Torrent</span>, <span class="hlFld-ContribAuthor ">Laura  Pérez-Benito</span>, <span class="hlFld-ContribAuthor ">Gary  Tresadern</span>. </span><span class="cited-content_cbyCitation_article-title">Computational Drug Design Applied to the Study of Metabotropic Glutamate Receptors. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2019,</strong> <em>24 </em>
                                    (6)
                                     , 1098. <a href="https://doi.org/10.3390/molecules24061098" title="DOI URL">https://doi.org/10.3390/molecules24061098</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules24061098&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules24061098%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DComputational%252BDrug%252BDesign%252BApplied%252Bto%252Bthe%252BStudy%252Bof%252BMetabotropic%252BGlutamate%252BReceptors%26aulast%3DLlinas%2Bdel%2BTorrent%26aufirst%3DClaudia%26date%3D2019%26date%3D2019%26volume%3D24%26issue%3D6%26spage%3D1098" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Maarten L.J.  Doornbos</span>, <span class="hlFld-ContribAuthor ">Ilse  Van der Linden</span>, <span class="hlFld-ContribAuthor ">Liesbeth  Vereyken</span>, <span class="hlFld-ContribAuthor ">Gary  Tresadern</span>, <span class="hlFld-ContribAuthor ">Adriaan P.  IJzerman</span>, <span class="hlFld-ContribAuthor ">Hilde  Lavreysen</span>, <span class="hlFld-ContribAuthor ">Laura H.  Heitman</span>. </span><span class="cited-content_cbyCitation_article-title">Constitutive activity of the metabotropic glutamate receptor 2 explored with a whole-cell label-free biosensor. </span><span class="cited-content_cbyCitation_journal-name">Biochemical Pharmacology</span><span> <strong>2018,</strong> <em>152 </em>, 201-210. <a href="https://doi.org/10.1016/j.bcp.2018.03.026" title="DOI URL">https://doi.org/10.1016/j.bcp.2018.03.026</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bcp.2018.03.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bcp.2018.03.026%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochemical%2520Pharmacology%26atitle%3DConstitutive%252Bactivity%252Bof%252Bthe%252Bmetabotropic%252Bglutamate%252Breceptor%252B2%252Bexplored%252Bwith%252Ba%252Bwhole-cell%252Blabel-free%252Bbiosensor%26aulast%3DDoornbos%26aufirst%3DMaarten%2BL.J.%26date%3D2018%26volume%3D152%26spage%3D201%26epage%3D210" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Alan J.  Cross</span>, <span class="hlFld-ContribAuthor ">Robert  Anthenelli</span>, <span class="hlFld-ContribAuthor ">Xia  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Metabotropic Glutamate Receptors 2 and 3 as Targets for Treating Nicotine Addiction. </span><span class="cited-content_cbyCitation_journal-name">Biological Psychiatry</span><span> <strong>2018,</strong> <em>83 </em>
                                    (11)
                                     , 947-954. <a href="https://doi.org/10.1016/j.biopsych.2017.11.021" title="DOI URL">https://doi.org/10.1016/j.biopsych.2017.11.021</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.biopsych.2017.11.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.biopsych.2017.11.021%26sid%3Dliteratum%253Aachs%26jtitle%3DBiological%2520Psychiatry%26atitle%3DMetabotropic%252BGlutamate%252BReceptors%252B2%252Band%252B3%252Bas%252BTargets%252Bfor%252BTreating%252BNicotine%252BAddiction%26aulast%3DCross%26aufirst%3DAlan%2BJ.%26date%3D2018%26volume%3D83%26issue%3D11%26spage%3D947%26epage%3D954" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">. </span><span class="cited-content_cbyCitation_article-title">4-(Hetero)Arylpiperidines. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2018,</strong>,, 155-193. <a href="https://doi.org/10.1002/9781118686263.ch5" title="DOI URL">https://doi.org/10.1002/9781118686263.ch5</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/9781118686263.ch5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F9781118686263.ch5%26sid%3Dliteratum%253Aachs%26atitle%3D4-%252528Hetero%252529Arylpiperidines%26date%3D2018%26date%3D2018%26spage%3D155%26epage%3D193%26pub%3DJohn%2520Wiley%2520%2526%2520Sons%252C%2520Inc%26atitle%3DPrivileged%252BStructures%252Bin%252BDrug%252BDiscovery%26aulast%3DYet%26aufirst%3DLarry%26date%3D2018%26volume%3D57" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Katsushi  Kumata</span>, <span class="hlFld-ContribAuthor ">Tomoteru  Yamasaki</span>, <span class="hlFld-ContribAuthor ">Akiko  Hatori</span>, <span class="hlFld-ContribAuthor ">Yiding  Zhang</span>, <span class="hlFld-ContribAuthor ">Wakana  Mori</span>, <span class="hlFld-ContribAuthor ">Masayuki  Fujinaga</span>, <span class="hlFld-ContribAuthor ">Lin  Xie</span>, <span class="hlFld-ContribAuthor ">Takayuki  Okubo</span>, <span class="hlFld-ContribAuthor ">Nobuki  Nengaki</span>, <span class="hlFld-ContribAuthor ">Ming-Rong  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and in vitro evaluation of three novel radiotracers for imaging of metabotropic glutamate receptor subtype 2 in rat brain. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2017,</strong> <em>27 </em>
                                    (14)
                                     , 3139-3143. <a href="https://doi.org/10.1016/j.bmcl.2017.05.029" title="DOI URL">https://doi.org/10.1016/j.bmcl.2017.05.029</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2017.05.029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2017.05.029%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DSynthesis%252Band%252Bin%252Bvitro%252Bevaluation%252Bof%252Bthree%252Bnovel%252Bradiotracers%252Bfor%252Bimaging%252Bof%252Bmetabotropic%252Bglutamate%252Breceptor%252Bsubtype%252B2%252Bin%252Brat%252Bbrain%26aulast%3DKumata%26aufirst%3DKatsushi%26date%3D2017%26volume%3D27%26issue%3D14%26spage%3D3139%26epage%3D3143" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Laura  Pérez-Benito</span>, <span class="hlFld-ContribAuthor ">Maarten L.J.  Doornbos</span>, <span class="hlFld-ContribAuthor ">Arnau  Cordomí</span>, <span class="hlFld-ContribAuthor ">Luc  Peeters</span>, <span class="hlFld-ContribAuthor ">Hilde  Lavreysen</span>, <span class="hlFld-ContribAuthor ">Leonardo  Pardo</span>, <span class="hlFld-ContribAuthor ">Gary  Tresadern</span>. </span><span class="cited-content_cbyCitation_article-title">Molecular Switches of Allosteric Modulation of the Metabotropic Glutamate 2 Receptor. </span><span class="cited-content_cbyCitation_journal-name">Structure</span><span> <strong>2017,</strong> <em>25 </em>
                                    (7)
                                     , 1153-1162.e4. <a href="https://doi.org/10.1016/j.str.2017.05.021" title="DOI URL">https://doi.org/10.1016/j.str.2017.05.021</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.str.2017.05.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.str.2017.05.021%26sid%3Dliteratum%253Aachs%26jtitle%3DStructure%26atitle%3DMolecular%252BSwitches%252Bof%252BAllosteric%252BModulation%252Bof%252Bthe%252BMetabotropic%252BGlutamate%252B2%252BReceptor%26aulast%3DP%25C3%25A9rez-Benito%26aufirst%3DLaura%26date%3D2017%26volume%3D25%26issue%3D7%26spage%3D1153%26epage%3D1162.e4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Cameron S.  Metcalf</span>, <span class="hlFld-ContribAuthor ">Brian D.  Klein</span>, <span class="hlFld-ContribAuthor ">Misty D.  Smith</span>, <span class="hlFld-ContribAuthor ">Tim  Pruess</span>, <span class="hlFld-ContribAuthor ">Marc  Ceusters</span>, <span class="hlFld-ContribAuthor ">Hilde  Lavreysen</span>, <span class="hlFld-ContribAuthor ">Stefan  Pype</span>, <span class="hlFld-ContribAuthor ">Nancy  Van Osselaer</span>, <span class="hlFld-ContribAuthor ">Roy  Twyman</span>, <span class="hlFld-ContribAuthor ">H. Steve  White</span>. </span><span class="cited-content_cbyCitation_article-title">Efficacy of mGlu
              2
              -positive allosteric modulators alone and in combination with levetiracetam in the mouse 6 Hz model of psychomotor seizures. </span><span class="cited-content_cbyCitation_journal-name">Epilepsia</span><span> <strong>2017,</strong> <em>58 </em>
                                    (3)
                                     , 484-493. <a href="https://doi.org/10.1111/epi.13659" title="DOI URL">https://doi.org/10.1111/epi.13659</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/epi.13659&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fepi.13659%26sid%3Dliteratum%253Aachs%26jtitle%3DEpilepsia%26atitle%3DEfficacy%252Bof%252BmGlu%252B2%252B-positive%252Ballosteric%252Bmodulators%252Balone%252Band%252Bin%252Bcombination%252Bwith%252Blevetiracetam%252Bin%252Bthe%252Bmouse%252B6%252BHz%252Bmodel%252Bof%252Bpsychomotor%252Bseizures%26aulast%3DMetcalf%26aufirst%3DCameron%2BS.%26date%3D2017%26date%3D2017%26volume%3D58%26issue%3D3%26spage%3D484%26epage%3D493" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yufei  Ma</span>, <span class="hlFld-ContribAuthor ">Katsushi  Kumata</span>, <span class="hlFld-ContribAuthor ">Joji  Yui</span>, <span class="hlFld-ContribAuthor ">Yiding  Zhang</span>, <span class="hlFld-ContribAuthor ">Tomoteru  Yamasaki</span>, <span class="hlFld-ContribAuthor ">Akiko  Hatori</span>, <span class="hlFld-ContribAuthor ">Masayuki  Fujinaga</span>, <span class="hlFld-ContribAuthor ">Nobuki  Nengaki</span>, <span class="hlFld-ContribAuthor ">Lin  Xie</span>, <span class="hlFld-ContribAuthor ">Hui  Wang</span>, <span class="hlFld-ContribAuthor ">Ming-Rong  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and evaluation of 1-(cyclopropylmethyl)-4-(4-[ 11 C]methoxyphenyl)-piperidin-1-yl-2-oxo-1,2-dihydropyridine-3-carbonitrile ([ 11 C]CMDC) for PET imaging of metabotropic glutamate receptor 2 in the rat brain. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2017,</strong> <em>25 </em>
                                    (3)
                                     , 1014-1021. <a href="https://doi.org/10.1016/j.bmc.2016.12.011" title="DOI URL">https://doi.org/10.1016/j.bmc.2016.12.011</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2016.12.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2016.12.011%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DSynthesis%252Band%252Bevaluation%252Bof%252B1-%252528cyclopropylmethyl%252529-4-%2525284-%25255B%252B11%252BC%25255Dmethoxyphenyl%252529-piperidin-1-yl-2-oxo-1%25252C2-dihydropyridine-3-carbonitrile%252B%252528%25255B%252B11%252BC%25255DCMDC%252529%252Bfor%252BPET%252Bimaging%252Bof%252Bmetabotropic%252Bglutamate%252Breceptor%252B2%252Bin%252Bthe%252Brat%252Bbrain%26aulast%3DMa%26aufirst%3DYufei%26date%3D2017%26volume%3D25%26issue%3D3%26spage%3D1014%26epage%3D1021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sarah L.  Clarke</span>, <span class="hlFld-ContribAuthor ">Gerard P.  McGlacken</span>. </span><span class="cited-content_cbyCitation_article-title">Methyl fluorosulfonyldifluoroacetate (MFSDA): An Underutilised Reagent for Trifluoromethylation. </span><span class="cited-content_cbyCitation_journal-name">Chemistry - A European Journal</span><span> <strong>2017,</strong> <em>23 </em>
                                    (6)
                                     , 1219-1230. <a href="https://doi.org/10.1002/chem.201602511" title="DOI URL">https://doi.org/10.1002/chem.201602511</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/chem.201602511&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fchem.201602511%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistry%2520-%2520A%2520European%2520Journal%26atitle%3DMethyl%252Bfluorosulfonyldifluoroacetate%252B%252528MFSDA%252529%25253A%252BAn%252BUnderutilised%252BReagent%252Bfor%252BTrifluoromethylation%26aulast%3DClarke%26aufirst%3DSarah%2BL.%26date%3D2017%26date%3D2016%26volume%3D23%26issue%3D6%26spage%3D1219%26epage%3D1230" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chaobin  Jin</span>, <span class="hlFld-ContribAuthor ">Shutao  Ma</span>. </span><span class="cited-content_cbyCitation_article-title">Recent advances in the medicinal chemistry of group II and group III mGlu receptors. </span><span class="cited-content_cbyCitation_journal-name">MedChemComm</span><span> <strong>2017,</strong> <em>8 </em>
                                    (3)
                                     , 501-515. <a href="https://doi.org/10.1039/C6MD00612D" title="DOI URL">https://doi.org/10.1039/C6MD00612D</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C6MD00612D&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC6MD00612D%26sid%3Dliteratum%253Aachs%26jtitle%3DMedChemComm%26atitle%3DRecent%252Badvances%252Bin%252Bthe%252Bmedicinal%252Bchemistry%252Bof%252Bgroup%252BII%252Band%252Bgroup%252BIII%252BmGlu%252Breceptors%26aulast%3DJin%26aufirst%3DChaobin%26date%3D2017%26date%3D2017%26volume%3D8%26issue%3D3%26spage%3D501%26epage%3D515" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xuan-Xuan  Du</span>, <span class="hlFld-ContribAuthor ">Rong  Huang</span>, <span class="hlFld-ContribAuthor ">Chang-Long  Yang</span>, <span class="hlFld-ContribAuthor ">Jun  Lin</span>, <span class="hlFld-ContribAuthor ">Sheng-Jiao  Yan</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and evaluation of the antitumor activity of highly functionalised pyridin-2-ones and pyrimidin-4-ones. </span><span class="cited-content_cbyCitation_journal-name">RSC Advances</span><span> <strong>2017,</strong> <em>7 </em>
                                    (64)
                                     , 40067-40073. <a href="https://doi.org/10.1039/C7RA06466G" title="DOI URL">https://doi.org/10.1039/C7RA06466G</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C7RA06466G&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC7RA06466G%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Advances%26atitle%3DSynthesis%252Band%252Bevaluation%252Bof%252Bthe%252Bantitumor%252Bactivity%252Bof%252Bhighly%252Bfunctionalised%252Bpyridin-2-ones%252Band%252Bpyrimidin-4-ones%26aulast%3DDu%26aufirst%3DXuan-Xuan%26date%3D2017%26date%3D2017%26volume%3D7%26issue%3D64%26spage%3D40067%26epage%3D40073" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Justine M.  Kent</span>, <span class="hlFld-ContribAuthor ">Ella  Daly</span>, <span class="hlFld-ContribAuthor ">Iva  Kezic</span>, <span class="hlFld-ContribAuthor ">Rosanne  Lane</span>, <span class="hlFld-ContribAuthor ">Pilar  Lim</span>, <span class="hlFld-ContribAuthor ">Heidi  De Smedt</span>, <span class="hlFld-ContribAuthor ">Peter  De Boer</span>, <span class="hlFld-ContribAuthor ">Luc  Van Nueten</span>, <span class="hlFld-ContribAuthor ">Wayne C.  Drevets</span>, <span class="hlFld-ContribAuthor ">Marc  Ceusters</span>. </span><span class="cited-content_cbyCitation_article-title">Efficacy and safety of an adjunctive mGlu2 receptor positive allosteric modulator to a SSRI/SNRI in anxious depression. </span><span class="cited-content_cbyCitation_journal-name">Progress in Neuro-Psychopharmacology and Biological Psychiatry</span><span> <strong>2016,</strong> <em>67 </em>, 66-73. <a href="https://doi.org/10.1016/j.pnpbp.2016.01.009" title="DOI URL">https://doi.org/10.1016/j.pnpbp.2016.01.009</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.pnpbp.2016.01.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.pnpbp.2016.01.009%26sid%3Dliteratum%253Aachs%26jtitle%3DProgress%2520in%2520Neuro-Psychopharmacology%2520and%2520Biological%2520Psychiatry%26atitle%3DEfficacy%252Band%252Bsafety%252Bof%252Ban%252Badjunctive%252BmGlu2%252Breceptor%252Bpositive%252Ballosteric%252Bmodulator%252Bto%252Ba%252BSSRI%25252FSNRI%252Bin%252Banxious%252Bdepression%26aulast%3DKent%26aufirst%3DJustine%2BM.%26date%3D2016%26volume%3D67%26spage%3D66%26epage%3D73" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">A.  Ahnaou</span>, <span class="hlFld-ContribAuthor ">P.  de Boer</span>, <span class="hlFld-ContribAuthor ">H.  Lavreysen</span>, <span class="hlFld-ContribAuthor ">H.  Huysmans</span>, <span class="hlFld-ContribAuthor ">V.  Sinha</span>, <span class="hlFld-ContribAuthor ">L.  Raeymaekers</span>, <span class="hlFld-ContribAuthor ">T.  Van De Casteele</span>, <span class="hlFld-ContribAuthor ">J.M.  Cid</span>, <span class="hlFld-ContribAuthor ">L.  Van Nueten</span>, <span class="hlFld-ContribAuthor ">G.J.  Macdonald</span>, <span class="hlFld-ContribAuthor ">J.A.  Kemp</span>, <span class="hlFld-ContribAuthor ">W.H.I.M.  Drinkenburg</span>. </span><span class="cited-content_cbyCitation_article-title">Translational neurophysiological markers for activity of the metabotropic glutamate receptor (mGluR2) modulator JNJ-40411813: Sleep EEG correlates in rodents and healthy men. </span><span class="cited-content_cbyCitation_journal-name">Neuropharmacology</span><span> <strong>2016,</strong> <em>103 </em>, 290-305. <a href="https://doi.org/10.1016/j.neuropharm.2015.11.031" title="DOI URL">https://doi.org/10.1016/j.neuropharm.2015.11.031</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.neuropharm.2015.11.031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.neuropharm.2015.11.031%26sid%3Dliteratum%253Aachs%26jtitle%3DNeuropharmacology%26atitle%3DTranslational%252Bneurophysiological%252Bmarkers%252Bfor%252Bactivity%252Bof%252Bthe%252Bmetabotropic%252Bglutamate%252Breceptor%252B%252528mGluR2%252529%252Bmodulator%252BJNJ-40411813%25253A%252BSleep%252BEEG%252Bcorrelates%252Bin%252Brodents%252Band%252Bhealthy%252Bmen%26aulast%3DAhnaou%26aufirst%3DA.%26date%3D2016%26volume%3D103%26spage%3D290%26epage%3D305" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mark E.  Layton</span>, <span class="hlFld-ContribAuthor ">Alexander J.  Reif</span>, <span class="hlFld-ContribAuthor ">Timothy J.  Hartingh</span>, <span class="hlFld-ContribAuthor ">Kevin  Rodzinak</span>, <span class="hlFld-ContribAuthor ">Vadim  Dudkin</span>, <span class="hlFld-ContribAuthor ">Cheng  Wang</span>, <span class="hlFld-ContribAuthor ">Ken  Arrington</span>, <span class="hlFld-ContribAuthor ">Michael J.  Kelly</span>, <span class="hlFld-ContribAuthor ">Robert M.  Garbaccio</span>, <span class="hlFld-ContribAuthor ">Julie A.  O’Brien</span>, <span class="hlFld-ContribAuthor ">Brian C.  Magliaro</span>, <span class="hlFld-ContribAuthor ">Jason M.  Uslaner</span>, <span class="hlFld-ContribAuthor ">Sarah L.  Huszar</span>, <span class="hlFld-ContribAuthor ">Kerry L.  Fillgrove</span>, <span class="hlFld-ContribAuthor ">Cuyue  Tang</span>, <span class="hlFld-ContribAuthor ">Yuhsin  Kuo</span>, <span class="hlFld-ContribAuthor ">Marlene A.  Jacobson</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of 5-aryl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-ones as positive allosteric modulators of metabotropic glutamate subtype-2 (mGlu2) receptors with efficacy in a preclinical model of psychosis. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2016,</strong> <em>26 </em>
                                    (4)
                                     , 1260-1264. <a href="https://doi.org/10.1016/j.bmcl.2016.01.021" title="DOI URL">https://doi.org/10.1016/j.bmcl.2016.01.021</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2016.01.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2016.01.021%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252B5-aryl-1%25252C3-dihydro-2H-imidazo%25255B4%25252C5-b%25255Dpyridin-2-ones%252Bas%252Bpositive%252Ballosteric%252Bmodulators%252Bof%252Bmetabotropic%252Bglutamate%252Bsubtype-2%252B%252528mGlu2%252529%252Breceptors%252Bwith%252Befficacy%252Bin%252Ba%252Bpreclinical%252Bmodel%252Bof%252Bpsychosis%26aulast%3DLayton%26aufirst%3DMark%2BE.%26date%3D2016%26volume%3D26%26issue%3D4%26spage%3D1260%26epage%3D1264" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Maarten L J  Doornbos</span>, <span class="hlFld-ContribAuthor ">Laura  Pérez-Benito</span>, <span class="hlFld-ContribAuthor ">Gary  Tresadern</span>, <span class="hlFld-ContribAuthor ">Thea  Mulder-Krieger</span>, <span class="hlFld-ContribAuthor ">Ilse  Biesmans</span>, <span class="hlFld-ContribAuthor ">Andrés A  Trabanco</span>, <span class="hlFld-ContribAuthor ">Jose María  Cid</span>, <span class="hlFld-ContribAuthor ">Hilde  Lavreysen</span>, <span class="hlFld-ContribAuthor ">Adriaan P  IJzerman</span>, <span class="hlFld-ContribAuthor ">Laura H  Heitman</span>. </span><span class="cited-content_cbyCitation_article-title">Molecular mechanism of positive allosteric modulation of the metabotropic glutamate receptor 2 by JNJ-46281222. </span><span class="cited-content_cbyCitation_journal-name">British Journal of Pharmacology</span><span> <strong>2016,</strong> <em>173 </em>
                                    (3)
                                     , 588-600. <a href="https://doi.org/10.1111/bph.13390" title="DOI URL">https://doi.org/10.1111/bph.13390</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/bph.13390&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fbph.13390%26sid%3Dliteratum%253Aachs%26jtitle%3DBritish%2520Journal%2520of%2520Pharmacology%26atitle%3DMolecular%252Bmechanism%252Bof%252Bpositive%252Ballosteric%252Bmodulation%252Bof%252Bthe%252Bmetabotropic%252Bglutamate%252Breceptor%252B2%252Bby%252BJNJ-46281222%26aulast%3DDoornbos%26aufirst%3DMaarten%2BL%2BJ%26date%3D2016%26date%3D2016%26volume%3D173%26issue%3D3%26spage%3D588%26epage%3D600" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Joanna M.  Wierońska</span>, <span class="hlFld-ContribAuthor ">Stevin H.  Zorn</span>, <span class="hlFld-ContribAuthor ">Dario  Doller</span>, <span class="hlFld-ContribAuthor ">Andrzej  Pilc</span>. </span><span class="cited-content_cbyCitation_article-title">Metabotropic glutamate receptors as targets for new antipsychotic drugs: Historical perspective and critical comparative assessment. </span><span class="cited-content_cbyCitation_journal-name">Pharmacology & Therapeutics</span><span> <strong>2016,</strong> <em>157 </em>, 10-27. <a href="https://doi.org/10.1016/j.pharmthera.2015.10.007" title="DOI URL">https://doi.org/10.1016/j.pharmthera.2015.10.007</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.pharmthera.2015.10.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.pharmthera.2015.10.007%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmacology%2520%2526%2520Therapeutics%26atitle%3DMetabotropic%252Bglutamate%252Breceptors%252Bas%252Btargets%252Bfor%252Bnew%252Bantipsychotic%252Bdrugs%25253A%252BHistorical%252Bperspective%252Band%252Bcritical%252Bcomparative%252Bassessment%26aulast%3DWiero%25C5%2584ska%26aufirst%3DJoanna%2BM.%26date%3D2016%26volume%3D157%26spage%3D10%26epage%3D27" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gary  Tresadern</span>, <span class="hlFld-ContribAuthor ">José-Maria  Cid</span>, <span class="hlFld-ContribAuthor ">Andrés A.  Trabanco</span>. </span><span class="cited-content_cbyCitation_article-title">QSAR design of triazolopyridine mGlu2 receptor positive allosteric modulators. </span><span class="cited-content_cbyCitation_journal-name">Journal of Molecular Graphics and Modelling</span><span> <strong>2014,</strong> <em>53 </em>, 82-91. <a href="https://doi.org/10.1016/j.jmgm.2014.07.006" title="DOI URL">https://doi.org/10.1016/j.jmgm.2014.07.006</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jmgm.2014.07.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jmgm.2014.07.006%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Molecular%2520Graphics%2520and%2520Modelling%26atitle%3DQSAR%252Bdesign%252Bof%252Btriazolopyridine%252BmGlu2%252Breceptor%252Bpositive%252Ballosteric%252Bmodulators%26aulast%3DTresadern%26aufirst%3DGary%26date%3D2014%26volume%3D53%26spage%3D82%26epage%3D91" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-15/jm500496m/production/images/medium/jm-2014-00496m_0016.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-15/jm500496m/production/images/large/jm-2014-00496m_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500496m&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-15/jm500496m/production/images/medium/jm-2014-00496m_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-15/jm500496m/production/images/large/jm-2014-00496m_0001.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Strategies followed for the exploration of HTS hit <b>5</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-15/jm500496m/production/images/large/jm-2014-00496m_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500496m&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-15/jm500496m/production/images/medium/jm-2014-00496m_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-15/jm500496m/production/images/large/jm-2014-00496m_0003.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Preparation of 4-Bromopyridone Building Blocks <b>41a</b>–<b>g</b>, <b>46</b>, and <b>47a</b>–<b>c</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-15/jm500496m/production/images/large/jm-2014-00496m_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500496m&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) K<sub>2</sub>CO<sub>3</sub>, MeCN, 100 °C, 16 h; (b) NaOH, H<sub>2</sub>O, reflux, 18 h; (c) POBr<sub>3</sub>, DMF, 110 °C, 1–3 h; (d) NIS, AcOH, rt, 1 h; (e) FSO<sub>2</sub>CF<sub>2</sub>CO<sub>2</sub>Me, CuI, DMF, 100 °C, 5 h; (f) H<sub>2</sub>, Pd/C, EtOH, rt, 2 h.</p></p></figure><figure data-id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-15/jm500496m/production/images/medium/jm-2014-00496m_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-15/jm500496m/production/images/large/jm-2014-00496m_0004.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of the Final Compounds <b>8</b>–<b>21</b>, <b>26</b>–<b>29</b>, <b>31</b>, <b>32</b>, and <b>34</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-15/jm500496m/production/images/large/jm-2014-00496m_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500496m&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) amine, 2-(2′-di-<i>tert</i>-butylphosphine)biphenylpalladium(II) acetate, K<sub>3</sub>PO<sub>4</sub>, 1,4-dioxane, 85 °C, 2–12 h; (b) amine, DIPEA, CH<sub>3</sub>CN, 140–170 °C, 10–35 min, microwave; (c) amine, Pd(OAc)<sub>2</sub>, BINAP, <sup><i>t</i></sup>BuONa, toluene, 100 °C, 16 h.</p></p></figure><figure data-id="sch3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-15/jm500496m/production/images/medium/jm-2014-00496m_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-15/jm500496m/production/images/large/jm-2014-00496m_0005.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of the Final Compounds <b>22</b>–<b>25</b> and <b>30</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-15/jm500496m/production/images/large/jm-2014-00496m_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500496m&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) amine, DIPEA, CH<sub>3</sub>CN, 140–170 °C, 10–35 min, microwave; (b) H<sub>2</sub>, Pd/C, MeOH or AcOEt, rt, 4–16 h; (c) H<sub>2</sub>, PtO<sub>2</sub>, AcOH, MeOH, rt, 72 h; (d) Et<sub>3</sub>SiH, TFA, rt, 24 h.</p></p></figure><figure data-id="sch4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-15/jm500496m/production/images/medium/jm-2014-00496m_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-15/jm500496m/production/images/large/jm-2014-00496m_0006.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of the Final Compounds <b>33</b>,<b> 35</b>, and <b>36</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-15/jm500496m/production/images/large/jm-2014-00496m_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500496m&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) amine, Pd(OAc)<sub>2</sub>, BINAP, <sup><i>t</i></sup>BuONa, toluene, 100 °C, 16 h; (b) NCS, DCM, rt, 10–20 min.</p></p></figure><figure data-id="sch5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-15/jm500496m/production/images/medium/jm-2014-00496m_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-15/jm500496m/production/images/large/jm-2014-00496m_0007.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of the Final Compounds <b>6</b> and <b>7</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-15/jm500496m/production/images/large/jm-2014-00496m_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500496m&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) POBr<sub>3</sub>, DMF, 110 °C, 1–3 h; (b) phenylacetylene, PdCl<sub>2</sub>(PPh<sub>3</sub>)<sub>2</sub>, Et<sub>3</sub>N, CuI, PPh<sub>3</sub>, THF, 90 °C, 10 h; (c) H<sub>2</sub>, Pd/C, MeOH, rt, 3 h; (d) BnBr, Cs<sub>2</sub>CO<sub>3</sub>, CH<sub>3</sub>CN/DMF, 130 °C, 20 min, microwave.</p></p></figure><figure data-id="fig2" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-15/jm500496m/production/images/medium/jm-2014-00496m_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-15/jm500496m/production/images/large/jm-2014-00496m_0002.jpeg" id="rightTab-fx10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Effect of <b>36</b> or vehicle (20% CD + 1HCl) on sleep–wake organization in rats during 20 consecutive hours and after a single oral dose. Mean percentage of occurrence per 30 min period is indicated for each sleep–wake state. Shaded area indicates dark period. Small bar charts indicate amounts of vigilance states in minutes (±SEM, <i>n</i> = 8 for each group) during the first 4 h postadministration. Dots on the lines of the graph indicate <i>p</i> < 0.05 versus vehicle (Wilcoxon–Mann–Whitney rank sum); * indicates <i>p</i> < 0.05: Wilcoxon–Mann–Whitney rank sum tests compared to vehicle values.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-15/jm500496m/production/images/large/jm-2014-00496m_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500496m&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i86">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_23552" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_23552" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 51 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Kew, J. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kemp, J. A.</span><span> </span><span class="NLM_article-title">Ionotropic and metabotropic glutamate receptor, structure and pharmacology</span> <span class="citation_source-journal">Psychoharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">182</span><span class="NLM_x">, </span> <span class="NLM_fpage">320</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Fjm500496m&amp;key=10.1007%2Fs00213-005-0152-y" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=182&publication_year=2005&pages=320&author=J.+N.+Kewauthor=J.+A.+Kemp&title=Ionotropic+and+metabotropic+glutamate+receptor%2C+structure+and+pharmacology"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1007%2Fs00213-005-0152-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00213-005-0152-y%26sid%3Dliteratum%253Aachs%26aulast%3DKew%26aufirst%3DJ.%2BN.%26aulast%3DKemp%26aufirst%3DJ.%2BA.%26atitle%3DIonotropic%2520and%2520metabotropic%2520glutamate%2520receptor%252C%2520structure%2520and%2520pharmacology%26jtitle%3DPsychoharmacology%26date%3D2005%26volume%3D182%26spage%3D320" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Pin, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galvez, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prezeau, L.</span><span> </span><span class="NLM_article-title">Evolution, structure, and activation mechanism of family 3/C G-protein-coupled receptors</span> <span class="citation_source-journal">Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">98</span><span class="NLM_x">, </span> <span class="NLM_fpage">325</span><span class="NLM_x">–</span> <span class="NLM_lpage">354</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Fjm500496m&amp;key=10.1016%2FS0163-7258%2803%2900038-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Fjm500496m&amp;key=12782243" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Fjm500496m&amp;key=1%3ACAS%3A528%3ADC%252BD3sXktVOqsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2003&pages=325-354&author=J.+P.+Pinauthor=T.+Galvezauthor=L.+Prezeau&title=Evolution%2C+structure%2C+and+activation+mechanism+of+family+3%2FC+G-protein-coupled+receptors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Evolution, structure, and activation mechanism of family 3/C G-protein-coupled receptors</span></div><div class="casAuthors">Pin, Jean-Philippe; Galvez, Thierry; Prezeau, Laurent</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">325-354</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">A review.  G-protein-coupled receptors (GPCRs) represent one of the largest gene families in the animal genome.  These receptors can be classified into several groups based on the sequence similarity of their common heptahelical domain.  The family 3 (or C) GPCRs are receptors for the main neurotransmitters glutamate and γ-aminobutyric acid, for Ca2+, for sweet and amino acid taste compds., and for some pheromone mols., as well as for odorants in fish.  Although none of these family 3 receptors have been found in plants, members have been identified in ancient organisms, such as slime molds (Dictyostelium) and sponges.  Like any other GPCRs, family 3 receptors possess a transmembrane heptahelical domain responsible for G-protein activation.  However, most of these identified receptors also possess a large extracellular domain that is responsible for ligand recognition, is structurally similar to bacterial periplasmic proteins involved in the transport of small mols., and is called a Venus Flytrap module.  The recent resoln. of the structure of this binding domain in one of these receptors, the metabotropic glutamate 1 receptor, together with the recent demonstration that these receptors are dimers, revealed a unique mechanism of activation for these GPCRs.  Such data open new possibilities in the development of drugs aimed at modulating these receptors, and raise a no. of interesting questions on the activation mechanism of the other GPCRs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqNRDDmZSLFrVg90H21EOLACvtfcHk0lhFDphQY-W_Wg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXktVOqsb8%253D&md5=33ed658debc421c5dbd63a8b6dbf56b1</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2FS0163-7258%2803%2900038-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0163-7258%252803%252900038-X%26sid%3Dliteratum%253Aachs%26aulast%3DPin%26aufirst%3DJ.%2BP.%26aulast%3DGalvez%26aufirst%3DT.%26aulast%3DPrezeau%26aufirst%3DL.%26atitle%3DEvolution%252C%2520structure%252C%2520and%2520activation%2520mechanism%2520of%2520family%25203%252FC%2520G-protein-coupled%2520receptors%26jtitle%3DPharmacol.%2520Ther.%26date%3D2003%26volume%3D98%26spage%3D325%26epage%3D354" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Brauner-Osborne, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wellendorph, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jensen, A. A.</span><span> </span><span class="NLM_article-title">Structure, pharmacology and therapeutic prospects of family C G-protein coupled receptors</span> <span class="citation_source-journal">Curr. Drug Targets</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">169</span><span class="NLM_x">–</span> <span class="NLM_lpage">184</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm500496m&amp;key=10.2174%2F138945007779315614" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Fjm500496m&amp;key=17266540" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm500496m&amp;key=1%3ACAS%3A280%3ADC%252BD2s%252FmtF2kuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2007&pages=169-184&author=H.+Brauner-Osborneauthor=P.+Wellendorphauthor=A.+A.+Jensen&title=Structure%2C+pharmacology+and+therapeutic+prospects+of+family+C+G-protein+coupled+receptors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Structure, pharmacology and therapeutic prospects of family C G-protein coupled receptors</span></div><div class="casAuthors">Brauner-Osborne Hans; Wellendorph Petrine; Jensen Anders A</div><div class="citationInfo"><span class="NLM_cas:title">Current drug targets</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">169-84</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Family C of G-protein coupled receptors (GPCRs) from humans is constituted by eight metabotropic glutamate (mGlu(1-8)) receptors, two heterodimeric gamma-aminobutyric acid(B) (GABA(B)) receptors, a calcium-sensing receptor (CaR), three taste (T1R) receptors, a promiscuous L-alpha-amino acid receptor (GPRC6A), and five orphan receptors.  Aside from the orphan receptors, the family C GPCRs are characterised by a large amino-terminal domain, which bind the endogenous orthosteric agonists.  Recently, a number of allosteric modulators binding to the seven transmembrane domains of the receptors have also been reported.  Family C GPCRs regulate a number of important physiological functions and are thus intensively pursued as drug targets.  So far, two drugs acting at family C receptors (the GABA(B) agonist baclofen and the positive allosteric CaR modulator cinacalcet) have been marketed.  Cinacalcet is the first allosteric GPCR modulator to enter the market, which demonstrates that the therapeutic principle of allosteric modulation can also be extended to this important drug target class.  In this review we outline the structure and function of family C GPCRs with particular focus on the ligand binding sites, and we present the most important pharmacological agents and the therapeutic prospects of the receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRMO1HRaArq6WxpATR2EQURfW6udTcc2eYpUWQV2d7Pxbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2s%252FmtF2kuw%253D%253D&md5=242ec346ee4fd59c033b5574983fd164</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.2174%2F138945007779315614&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138945007779315614%26sid%3Dliteratum%253Aachs%26aulast%3DBrauner-Osborne%26aufirst%3DH.%26aulast%3DWellendorph%26aufirst%3DP.%26aulast%3DJensen%26aufirst%3DA.%2BA.%26atitle%3DStructure%252C%2520pharmacology%2520and%2520therapeutic%2520prospects%2520of%2520family%2520C%2520G-protein%2520coupled%2520receptors%26jtitle%3DCurr.%2520Drug%2520Targets%26date%3D2007%26volume%3D8%26spage%3D169%26epage%3D184" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Lavreysen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dautzenberg, F.</span><span> </span><span class="NLM_article-title">Therapeutic potential of group III metabotropic glutamate receptors</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">671</span><span class="NLM_x">–</span> <span class="NLM_lpage">684</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Fjm500496m&amp;key=10.2174%2F092986708783885246" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Fjm500496m&amp;key=18336281" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm500496m&amp;key=1%3ACAS%3A528%3ADC%252BD1cXnsVyitrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2008&pages=671-684&author=H.+Lavreysenauthor=F.+Dautzenberg&title=Therapeutic+potential+of+group+III+metabotropic+glutamate+receptors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic potential of group III metabotropic glutamate receptors</span></div><div class="casAuthors">Lavreysen, Hilde; Dautzenberg, Frank M.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">671-684</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Metabotropic glutamate (mGlu) receptors have received much attention, driven by a strong belief in the potential of these modulatory glutamate receptors as drug targets.  So far, major drug discovery programs have largely focused on group I (mGlu1 and 5) and II (mGlu2 and 3) mGlu receptors, which have been implicated in neuropathol. and various psychiatric disorders.  The four group III representatives (mGlu4, mGlu6, mGlu7 and mGlu8) are less understood, mainly due to the paucity of specific compds.  Recent advances in the identification of selective or specific compds., and the generation of transgenic animals have, however, revealed important insights into the potential role of group III receptors in the pathophysiol. of neurol. and mood disorders.  Activation of the mGlu4 receptor seems to be beneficial for treating Parkinson-like symptoms and a potential role in the treatment of mood disorders is slowly growing.  Similarly, genetic inactivation studies and usage of relatively selective agonists strongly support the involvement of the mGlu8 receptor for anxiety disorders.  In contrast, controversial data have been obtained for the mGlu7 receptor.  While mGlu7 receptor-deficient animals show an anxiolytic profile in several in vivo readouts, the first selective allosteric agonist AMN082 has also been reported to improve anxiety-like behavior despite activating the stress axis.  The least investigated receptor remains the mGlu6 receptor, which is mostly based on its predominant expression in the retina.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGospyk97dw1LbVg90H21EOLACvtfcHk0ljXobGLZzQViw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXnsVyitrc%253D&md5=a1c617d857505cdc80f35259f8ddd31d</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.2174%2F092986708783885246&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986708783885246%26sid%3Dliteratum%253Aachs%26aulast%3DLavreysen%26aufirst%3DH.%26aulast%3DDautzenberg%26aufirst%3DF.%26atitle%3DTherapeutic%2520potential%2520of%2520group%2520III%2520metabotropic%2520glutamate%2520receptors%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2008%26volume%3D15%26spage%3D671%26epage%3D684" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Niswender, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conn, P. J.</span><span> </span><span class="NLM_article-title">Metabotropic glutamate receptors: physiology, pharmacology, and disease</span> <span class="citation_source-journal">Annu. Rev. Pharmacol. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">295</span><span class="NLM_x">–</span> <span class="NLM_lpage">322</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Fjm500496m&amp;key=10.1146%2Fannurev.pharmtox.011008.145533" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Fjm500496m&amp;key=20055706" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Fjm500496m&amp;key=1%3ACAS%3A528%3ADC%252BC3cXisVelurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2010&pages=295-322&author=C.+M.+Niswenderauthor=P.+J.+Conn&title=Metabotropic+glutamate+receptors%3A+physiology%2C+pharmacology%2C+and+disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Metabotropic glutamate receptors: physiology, pharmacology, and disease</span></div><div class="casAuthors">Niswender, Colleen M.; Conn, P. Jeffrey</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Pharmacology and Toxicology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">295-322</span>CODEN:
                <span class="NLM_cas:coden">ARPTDI</span>;
        ISSN:<span class="NLM_cas:issn">0362-1642</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  The metabotropic glutamate receptors (mGluRs) are family C G-protein-coupled receptors that participate in the modulation of synaptic transmission and neuronal excitability throughout the central nervous system.  The mGluRs bind glutamate within a large extracellular domain and transmit signals through the receptor protein to intracellular signaling partners.  A great deal of progress was made in detg. the mechanisms by which mGluRs are activated, proteins with which they interact, and orthosteric and allosteric ligands that can modulate receptor activity.  The widespread expression of mGluRs makes these receptors particularly attractive drug targets, and recent studies continue to validate the therapeutic utility of mGluR ligands in neurol. and psychiatric disorders such as Alzheimer's disease, Parkinson's disease, anxiety, depression, and schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9idcZk-YH9LVg90H21EOLACvtfcHk0ljXobGLZzQViw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXisVelurg%253D&md5=4e7c2fa7dec6b3e3227e32fb7653423b</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1146%2Fannurev.pharmtox.011008.145533&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.pharmtox.011008.145533%26sid%3Dliteratum%253Aachs%26aulast%3DNiswender%26aufirst%3DC.%2BM.%26aulast%3DConn%26aufirst%3DP.%2BJ.%26atitle%3DMetabotropic%2520glutamate%2520receptors%253A%2520physiology%252C%2520pharmacology%252C%2520and%2520disease%26jtitle%3DAnnu.%2520Rev.%2520Pharmacol.%2520Toxicol.%26date%3D2010%26volume%3D50%26spage%3D295%26epage%3D322" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Wright, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salhoff, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kingston, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calligaro, D. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Monn, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schoepp, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marek, G. J.</span><span> </span><span class="NLM_article-title">CNS distribution of metabotropic glutamate 2 and 3 receptors: transgenic mice and [3H]LY459477 autoradiography</span> <span class="citation_source-journal">Neuropharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">89</span><span class="NLM_x">–</span> <span class="NLM_lpage">98</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Fjm500496m&amp;key=10.1016%2Fj.neuropharm.2012.01.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Fjm500496m&amp;key=22313530" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Fjm500496m&amp;key=1%3ACAS%3A528%3ADC%252BC38XisFKnt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2013&pages=89-98&author=R.+A.+Wrightauthor=B.+G.+Johnsonauthor=C.+Zhangauthor=C.+Salhoffauthor=A.+E.+Kingstonauthor=D.+O.+Calligaroauthor=J.+A.+Monnauthor=D.+D.+Schoeppauthor=G.+J.+Marek&title=CNS+distribution+of+metabotropic+glutamate+2+and+3+receptors%3A+transgenic+mice+and+%5B3H%5DLY459477+autoradiography"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">CNS distribution of metabotropic glutamate 2 and 3 receptors: Transgenic mice and [3H]LY459477 autoradiography</span></div><div class="casAuthors">Wright, Rebecca A.; Johnson, Bryan G.; Zhang, Ce; Salhoff, Craig; Kingston, Ann E.; Calligaro, David O.; Monn, James A.; Schoepp, Darryle D.; Marek, Gerard J.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">89-98</span>CODEN:
                <span class="NLM_cas:coden">NEPHBW</span>;
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Group II metabotropic glutamate (mGlu) receptor agonists were efficacious in randomized clin. research trials for schizophrenia and generalized anxiety disorder.  The regional quantification of mGlu2 and mGlu3 receptors remains unknown.  A selective and structurally novel mGlu2/3 receptor agonist, 2-amino-4-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (LY 459477) was tritiated and the distribution of mGlu2 and mGlu3 receptors was studied in transgenic mice lacking either mGlu2, mGlu3 or both receptors.  LY 459477 is an agonist with 1-2 nM potency for rodent and human mGlu2 and mGlu3 receptors.  The functional selectivity of LY 459477 was demonstrated by over 640-fold selectivity and the displacement binding selectivity was greater than 320-fold for all glutamate receptors except mGlu6 (∼230-fold).  More than 1000-fold selectivity was demonstrated for all non-glutamate receptors known to be targeted by antipsychotic drugs.  Like atypical antipsychotic drugs, LY 459477 reversed in vitro electrophysiol. effects of a serotonergic hallucinogen and behavioral effects of phencyclidine or amphetamine.  There was virtually no binding of [3H]LY459477 to any brain region in mice with a deletion of both mGlu2 and mGlu3 receptors.  Regions enriched in mGlu2 receptors included the medial prefrontal cortex, select hippocampal regions, the medial mammillary nucleus, the medial habenula, and the cerebellar granular cell layer.  Regions enriched in mGlu3 receptors were the dorsolateral entorhinal cortex, the hippocampal CA1 field, the piriform cortex, the substantia nigra, the thalamic reticular nucleus, and primary sensory thalamic nuclei.  These findings suggest [3H]LY 459477 should be a useful tool to further define the role of mGlu2 and mGlu3 receptors throughout the brain with respect to major neuropsychiatric syndromes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqnwwF-vjfXbVg90H21EOLACvtfcHk0lgZjo6um4A-SA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XisFKnt7g%253D&md5=b917b3e90d301fe96be384030305fab6</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2012.01.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2012.01.019%26sid%3Dliteratum%253Aachs%26aulast%3DWright%26aufirst%3DR.%2BA.%26aulast%3DJohnson%26aufirst%3DB.%2BG.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DSalhoff%26aufirst%3DC.%26aulast%3DKingston%26aufirst%3DA.%2BE.%26aulast%3DCalligaro%26aufirst%3DD.%2BO.%26aulast%3DMonn%26aufirst%3DJ.%2BA.%26aulast%3DSchoepp%26aufirst%3DD.%2BD.%26aulast%3DMarek%26aufirst%3DG.%2BJ.%26atitle%3DCNS%2520distribution%2520of%2520metabotropic%2520glutamate%25202%2520and%25203%2520receptors%253A%2520transgenic%2520mice%2520and%2520%255B3H%255DLY459477%2520autoradiography%26jtitle%3DNeuropharmacology%26date%3D2013%26volume%3D66%26spage%3D89%26epage%3D98" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Schoepp, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marek, G. J.</span><span> </span><span class="NLM_article-title">Preclinical pharmacology of mGluR2/3 receptor agonists: novel agents for schizophrenia?</span> <span class="citation_source-journal">Curr. Drug Targets: CNS Neurol. Disord.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">215</span><span class="NLM_x">–</span> <span class="NLM_lpage">225</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Fjm500496m&amp;key=10.2174%2F1568007024606177" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Fjm500496m&amp;key=12769628" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Fjm500496m&amp;key=1%3ACAS%3A528%3ADC%252BD38XjvV2nu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2002&pages=215-225&author=D.+D.+Schoeppauthor=G.+J.+Marek&title=Preclinical+pharmacology+of+mGluR2%2F3+receptor+agonists%3A+novel+agents+for+schizophrenia%3F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical pharmacology of mGlu2/3 receptor agonists: novel agents for schizophrenia?</span></div><div class="casAuthors">Schoepp, Darryle D.; Marek, Gerard J.</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Targets: CNS & Neurological Disorders</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">215-225</span>CODEN:
                <span class="NLM_cas:coden">CDTCCC</span>;
        ISSN:<span class="NLM_cas:issn">1568-007X</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Agonists for mGlu2/3 receptors decrease the evoked release of glutamate at certain (ie. forebrain / limbic) glutamatergic synapses, indicating that the functional role of mGlu2 and/or mGlu3 receptors is to suppress glutamate excitations.  This offers a mechanism for dampening glutamate excitation under pathol. states resulting from excessive glutamate release.  Based, in part, on the psychotomimetic actions of phencyclidine (PCP)-like drugs, excessive or pathol. glutamate release has been implicated in a no. of clin. conditions including psychosis.  With this in mind, the pharmacol. of multiple mGlu2/3 receptor agonists have been investigated in PCP treated rats.  Agonists for mGlu2/3 receptors such as LY354740 and LY379268 have been shown to block certain behavioral responses to PCP in rats.  The effects of mGlu2/3 agonists on PCP-induced behaviors are blocked by a low doses of a selective mGlu2/3 receptor antagonist, indicating that these actions are mediated via mGlu2/3 receptors.  In addn., mGlu2/3 agonists potently suppress glutamate release in rat prefrontal cortex, as reflected by excitatory post-synaptic potentials (EPSPs) induced by serotonin (5-HT) acting on 5HT2A receptors.  These actions of LY354740 and LY379268 are also blocked by a selective mGlu2/3 antagonist.  Atypical antipsychotic drugs such as clozapine also suppress 5-HT-induced EPSPs in this brain region, thus suggesting a common pathway for the actions of atypical antipsychotic drugs and mGlu2/3 receptor agonists.  As glutamatergic dysfunction has been implicated in psychotic states and possibly in the etiol. of schizophrenia, clin. studies with mGlu2/3 agonists may be warranted to further explore the validity of the glutamatergic hypothesis of schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPEl6C2-lj4rVg90H21EOLACvtfcHk0lgZjo6um4A-SA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XjvV2nu7o%253D&md5=7b0d86049ef459f8bc419e63cfd6b653</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.2174%2F1568007024606177&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568007024606177%26sid%3Dliteratum%253Aachs%26aulast%3DSchoepp%26aufirst%3DD.%2BD.%26aulast%3DMarek%26aufirst%3DG.%2BJ.%26atitle%3DPreclinical%2520pharmacology%2520of%2520mGluR2%252F3%2520receptor%2520agonists%253A%2520novel%2520agents%2520for%2520schizophrenia%253F%26jtitle%3DCurr.%2520Drug%2520Targets%253A%2520CNS%2520Neurol.%2520Disord.%26date%3D2002%26volume%3D1%26spage%3D215%26epage%3D225" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Moghaddam, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adams, B. W.</span><span> </span><span class="NLM_article-title">Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">281</span><span class="NLM_x">, </span> <span class="NLM_fpage">477</span><span class="NLM_x">–</span> <span class="NLM_lpage">484</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=281&publication_year=1998&pages=477-484&author=B.+Moghaddamauthor=B.+W.+Adams&title=Reversal+of+phencyclidine+effects+by+a+group+II+metabotropic+glutamate+receptor+agonist+in+rats"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMoghaddam%26aufirst%3DB.%26aulast%3DAdams%26aufirst%3DB.%2BW.%26atitle%3DReversal%2520of%2520phencyclidine%2520effects%2520by%2520a%2520group%2520II%2520metabotropic%2520glutamate%2520receptor%2520agonist%2520in%2520rats%26jtitle%3DScience%26date%3D1998%26volume%3D281%26spage%3D477%26epage%3D484" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Cartmell, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Monn, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schoepp, D. D.</span><span> </span><span class="NLM_article-title">The metabotropic glutamate 2/3 receptor agonists LY354740 and LY379268 selectively attenuate phencyclidine versus d-amphetamine motor behaviors in rats</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">291</span><span class="NLM_x">, </span> <span class="NLM_fpage">161</span><span class="NLM_x">–</span> <span class="NLM_lpage">170</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Fjm500496m&amp;key=10490900" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Fjm500496m&amp;key=1%3ACAS%3A528%3ADyaK1MXmtlaks7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=291&publication_year=1999&pages=161-170&author=J.+Cartmellauthor=J.+A.+Monnauthor=D.+D.+Schoepp&title=The+metabotropic+glutamate+2%2F3+receptor+agonists+LY354740+and+LY379268+selectively+attenuate+phencyclidine+versus+d-amphetamine+motor+behaviors+in+rats"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">The metabotropic glutamate 2/3 receptor agonists LY354740 and LY379268 selectively attenuate phencyclidine versus d-amphetamine motor behaviors in rats</span></div><div class="casAuthors">Cartmell, Jayne; Monn, James A.; Schoepp, Darryle D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">291</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">161-170</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Previous animal studies have indicated that drugs targeted at metabotropic glutamate (mGlu) receptors may be useful for treatment of psychosis.  In this article, the effects of the novel, potent, and selective mGlu2/3 receptor agonists LY354740 and LY379268, and the clin. effective agents clozapine and haloperidol, were investigated using phencyclidine (PCP; 5 mg/kg)- vs. d-amphetamine (AMP; 3 mg/kg)-evoked motor activities.  LY354740 (1-10 mg/kg s.c.), LY379268 (0.3-3 mg/kg s.c.), clozapine (1-10 mg/kg s.c.), and haloperidol (0.03-1 mg/kg s.c.) reversed the increases in ambulations, fine motor (nonambulatory) movements, and decreased time at rest evoked by PCP.  Furthermore, the inhibitions of the PCP response by the mGlu2/3 agonist LY379268, but not by clozapine, were completely reversed by the selective mGlu2/3 receptor antagonist LY341495.  Doses of LY354740 and LY379268 that blocked the effects on PCP had no effects on rotorod performance, and (with the exception of rearing behavior) had minimal effects on AMP-evoked motor activities.  Clozapine blocked AMP-induced rearing but enhanced AMP-induced ambulations and fine movements at the lower doses (1 and 3 mg/kg).  Unlike the mGlu2/3 agonists, the highest dose of clozapine tested (10 mg/kg) impaired animals on the rotorod.  Haloperidol potently blocked all PCP and AMP effects, but only at doses assocd. with motor impairment.  These data demonstrate that mGlu2/3 receptor agonists act via a unique mechanism to selectively block PCP-induced behaviors.  Moreover, the marked mGlu2/3 receptor-mediated inhibitions of PCP-evoked behaviors by LY354740 and LY379268, with minimal effects on AMP, may indicate potential antipsychotic effects in humans in the absence of dopamine mediated extrapyramidal side effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpj6C09T4kWFLVg90H21EOLACvtfcHk0lilcuNZ3xktpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXmtlaks7g%253D&md5=93425a0c85f8dfbea2a7cd5323e645c2</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCartmell%26aufirst%3DJ.%26aulast%3DMonn%26aufirst%3DJ.%2BA.%26aulast%3DSchoepp%26aufirst%3DD.%2BD.%26atitle%3DThe%2520metabotropic%2520glutamate%25202%252F3%2520receptor%2520agonists%2520LY354740%2520and%2520LY379268%2520selectively%2520attenuate%2520phencyclidine%2520versus%2520d-amphetamine%2520motor%2520behaviors%2520in%2520rats%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1999%26volume%3D291%26spage%3D161%26epage%3D170" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Patil, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martenyi, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lowe, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jackson, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andreev, B. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Avedisova, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bardenstein, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gurovich, I. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morozova, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mosolov, S. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neznanov, N. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reznik, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smulevich, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tochilov, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Monn, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schoepp, D. D.</span><span> </span><span class="NLM_article-title">Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial</span> <span class="citation_source-journal">Nat. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">1102</span><span class="NLM_x">–</span> <span class="NLM_lpage">1107</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Fjm500496m&amp;key=10.1038%2Fnm1632" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Fjm500496m&amp;key=17767166" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Fjm500496m&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVSgtrvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2007&pages=1102-1107&author=S.+T.+Patilauthor=L.+Zhangauthor=F.+Martenyiauthor=S.+L.+Loweauthor=K.+A.+Jacksonauthor=B.+V.+Andreevauthor=A.+S.+Avedisovaauthor=L.+M.+Bardensteinauthor=I.+Y.+Gurovichauthor=M.+A.+Morozovaauthor=S.+N.+Mosolovauthor=N.+G.+Neznanovauthor=A.+M.+Reznikauthor=A.+B.+Smulevichauthor=V.+A.+Tochilovauthor=B.+G.+Johnsonauthor=J.+A.+Monnauthor=D.+D.+Schoepp&title=Activation+of+mGlu2%2F3+receptors+as+a+new+approach+to+treat+schizophrenia%3A+a+randomized+Phase+2+clinical+trial"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial</span></div><div class="casAuthors">Patil, Sandeep T.; Zhang, Lu; Martenyi, Ferenc; Lowe, Stephen L.; Jackson, Kimberley A.; Andreev, Boris V.; Avedisova, Alla S.; Bardenstein, Leonid M.; Gurovich, Issak Y.; Morozova, Margarita A.; Mosolov, Sergey N.; Neznanov, Nikolai G.; Reznik, Alexander M.; Smulevich, Anatoly B.; Tochilov, Vladimir A.; Johnson, Bryan G.; Monn, James A.; Schoepp, Darryle D.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1102-1107</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Schizophrenia is a chronic, complex and heterogeneous mental disorder, with pathol. features of disrupted neuronal excitability and plasticity within limbic structures of the brain.  These pathol. features manifest behaviorally as pos. symptoms (including hallucinations, delusions and thought disorder), neg. symptoms (such as social withdrawal, apathy and emotional blunting) and other psychopathol. symptoms (such as psychomotor retardation, lack of insight, poor attention and impulse control).  Altered glutamate neurotransmission has for decades been linked to schizophrenia, but all commonly prescribed antipsychotics act on dopamine receptors.  LY404039 is a selective agonist for metabotropic glutamate 2/3 (mGlu2/3) receptors and has shown antipsychotic potential in animal studies.  With data from rodents, we provide new evidence that mGlu2/3 receptor agonists work by a distinct mechanism different from that of olanzapine.  To clin. test this mechanism, an oral prodrug of LY404039 (LY2140023) was evaluated in schizophrenic patients with olanzapine as an active control in a randomized, three-armed, double-blind, placebo-controlled study.  Treatment with LY2140023, like treatment with olanzapine, was safe and well-tolerated; treated patients showed statistically significant improvements in both pos. and neg. symptoms of schizophrenia compared to placebo (P < 0.001 at week 4).  Notably, patients treated with LY2140023 did not differ from placebo-treated patients with respect to prolactin elevation, extrapyramidal symptoms or wt. gain.  These data suggest that mGlu2/3 receptor agonists have antipsychotic properties and may provide a new alternative for the treatment of schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYtB0jdSzAQrVg90H21EOLACvtfcHk0lilcuNZ3xktpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVSgtrvF&md5=afab88e888cba7e72e14c4e949f894d7</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2Fnm1632&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm1632%26sid%3Dliteratum%253Aachs%26aulast%3DPatil%26aufirst%3DS.%2BT.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DMartenyi%26aufirst%3DF.%26aulast%3DLowe%26aufirst%3DS.%2BL.%26aulast%3DJackson%26aufirst%3DK.%2BA.%26aulast%3DAndreev%26aufirst%3DB.%2BV.%26aulast%3DAvedisova%26aufirst%3DA.%2BS.%26aulast%3DBardenstein%26aufirst%3DL.%2BM.%26aulast%3DGurovich%26aufirst%3DI.%2BY.%26aulast%3DMorozova%26aufirst%3DM.%2BA.%26aulast%3DMosolov%26aufirst%3DS.%2BN.%26aulast%3DNeznanov%26aufirst%3DN.%2BG.%26aulast%3DReznik%26aufirst%3DA.%2BM.%26aulast%3DSmulevich%26aufirst%3DA.%2BB.%26aulast%3DTochilov%26aufirst%3DV.%2BA.%26aulast%3DJohnson%26aufirst%3DB.%2BG.%26aulast%3DMonn%26aufirst%3DJ.%2BA.%26aulast%3DSchoepp%26aufirst%3DD.%2BD.%26atitle%3DActivation%2520of%2520mGlu2%252F3%2520receptors%2520as%2520a%2520new%2520approach%2520to%2520treat%2520schizophrenia%253A%2520a%2520randomized%2520Phase%25202%2520clinical%2520trial%26jtitle%3DNat.%2520Med.%26date%3D2007%26volume%3D13%26spage%3D1102%26epage%3D1107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Kinon, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Millen, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osuntokun, O. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kollack-Walker, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kimberley, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ludmila, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Natalia, J.</span><span> </span><span class="NLM_article-title">A multicenter, inpatient, phase 2, double-blind, placebo-controled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia</span> <span class="citation_source-journal">J. Clin. Psychopharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">349</span><span class="NLM_x">–</span> <span class="NLM_lpage">355</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Fjm500496m&amp;key=10.1097%2FJCP.0b013e318218dcd5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Fjm500496m&amp;key=21508856" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Fjm500496m&amp;key=1%3ACAS%3A528%3ADC%252BC3MXltlyrtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2011&pages=349-355&author=B.+J.+Kinonauthor=L.+Zhangauthor=B.+A.+Millenauthor=O.+O.+Osuntokunauthor=J.+E.+Williamsauthor=S.+Kollack-Walkerauthor=J.+Kimberleyauthor=K.+Ludmilaauthor=J.+Natalia&title=A+multicenter%2C+inpatient%2C+phase+2%2C+double-blind%2C+placebo-controled+dose-ranging+study+of+LY2140023+monohydrate+in+patients+with+DSM-IV+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia</span></div><div class="casAuthors">Kinon, Bruce J.; Zhang, Lu; Millen, Brian A.; Osuntokun, Olawale O.; Williams, Judy E.; Kollack-Walker, Sara; Jackson, Kimberley; Kryzhanovskaya, Ludmila; Jarkova, Natalia</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Psychopharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">349-355</span>CODEN:
                <span class="NLM_cas:coden">JCPYDR</span>;
        ISSN:<span class="NLM_cas:issn">0271-0749</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">The primary objective of this study was to test the hypothesis that 1 or more dose levels of LY2140023 monohydrate, an oral prodrug of the potent metabotropic glutamate (mGlu) 2/3 receptor agonist LY404039, given to patients with schizophrenia for 4 wk would demonstrate significantly greater efficacy than placebo.  The HBBI study was a multicenter, randomized, double-blind, parallel, placebo- and active-controlled trial.  Male and female patients aged 18 to 65 years who met the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria for schizophrenia were randomized in a 2:2:2:2:2:1 ratio to receive 5-, 20-, 40-, or 80-mg LY2140023 monohydrate twice daily, placebo twice daily, or placebo (am) and 15 mg of olanzapine (pm) daily.  Efficacy was defined as the change from baseline on the Pos. and Neg. Syndrome Scale (PANSS) total score assessed at 4 wk.  The primary anal. did not show that any of the 4 LY2140023 monohydrate doses were more efficacious than placebo as measured by the PANSS total score.  Similarly, olanzapine did not significantly sep. from placebo.  A higher-than-anticipated treatment effect (14.6-point improvement) in the placebo group was obsd. on PANSS total score.  LY2140023 monohydrate was generally well tolerated, although 4 patients reported the serious adverse event of convulsion.  LY2140023 monohydrate-treated patients showed little change in dopamine-related adverse events and wt.  The results of the HBBI study are considered to be inconclusive because LY2140023 monohydrate and the active control olanzapine did not sep. from placebo in the treatment of patients with acutely exacerbated schizophrenia.  Addnl. efficacy, safety, and tolerability testing are needed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvjveJZO8DRLVg90H21EOLACvtfcHk0lilcuNZ3xktpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXltlyrtLg%253D&md5=e7e675c1bc334c0d49f9a72783dca976</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1097%2FJCP.0b013e318218dcd5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FJCP.0b013e318218dcd5%26sid%3Dliteratum%253Aachs%26aulast%3DKinon%26aufirst%3DB.%2BJ.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DMillen%26aufirst%3DB.%2BA.%26aulast%3DOsuntokun%26aufirst%3DO.%2BO.%26aulast%3DWilliams%26aufirst%3DJ.%2BE.%26aulast%3DKollack-Walker%26aufirst%3DS.%26aulast%3DKimberley%26aufirst%3DJ.%26aulast%3DLudmila%26aufirst%3DK.%26aulast%3DNatalia%26aufirst%3DJ.%26atitle%3DA%2520multicenter%252C%2520inpatient%252C%2520phase%25202%252C%2520double-blind%252C%2520placebo-controled%2520dose-ranging%2520study%2520of%2520LY2140023%2520monohydrate%2520in%2520patients%2520with%2520DSM-IV%2520schizophrenia%26jtitle%3DJ.%2520Clin.%2520Psychopharmacol.%26date%3D2011%26volume%3D31%26spage%3D349%26epage%3D355" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Kinon, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gómez, J. C.</span><span> </span><span class="NLM_article-title">Clinical development of pomaglumetad methionil: a non-dopaminergic treatment for schizophrenia</span> <span class="citation_source-journal">Neuropharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">82</span><span class="NLM_x">–</span> <span class="NLM_lpage">86</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2013&pages=82-86&author=B.+J.+Kinonauthor=J.+C.+G%C3%B3mez&title=Clinical+development+of+pomaglumetad+methionil%3A+a+non-dopaminergic+treatment+for+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKinon%26aufirst%3DB.%2BJ.%26aulast%3DG%25C3%25B3mez%26aufirst%3DJ.%2BC.%26atitle%3DClinical%2520development%2520of%2520pomaglumetad%2520methionil%253A%2520a%2520non-dopaminergic%2520treatment%2520for%2520schizophrenia%26jtitle%3DNeuropharmacology%26date%3D2013%26volume%3D66%26spage%3D82%26epage%3D86" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span>Lilly Stops Phase III development of pomaglumetad methionil for the treatment of schizophrenia based on efficacy results; <span class="NLM_publisher-name">Eli Lilly and Co.</span>: <span class="NLM_publisher-loc">Indianapolis, IN</span>,<span class="NLM_x"> </span><span class="NLM_year">2012</span><span class="NLM_x">; </span><a href="https://investor.lilly.com/releasedetail.cfm?ReleaseID=703018" class="extLink">https://investor.lilly.com/releasedetail.cfm?ReleaseID=703018</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Lilly+Stops+Phase+III+development+of+pomaglumetad+methionil+for+the+treatment+of+schizophrenia+based+on+efficacy+results%3B+Eli+Lilly+and+Co.%3A+Indianapolis%2C+IN%2C+2012%3B+https%3A%2F%2Finvestor.lilly.com%2Freleasedetail.cfm%3FReleaseID%3D703018."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dreport%26sid%3Dliteratum%253Aachs%26jtitle%3DLilly%2520Stops%2520Phase%2520III%2520development%2520of%2520pomaglumetad%2520methionil%2520for%2520the%2520treatment%2520of%2520schizophrenia%2520based%2520on%2520efficacy%2520results%26pub%3DEli%2520Lilly%2520and%2520Co%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Schoepp, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wright, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levine, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaydos, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Potter, W. Z.</span><span> </span><span class="NLM_article-title">LY354740, an mGlu2/3 receptor agonist as a novel approach to treat anxiety/stress</span> <span class="citation_source-journal">Stress</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">189</span><span class="NLM_x">–</span> <span class="NLM_lpage">197</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Fjm500496m&amp;key=10.1080%2F1025389031000146773" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Fjm500496m&amp;key=13129812" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Fjm500496m&amp;key=1%3ACAS%3A528%3ADC%252BD3sXntFCmur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2003&pages=189-197&author=D.+D.+Schoeppauthor=R.+A.+Wrightauthor=L.+R.+Levineauthor=B.+Gaydosauthor=W.+Z.+Potter&title=LY354740%2C+an+mGlu2%2F3+receptor+agonist+as+a+novel+approach+to+treat+anxiety%2Fstress"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">LY354740, an mGlu2/3 receptor agonist as a novel approach to treat anxiety/stress</span></div><div class="casAuthors">Schoepp, Darryle D.; Wright, Rebecca A.; Levine, Louise R.; Gaydos, Brenda; Potter, William Z.</div><div class="citationInfo"><span class="NLM_cas:title">Stress (Abingdon, United Kingdom)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">189-197</span>CODEN:
                <span class="NLM_cas:coden">STREFR</span>;
        ISSN:<span class="NLM_cas:issn">1025-3890</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  Metabotropic glutamate (mGlu) receptors, which include mGlu1-8 receptors, are a heterogeneous family of G-protein coupled receptors (GPCRs) that function to modulate neuronal excitation and plasticity via pre-synaptic, post-synaptic and glial mechanisms.  Agonists for group II mGlu receptors (mGlu2 and mGlu3), such as LY354740, have been shown to suppress enhanced glutamatergic excitations in brain synapses known to be involved in the expression of fear/anxiety in animals and humans.  Systemic administration of LY354740 increases open-arm time in the elevated plus maze in mice under conditions of moderate to severe stress, blocks the expression but not development of fear-potentiated startle in rats, prevents lactate-induced panic-like responses in panic-prone rats, and attenuates certain physiol., behavioral, and neurochem. consequences of acute stress in rodents.  In these preclin. models, LY354740 does not produce the side-effects (e.g. sedation) that are assocd. with other anxiolytic agents such as benzodiazepines.  Early clin. results with LY354740 have demonstrated safety and efficacy in a human anxiety model (panic provocation induced by CO2 challenge).  Collectively, these data indicate mGlu2/3 receptor agonists such as LY354740 represent a promising new approach for treatment of anxiety and stress-related disorders in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfLnHWtpR8orVg90H21EOLACvtfcHk0ljOcPePXO4ckw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXntFCmur4%253D&md5=7928235c6b07bb4a8f83c6f635986a1a</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1080%2F1025389031000146773&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F1025389031000146773%26sid%3Dliteratum%253Aachs%26aulast%3DSchoepp%26aufirst%3DD.%2BD.%26aulast%3DWright%26aufirst%3DR.%2BA.%26aulast%3DLevine%26aufirst%3DL.%2BR.%26aulast%3DGaydos%26aufirst%3DB.%26aulast%3DPotter%26aufirst%3DW.%2BZ.%26atitle%3DLY354740%252C%2520an%2520mGlu2%252F3%2520receptor%2520agonist%2520as%2520a%2520novel%2520approach%2520to%2520treat%2520anxiety%252Fstress%26jtitle%3DStress%26date%3D2003%26volume%3D6%26spage%3D189%26epage%3D197" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Woolley, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pemberton, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bate, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corti, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, D. N. C.</span><span> </span><span class="NLM_article-title">The mGlu2 but not the mGlu3 receptor mediates the actions of the mGluR2/3 agonist, LY379268, in mouse models predictive of antipsychotic activity</span> <span class="citation_source-journal">Psychopharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">196</span><span class="NLM_x">, </span> <span class="NLM_fpage">431</span><span class="NLM_x">–</span> <span class="NLM_lpage">440</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=196&publication_year=2008&pages=431-440&author=M.+L.+Woolleyauthor=D.+J.+Pembertonauthor=S.+Bateauthor=C.+Cortiauthor=D.+N.+C.+Jones&title=The+mGlu2+but+not+the+mGlu3+receptor+mediates+the+actions+of+the+mGluR2%2F3+agonist%2C+LY379268%2C+in+mouse+models+predictive+of+antipsychotic+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWoolley%26aufirst%3DM.%2BL.%26aulast%3DPemberton%26aufirst%3DD.%2BJ.%26aulast%3DBate%26aufirst%3DS.%26aulast%3DCorti%26aufirst%3DC.%26aulast%3DJones%26aufirst%3DD.%2BN.%2BC.%26atitle%3DThe%2520mGlu2%2520but%2520not%2520the%2520mGlu3%2520receptor%2520mediates%2520the%2520actions%2520of%2520the%2520mGluR2%252F3%2520agonist%252C%2520LY379268%252C%2520in%2520mouse%2520models%2520predictive%2520of%2520antipsychotic%2520activity%26jtitle%3DPsychopharmacology%26date%3D2008%26volume%3D196%26spage%3D431%26epage%3D440" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Fell, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Svensson, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schoepp, D. D.</span><span> </span><span class="NLM_article-title">Evidence for the role of mGlu2 not mGlu3 receptors in the preclinical antipsychotic pharmacology of the mGlu2/3 receptor agonist LY404039</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">326</span><span class="NLM_x">, </span> <span class="NLM_fpage">209</span><span class="NLM_x">–</span> <span class="NLM_lpage">217</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Fjm500496m&amp;key=10.1124%2Fjpet.108.136861" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Fjm500496m&amp;key=18424625" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Fjm500496m&amp;key=1%3ACAS%3A528%3ADC%252BD1cXotlyltrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=326&publication_year=2008&pages=209-217&author=M.+J.+Fellauthor=K.+A.+Svenssonauthor=B.+G.+Johnsonauthor=D.+D.+Schoepp&title=Evidence+for+the+role+of+mGlu2+not+mGlu3+receptors+in+the+preclinical+antipsychotic+pharmacology+of+the+mGlu2%2F3+receptor+agonist+LY404039"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Evidence for the role of metabotropic glutamate (mGlu)2 not mGlu3 receptors in the preclinical antipsychotic pharmacology of the mGlu2/3 receptor agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]hexane-4,6-dicarboxylic acid (LY404039)</span></div><div class="casAuthors">Fell, Matthew J.; Svensson, Kjell A.; Johnson, Bryan G.; Schoepp, Darryle D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">326</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">209-217</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">(-)-(1R,4S,5S,6S)-4-Amino-2-sulfonylbicyclo[3.1.0]hexane-4,6-dicarboxylic acid (LY404039) is a potent and selective group II metabotropic glutamate [(mGlu)2 and mGlu3] receptor agonist for which its prodrug LY2140023 [(1R,4S,5S,6S)-2-thiabicyclo[3.1.0]-hexane-4,6-dicarboxylic acid,4-[(2S)-2-amino-4-(methylthio)-1-oxobutyl]amino-, 2,2-dioxide monohydrate] has recently been shown to have efficacy in the treatment of the pos. and neg. symptoms of schizophrenia.  In this article, we use mGlu receptor-deficient mice to investigate the relative contribution of mGlu2 and mGlu3 receptors in mediating the antipsychotic profile of LY404039 in the phencyclidine (PCP) and d-amphetamine (AMP) models of psychosis.  To further explore the mechanism of action of LY404039, we compared the drugs' ability to block PCP-induced hyperlocomotion to that of atypical antipsychotics in wild-type and mice lacking mGlu2/3 receptors.  In wild-type animals, LY404039 (3-30 mg/kg i.p.) significantly reversed AMP (5 mg/kg, i.p.)-induced increases in ambulations, distance traveled, and reduced time spent at rest.  LY404039 reversed PCP (7.5 mg/kg i.p.)-evoked behaviors at 10 mg/kg.  The antipsychotic-like effects of LY404039 (10 mg/kg i.p.) on PCP and AMP-evoked behavioral activation were absent in mGlu2 and mGlu2/3 but not in mGlu3 receptor-deficient mice, indicating that the activation of mGlu2 and not mGlu3 receptors is responsible for the antipsychotic-like effects of the mGlu2/3 receptor agonist LY404039.  In contrast, the atypical antipsychotic drugs clozapine and risperidone inhibited PCP-evoked behaviors in both wild-type and mGlu2/3 receptor-deficient mice.  These data demonstrate that the antipsychotic-like effects of the mGlu2/3 receptor agonist LY404039 in psychostimulant models of psychosis are mechanistically distinct from those of atypical antipsychotic drugs and are dependent on functional mGlu2 and not mGlu3 receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQQM2jpXbmkLVg90H21EOLACvtfcHk0lj2JsTM8sToTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXotlyltrw%253D&md5=795527aeddef2ee2829f2ae2c6803b6e</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1124%2Fjpet.108.136861&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.108.136861%26sid%3Dliteratum%253Aachs%26aulast%3DFell%26aufirst%3DM.%2BJ.%26aulast%3DSvensson%26aufirst%3DK.%2BA.%26aulast%3DJohnson%26aufirst%3DB.%2BG.%26aulast%3DSchoepp%26aufirst%3DD.%2BD.%26atitle%3DEvidence%2520for%2520the%2520role%2520of%2520mGlu2%2520not%2520mGlu3%2520receptors%2520in%2520the%2520preclinical%2520antipsychotic%2520pharmacology%2520of%2520the%2520mGlu2%252F3%2520receptor%2520agonist%2520LY404039%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2008%26volume%3D326%26spage%3D209%26epage%3D217" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Galici, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Echemendia, N. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguez, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conn, P. J.</span><span> </span><span class="NLM_article-title">A selective allosteric potentiator of metabotropic glutamate (mGlu) 2 receptors has effects similar to an orthosteric mGlu2/3 receptor agonist in mouse models predictive of antipsychotic activity</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">315</span><span class="NLM_x">, </span> <span class="NLM_fpage">1181</span><span class="NLM_x">–</span> <span class="NLM_lpage">1187</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Fjm500496m&amp;key=10.1124%2Fjpet.105.091074" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Fjm500496m&amp;key=16123306" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Fjm500496m&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlalurjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=315&publication_year=2005&pages=1181-1187&author=R.+Galiciauthor=N.+G.+Echemendiaauthor=A.+L.+Rodriguezauthor=P.+J.+Conn&title=A+selective+allosteric+potentiator+of+metabotropic+glutamate+%28mGlu%29+2+receptors+has+effects+similar+to+an+orthosteric+mGlu2%2F3+receptor+agonist+in+mouse+models+predictive+of+antipsychotic+activity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">A selective allosteric potentiator of metabotropic glutamate (mGlu) 2 receptors has effects similar to an orthosteric mGlu2/3 receptor agonist in mouse models predictive of antipsychotic activity</span></div><div class="casAuthors">Galici, Ruggero; Echemendia, Nicholas G.; Rodriguez, Alice L.; Conn, P. Jeffrey</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">315</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1181-1187</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Recent studies suggest that agonists of group II metabotropic glutamate (mGlu) receptors (mGlu2/3) have potential utility as novel therapeutic agents for treatment of psychiatric disorders such as anxiety and schizophrenia.  Agonists of mGlu2/3 receptors block amphetamine- and phencyclidine (PCP)-induced hyperlocomotor activity in rodents, two actions that may predict potential antipsychotic activity of these compds.  We now report that LY487379 [N-(4-(2-methoxyphenoxy)phenyl)-N-(2,2,2-trifluoroethylsulfonyl)pyrid-3-ylmethylamine],a recently described selective allosteric potentiator of mGlu2 receptor, has behavioral effects similar to mGlu2/3 receptor agonists.  LY487379 and LY379268 [(-)-2-oxa-4-aminobicyclo[3.1.0]hexane-4,6-dicarboxylate], an ortho-steric mGlu2/3 receptor agonist, induced similar dose-dependent redns. in PCP- and amphetamine-induced hyperlocomotor activity in C57BL6/J mice at doses that did not significantly alter spontaneous locomotor activity.  These effects were blocked by the mGlu2/3 receptor antagonist LY341495 [(2S)-2-amino-2-[(1S,2S)-2-carboxycycloprop-1-yl]-3-(xanth-9-yl) propanoic acid].  LY487379 had a short duration of action compared with LY379268.  Furthermore, unlike the mGlu2/3 agonist, LY487379 reversed amphetamine-induced disruption of prepulse inhibition of the acoustic startle reflex.  When LY379268 was given chronically, it failed to block amphetamine- and PCP-induced hyperlocomotor activity.  The finding that the effects of an orthosteric mGlu2/3 receptor agonist in these models can be mimicked by a selective allosteric potentiator of mGlu2 suggests that these effects are mediated by the mGlu2 receptor subtype.  Furthermore, these data raise the possibility that a selective allosteric potentiator of mGlu2 receptor could have utility as a novel approach for the treatment of schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvwi3qgWI8frVg90H21EOLACvtfcHk0likyr8FFXG6Uw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlalurjJ&md5=93effc12fc976519477f1cf4a36e84f5</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1124%2Fjpet.105.091074&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.105.091074%26sid%3Dliteratum%253Aachs%26aulast%3DGalici%26aufirst%3DR.%26aulast%3DEchemendia%26aufirst%3DN.%2BG.%26aulast%3DRodriguez%26aufirst%3DA.%2BL.%26aulast%3DConn%26aufirst%3DP.%2BJ.%26atitle%3DA%2520selective%2520allosteric%2520potentiator%2520of%2520metabotropic%2520glutamate%2520%2528mGlu%2529%25202%2520receptors%2520has%2520effects%2520similar%2520to%2520an%2520orthosteric%2520mGlu2%252F3%2520receptor%2520agonist%2520in%2520mouse%2520models%2520predictive%2520of%2520antipsychotic%2520activity%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2005%26volume%3D315%26spage%3D1181%26epage%3D1187" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Conn, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christopoulos, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindsley, C. W.</span><span> </span><span class="NLM_article-title">Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders</span> <span class="citation_source-journal">Nat. Rev. Drug. Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">41</span><span class="NLM_x">–</span> <span class="NLM_lpage">54</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Fjm500496m&amp;key=10.1038%2Fnrd2760" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Fjm500496m&amp;key=19116626" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Fjm500496m&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsFCkurfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=41-54&author=P.+J.+Connauthor=A.+Christopoulosauthor=C.+W.+Lindsley&title=Allosteric+modulators+of+GPCRs%3A+a+novel+approach+for+the+treatment+of+CNS+disorders"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders</span></div><div class="casAuthors">Conn, P. Jeffrey; Christopoulos, Arthur; Lindsley, Craig W.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">41-54</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Despite G-protein-coupled receptors (GPCRs) being among the most fruitful targets for marketed drugs, intense discovery efforts for several GPCR subtypes have failed to deliver selective drug candidates.  Historically, drug discovery programs for GPCR ligands have been dominated by efforts to develop agonists and antagonists that act at orthosteric sites for endogenous ligands.  However, in recent years, there have been tremendous advances in the discovery of novel ligands for GPCRs that act at allosteric sites to regulate receptor function.  These compds. provide high selectivity, novel modes of efficacy and may lead to novel therapeutic agents for the treatment of multiple psychiatric and neurol. human disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmn5h5XCcPKbVg90H21EOLACvtfcHk0likyr8FFXG6Uw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsFCkurfF&md5=e109e94fe3e2c1fcfd480dc84c6609f7</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1038%2Fnrd2760&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2760%26sid%3Dliteratum%253Aachs%26aulast%3DConn%26aufirst%3DP.%2BJ.%26aulast%3DChristopoulos%26aufirst%3DA.%26aulast%3DLindsley%26aufirst%3DC.%2BW.%26atitle%3DAllosteric%2520modulators%2520of%2520GPCRs%253A%2520a%2520novel%2520approach%2520for%2520the%2520treatment%2520of%2520CNS%2520disorders%26jtitle%3DNat.%2520Rev.%2520Drug.%2520Discovery%26date%3D2009%26volume%3D8%26spage%3D41%26epage%3D54" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Pin, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parmentier, M.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prezeau, L.</span><span> </span><span class="NLM_article-title">Positive allosteric modulators for g-aminobutyric acidB receptors open new routes for the development of drugs targeting family 3 G-protein-coupled receptors</span> <span class="citation_source-journal">Mol. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">881</span><span class="NLM_x">–</span> <span class="NLM_lpage">884</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2001&pages=881-884&author=J.+P.+Pinauthor=M.-L.+Parmentierauthor=L.+Prezeau&title=Positive+allosteric+modulators+for+g-aminobutyric+acidB+receptors+open+new+routes+for+the+development+of+drugs+targeting+family+3+G-protein-coupled+receptors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPin%26aufirst%3DJ.%2BP.%26aulast%3DParmentier%26aufirst%3DM.-L.%26aulast%3DPrezeau%26aufirst%3DL.%26atitle%3DPositive%2520allosteric%2520modulators%2520for%2520g-aminobutyric%2520acidB%2520receptors%2520open%2520new%2520routes%2520for%2520the%2520development%2520of%2520drugs%2520targeting%2520family%25203%2520G-protein-coupled%2520receptors%26jtitle%3DMol.%2520Pharmacol.%26date%3D2001%26volume%3D60%26spage%3D881%26epage%3D884" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Gjoni, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Urwyler, S.</span><span> </span><span class="NLM_article-title">Receptor activation involving positive allosteric modulation, unlike full agonism, does not result in GABAB receptor desensitization</span> <span class="citation_source-journal">Neuropharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">1293</span><span class="NLM_x">–</span> <span class="NLM_lpage">1299</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2008&pages=1293-1299&author=T.+Gjoniauthor=S.+Urwyler&title=Receptor+activation+involving+positive+allosteric+modulation%2C+unlike+full+agonism%2C+does+not+result+in+GABAB+receptor+desensitization"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGjoni%26aufirst%3DT.%26aulast%3DUrwyler%26aufirst%3DS.%26atitle%3DReceptor%2520activation%2520involving%2520positive%2520allosteric%2520modulation%252C%2520unlike%2520full%2520agonism%252C%2520does%2520not%2520result%2520in%2520GABAB%2520receptor%2520desensitization%26jtitle%3DNeuropharmacology%26date%3D2008%26volume%3D55%26spage%3D1293%26epage%3D1299" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Trabanco, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cid, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lavreysen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macdonald, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tresadern, G.</span><span> </span><span class="NLM_article-title">Progress in the development of positive allosteric modulators of the metabotropic glutamate receptor 2</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">47</span><span class="NLM_x">–</span> <span class="NLM_lpage">68</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Fjm500496m&amp;key=10.2174%2F092986711793979706" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Fjm500496m&amp;key=21110815" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Fjm500496m&amp;key=1%3ACAS%3A528%3ADC%252BC3MXkslahs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2011&pages=47-68&author=A.+A.+Trabancoauthor=J.+M.+Cidauthor=H.+Lavreysenauthor=G.+J.+Macdonaldauthor=G.+Tresadern&title=Progress+in+the+development+of+positive+allosteric+modulators+of+the+metabotropic+glutamate+receptor+2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Progress in the development of positive allosteric modulators of the metabotropic glutamate receptor 2</span></div><div class="casAuthors">Trabanco, A. A.; Cid, J. M.; Lavreysen, H.; MacDonald, G. J.; Tresadern, G.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">47-68</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The metabotropic glutamate type 2 (mGlu2) receptor is a G-protein coupled receptor (GPCR) expressed on presynaptic nerve terminals where it neg. modulates glutamate and GABA release.  Mixed mGlu2/mGlu3 orthosteric agonists such as LY354740 have shown activity in a range of preclin. animal models of anxiety and schizophrenia.  Clin. work with LY354740 demonstrated activity in a CO2 inhalation study suggesting application in the treatment of anxiety related disorders.  Subsequently, a related prodrug LY2140023 demonstrated improvements in pos. and neg. symptoms in patients suffering from schizophrenia.  These mols. exhibit combined mGlu2/mGlu3 activity although there is evidence from knock-out studies that preclin. anti-psychotic effects may be mediated via the mGlu2 receptor.  An alternative avenue for modulating GPCRs is to act via allosteric mechanisms, binding at a different site from the orthosteric agonist.  Since the first discovery of mGlu2 pos. allosteric modulators (PAMs) such as 2,2,2-TEMPS and BINA, multiple families of mGlu2 modulators have been reported and several have entered into clin. development.  This review focuses on recent advances in the development of novel mGlu2 PAMs by anal. of compds. disclosed in research articles and patent literature between 2007 and 2010.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkHtOXKWJY9rVg90H21EOLACvtfcHk0lj_IFcKtC_QCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXkslahs7g%253D&md5=b4059bdfb0001b97cde8ec0e30032a48</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.2174%2F092986711793979706&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986711793979706%26sid%3Dliteratum%253Aachs%26aulast%3DTrabanco%26aufirst%3DA.%2BA.%26aulast%3DCid%26aufirst%3DJ.%2BM.%26aulast%3DLavreysen%26aufirst%3DH.%26aulast%3DMacdonald%26aufirst%3DG.%2BJ.%26aulast%3DTresadern%26aufirst%3DG.%26atitle%3DProgress%2520in%2520the%2520development%2520of%2520positive%2520allosteric%2520modulators%2520of%2520the%2520metabotropic%2520glutamate%2520receptor%25202%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2011%26volume%3D18%26spage%3D47%26epage%3D68" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Trabanco, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cid, J. M.</span><span> </span><span class="NLM_article-title">mGluR2 positive allosteric modulators (PAMs): a patent review (2009–present)</span> <span class="citation_source-journal">Expert Opin. Ther. Patents</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">629</span><span class="NLM_x">–</span> <span class="NLM_lpage">647</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Fjm500496m&amp;key=10.1517%2F13543776.2013.777043" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Fjm500496m&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmt1Sjtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=629-647&author=A.+A.+Trabancoauthor=J.+M.+Cid&title=mGluR2+positive+allosteric+modulators+%28PAMs%29%3A+a+patent+review+%282009%E2%80%93present%29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">mGluR2 positive allosteric modulators: a patent review (2009 - present)</span></div><div class="casAuthors">Trabanco, Andres A.; Cid, Jose Maria</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">629-647</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: The mGlu2 receptor, which belongs to the group II subfamily of metabotropic glutamate receptors (mGlu) along with the mGlu3 receptor, has proven to be of particular importance in neuropharmacol.  Preferentially expressed on presynaptic nerve terminals, the mGlu2 receptor neg. modulates glutamate and GABA release and is widely distributed in the brain.  High levels of mGlu2 receptors are seen in brain areas such as prefrontal cortex, hippocampus and amygdala where glutamate hyperfunction may be implicated in disorders and diseases such as anxiety and schizophrenia.  Given the promise offered by mGlu2/3 receptor activation, there is increased interest in identifying small mols. which activate the receptor.  A preferred approach is via pos. allosteric modulators (PAMs) which bind at an alternative site to agonists.Areas covered: This review covers the patent applications which were published between Apr. 2009 and Dec. 2012 on PAMs of the mGlu2, and it is a continuation of an earlier review published in this journal.Expert opinion: Advances in medicinal chem. and pharmacol. have set the stage in the field of mGlu2 receptor PAMs.  Compds. currently advancing in clin. trials will soon establish the therapeutic potential of this allosteric approach.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsVxJNadzKPbVg90H21EOLACvtfcHk0lj_IFcKtC_QCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmt1Sjtr4%253D&md5=af828df2b2c206094dd373bb93e37363</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1517%2F13543776.2013.777043&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543776.2013.777043%26sid%3Dliteratum%253Aachs%26aulast%3DTrabanco%26aufirst%3DA.%2BA.%26aulast%3DCid%26aufirst%3DJ.%2BM.%26atitle%3DmGluR2%2520positive%2520allosteric%2520modulators%2520%2528PAMs%2529%253A%2520a%2520patent%2520review%2520%25282009%25E2%2580%2593present%2529%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Patents%26date%3D2013%26volume%3D23%26spage%3D629%26epage%3D647" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Lorrain, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schaffhauser, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, U. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baccei, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Correa, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowe, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguez, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varney, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pinkerton, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vernier, J.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bristow, L. J.</span><span> </span><span class="NLM_article-title">Group II mGlu receptor activation suppresses norepinephrine release in the ventral hippocampus and locomotor responses to acute ketamine challenge</span> <span class="citation_source-journal">Neuropsychopharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">1622</span><span class="NLM_x">–</span> <span class="NLM_lpage">1632</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Fjm500496m&amp;key=10.1038%2Fsj.npp.1300238" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Fjm500496m&amp;key=12825094" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Fjm500496m&amp;key=1%3ACAS%3A528%3ADC%252BD3sXmsFeisLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2003&pages=1622-1632&author=D.+S.+Lorrainauthor=H.+Schaffhauserauthor=U.+C.+Campbellauthor=C.+S.+Bacceiauthor=L.+D.+Correaauthor=B.+Roweauthor=D.+E.+Rodriguezauthor=J.+J.+Andersonauthor=M.+A.+Varneyauthor=A.+B.+Pinkertonauthor=J.-M.+Vernierauthor=L.+J.+Bristow&title=Group+II+mGlu+receptor+activation+suppresses+norepinephrine+release+in+the+ventral+hippocampus+and+locomotor+responses+to+acute+ketamine+challenge"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Group II mGlu receptor activation suppresses norepinephrine release in the ventral hippocampus and locomotor responses to acute ketamine challenge</span></div><div class="casAuthors">Lorrain, Daniel S.; Schaffhauser, Herve; Campbell, Una C.; Baccei, Christopher S.; Correa, Lucia D.; Rowe, Blake; Rodriguez, Dana E.; Anderson, Jeffery J.; Varney, Mark A.; Pinkerton, Anthony B.; Vernier, Jean-Michel; Bristow, Linda J.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1622-1632</span>CODEN:
                <span class="NLM_cas:coden">NEROEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-133X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Group II mGlu receptor agonists (eg LY379268 and LY354740) have been shown to reverse many of the behavioral responses to PCP as well as glutamate release elicited by PCP and ketamine.  In the present set of expts., the authors used in vivo microdialysis to show that, in addn. to reversing PCP- and ketamine-evoked glutamate release, group II mGlu receptor stimulation also prevents ketamine-evoked norepinephrine (NE) release.  Pretreating animals with the mixed 2/3 metabotropic glutamate (mGlu2/3) receptor agonist LY379268 (0.3-10 mg/kg) dose-dependently inhibited ketamine (25 mg/kg)-evoked NE release in the ventral hippocampus (VHipp).  Ketamine hyperactivity was also reduced in a similar dose range.  Following the authors' initial observation on NE release, they conducted a series of microinjection expts. to reveal that the inhibitory effects of LY379268 on VHipp NE release may be linked to glutamate transmission within the medial prefrontal cortex.  Finally, the authors were able to mimic the inhibitory effects of LY379268 on ketamine-evoked NE release by using a novel mGlu2 receptor selective pos. modulator.  (+/-) 2,2,2-Trifluoroethyl [3-(1-methyl-butoxy)-phenyl]-pyridin-3-ylmethyl-sulfonamide (2,2,2-TEMPS, characterized through in vitro GTPγS binding) at a dose of 100 mg/kg significantly reduced the NE response.  Together, these results demonstrate a novel means to suppress noradrenergic neurotransmission (i.e. by activating mGlu2 receptors) and may, therefore, have important implications for neuropsychiatric disorders in which aberrant activation of the noradrenergic system is thought to be involved.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1EmzIVF7NI7Vg90H21EOLACvtfcHk0lj_IFcKtC_QCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXmsFeisLY%253D&md5=b17d585f28f71d8ef7d52cdcac2697f5</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1038%2Fsj.npp.1300238&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.npp.1300238%26sid%3Dliteratum%253Aachs%26aulast%3DLorrain%26aufirst%3DD.%2BS.%26aulast%3DSchaffhauser%26aufirst%3DH.%26aulast%3DCampbell%26aufirst%3DU.%2BC.%26aulast%3DBaccei%26aufirst%3DC.%2BS.%26aulast%3DCorrea%26aufirst%3DL.%2BD.%26aulast%3DRowe%26aufirst%3DB.%26aulast%3DRodriguez%26aufirst%3DD.%2BE.%26aulast%3DAnderson%26aufirst%3DJ.%2BJ.%26aulast%3DVarney%26aufirst%3DM.%2BA.%26aulast%3DPinkerton%26aufirst%3DA.%2BB.%26aulast%3DVernier%26aufirst%3DJ.-M.%26aulast%3DBristow%26aufirst%3DL.%2BJ.%26atitle%3DGroup%2520II%2520mGlu%2520receptor%2520activation%2520suppresses%2520norepinephrine%2520release%2520in%2520the%2520ventral%2520hippocampus%2520and%2520locomotor%2520responses%2520to%2520acute%2520ketamine%2520challenge%26jtitle%3DNeuropsychopharmacology%26date%3D2003%26volume%3D28%26spage%3D1622%26epage%3D1632" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Johnson, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baez, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jagdmann, G. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Britton, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Large, T. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Callagaro, D. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tizzano, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Monn, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schoepp, D. D.</span><span> </span><span class="NLM_article-title">Discovery of allosteric potentiators for the metabotropic glutamate 2 receptor: synthesis and subtype selectivity of <i>N</i>-(4-(2-methoxyphenoxy)phenyl)-<i>N</i>-(2,2,2-trifluoroethylsulfonyl)pyrid-3-ylmethylamine</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">3189</span><span class="NLM_x">–</span> <span class="NLM_lpage">3192</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm034015u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=3189-3192&author=M.+P.+Johnsonauthor=M.+Baezauthor=G.+E.+Jagdmannauthor=T.+C.+Brittonauthor=T.+H.+Largeauthor=D.+O.+Callagaroauthor=J.+P.+Tizzanoauthor=J.+A.+Monnauthor=D.+D.+Schoepp&title=Discovery+of+allosteric+potentiators+for+the+metabotropic+glutamate+2+receptor%3A+synthesis+and+subtype+selectivity+of+N-%284-%282-methoxyphenoxy%29phenyl%29-N-%282%2C2%2C2-trifluoroethylsulfonyl%29pyrid-3-ylmethylamine"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Fjm034015u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm034015u%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DM.%2BP.%26aulast%3DBaez%26aufirst%3DM.%26aulast%3DJagdmann%26aufirst%3DG.%2BE.%26aulast%3DBritton%26aufirst%3DT.%2BC.%26aulast%3DLarge%26aufirst%3DT.%2BH.%26aulast%3DCallagaro%26aufirst%3DD.%2BO.%26aulast%3DTizzano%26aufirst%3DJ.%2BP.%26aulast%3DMonn%26aufirst%3DJ.%2BA.%26aulast%3DSchoepp%26aufirst%3DD.%2BD.%26atitle%3DDiscovery%2520of%2520allosteric%2520potentiators%2520for%2520the%2520metabotropic%2520glutamate%25202%2520receptor%253A%2520synthesis%2520and%2520subtype%2520selectivity%2520of%2520N-%25284-%25282-methoxyphenoxy%2529phenyl%2529-N-%25282%252C2%252C2-trifluoroethylsulfonyl%2529pyrid-3-ylmethylamine%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D3189%26epage%3D3192" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Pinkerton, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vernier, J.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schaffhauser, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowe, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, U. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguez, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lorrain, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baccei, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daggett, L. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bristow, L. J.</span><span> </span><span class="NLM_article-title">Phenyl-tetrazolyl acetophenones: discovery of positive allosteric potentiators for the metabotropic glutamate 2 receptor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">4595</span><span class="NLM_x">–</span> <span class="NLM_lpage">4599</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm040088h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=4595-4599&author=A.+B.+Pinkertonauthor=J.-M.+Vernierauthor=H.+Schaffhauserauthor=B.+A.+Roweauthor=U.+C.+Campbellauthor=D.+E.+Rodriguezauthor=D.+S.+Lorrainauthor=C.+S.+Bacceiauthor=L.+P.+Daggettauthor=L.+J.+Bristow&title=Phenyl-tetrazolyl+acetophenones%3A+discovery+of+positive+allosteric+potentiators+for+the+metabotropic+glutamate+2+receptor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fjm040088h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm040088h%26sid%3Dliteratum%253Aachs%26aulast%3DPinkerton%26aufirst%3DA.%2BB.%26aulast%3DVernier%26aufirst%3DJ.-M.%26aulast%3DSchaffhauser%26aufirst%3DH.%26aulast%3DRowe%26aufirst%3DB.%2BA.%26aulast%3DCampbell%26aufirst%3DU.%2BC.%26aulast%3DRodriguez%26aufirst%3DD.%2BE.%26aulast%3DLorrain%26aufirst%3DD.%2BS.%26aulast%3DBaccei%26aufirst%3DC.%2BS.%26aulast%3DDaggett%26aufirst%3DL.%2BP.%26aulast%3DBristow%26aufirst%3DL.%2BJ.%26atitle%3DPhenyl-tetrazolyl%2520acetophenones%253A%2520discovery%2520of%2520positive%2520allosteric%2520potentiators%2520for%2520the%2520metabotropic%2520glutamate%25202%2520receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D4595%26epage%3D4599" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Fell, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Witkin, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Falcone, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Katner, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perry, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hart, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rorick-Kehn, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Overshiner, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rasmussen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaney, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benvenga, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marlow, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thompson, L. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lueck, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wafford, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seidel, W. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edgar, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quests, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Felder, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heinz, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nikolayev, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuo, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mayhugh, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khilevich, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ebert, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eckstein, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ackermann, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swanson, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Catlow, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dean, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jackson, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tauscher-Wisniewski, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marek, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schkeryantz, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Svensson, K. A.</span><span> </span><span class="NLM_article-title"><i>N</i>-(4-((2-(Trifluoromethyl)-3-hydroxy-4-(isobutyryl)phenoxy)methyl) benzyl)-1-methyl-1<i>H</i>-imidazole-4-carboxamide (THIIC), a novel metabotropic glutamate 2 potentiator with potential anxiolytic/antidepressant properties: in vivo profiling suggests a link between behavioral and central nervous system neurochemical change</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">336</span><span class="NLM_x">, </span> <span class="NLM_fpage">165</span><span class="NLM_x">–</span> <span class="NLM_lpage">177</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Fjm500496m&amp;key=10.1124%2Fjpet.110.172957" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Fjm500496m&amp;key=20947638" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Fjm500496m&amp;key=1%3ACAS%3A528%3ADC%252BC3MXls1erug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=336&publication_year=2011&pages=165-177&author=M.+J.+Fellauthor=J.+M.+Witkinauthor=J.+F.+Falconeauthor=J.+S.+Katnerauthor=K.+W.+Perryauthor=J.+Hartauthor=L.+Rorick-Kehnauthor=C.+D.+Overshinerauthor=K.+Rasmussenauthor=S.+F.+Chaneyauthor=M.+J.+Benvengaauthor=X.+Liauthor=D.+L.+Marlowauthor=L.+K.+Thompsonauthor=S.+K.+Lueckauthor=K.+A.+Waffordauthor=W.+F.+Seidelauthor=D.+M.+Edgarauthor=A.+T.+Questsauthor=C.+C.+Felderauthor=X.+Wangauthor=B.+A.+Heinzauthor=A.+Nikolayevauthor=M.+S.+Kuoauthor=D.+Mayhughauthor=A.+Khilevichauthor=D.+Zhangauthor=P.+J.+Ebertauthor=J.+A.+Ecksteinauthor=B.+L.+Ackermannauthor=S.+P.+Swansonauthor=J.+T.+Catlowauthor=R.+A.+Deanauthor=K.+Jacksonauthor=S.+Tauscher-Wisniewskiauthor=G.+J.+Marekauthor=J.+M.+Schkeryantzauthor=K.+A.+Svensson&title=N-%284-%28%282-%28Trifluoromethyl%29-3-hydroxy-4-%28isobutyryl%29phenoxy%29methyl%29+benzyl%29-1-methyl-1H-imidazole-4-carboxamide+%28THIIC%29%2C+a+novel+metabotropic+glutamate+2+potentiator+with+potential+anxiolytic%2Fantidepressant+properties%3A+in+vivo+profiling+suggests+a+link+between+behavioral+and+central+nervous+system+neurochemical+change"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">N-(4-((2-(trifluoromethyl)-3-hydroxy-4-(isobutyryl)phenoxy)methyl)benzyl)-1-methyl-1H-imidazole-4-carboxamide (THIIC), a novel metabotropic glutamate 2 potentiator with potential anxiolytic/antidepressant properties: in vivo profiling suggests a link between behavioral and central nervous system neurochemical changes</span></div><div class="casAuthors">Fell, Matthew J.; Witkin, Jeffrey M.; Falcone, Julie F.; Katner, Jason S.; Perry, Kenneth W.; Hart, John; Rorick-Kehn, Linda; Overshiner, Carl D.; Rasmussen, Kurt; Chaney, Stephen F.; Benvenga, Mark J.; Li, Xia; Marlow, Deanna L.; Thompson, Linda K.; Luecke, Susan K.; Wafford, Keith A.; Seidel, Wesley F.; Edgar, Dale M.; Quets, Anne T.; Felder, Christian C.; Wang, XuShan; Heinz, Beverly A.; Nikolayev, Alexander; Kuo, Ming-Shang; Mayhugh, Daniel; Khilevich, Albert; Zhang, Deyi; Ebert, Philip J.; Eckstein, James A.; Ackermann, Bradley L.; Swanson, Steven P.; Catlow, John T.; Dean, Robert A.; Jackson, Kimberley; Tauscher-Wisniewski, Sitra; Marek, Gerard J.; Schkeryantz, Jeffrey M.; Svensson, Kjell A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">336</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">165-177</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The normalization of excessive glutamatergic neurotransmission through the activation of metabotropic glutamate 2 (mGlu2) receptors may have therapeutic potential in a variety of psychiatric disorders, including anxiety/depression and schizophrenia.  Here, we characterize the pharmacol. properties of N-(4-((2-(trifluoromethyl)-3-hydroxy-4-(isobutyryl)phenoxy)methyl)benzyl)-1-methyl-1H-imidazole-4-carboxamide (THIIC), a structurally novel, potent, and selective allosteric potentiator of human and rat mGlu2 receptors (EC50 = 23 and 13 nM, resp.).  THIIC produced anxiolytic-like efficacy in the rat stress-induced hyperthermia assay and the mouse stress-induced elevation of cerebellar cGMP and marble-burying assays.  THIIC also produced robust activity in three assays that detect antidepressant-like activity, including the mouse forced-swim test, the rat differential reinforcement of low rate 72-s assay, and the rat dominant-submissive test, with a maximal response similar to that of impiramine.  Effects of THIIC in the forced-swim test and marble burying were deleted in mGlu2 receptor null mice.  Anal. of sleep EEG showed that THIIC had a sleep-promoting profile with increased non-rapid eye movement (REM) and decreased REM sleep.  THIIC also decreased the dark phase increase in extracellular histamine in the medial prefrontal cortex and decreased levels of the histamine metabolite tele-methylhistamine (t-MeHA) in rat cerebrospinal fluid.  Collectively, these results indicate that the novel mGlu2-pos. allosteric modulator THIIC has robust activity in models used to predict anxiolytic/antidepressant efficacy, substantiating, at least with this mol., differentiation in the biol. impact of mGlu2 potentiation vs. mGlu2/3 orthosteric agonism.  In addn., we provide evidence that sleep EEG and CSF t-MeHA might function as viable biomarker approaches to facilitate the translational development of THIIC and other mGlu2 potentiators.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocfm6DC8ijJrVg90H21EOLACvtfcHk0lhWOqYs6YrbhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXls1erug%253D%253D&md5=ab138f946460f041067c5330a1b5217a</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1124%2Fjpet.110.172957&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.110.172957%26sid%3Dliteratum%253Aachs%26aulast%3DFell%26aufirst%3DM.%2BJ.%26aulast%3DWitkin%26aufirst%3DJ.%2BM.%26aulast%3DFalcone%26aufirst%3DJ.%2BF.%26aulast%3DKatner%26aufirst%3DJ.%2BS.%26aulast%3DPerry%26aufirst%3DK.%2BW.%26aulast%3DHart%26aufirst%3DJ.%26aulast%3DRorick-Kehn%26aufirst%3DL.%26aulast%3DOvershiner%26aufirst%3DC.%2BD.%26aulast%3DRasmussen%26aufirst%3DK.%26aulast%3DChaney%26aufirst%3DS.%2BF.%26aulast%3DBenvenga%26aufirst%3DM.%2BJ.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DMarlow%26aufirst%3DD.%2BL.%26aulast%3DThompson%26aufirst%3DL.%2BK.%26aulast%3DLueck%26aufirst%3DS.%2BK.%26aulast%3DWafford%26aufirst%3DK.%2BA.%26aulast%3DSeidel%26aufirst%3DW.%2BF.%26aulast%3DEdgar%26aufirst%3DD.%2BM.%26aulast%3DQuests%26aufirst%3DA.%2BT.%26aulast%3DFelder%26aufirst%3DC.%2BC.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DHeinz%26aufirst%3DB.%2BA.%26aulast%3DNikolayev%26aufirst%3DA.%26aulast%3DKuo%26aufirst%3DM.%2BS.%26aulast%3DMayhugh%26aufirst%3DD.%26aulast%3DKhilevich%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DEbert%26aufirst%3DP.%2BJ.%26aulast%3DEckstein%26aufirst%3DJ.%2BA.%26aulast%3DAckermann%26aufirst%3DB.%2BL.%26aulast%3DSwanson%26aufirst%3DS.%2BP.%26aulast%3DCatlow%26aufirst%3DJ.%2BT.%26aulast%3DDean%26aufirst%3DR.%2BA.%26aulast%3DJackson%26aufirst%3DK.%26aulast%3DTauscher-Wisniewski%26aufirst%3DS.%26aulast%3DMarek%26aufirst%3DG.%2BJ.%26aulast%3DSchkeryantz%26aufirst%3DJ.%2BM.%26aulast%3DSvensson%26aufirst%3DK.%2BA.%26atitle%3DN-%25284-%2528%25282-%2528Trifluoromethyl%2529-3-hydroxy-4-%2528isobutyryl%2529phenoxy%2529methyl%2529%2520benzyl%2529-1-methyl-1H-imidazole-4-carboxamide%2520%2528THIIC%2529%252C%2520a%2520novel%2520metabotropic%2520glutamate%25202%2520potentiator%2520with%2520potential%2520anxiolytic%252Fantidepressant%2520properties%253A%2520in%2520vivo%2520profiling%2520suggests%2520a%2520link%2520between%2520behavioral%2520and%2520central%2520nervous%2520system%2520neurochemical%2520change%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2011%26volume%3D336%26spage%3D165%26epage%3D177" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Johnson, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fitz, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engleman, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Svensson, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schkeryantz, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shekhar, A.</span><span> </span><span class="NLM_article-title">Group II metabotropic glutamate receptor type 2 allosteric potentiators prevent sodium lactate-induced panic-like response in panic-vulnerable rats</span> <span class="citation_source-journal">J. Psychopharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">152</span><span class="NLM_x">–</span> <span class="NLM_lpage">61</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Fjm500496m&amp;key=10.1177%2F0269881112454230" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Fjm500496m&amp;key=22914798" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Fjm500496m&amp;key=1%3ACAS%3A280%3ADC%252BC38bgsFehtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2013&pages=152-61&author=P.+L.+Johnsonauthor=S.+D.+Fitzauthor=E.+A.+Englemanauthor=K.+A.+Svenssonauthor=J.+M.+Schkeryantzauthor=A.+Shekhar&title=Group+II+metabotropic+glutamate+receptor+type+2+allosteric+potentiators+prevent+sodium+lactate-induced+panic-like+response+in+panic-vulnerable+rats"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Group II metabotropic glutamate receptor type 2 allosteric potentiators prevent sodium lactate-induced panic-like response in panic-vulnerable rats</span></div><div class="casAuthors">Johnson Philip L; Fitz Stephanie D; Engleman Eric A; Svensson Kjell A; Schkeryantz Jeffrey M; Shekhar Anantha</div><div class="citationInfo"><span class="NLM_cas:title">Journal of psychopharmacology (Oxford, England)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">152-61</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Rats with chronic inhibition of GABA synthesis by infusion of l-allyglycine, a glutamic acid decarboxylase inhibitor, into their dorsomedial/perifornical hypothalamus are anxious and exhibit panic-like cardio-respiratory responses to treatment with intravenous (i.v.) sodium lactate (NaLac) infusions, in a manner similar to what occurs in patients with panic disorder.  We previously showed that either NMDA receptor antagonists or metabotropic glutamate receptor type 2/3 receptor agonists can block such a NaLac response, suggesting that a glutamate mechanism is contributing to this panic-like state.  Using this animal model of panic, we tested the efficacy of CBiPES and THIIC, which are selective group II metabotropic glutamate type 2 receptor allosteric potentiators (at 10-30 mg/kg i.p.), in preventing NaLac-induced panic-like behavioral and cardiovascular responses.  The positive control was alprazolam (3mg/kg i.p.), a clinically effective anti-panic benzodiazepine.  As predicted, panic-prone rats given a NaLac challenge displayed NaLac-induced panic-like cardiovascular (i.e. tachycardia and hypertensive) responses and "anxiety" (i.e. decreased social interaction time) and "flight" (i.e. increased locomotion) -associated behaviors; however, systemic injection of the panic-prone rats with CBiPES, THIIC or alprazolam prior to the NaLac dose blocked all NaLac-induced panic-like behaviors and cardiovascular responses.  These data suggested that in a rat animal model, selective group II metabotropic glutamate type 2 receptor allosteric potentiators show an anti-panic efficacy similar to alprazolam.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSZyMXZ3JfLnYqdXsLcGTEUfW6udTcc2eb3d0avr7nWu7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38bgsFehtA%253D%253D&md5=531af9f63a70e174839cee84c4cbe39d</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1177%2F0269881112454230&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0269881112454230%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DP.%2BL.%26aulast%3DFitz%26aufirst%3DS.%2BD.%26aulast%3DEngleman%26aufirst%3DE.%2BA.%26aulast%3DSvensson%26aufirst%3DK.%2BA.%26aulast%3DSchkeryantz%26aufirst%3DJ.%2BM.%26aulast%3DShekhar%26aufirst%3DA.%26atitle%3DGroup%2520II%2520metabotropic%2520glutamate%2520receptor%2520type%25202%2520allosteric%2520potentiators%2520prevent%2520sodium%2520lactate-induced%2520panic-like%2520response%2520in%2520panic-vulnerable%2520rats%26jtitle%3DJ.%2520Psychopharmacol.%26date%3D2013%26volume%3D27%26spage%3D152%26epage%3D61" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Cid, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duvey, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cluzeau, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nhem, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macary, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raux, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poirier, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muller, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolea, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finn, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Urios, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Epping-Jordan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chamelot, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Derouet, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Girard, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacDonald, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vega, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Lucas, A. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matesanz, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lavreysen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Linares, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oehlrich, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oyarzabal, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tresadern, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trabanco, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andres, J. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le Poul, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Imogai, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lutjens, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rocher, J.-P.</span><span> </span><span class="NLM_article-title">Discovery of 1,5-disubstituted pyridones: a new class of positive allosteric modulators of the metabotropic glutamate 2 receptor</span> <span class="citation_source-journal">ACS Chem. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">788</span><span class="NLM_x">–</span> <span class="NLM_lpage">795</span></span><div class="citationLinks">[<a href="/doi/10.1021/cn1000638" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Fjm500496m&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVGgsbzO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2010&pages=788-795&author=J.+M.+Cidauthor=G.+Duveyauthor=P.+Cluzeauauthor=V.+Nhemauthor=K.+Macaryauthor=A.+Rauxauthor=N.+Poirierauthor=J.+Mullerauthor=C.+Boleaauthor=T.+Finnauthor=I.+Uriosauthor=M.+Epping-Jordanauthor=E.+Chamelotauthor=F.+Derouetauthor=F.+Girardauthor=G.+J.+MacDonaldauthor=J.+A.+Vegaauthor=A.+I.+de+Lucasauthor=E.+Matesanzauthor=H.+Lavreysenauthor=M.+L.+Linaresauthor=D.+Oehlrichauthor=J.+Oyarzabalauthor=G.+Tresadernauthor=A.+A.+Trabancoauthor=J.+I.+Andresauthor=E.+Le+Poulauthor=H.+Imogaiauthor=R.+Lutjensauthor=J.-P.+Rocher&title=Discovery+of+1%2C5-disubstituted+pyridones%3A+a+new+class+of+positive+allosteric+modulators+of+the+metabotropic+glutamate+2+receptor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 1,5-Disubstituted Pyridones: A New Class of Positive Allosteric Modulators of the Metabotropic Glutamate 2 Receptor</span></div><div class="casAuthors">Cid, Jose Maria; Duvey, Guillaume; Cluzeau, Philippe; Nhem, Vanthea; Macary, Karim; Raux, Alexandre; Poirier, Nicolas; Muller, Jessica; Bolea, Christelle; Finn, Terry; Urios, Isabelle; Epping-Jordan, Mark; Chamelot, Emilie; Derouet, Francis; Girard, Francoise; MacDonald, Gregor J.; Vega, Juan Antonio; de Lucas, Ana Isabel; Matesanz, Encarnacion; Lavreysen, Hilde; Linares, Maria Lourdes; Oehlrich, Daniel; Oyarzabal, Julen; Tresadern, Gary; Trabanco, Andres A.; Andres, Jose Ignacio; Le Poul, Emmanuel; Imogai, Hassan; Lutjens, Robert; Rocher, Jean-Philippe</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">788-795</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of 1,5-disubstituted pyridones was identified as pos. allosteric modulators (PAMs) of the metabotropic glutamate receptor 2 (mGluR2) via high throughput screening (HTS).  Subsequent SAR exploration led to the identification of several compds. with improved in vitro activity.  Lead compd. 8 (I) was further profiled and found to attenuate the increase in PCP induced locomotor activity in mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-saUfhQDgzLVg90H21EOLACvtfcHk0libgQVOvQ4l6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVGgsbzO&md5=85204e53809a7efcbd7d9fb5f04a3601</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fcn1000638&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcn1000638%26sid%3Dliteratum%253Aachs%26aulast%3DCid%26aufirst%3DJ.%2BM.%26aulast%3DDuvey%26aufirst%3DG.%26aulast%3DCluzeau%26aufirst%3DP.%26aulast%3DNhem%26aufirst%3DV.%26aulast%3DMacary%26aufirst%3DK.%26aulast%3DRaux%26aufirst%3DA.%26aulast%3DPoirier%26aufirst%3DN.%26aulast%3DMuller%26aufirst%3DJ.%26aulast%3DBolea%26aufirst%3DC.%26aulast%3DFinn%26aufirst%3DT.%26aulast%3DUrios%26aufirst%3DI.%26aulast%3DEpping-Jordan%26aufirst%3DM.%26aulast%3DChamelot%26aufirst%3DE.%26aulast%3DDerouet%26aufirst%3DF.%26aulast%3DGirard%26aufirst%3DF.%26aulast%3DMacDonald%26aufirst%3DG.%2BJ.%26aulast%3DVega%26aufirst%3DJ.%2BA.%26aulast%3Dde%2BLucas%26aufirst%3DA.%2BI.%26aulast%3DMatesanz%26aufirst%3DE.%26aulast%3DLavreysen%26aufirst%3DH.%26aulast%3DLinares%26aufirst%3DM.%2BL.%26aulast%3DOehlrich%26aufirst%3DD.%26aulast%3DOyarzabal%26aufirst%3DJ.%26aulast%3DTresadern%26aufirst%3DG.%26aulast%3DTrabanco%26aufirst%3DA.%2BA.%26aulast%3DAndres%26aufirst%3DJ.%2BI.%26aulast%3DLe%2BPoul%26aufirst%3DE.%26aulast%3DImogai%26aufirst%3DH.%26aulast%3DLutjens%26aufirst%3DR.%26aulast%3DRocher%26aufirst%3DJ.-P.%26atitle%3DDiscovery%2520of%25201%252C5-disubstituted%2520pyridones%253A%2520a%2520new%2520class%2520of%2520positive%2520allosteric%2520modulators%2520of%2520the%2520metabotropic%2520glutamate%25202%2520receptor%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2010%26volume%3D1%26spage%3D788%26epage%3D795" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Cid, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duvey, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tresadern, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nhem, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Funary, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cluzeau, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vega, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Lucas, A. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matesanz, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alonso, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Linares, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andres, J. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poli, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lutjens, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Imogai, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rocher, J.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacDonald, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oehlrich, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lavreysen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahnaou, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drinkenburg, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mackie, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trabanco, A. A.</span><span> </span><span class="NLM_article-title">Discovery of 1,4-disubstituted 3-cyano-2-pyridones: a new class of positive allosteric modulators of the metabotropic glutamate 2 receptor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">2388</span><span class="NLM_x">–</span> <span class="NLM_lpage">2405</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm2016864" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=2388-2405&author=J.+M.+Cidauthor=G.+Duveyauthor=G.+Tresadernauthor=V.+Nhemauthor=R.+Funaryauthor=P.+Cluzeauauthor=J.+A.+Vegaauthor=A.+I.+de+Lucasauthor=E.+Matesanzauthor=J.+M.+Alonsoauthor=M.+L.+Linaresauthor=J.+I.+Andresauthor=S.+Poliauthor=R.+Lutjensauthor=H.+Imogaiauthor=J.-P.+Rocherauthor=G.+J.+MacDonaldauthor=D.+Oehlrichauthor=H.+Lavreysenauthor=A.+Ahnaouauthor=W.+Drinkenburgauthor=C.+Mackieauthor=A.+A.+Trabanco&title=Discovery+of+1%2C4-disubstituted+3-cyano-2-pyridones%3A+a+new+class+of+positive+allosteric+modulators+of+the+metabotropic+glutamate+2+receptor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Fjm2016864&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2016864%26sid%3Dliteratum%253Aachs%26aulast%3DCid%26aufirst%3DJ.%2BM.%26aulast%3DDuvey%26aufirst%3DG.%26aulast%3DTresadern%26aufirst%3DG.%26aulast%3DNhem%26aufirst%3DV.%26aulast%3DFunary%26aufirst%3DR.%26aulast%3DCluzeau%26aufirst%3DP.%26aulast%3DVega%26aufirst%3DJ.%2BA.%26aulast%3Dde%2BLucas%26aufirst%3DA.%2BI.%26aulast%3DMatesanz%26aufirst%3DE.%26aulast%3DAlonso%26aufirst%3DJ.%2BM.%26aulast%3DLinares%26aufirst%3DM.%2BL.%26aulast%3DAndres%26aufirst%3DJ.%2BI.%26aulast%3DPoli%26aufirst%3DS.%26aulast%3DLutjens%26aufirst%3DR.%26aulast%3DImogai%26aufirst%3DH.%26aulast%3DRocher%26aufirst%3DJ.-P.%26aulast%3DMacDonald%26aufirst%3DG.%2BJ.%26aulast%3DOehlrich%26aufirst%3DD.%26aulast%3DLavreysen%26aufirst%3DH.%26aulast%3DAhnaou%26aufirst%3DA.%26aulast%3DDrinkenburg%26aufirst%3DW.%26aulast%3DMackie%26aufirst%3DC.%26aulast%3DTrabanco%26aufirst%3DA.%2BA.%26atitle%3DDiscovery%2520of%25201%252C4-disubstituted%25203-cyano-2-pyridones%253A%2520a%2520new%2520class%2520of%2520positive%2520allosteric%2520modulators%2520of%2520the%2520metabotropic%2520glutamate%25202%2520receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D2388%26epage%3D2405" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Tresadern, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cid, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacDonald, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vega, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Lucas, A. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matesanz, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Linares, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oehlrich, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lavreysen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Biesmans, Ilse</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trabanco, A. A.</span><span> </span><span class="NLM_article-title">Scaffold hopping from pyridones to imidazo[1,2-a]pyridines. new positive allosteric modulators of metabotropic glutamate 2 receptor</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">175</span><span class="NLM_x">–</span> <span class="NLM_lpage">179</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=175-179&author=G.+Tresadernauthor=J.+M.+Cidauthor=G.+J.+MacDonaldauthor=J.+A.+Vegaauthor=A.+I.+de+Lucasauthor=A.+Garciaauthor=E.+Matesanzauthor=M.+L.+Linaresauthor=D.+Oehlrichauthor=H.+Lavreysenauthor=Ilse+Biesmansauthor=A.+A.+Trabanco&title=Scaffold+hopping+from+pyridones+to+imidazo%5B1%2C2-a%5Dpyridines.+new+positive+allosteric+modulators+of+metabotropic+glutamate+2+receptor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTresadern%26aufirst%3DG.%26aulast%3DCid%26aufirst%3DJ.%2BM.%26aulast%3DMacDonald%26aufirst%3DG.%2BJ.%26aulast%3DVega%26aufirst%3DJ.%2BA.%26aulast%3Dde%2BLucas%26aufirst%3DA.%2BI.%26aulast%3DGarcia%26aufirst%3DA.%26aulast%3DMatesanz%26aufirst%3DE.%26aulast%3DLinares%26aufirst%3DM.%2BL.%26aulast%3DOehlrich%26aufirst%3DD.%26aulast%3DLavreysen%26aufirst%3DH.%26aulast%3DBiesmans%26aufirst%3DIlse%26aulast%3DTrabanco%26aufirst%3DA.%2BA.%26atitle%3DScaffold%2520hopping%2520from%2520pyridones%2520to%2520imidazo%255B1%252C2-a%255Dpyridines.%2520new%2520positive%2520allosteric%2520modulators%2520of%2520metabotropic%2520glutamate%25202%2520receptor%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D175%26epage%3D179" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Trabanco, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tresadern, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacDonald, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vega, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Lucas, A. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matesanz, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Linares, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alonso de Diego, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alonso, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oehlrich, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahnaou, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drinkenburg, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mackie, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andres, J. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lavreysen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cid, J. M.</span><span> </span><span class="NLM_article-title">Imidazo[1,2-a]pyridines: orally active positive allosteric modulators of the metabotropic glutamate 2 receptor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">2688</span><span class="NLM_x">–</span> <span class="NLM_lpage">2701</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm201561r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=2688-2701&author=A.+A.+Trabancoauthor=G.+Tresadernauthor=G.+J.+MacDonaldauthor=J.+A.+Vegaauthor=A.+I.+de+Lucasauthor=E.+Matesanzauthor=A.+Garciaauthor=M.+L.+Linaresauthor=S.+A.+Alonso+de+Diegoauthor=J.+M.+Alonsoauthor=D.+Oehlrichauthor=A.+Ahnaouauthor=W.+Drinkenburgauthor=C.+Mackieauthor=J.+I.+Andresauthor=H.+Lavreysenauthor=J.+M.+Cid&title=Imidazo%5B1%2C2-a%5Dpyridines%3A+orally+active+positive+allosteric+modulators+of+the+metabotropic+glutamate+2+receptor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Fjm201561r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201561r%26sid%3Dliteratum%253Aachs%26aulast%3DTrabanco%26aufirst%3DA.%2BA.%26aulast%3DTresadern%26aufirst%3DG.%26aulast%3DMacDonald%26aufirst%3DG.%2BJ.%26aulast%3DVega%26aufirst%3DJ.%2BA.%26aulast%3Dde%2BLucas%26aufirst%3DA.%2BI.%26aulast%3DMatesanz%26aufirst%3DE.%26aulast%3DGarcia%26aufirst%3DA.%26aulast%3DLinares%26aufirst%3DM.%2BL.%26aulast%3DAlonso%2Bde%2BDiego%26aufirst%3DS.%2BA.%26aulast%3DAlonso%26aufirst%3DJ.%2BM.%26aulast%3DOehlrich%26aufirst%3DD.%26aulast%3DAhnaou%26aufirst%3DA.%26aulast%3DDrinkenburg%26aufirst%3DW.%26aulast%3DMackie%26aufirst%3DC.%26aulast%3DAndres%26aufirst%3DJ.%2BI.%26aulast%3DLavreysen%26aufirst%3DH.%26aulast%3DCid%26aufirst%3DJ.%2BM.%26atitle%3DImidazo%255B1%252C2-a%255Dpyridines%253A%2520orally%2520active%2520positive%2520allosteric%2520modulators%2520of%2520the%2520metabotropic%2520glutamate%25202%2520receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D2688%26epage%3D2701" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Cid, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tresadern, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vega, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Lucas, A. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matesanz, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iturrino, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Linares, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andres, J. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacDonald, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohelrich, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lavreysen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Megens, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahnaou, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drinkenburg, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mackie, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pype, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallacher, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trabanco, A. A.</span><span> </span><span class="NLM_article-title">Discovery of 3-cyclopropylmethyl-7-(4-phenylpiperidin-1-yl)-8-trifluoromethyl-1,2,4-triazolo[4,3-<i>a</i>]pyridine (JNJ-42153605): a positive allosteric modulator of the metabotropic glutamate 2 receptor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">8770</span><span class="NLM_x">–</span> <span class="NLM_lpage">8789</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm3010724" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=8770-8789&author=J.+M.+Cidauthor=G.+Tresadernauthor=J.+A.+Vegaauthor=A.+I.+de+Lucasauthor=E.+Matesanzauthor=L.+Iturrinoauthor=M.+L.+Linaresauthor=A.+Garciaauthor=J.+I.+Andresauthor=G.+J.+MacDonaldauthor=G.+Ohelrichauthor=H.+Lavreysenauthor=A.+Megensauthor=A.+Ahnaouauthor=W.+Drinkenburgauthor=C.+Mackieauthor=S.+Pypeauthor=D.+Gallacherauthor=A.+A.+Trabanco&title=Discovery+of+3-cyclopropylmethyl-7-%284-phenylpiperidin-1-yl%29-8-trifluoromethyl-1%2C2%2C4-triazolo%5B4%2C3-a%5Dpyridine+%28JNJ-42153605%29%3A+a+positive+allosteric+modulator+of+the+metabotropic+glutamate+2+receptor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Fjm3010724&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3010724%26sid%3Dliteratum%253Aachs%26aulast%3DCid%26aufirst%3DJ.%2BM.%26aulast%3DTresadern%26aufirst%3DG.%26aulast%3DVega%26aufirst%3DJ.%2BA.%26aulast%3Dde%2BLucas%26aufirst%3DA.%2BI.%26aulast%3DMatesanz%26aufirst%3DE.%26aulast%3DIturrino%26aufirst%3DL.%26aulast%3DLinares%26aufirst%3DM.%2BL.%26aulast%3DGarcia%26aufirst%3DA.%26aulast%3DAndres%26aufirst%3DJ.%2BI.%26aulast%3DMacDonald%26aufirst%3DG.%2BJ.%26aulast%3DOhelrich%26aufirst%3DG.%26aulast%3DLavreysen%26aufirst%3DH.%26aulast%3DMegens%26aufirst%3DA.%26aulast%3DAhnaou%26aufirst%3DA.%26aulast%3DDrinkenburg%26aufirst%3DW.%26aulast%3DMackie%26aufirst%3DC.%26aulast%3DPype%26aufirst%3DS.%26aulast%3DGallacher%26aufirst%3DD.%26aulast%3DTrabanco%26aufirst%3DA.%2BA.%26atitle%3DDiscovery%2520of%25203-cyclopropylmethyl-7-%25284-phenylpiperidin-1-yl%2529-8-trifluoromethyl-1%252C2%252C4-triazolo%255B4%252C3-a%255Dpyridine%2520%2528JNJ-42153605%2529%253A%2520a%2520positive%2520allosteric%2520modulator%2520of%2520the%2520metabotropic%2520glutamate%25202%2520receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D8770%26epage%3D8789" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Kent, J.; Anghelescu, I.-G.; Kezic, I.; Daly, E.; Ceusters, M.; De Smedt, H.; Van Nueten, L.; De Boer, P.</span>Safety, tolerability and potential therapeutic efficacy of a novel glutamate modulator as adjunctive treatment in patients with schizophrenia, <span class="NLM_conf-name">166th Annual Meeting of the American Psychiatric Association</span>, <span class="NLM_conf-loc">San Francisco, CA</span>, <span class="NLM_conf-date">May 18–22</span>,<span class="NLM_x"> </span><span class="NLM_year">2013</span><span class="NLM_x">; </span>Abstract, 3160-P.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&conference=166th+Annual+Meeting+of+the+American+Psychiatric+Association&author=J.+Kent&author=I.-G.+Anghelescu&author=I.+Kezic&author=E.+Daly&author=M.+Ceusters&author=H.+De+Smedt&author=L.+Van+Nueten&author=P.+De+Boer&title=Safety%2C+tolerability+and+potential+therapeutic+efficacy+of+a+novel+glutamate+modulator+as+adjunctive+treatment+in+patients+with+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DKent%26aufirst%3DJ.%26jtitle%3DSafety%252C%2520tolerability%2520and%2520potential%2520therapeutic%2520efficacy%2520of%2520a%2520novel%2520glutamate%2520modulator%2520as%2520adjunctive%2520treatment%2520in%2520patients%2520with%2520schizophrenia%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span>Investigation of the safety, tolerability and potential therapeutic effects of JNJ-40411813 in patients with schizophrenia. <a href="http://clinicaltrials.gov/show/NCT01323205" class="extLink">http://clinicaltrials.gov/show/NCT01323205</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Investigation+of+the+safety%2C+tolerability+and+potential+therapeutic+effects+of+JNJ-40411813+in+patients+with+schizophrenia.+http%3A%2F%2Fclinicaltrials.gov%2Fshow%2FNCT01323205."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Hopkins, C. R.</span><span> </span><span class="NLM_article-title">Is there a path forward for mGlu2 positive allosteric modulators for the treatment of schizophrenia?</span> <span class="citation_source-journal">ACS Chem. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">211</span><span class="NLM_x">–</span> <span class="NLM_lpage">213</span></span><div class="citationLinks">[<a href="/doi/10.1021/cn400023y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Fjm500496m&amp;key=1%3ACAS%3A528%3ADC%252BC3sXitlCju7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=211-213&author=C.+R.+Hopkins&title=Is+there+a+path+forward+for+mGlu2+positive+allosteric+modulators+for+the+treatment+of+schizophrenia%3F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Is There a Path Forward for mGlu2 Positive Allosteric Modulators for the Treatment of Schizophrenia?</span></div><div class="casAuthors">Hopkins, Corey R.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">211-213</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Two recent Phase II results show opposing outcomes for the potential of activators of mGlu2 in the treatment of schizophrenia.  The first outcome revealed that Eli Lilly's mGlu2/3 agonist, pomaglumetad methionil (LY2140023), failed to meet the primary efficacy end point.  The second report showed the mGlu2 pos. allosteric modulator (PAM) from Addex (ADX71149) in conjunction with Janssen Research & Development met the primary objectives of safety, tolerability and demonstrated an effect on neg. symptoms in patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlDn7Grx63q7Vg90H21EOLACvtfcHk0lgTBBFsSyO3tg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXitlCju7o%253D&md5=0f37080968935b34a0b2a56f30168367</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Fcn400023y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcn400023y%26sid%3Dliteratum%253Aachs%26aulast%3DHopkins%26aufirst%3DC.%2BR.%26atitle%3DIs%2520there%2520a%2520path%2520forward%2520for%2520mGlu2%2520positive%2520allosteric%2520modulators%2520for%2520the%2520treatment%2520of%2520schizophrenia%253F%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2013%26volume%3D4%26spage%3D211%26epage%3D213" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span>AstraZeneca 2010 financial results. <a href="http://www.astrazeneca.com/Investors/financial-information/Financial-results/2010-Financial-results" class="extLink">http://www.astrazeneca.com/Investors/financial-information/Financial-results/2010-Financial-results</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=AstraZeneca+2010+financial+results.+http%3A%2F%2Fwww.astrazeneca.com%2FInvestors%2Ffinancial-information%2FFinancial-results%2F2010-Financial-results."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Litman, R. E.; Smith, M. A.; Doherty, J.; Cross, A.; Raines, S.; Zukin, S.</span>AZD8524, a positive allosteric modulator at the mGluR2 receptor, does not improve symptoms in schizophrenia: a proof of principle study, <span class="NLM_conf-name">53rd NCDEU: an annual meeting sponsored by ASCP</span>, <span class="NLM_conf-loc">Hollywood, Florida</span>, <span class="NLM_conf-date">May 28–31</span>,<span class="NLM_x"> </span><span class="NLM_year">2013</span><span class="NLM_x">; </span>Poster 83.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&conference=53rd+NCDEU%3A+an+annual+meeting+sponsored+by+ASCP&author=R.+E.+Litman&author=M.+A.+Smith&author=J.+Doherty&author=A.+Cross&author=S.+Raines&author=S.+Zukin&title=AZD8524%2C+a+positive+allosteric+modulator+at+the+mGluR2+receptor%2C+does+not+improve+symptoms+in+schizophrenia%3A+a+proof+of+principle+study"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DLitman%26aufirst%3DR.%2BE.%26jtitle%3DAZD8524%252C%2520a%2520positive%2520allosteric%2520modulator%2520at%2520the%2520mGluR2%2520receptor%252C%2520does%2520not%2520improve%2520symptoms%2520in%2520schizophrenia%253A%2520a%2520proof%2520of%2520principle%2520study%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span>Addex reports top-line data from a successful phase 2a clinical study with ADX71149 in schizophrenia patients. <a href="http://www.addextherapeutics.com/investors/press-releases/news-details/article/addex-reports-top-line-data-from-a-successful-phase-2a-clinical-study-with-adx71149-in-schizophrenia/" class="extLink">http://www.addextherapeutics.com/investors/press-releases/news-details/article/addex-reports-top-line-data-from-a-successful-phase-2a-clinical-study-with-adx71149-in-schizophrenia/</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Addex+reports+top-line+data+from+a+successful+phase+2a+clinical+study+with+ADX71149+in+schizophrenia+patients.+http%3A%2F%2Fwww.addextherapeutics.com%2Finvestors%2Fpress-releases%2Fnews-details%2Farticle%2Faddex-reports-top-line-data-from-a-successful-phase-2a-clinical-study-with-adx71149-in-schizophrenia%2F."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">Lavreysen, H.</span>Discovery and early clinical development of novel mGlu2 receptor PAMs, <span class="NLM_conf-name">American College of Neuropsychopharmacology 52nd Annual Meeting</span>, <span class="NLM_conf-loc">Hollywood, Florida</span>, <span class="NLM_conf-date">Dec 8–12</span>,<span class="NLM_x"> </span><span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&conference=American+College+of+Neuropsychopharmacology+52nd+Annual+Meeting&author=H.+Lavreysen&title=Discovery+and+early+clinical+development+of+novel+mGlu2+receptor+PAMs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DLavreysen%26aufirst%3DH.%26jtitle%3DDiscovery%2520and%2520early%2520clinical%2520development%2520of%2520novel%2520mGlu2%2520receptor%2520PAMs%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span>A study of JNJ-40411813 as supplementary treatment to an antidepressant in adults with depression and anxiety symptoms. <a href="http://clinicaltrials.gov/show/NCT01582815" class="extLink">http://clinicaltrials.gov/show/NCT01582815</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=A+study+of+JNJ-40411813+as+supplementary+treatment+to+an+antidepressant+in+adults+with+depression+and+anxiety+symptoms.+http%3A%2F%2Fclinicaltrials.gov%2Fshow%2FNCT01582815."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span>Addex Reports top-line data from ADX71149 phase 2a study in patients with major depressive disorder (MDD) with significant anxiety symptoms. <a href="http://www.addextherapeutics.com/investors/press-releases/news-details/article/addex-reports-top-line-data-from-adx71149-phase-2a-study-in-patients-with-major-depressive-disorder/" class="extLink">http://www.addextherapeutics.com/investors/press-releases/news-details/article/addex-reports-top-line-data-from-adx71149-phase-2a-study-in-patients-with-major-depressive-disorder/</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Addex+Reports+top-line+data+from+ADX71149+phase+2a+study+in+patients+with+major+depressive+disorder+%28MDD%29+with+significant+anxiety+symptoms.+http%3A%2F%2Fwww.addextherapeutics.com%2Finvestors%2Fpress-releases%2Fnews-details%2Farticle%2Faddex-reports-top-line-data-from-adx71149-phase-2a-study-in-patients-with-major-depressive-disorder%2F."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group">Cid-Nuñez, J. M.; Trabanco-Suarez, A. A.; Macdonald, G. J.; Duvey, G. A. J.; Lütjens, R. J.</span>Preparation of 1,4-disubstituted 3-cyanopyridone derivatives as positive mGluR2 receptor modulators. WO/2008/107480,<span class="NLM_x"> </span><span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=J.+M.+Cid-Nu%C3%B1ez&author=A.+A.+Trabanco-Suarez&author=G.+J.+Macdonald&author=G.+A.+J.+Duvey&author=R.+J.+L%C3%BCtjens&title=Preparation+of+1%2C4-disubstituted+3-cyanopyridone+derivatives+as+positive+mGluR2+receptor+modulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCid-Nu%25C3%25B1ez%26aufirst%3DJ.%2BM.%26jtitle%3DPreparation%2520of%25201%252C4-disubstituted%25203-cyanopyridone%2520derivatives%2520as%2520positive%2520mGluR2%2520receptor%2520modulators%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group">Cid-Nuñez, J. M.; Trabanco-Suárez, A. A.; Macdonald, G. J.; Duvey, G. A. J.; Lütjens, R. J.</span>Preparation of 3-cyano-4-(4-phenylpiperidin-1-yl)-pyridin-2-one derivatives for treating and preventing neurol. and psychiatric diseases associated with glutamate dysfunction. WO/2008/107479,<span class="NLM_x"> </span><span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=J.+M.+Cid-Nu%C3%B1ez&author=A.+A.+Trabanco-Su%C3%A1rez&author=G.+J.+Macdonald&author=G.+A.+J.+Duvey&author=R.+J.+L%C3%BCtjens&title=Preparation+of+3-cyano-4-%284-phenylpiperidin-1-yl%29-pyridin-2-one+derivatives+for+treating+and+preventing+neurol.+and+psychiatric+diseases+associated+with+glutamate+dysfunction"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCid-Nu%25C3%25B1ez%26aufirst%3DJ.%2BM.%26jtitle%3DPreparation%2520of%25203-cyano-4-%25284-phenylpiperidin-1-yl%2529-pyridin-2-one%2520derivatives%2520for%2520treating%2520and%2520preventing%2520neurol.%2520and%2520psychiatric%2520diseases%2520associated%2520with%2520glutamate%2520dysfunction%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group">Cid-Nuñez, J. M.; Trabanco-Suárez, A. A.; Macdonald, G. J.; Duvey, G. A. J.; Lütjens, R. J.; Finn, T. P.</span>Preparation of bipyridinones as positive allosteric modulators of mGluR2 for treating neurological and psychiatric disorders. WO/2009/033704,<span class="NLM_x"> </span><span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=J.+M.+Cid-Nu%C3%B1ez&author=A.+A.+Trabanco-Su%C3%A1rez&author=G.+J.+Macdonald&author=G.+A.+J.+Duvey&author=R.+J.+L%C3%BCtjens&author=T.+P.+Finn&title=Preparation+of+bipyridinones+as+positive+allosteric+modulators+of+mGluR2+for+treating+neurological+and+psychiatric+disorders"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCid-Nu%25C3%25B1ez%26aufirst%3DJ.%2BM.%26jtitle%3DPreparation%2520of%2520bipyridinones%2520as%2520positive%2520allosteric%2520modulators%2520of%2520mGluR2%2520for%2520treating%2520neurological%2520and%2520psychiatric%2520disorders%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="note"><p class="first last">The in vitro [<sup>35</sup>S]GTPγS assay provides two measures of compound activity: pEC<sub>50</sub>, which is defined as the negative logarithm of the concentration at which half-maximal potentiation of glutamate is reached, and the maximal increase in observed glutamate response, the % <i>E</i><sub>MAX</sub>.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="note"><p class="first last">Compound <b>6</b> was incubated with human and rat liver microsomes at 0.4% final solvent concentration (0.16% DMSO and 0.24% CH<sub>3</sub>CN). The study was conducted to identify the main metabolites formed after 0 min (control) and 60 min of incubation time in the presence of an NADPH generating system at 37 °C. Test concentration of <b>6</b> was 5 μM. Samples were compared to the control incubations in which compound was added at termination. Data were acquired on a Waters UPLC/QToF Premier mass spectrometer using a 10 min generic UPLC method and a generic MSe method. Complementary MS/MS experiments were performed when necessary. An Acquity UPLC C18 (2.1 mm × 100 mm, 1.8 μm) column was used. Interpretation of data was performed with Waters Metabolynx software.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group">Lavreysen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langlois, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahnaou, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drinkenburg, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">te Riele, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Biesmans, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van der Linden, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peeters, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Megens, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wintmolders, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cid, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trabanco, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andres, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dautzenberg, F. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lutjens, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macdonald, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atack, J. R.</span><span> </span><span class="NLM_article-title">Pharmacological characterization of JNJ-40068782, a new potent, selective and systemically active positive allosteric modulator of the mGlu2 receptor and its radioligand [3H]JNJ-40068782</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">346</span><span class="NLM_x">, </span> <span class="NLM_fpage">514</span><span class="NLM_x">–</span> <span class="NLM_lpage">527</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Fjm500496m&amp;key=10.1124%2Fjpet.113.204990" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Fjm500496m&amp;key=23766542" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Fjm500496m&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtlCmtbbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=346&publication_year=2013&pages=514-527&author=H.+Lavreysenauthor=X.+Langloisauthor=A.+Ahnaouauthor=W.+Drinkenburgauthor=P.+te+Rieleauthor=I.+Biesmansauthor=I.+Van+der+Lindenauthor=L.+Peetersauthor=A.+Megensauthor=C.+Wintmoldersauthor=J.+Cidauthor=A.+A.+Trabancoauthor=I.+Andresauthor=F.+M.+Dautzenbergauthor=R.+Lutjensauthor=G.+Macdonaldauthor=J.+R.+Atack&title=Pharmacological+characterization+of+JNJ-40068782%2C+a+new+potent%2C+selective+and+systemically+active+positive+allosteric+modulator+of+the+mGlu2+receptor+and+its+radioligand+%5B3H%5DJNJ-40068782"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological characterization of JNJ-40068782, a new potent, selective, and systemically active positive allosteric modulator of the mGlu2 receptor and its radioligand [3H]JNJ-40068782</span></div><div class="casAuthors">Lavreysen, Hilde; Langlois, Xavier; Ahnaou, Abdel; Drinkenburg, Wilhelmus; te Riele, Paula; Biesmans, Ilse; Van der Linden, Ilse; Peeters, Luc; Megens, Anton; Wintmolders, Cindy; Cid, Jose Maria; Trabanco, Andres A.; Andres, Jose Ignacio; Dautzenberg, Frank M.; Lutjens, Robert; MacDonald, Gregor; Atack, John R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">346</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">514-527</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Modulation of the metabotropic glutamate type 2 (mGlu2) receptor is considered a promising target for the treatment of central nervous system diseases such as schizophrenia.  Here, we describe the pharmacol. properties of the novel mGlu2 receptor pos. allosteric modulator (PAM) 3-cyano-1-cyclopropylmethyl-4-(4-phenyl-piperidin-1-yl)-pyridine-2(1H)-one (JNJ-40068782) and its radioligand [3H]JNJ-40068782.  In guanosine 5'-O-(3-[35S]thio)triphosphate binding, JNJ-40068782 produced a leftward and upward shift in the glutamate concn.-effect curve at human recombinant mGlu2 receptors.  The EC50 of JNJ-40068782 for potentiation of an EC20-equivalent concn. of glutamate was 143 nM.  Although JNJ-40068782 did not affect binding of the orthosteric antagonist [3H]2S-2-amino-2-(1S,2S-2-carboxycyclopropyl-1-yl)-3-(xanth-9-yl)propanoic acid (LY-341495), it did potentiate the binding of the agonist [3H](2S,2'R,3'R)-2-(2',3'-dicarboxylcyclopropyl)glycine (DCG-IV), demonstrating that it can allosterically affect binding at the agonist recognition site.  The binding of [3H]JNJ-40068782 to human recombinant mGlu2 receptors in Chinese hamster ovary cells and rat brain receptors was saturable with a KD of ∼10 nM.  In rat brain, the anat. distribution of [3H]JNJ-40068782 was consistent with mGlu2 expression previously described and was most abundant in cortex and hippocampus.  The ability of structurally unrelated PAMs to displace [3H]JNJ-40068782 suggests that PAMs may bind to common determinants within the same site.  It is noteworthy that agonists also increased the binding affinity of [3H]JNJ-40068782.  JNJ-40068782 influenced rat sleep-wake organization by decreasing rapid eye movement sleep with a lowest active dose of 3 mg/kg PO.  In mice, JNJ-40068782 reversed phencyclidine-induced hyperlocomotion with an ED50 of 5.7 mg/kg s.c.  Collectively, the present data demonstrate that JNJ-40068782 has utility in investigating the potential of mGlu2 modulation for the treatment of diseases characterized by disturbed glutamatergic signaling and highlight the value of [3H]JNJ-40068782 in exploring allosteric binding.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9aUNTs3sN4bVg90H21EOLACvtfcHk0liDLUrDLYCMkQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtlCmtbbJ&md5=78f9f2a656c7b36196d91109d4decffc</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1124%2Fjpet.113.204990&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.113.204990%26sid%3Dliteratum%253Aachs%26aulast%3DLavreysen%26aufirst%3DH.%26aulast%3DLanglois%26aufirst%3DX.%26aulast%3DAhnaou%26aufirst%3DA.%26aulast%3DDrinkenburg%26aufirst%3DW.%26aulast%3Dte%2BRiele%26aufirst%3DP.%26aulast%3DBiesmans%26aufirst%3DI.%26aulast%3DVan%2Bder%2BLinden%26aufirst%3DI.%26aulast%3DPeeters%26aufirst%3DL.%26aulast%3DMegens%26aufirst%3DA.%26aulast%3DWintmolders%26aufirst%3DC.%26aulast%3DCid%26aufirst%3DJ.%26aulast%3DTrabanco%26aufirst%3DA.%2BA.%26aulast%3DAndres%26aufirst%3DI.%26aulast%3DDautzenberg%26aufirst%3DF.%2BM.%26aulast%3DLutjens%26aufirst%3DR.%26aulast%3DMacdonald%26aufirst%3DG.%26aulast%3DAtack%26aufirst%3DJ.%2BR.%26atitle%3DPharmacological%2520characterization%2520of%2520JNJ-40068782%252C%2520a%2520new%2520potent%252C%2520selective%2520and%2520systemically%2520active%2520positive%2520allosteric%2520modulator%2520of%2520the%2520mGlu2%2520receptor%2520and%2520its%2520radioligand%2520%255B3H%255DJNJ-40068782%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2013%26volume%3D346%26spage%3D514%26epage%3D527" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group">Feinberg, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, I. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schoepp, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, K.</span><span> </span><span class="NLM_article-title">The selective group mGlu2/3 receptor agonist LY379268 suppresses REM sleep and fast EEG in the rat</span> <span class="citation_source-journal">Pharmacol., Biochem. Behav.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">73</span><span class="NLM_x">, </span> <span class="NLM_fpage">467</span><span class="NLM_x">–</span> <span class="NLM_lpage">74</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2002&pages=467-74&author=I.+Feinbergauthor=I.+G.+Campbellauthor=D.+D.+Schoeppauthor=K.+Anderson&title=The+selective+group+mGlu2%2F3+receptor+agonist+LY379268+suppresses+REM+sleep+and+fast+EEG+in+the+rat"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFeinberg%26aufirst%3DI.%26aulast%3DCampbell%26aufirst%3DI.%2BG.%26aulast%3DSchoepp%26aufirst%3DD.%2BD.%26aulast%3DAnderson%26aufirst%3DK.%26atitle%3DThe%2520selective%2520group%2520mGlu2%252F3%2520receptor%2520agonist%2520LY379268%2520suppresses%2520REM%2520sleep%2520and%2520fast%2520EEG%2520in%2520the%2520rat%26jtitle%3DPharmacol.%252C%2520Biochem.%2520Behav.%26date%3D2002%26volume%3D73%26spage%3D467%26epage%3D74" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group">Ahnaou, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dautzenberg, F. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geys, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Imogai, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibelin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moechars, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steckler, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drinkenburg, W. H.</span><span> </span><span class="NLM_article-title">Modulation of group II metabotropic glutamate receptor (mGlu2) elicits common changes in rat and mice sleep–wake architecture</span> <span class="citation_source-journal">Eur. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">603</span><span class="NLM_x">, </span> <span class="NLM_fpage">62</span><span class="NLM_x">–</span> <span class="NLM_lpage">72</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Fjm500496m&amp;key=10.1016%2Fj.ejphar.2008.11.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Fjm500496m&amp;key=19046965" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Fjm500496m&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFCjsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=603&publication_year=2009&pages=62-72&author=A.+Ahnaouauthor=F.+M.+Dautzenbergauthor=H.+Geysauthor=H.+Imogaiauthor=A.+Gibelinauthor=D.+Moecharsauthor=T.+Stecklerauthor=W.+H.+Drinkenburg&title=Modulation+of+group+II+metabotropic+glutamate+receptor+%28mGlu2%29+elicits+common+changes+in+rat+and+mice+sleep%E2%80%93wake+architecture"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Modulation of group II metabotropic glutamate receptor (mGlu2) elicits common changes in rat and mice sleep-wake architecture</span></div><div class="casAuthors">Ahnaou, Abdellah; Dautzenberg, Frank M.; Geys, Helena; Imogai, Hassan; Gibelin, Antoine; Moechars, Dieder; Steckler, Thomas; Drinkenburg, Wilhelmus H. I. M.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">603</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">62-72</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Compiling pharmacol. evidence implicates metabotropic glutamate mGlu2 receptors in the regulation of emotional states and suggests pos. modulators as a novel therapeutic approach of Anxiety/Depression and Schizophrenia.  Here, we investigated s.c. effects of the metabotropic glutamate mGlu2/3 agonist (LY354740) on sleep-wake architecture in rat.  To confirm the specific effects on rapid eye movement (REM) sleep were mediated via metabotropic glutamate mGlu2 receptors, we characterized the sleep-wake cycles in metabotropic glutamate mGlu2 receptor deficient mice (mGlu2R-/-) and their arousal response to LY354740.  We furthermore examd. effects on sleep behavior in rats of the pos. allosteric modulator, biphenyl-indanone A (BINA) alone and in combination with LY354740 at sub-EDs.  LY354740 (1, 3 and 10 mg/kg) dose-dependently suppressed REM sleep and prolonged its onset latency.  Metabotropic glutamate mGlu2R-/- and their wild type (WT) littermates exhibited similar spontaneous sleep-wake phenotype, while LY354740 (10 mg/kg) significantly affected REM sleep variables in WT but not in the mutant.  In rats, BINA (1, 3, 10, 20, 40 mg/kg) dose-dependently suppressed REM sleep, lengthened its onset latency and slightly enhanced passive waking.  Addnl., combined treatment elicited a synergistic action on REM sleep variables.  Our findings show common changes of REM sleep variables following modulation of metabotropic glutamate mGlu2 receptor and support an active role of this receptor in the regulation of REM sleep.  The synergistic action of BINA on LY354740's effects on sleep pattern implies that pos. modulators would tune the endogenous glutamate tone suggesting potential benefit in the treatment of psychiatric disorders, in which REM sleep overdrive is manifested.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlUXqoXCoqp7Vg90H21EOLACvtfcHk0ljYuFlCM0dW8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFCjsbg%253D&md5=eb1e676deebb6b39aad64cf14a281bf2</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2008.11.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2008.11.018%26sid%3Dliteratum%253Aachs%26aulast%3DAhnaou%26aufirst%3DA.%26aulast%3DDautzenberg%26aufirst%3DF.%2BM.%26aulast%3DGeys%26aufirst%3DH.%26aulast%3DImogai%26aufirst%3DH.%26aulast%3DGibelin%26aufirst%3DA.%26aulast%3DMoechars%26aufirst%3DD.%26aulast%3DSteckler%26aufirst%3DT.%26aulast%3DDrinkenburg%26aufirst%3DW.%2BH.%26atitle%3DModulation%2520of%2520group%2520II%2520metabotropic%2520glutamate%2520receptor%2520%2528mGlu2%2529%2520elicits%2520common%2520changes%2520in%2520rat%2520and%2520mice%2520sleep%25E2%2580%2593wake%2520architecture%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2009%26volume%3D603%26spage%3D62%26epage%3D72" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="note"><p class="first last">Compound <b>36</b> was tested for agonist or antagonist activity on mGlu receptors in fluorescent Ca<sup>2+</sup> assays using HEK293 cells expressing human mGlu1, mGlu3, and mGlu5 receptors or [<sup>35</sup>S]GTPgS assays using L929 cells expressing human mGlu4 or CHO cells expressing rat mGlu6 receptors.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="note"><p class="first last">The CEREP selectivity screen was performed on the following targets: 5HT1A, 5HT2A, 5HT3, 5HT5A, 5HT6, 5HT7, A1, A2A, A3, AT1, Beta1, BK2, CCKA, CCR1, D1, D2, DAT, ETA, GAL2, H1, H2, IL8B, CXCR2, M1, M2, M3, MC4, NET, NK2, NK3, NPY1, NPY2, NT1, OP1, OP3, ORL1, V1A, VIP, SST, 5HT1B, α1, α2, BZD, CaCH, CICH, GABA, KCH, NaCH, and SKCaCH.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li></ol></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Fjm500496m&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2014.57.issue-15%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Fjm500496m%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/jm500496m" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                1MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67992cef8a613c10","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
